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Cardiovascular disease (CVD) is the leading cause of morbidity and mortality 
globally. Individuals should have their risk factors monitored and clinically 
managed to lower this risk, and many countries adopt similar prevention 
strategies targeting those at highest risk. One such high-risk group are those who 
have previously experienced a cardiovascular event, and consequently these 
patients are universally identified and targeted in risk management strategies. 
This thesis initially compared recommendations for the management of lipids in 
secondary prevention populations in a systematic review of national clinical 
guidelines. This found that statins were consistently recommended, but there 
were substantial differences in the use of lipid targets and the frequency of lipid 
monitoring after statin initiation, although annual lipid tests were the most 
frequently recommended. Aside from expert opinion, however, there was little 
robust evidence to support the recommendations for targets and monitoring 
frequency.  
Therefore, the frequency of lipid testing under the current guidelines is unlikely 
to be optimal for the management of many patients. Increased use of electronic 
health records could allow the development of algorithms to result in a 
personalised approach to lipid testing. Specifically, if most patients have lipid 
tests annually, the possibility that there are a group of patients that need less 
frequent monitoring can be assessed. The remainder of this thesis, therefore, 
aimed to explore this within a subgroup of the secondary prevention population, 
survivors of myocardial infarctions (MIs), within Greater Glasgow and Clyde 
(GGC), where current and previous guidelines recommend an annual lipid test.  
To achieve this, the cohort was first described to facilitate comparisons with 
external literature and to understand the ongoing real-life clinical management 
of these patients. Associations between adherence and the achievement of 
guideline-recommended lipid targets were then investigated with further 
hospitalisations for MIs and mortality. Finally, factors associated with non-
adherence and non-target lipids were identified and used to predict patients’ 
subsequent adherence and cholesterol levels, i.e. those who could receive 
reduced lipid monitoring.   
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Data was obtained from NHS GGC’s Safe Haven for 11,110 patients who 
experienced a non-fatal MI between 2009 and 2014, with follow up available 
until July 2017. Demographics were consistent with similar observational cohorts 
from other countries in the literature, including a greater proportion of males to 
females, an average age of 67 years, and approximately a fifth diagnosed with 
diabetes before their baseline MI. Estimated statin adherence, obtained through 
encashed prescribing records, found that two thirds achieved an average 
adherence during follow up ≥80% and 85% ≥50%. Three quarters of those with at 
least one lipid test achieved LDL ≤1.8mmol/l during follow up. Statin adherence 
did not fully account for LDL target achievement, but those with higher 
adherence were significantly more likely to achieve it. 
High adherence and lipid target attainment were common suggesting that there 
was a subset of patients for whom an annual lipid test could be considered 
unnecessary, as a further lipid test was unlikely to change any clinical decisions. 
Non-adherence and elevated lipids were separately significantly associated with 
increased mortality within this cohort (<80% adherence, HR (95% CI): 1.4 (1.3-
1.5); LDL>1.8mmol/l: 1.3 (1.2-1.4)), and with CVD mortality specifically (<80% 
adherence: 1.3 (1.1-1.5); LDL>1.8mmol/l: 1.3 (1.1-1.5)). Therefore, careful and 
accurate identification of low risk patients is needed to avoid increased 
mortality. 
Latent class analysis, a type of mixture model for categorical variables, was 
implemented to explore clustering and patterns within the data associated with 
lipid target achievement and adherence, into latent classes. For LDL 
≤1.8mmol/l, sensitivity of these classes was 83% and positive predictive value 
was 100%, meaning all those predicted to achieve the target did so. This positive 
predictive value was also observed when ≥50% adherence was considered, and 
sensitivity was 99%. The class share of those predicted to have ≥50% adherence 
was substantially larger, with 85% predicted to do so, compared to 42% for LDL 
≤1.8mmol/l. Associations between predicted classes and mortality showed that 
those predicted to have ≥50% adherence experienced lower rates of mortality, 
than those predicted not to. This was not the case for the LDL ≤1.8mmol/l, 
although the predictions performed no worse than those observed.  
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In conclusion, given lipid tests as part of an annual review can be expensive in 
terms of the time needed for repeat appointments and biochemistry, the 
purpose of these for secondary prevention CVD patients needs to be considered 
and clarified by guideline committees. Once a patient meets a lipid target and 
adherence continues to be high, clinical decisions are unlikely to change with 
further blood tests. The results in this thesis have shown that using previous 
adherence and lipid results, and demographic information, patients’ adherence 
can be accurately predicted and therefore could be used as a practical marker of 
lipid test’s necessity within a review. However, before the implementation of 
this approach should be considered, further validation of these results within 
other external observational cohorts is required, and a non-inferiority 
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Chapter 1 Introduction  
1.1 Cardiovascular Disease 
The cardiovascular system allows the circulation of blood around the body, 
which facilitates the quick and efficient delivery of nutrients, including oxygen, 
water, and amino acids, as well as the removal of the waste products of 
metabolism, such as carbon dioxide and urea, from the body’s tissues. This 
system also plays a key role in the transportation of hormones and components 
of the body’s immune system, as well as ensuring temperature regulation 
through the dispersion of heat from the body’s core (Evans, Horton-Szar and 
Newby, 2015). 
Conditions which affect the circulation of blood are often referred to under the 
term of cardiovascular disease (CVD), with the most common examples being 
Coronary Heart Disease and Stroke (Brown et al., 2015). These typically develop 
as either a result of thrombosis (the formation of blood clots) or atherosclerosis 
(SIGN, 2017). The latter is the deposition of lipids in the inner walls of blood 
vessels leading to their subsequent hardening and narrowing. Whilst this is 
thought to be present to some extent in all adults, this process can subsequently 
lead to a decreased capacity for blood flow due to the narrowing in the arteries 
(stenosis) or, in the worst case, a complete obstruction of a blood vessel. In both 
cases, a thrombus develops as a consequence of plaque rupture or plaque 
erosion, with the former the most likely to result in a complete occlusion (Evans, 
Horton-Szar and Newby, 2015). 
1.1.1 Role of Cholesterol in Atherosclerosis 
Atherosclerosis is the development of lesions in the intima (inner layer) of 
arteries causing it to thicken and consequently lead to the narrowing of the 
arteries (Hansson, 2005). The first step of their development occurs due to 
changes in the endothelium, often triggered by damage caused by known risk 
factors such as smoking, diabetes, and hypertension (Mundi et al., 2018). This 
typically occurs at sites in the arteries where blood flow is low or oscillating, 
such as near branch points (Bentzon et al., 2014; Mundi et al., 2018). The 
damage to the endothelium allows low-density lipoprotein (LDL) cholesterol to 
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permeate into, and accumulate in, the intima of the artery. This forms a fatty 
streak in the initial stages of lesion development, although these are present in 
many individuals and do not always progress to lesions (Hansson, 2005; Mundi et 
al., 2018). 
Free radicals oxidise the LDL in the intima, triggering an immune and 
inflammatory response (Hansson, 2005; Bentzon et al., 2014). Specifically, 
endothelial cells and smooth muscle cells attract further monocytes to the 
region so that they can differentiate as macrophages and infiltrate the streak 
(Bentzon et al., 2014). As the macrophages become lipid-laden, they progress 
into foam cells which, combined with the abundance of smooth muscle cells, 
leads to the development of an atherosclerotic lesion. This lesion (or plaque) has 
smooth muscle cells and a collagen matrix forming a cap to it (Hansson, 2005). 
Furthermore, as the process continues, the endothelium becomes damaged 
further, allowing more LDL to be retained within the lesion (Bentzon et al., 
2014). 
The thinnest point of the cap of the lesion is where a rupture is most likely to 
occur, and this is typically the region where macrophages have infiltrated to the 
greatest degree. This is as a result of macrophage-derived proteinases degrading 
collagen in the cap of the plaque and preventing its further formation (Hansson, 
2005; Bentzon et al., 2014). The increasing complexity of the lesion can lead to 
the development of artery tertiary lymphoid organs, which increases mechanical 
instability (Yin et al., 2016). When rupture does occur, this triggers the 
formation of a thrombus (blood clot), which can result in the blockage of the 
artery, causing ischaemia and infarction as a consequence (Hansson, 2005).  
1.1.2 Types of Cardiovascular Disease 
CVD is often used as an umbrella term to refer to many conditions that are 
illustrated in Figure 1.1. One such condition is coronary heart disease (CHD) 
which is another umbrella term which includes stable angina and acute coronary 
syndromes (ACS). Stable angina, characterised by central chest pain which 
subsides at rest, occurs as a result of atherosclerotic stenosis in one or more 
coronary arteries, with symptoms usually only experienced when the area of the 
affected vessel is reduced by approximately 70%. ACS, on the other hand, refers 
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to unstable angina, non-ST-elevation myocardial infarctions (NSTEMIs), and ST-
elevation myocardial infarctions (STEMIs), which are given in increasing order of 
severity. These conditions all occur when the cap on the lesions in the arteries 
becomes unstable leading to either its erosion or rupture. This then leads to the 
formation of a blood clot either on the surface of, or inside, the deposit causing 
further expansion of the lesion, with both locations leading to, at least partial, 
blockage of the blood vessel (Evans, Horton-Szar and Newby, 2015).  
Myocardial infarctions (MIs), which are often more commonly referred to as 
‘heart attacks’, refers to both NSTEMIs and STEMIs. These are triggered by a lack 
of supply to the myocardium (an area of heart muscle) resulting in cell death, 
with irreversible damage caused once the lack of blood supply has persisted for 
between twenty and forty minutes. The consequences of MIs include sudden 
death, arrhythmias (irregular, fast, or slow heart rates), and heart failure 
(Evans, Horton-Szar and Newby, 2015).  
Peripheral arterial disease (PAD) develops when atherosclerosis develops in the 
arteries supplying the lower limbs (and rarely the upper limbs). It is likely that 
most individuals with CHD will have PAD to some extent (Evans, Horton-Szar and 
Newby, 2015). 
Ischaemic strokes, which account for approximately 85% of all strokes, occur 
when blood flow is reduced due to a blockage of one of the arteries supplying 
the brain, causing cells in the affected area to die. This blockage is usually as a 
result of atherosclerosis, specifically, the blood clot formed as a result of a 
ruptured lipid deposit in a blood vessel. If this blockage is only temporary, this 
can result in a transient ischaemic attack (TIA). These often precede ischaemic 
strokes, with the risk being at its greatest in the week after and for those with 
longer lasting TIAs. Haemorrhagic strokes, which make up the remaining 15% of 
all strokes, occur as a result of bleeds into the brain’s functional tissue, with the 
primary mechanism thought to be hypertension (Albers et al., 2010). 
Finally, as atherosclerosis causes the walls of arteries to weaken, it is also the 
primary cause of aneurysms, though, as with haemorrhagic strokes, high blood 
pressure forms the main driver of their development. These occur when the 
three layers of the wall of an artery allow it to become permanently abnormally 
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dilated. Whilst this can occur in any artery, they are most common in the aorta 
(the largest artery in the body), specifically in the abdomen, with complications, 
such as a rupture and subsequent blood loss, more likely to occur as the size of 
aneurysm increases (Evans, Horton-Szar and Newby, 2015). 
 
Figure 1.1: Types of CVD  
1.1.3 Mortality and Morbidity 
The World Health Organization reported that CVD was responsible for 17.9 
million deaths globally in 2016 (World Health Organization, 2017b, 2020), with 
this anticipated to increase to more than 23 million by 2030 (Mathers and 
Loncar, 2006). In 2016, this made CVD the most common cause of death, and 
accounted for 44% of all deaths due to noncommunicable diseases. Furthermore, 
whilst the probability of death under the age of 70 due to CVD has decreased 
rapidly since 2000 worldwide and resulted in cancer becoming the leading cause 
of premature death in some high-income countries, this is not the case for 
lower-income countries. Indeed, in these instances, CVD is not only responsible 
for the most premature deaths, but also progress in reducing this mortality has 
been the slowest. This is possibly due to increases in the prevalence of CVD risk 
factors, such as obesity, but also the challenges faced by healthcare systems 
with many countries facing a dual burden of both communicable and non-
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In Europe, the fifth edition of the European Cardiovascular Disease Statistics 
found that diseases of the heart and circulatory system were responsible for 45% 
of all deaths (equivalent to nearly four million deaths), making them the leading 
cause of death in 2017. When individual causes were considered, CHD and stroke 
were the two largest. When this was restricted to just EU countries, the 
percentage of deaths as a result of CVD decreased to 37%. However, CVD 
remained the leading cause of death, ahead of cancer, and CHD and stroke 
remained the two single leading causes (Wilkins et al., 2017). 
In the UK, the number of deaths from CVD has decreased considerably since 1961 
when it was responsible for over half of all deaths. In 2016, according to figures 
published by the British Heart Foundation, 26% (equating to approximately 
150,000 deaths) of all deaths in the UK were as a result of CVD. Consistent with 
the European figures, CHD was one of the leading causes of mortality in the UK 
and was responsible for 66,000 deaths in 2016 (British Heart Foundation, 2018). 
When looking at Scotland in isolation, which has the highest CVD incidence and 
mortality rates within the UK, it was estimated that just over 15,000 people died 
as a result of CVD, with 6,700 of these due to CHD, in 2016 (Information Services 
Division, 2017; British Heart Foundation, 2018). 
Premature deaths, defined as deaths occurring prior to 75 years of age, are 
often considered to be preventable. In such cases, CVD was responsible for 1.3 
million deaths in Europe in 2017, with CHD being the single largest contributing 
cause. Within only EU countries, CVD was the second biggest cause of premature 
death, after cancer (Wilkins et al., 2017). In 2016, 42,000 premature deaths 
were due to CVD, of which approximately 5,000 were in Scotland. However, at a 
regional level, there were higher premature death rates reported in Northern 
England, Central Scotland, and South Wales, with the greatest death rates 
observed in the Glasgow and Greater Manchester regions (British Heart 
Foundation, 2018). 
The majority of the estimated 85 million people living with CVD in Europe in 
2015 had PAD or CHD, with the number likely to be higher when undiagnosed 
cases are additionally included. These two conditions were also thought to be 
the most prevalent when only EU countries were considered, where an 
estimated 49 million people were thought to be living with CVD (Wilkins et al., 
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2017). In the UK in 2016, there were an estimated seven million people living 
with CVD, with 685,000 in Scotland. Furthermore, the British Heart Foundation 
predicted that this number was likely to increase over the coming years given 
the increasingly ageing and growing population, together with improving survival 
rates from major cardiovascular events (British Heart Foundation, 2018).  
When major types of CVD were considered individually in the UK in 2016, CHD 
was the most prevalent with an estimated 2.3 million people affected, with over 
900,000 heart attack survivors. There were also an estimated 1.3 million people 
living with atrial fibrillation, which occurs when the heart rhythm becomes 
abnormal and can result in a stroke. There were 1.2 million stroke or TIA 
survivors (British Heart Foundation, 2018). 
1.2 Risk Classification for Cardiovascular Disease 
Many countries, including Scotland, adopt high-risk prevention strategies when 
endeavouring to reduce the incidence of CVD. These strategies can facilitate 
more easily achievable benefits than population-wide strategies, as those at 
greater risk can reduce their risk in absolute terms more substantially than those 
at a lower risk. Furthermore, in the case of the management of those with CVD, 
those at high risk are usually recommended medication which may have 
undesirable side effects. Therefore, if medication was prescribed to the whole 
population, those at very low risk of a cardiovascular event would have a lower 
benefit-risk ratio of such medications. Additionally, whilst high-risk prevention 
strategies do not prevent all cases of CVD, they are practical and cost-effective 
in a population and can complement population-wide strategies. As population-
wide strategies are more challenging to implement, greater attention is usually 
placed on identifying those at high risk to maximise a strategy’s effectiveness in 
reducing CVD (Wilson et al., 2017). 
In Scotland, where the data used for much of this project is based (as outlined 
subsequently in Chapter 1.8), patients are classified by healthcare professionals 
as being at high or low risk of a cardiovascular event in the next ten years. 
According to guidelines, risk assessments are recommended in all individuals 
over 40 years or those with a first degree relative with premature CVD or 
familial hypercholesterolaemia. The definition of high risk, which is illustrated in 
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Figure 1.2, classifies many groups of patients, including those with established 
disease, as high risk regardless of the presence of other known risk factors. For 
patients who do not fall within any of these categories, the Scottish national 
guidelines recommend the Scotland-specific CVD risk assessment tool ASSIGN, 
where a score of greater than 20% also represents the patient as being at high 
risk (ASSIGN, 2014; SIGN, 2017).  
 
Figure 1.2: Definition of High Risk According to SIGN's 2017 Guidelines for the Prevention 
and Management of CVD (adapted from SIGN, 2017) 
There are many modifiable and unmodifiable risk factors associated with the 
development of CVD which are well established both within the literature and 
the current CVD risk management guidelines, with many included in the ASSIGN 
assessment tool (ASSIGN, 2014). Therefore, within this section, risk factors are 
divided by those included within the ASSIGN tool, populations automatically 
identified as high risk by the current Scottish guidelines, and other risk factors 
discussed by them. However, many of these risk factors and high-risk populations 
are universal across guidelines for the risk management and prevention of 
cardiovascular disease with minimal variation between them.  
1.2.1 Risk Factors used in Cardiovascular Risk Scores 
1.2.1.1 Age  
The risk of experiencing a cardiovascular event increases with age to an extent 
greater than that identified by any modifiable risk factors. This is likely due to 
the resulting increased exposure to known risk factors that occurs as a result of 
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a longer lifespan, thereby increasing the likelihood of critical atherosclerosis to 
develop (Sniderman and Furberg, 2008). Furthermore, age also has an impact on 
known risk factors such as plasma total:high density lipoprotein (HDL) 
cholesterol ratios and blood pressure, where both are known to increase with 
age. Indeed, Jousilahti et al (1999), found in a Finnish follow up study with over 
14,000 individuals that increases in total cholesterol and blood pressure, 
together with relative weight and diabetes prevalence (also more likely to 
increase with age) were associated with cardiovascular events. These 
associations were particularly strong in women, suggesting the impact of age on 
cardiovascular risk is modified by a patient’s sex (Jousilahti et al., 1999). 
1.2.1.2 Sex  
Despite CVD being one of the leading causes of mortality in both men and 
women, the rates of the disease are considerably higher in men than in women. 
This disparity does decrease as age increases, with women only experiencing 
CVD at a higher rate than men in populations over the age of 75 years. In this 
age category though, this may be explained by survival bias arising from the 
greater life expectancy of women, as women are likely to represent a greater 
proportion of the population over the age of 75 years, and men who are 
susceptible to CVD have already died, making a higher rate of CVD more likely 
(Mosca, Barrett-Connor and Kass Wenger, 2011).  
The difference in cardiovascular risk between the two sexes is likely due to a 
combination of the differences in the prevalence of risk factors, differences in 
the impact of risk factors in each sex, and the role of the predominant sex 
hormones in men and women, specifically their influence on risk factors and an 
individual’s biology (Vitale, Mendelsohn and Rosano, 2009; Mosca, Barrett-
Connor and Kass Wenger, 2011; Appelman et al., 2014). In the case of the latter, 
it is widely believed that endogenous oestrogen reduces women’s cardiovascular 
risk, whilst endogenous androgen increases men’s. However, both sexes have 
each hormone present and their effects on cardiovascular risk are likely the 
same in both sexes, meaning that the difference in risk observed is likely due to 
the ratio of the hormones and their effects on vascular processes (Vitale, 
Mendelsohn and Rosano, 2009). Some risk factors for CVD are thought to have 
similar effects in men and women, such as hypertension and raised cholesterol 
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(Appelman et al., 2014). However, in women, prolonged smoking and diabetes 
increase cardiovascular risk to a greater extent than observed in men (Appelman 
et al., 2014), with the estimated effect of diabetes approximately negating the 
reduced cardiovascular risk experienced by women (Vitale, Mendelsohn and 
Rosano, 2009).  
1.2.1.3 Diabetes Mellitus 
Although the mortality and incidence of cardiovascular events in patients with 
Type 1 and Type 2 diabetes mellitus has decreased considerably over recent 
years, the risks of both remain between two and four times greater than those 
observed in the general population without diabetes (Rawshani et al., 2017), 
including in Scotland (Read et al., 2019). Whilst this decrease is likely to be as a 
result of a corresponding decrease in the prevalence, and increase in the 
control, of major cardiovascular risk factors both in patients with and without 
diabetes (Rawshani et al., 2017; Read et al., 2019), this difference in risk of 
cardiovascular events cannot be completely explained by the associations and 
coexistences of diabetes with other cardiovascular risk factors (Low Wang et al., 
2016). Consequently, various processes, with some likely interactions between 
them, have therefore been additionally implicated in the development of 
atherosclerosis in patients with diabetes including hyperglycaemia, insulin 
resistance, and endothelial dysfunction (Low Wang et al., 2016). 
However, the impact of hyperglycaemia in the increased risk of cardiovascular 
events is disputed. In many epidemiological studies, where confounding factors 
are likely present, its role is often the most evident. For example, one analysis 
of over 250,000 patients with Type 2 diabetes on the Swedish National Diabetes 
Register matched at a ratio of 1:5 with controls sourced from the population 
register between 1998 and 2012, found that a patient’s glycated haemoglobin 
level was a significant predictor of all cardiovascular outcomes, including acute 
MI. Furthermore, lower levels of glycated haemoglobin than those recommended 
as a treatment target were associated with even lower risks of a patient 
experiencing acute MI and stroke (Aidin Rawshani et al., 2018).  
In contrast, in three randomised controlled trials (RCTs) (ACCORD, ADVANCE and 
VADT) intensive glycaemic control did not show a significant reduction across a 
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variety of cardiovascular outcomes, despite significant decreases in 
microvascular disease. Furthermore, in ACCORD, an increased mortality rate was 
observed in those randomised to the intensive arm, resulting in early 
discontinuation of the trial, with exploratory analysis uncovering no explanation 
(Skyler et al., 2009). Moreover, in a recent analysis of the UK Biobank cohort, 
the association between HbA1c levels and cardiovascular risk has been shown to 
be substantially attenuated following adjustment for conventional risk factors, 
in populations with and without a diabetes diagnosis (Welsh et al., 2020). 
However, both trial populations and those in the UK Biobank have been shown to 
be a generally healthier population than those seen routinely in clinical practice 
(Welsh et al., 2020), possibly leading to discrepancies with other observational 
cohorts. Nonetheless, whilst other processes may have a role in the increased 
cardiovascular risk, it is likely that the elevated risk experienced by those with 
diabetes is largely due to the presence of other known and coexisting risk factors 
for CVD. 
1.2.1.4 Family History of Coronary Heart Disease and Stroke  
Information regarding a patient’s family history of cardiovascular events, 
especially those events which are considered to be premature, can be used to 
aid in the prediction of a patient’s cardiovascular risk. The impact of family 
history is likely to be mediated by the patient’s risk factors, including those 
occurring as a result of genetics and their environment. Despite this, its effect 
has still been shown to be a significant predictor of future events when 
adjustment for such factors has been performed (Kinra et al., 2003; Yarnell et 
al., 2003; Lloyd-Jones et al., 2004; Woodward, Brindle and Tunstall-Pedoe, 
2007).  
For example, in a study of around 10,000 men aged 50-59 years who completed 
self-administered questionnaires and were subsequently followed up for five 
years, total cholesterol, blood pressure, and age differed substantially between 
those who reported having a family history of CVD and those who did not. 
However, following adjustment for these risk factors and several others, the 
odds of a coronary event were 93% higher in those with a family history (Yarnell 
et al., 2003). This conclusion was also supported by Kinra et al (2003) who also 
found, over 43 years of follow up in approximately 8,500 males aged 16-30 at 
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baseline, that parental history of CVD was associated with fatal CHD following 
adjustment for other risk factors. Additionally, whilst a stronger association was 
found with paternal, rather than maternal, history, there was no evidence to 
suggest that this difference was significant, and therefore the cardiovascular 
history of both parents is relevant to risk prediction (Kinra et al., 2003).  
The risk of recall bias when acquiring family history from a patient has raised 
concerns. However, an analysis of 2,000 individuals in the Framingham Offspring 
cohort over eight years, where parental cardiovascular history could be 
validated, reported adjusted odds ratios for cardiovascular events of 2.0 and 1.7 
for men and women respectively, in individuals whose parents had experienced 
premature CHD (Lloyd-Jones et al., 2004). This estimate would therefore suggest 
that the effects of recall bias are likely to be small and the use of family history 
of CVD is likely to be effective in clinical practice. Indeed, family history was 
initially included in the ASSIGN equations with a view to it acting as an 
approximate marker for ethnicity as the sample size used to create the 
equations was insufficient to allow the detection of any ethnic differences in 
cardiovascular risk. Furthermore, the creators argued that an enquiry of the 
patient’s family history is likely to be less intimidating in a clinical scenario 
(Woodward, Brindle and Tunstall-Pedoe, 2007).  
1.2.1.5 Blood Pressure (Systolic)  
High blood pressure, or specifically hypertension, has a strong association with a 
patient’s cardiovascular risk. The Global Burden of Disease Study in 2010 found 
that, of 67 risk factors examined, high blood pressure had the largest 
attributable risk for CVD and one of the largest impacts on a patient’s disability-
adjusted life years (Lim et al., 2012).  
The relationship between a patient’s blood pressure and their cardiovascular risk 
appears to be linear, with values below those conventionally recommended as 
the intervention threshold still considered to be at an elevated risk when 
compared to patients with systolic blood pressure nearing 120mmHg (Vasan et 
al., 2001; Bundy et al., 2017). This has been made most evident in a meta-
analysis of over 140,000 individuals, where the lowest risk of CVD and mortality 
was found in patients with systolic blood pressure between 120 and 124mmHg 
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(Bundy et al., 2017). However, in some patients the consequences of lowering 
blood pressure to this extent (such as syncope) may make this target 
impractical, meaning that the risks and benefits of such a threshold should be 
considered carefully. Furthermore, another meta-analysis of 300,000 individuals 
showed that offering treatments to primary prevention patients whose baseline 
blood pressure is below the current threshold for treatment offered little benefit 
in terms of cardiovascular events (Brunström and Carlberg, 2018). This was also 
shown in a further meta-analysis by the Blood Pressure Lowering Treatment 
Trialists' Collaboration, who found that whilst relative risk reductions in 
cardiovascular risk were similar, the greatest absolute risk reductions were 
observed in those with a higher risk of an event (The Blood Pressure Lowering 
Treatment Trialists’ Collaboration, 2014). As a consequence, many current 
cardiovascular guidelines provide a threshold for anti-hypertensive treatments 
(Piepoli et al., 2016; SIGN, 2017; Whelton et al., 2018; NICE, 2019a).  
As with many risk factors included, high blood pressure has also been associated 
with, and tends to cluster with, other known risk factors including diabetes, 
obesity, and elevated cholesterol, as well as naturally increasing with age. 
However, the associated risk of high blood pressure cannot be fully explained by 
these other risk factors, making it an important risk factor for CVD (Kannel, 
1996). 
1.2.1.6 Smoking  
Despite the decreases in the prevalence of cigarette smoking in some countries 
(including Scotland) over the preceding decades, it remains one of the leading 
causes of acute MI. Indeed, the INTERHEART study of 27,000 patients found 
smoking to be the most strongly associated risk factor, with a population 
attributable risk of 35.7%, the highest of all the lifestyle factors considered 
(Yusuf et al., 2004). 
Smoking has also been shown to be associated with other known cardiovascular 
risk factors. For example, in the five year follow up of the Edinburgh Artery 
Study, lower dietary consumption of antioxidants, higher alcohol intake, lower 
HDL cholesterol, and elevated triglycerides were all associated with cigarette 
smoking. However, whilst the risk of PAD and coronary artery disease (CAD) was 
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attenuated following adjustment for these factors, hazard ratios of 2.72 and 
1.61 were observed for PAD and CAD in heavy smokers, though only the former 
retained statistical significance. A dose-response relationship was also observed, 
with those with a higher number of pack-years more likely to experience an 
event, particularly PAD (Price et al., 1999). 
The attenuation of effects observed by Price et al (1999) may suggest that the 
effects of cigarette smoking could be reduced by simply improving the detection 
and prevention of the coexisting risk factors. However, an analysis on the 
Framingham Offspring cohort noted that the effect of smoking had remained 
consistent across three decades of follow up when such prevention efforts had 
been occurring, thus suggesting that this may not be the case (Burke et al., 
2017). Furthermore, the full impact of the decrease in the prevalence of 
cigarette smoking, especially in the young, may not be observed for many years. 
Additionally, whilst former smokers have a lower risk than those who currently 
smoke and continue to, their risk of CVD does not fully reduce for a significant 
period after cessation (Yusuf et al., 2004). Nonetheless, some benefits can be 
observed early. For example, in Scotland, the implementation of smoke-free 
legislation in 2006 significantly reduced the number of ACS admissions and 
fatalities in a ten month period. This reduction occurred in both non-smokers 
and smokers, although the greatest reduction was in non-smokers and was likely 
due to a decrease in second-hand smoke exposure (Pell et al., 2008).  
1.2.1.7 Plasma Lipid Concentrations (Total and HDL Cholesterol)  
Details regarding the role of cholesterol, specifically LDL cholesterol, in the 
development of atherosclerosis are given in Chapter 1.1.1. Both total and HDL 
cholesterol values have been shown to have significant associations with the 
cardiovascular risk, with higher total cholesterol conferring a greater risk 
(Neaton et al., 1992; Smith et al., 1992), and higher HDL cholesterol associated 
with lower risk (Cooney et al., 2009; Bartlett et al., 2016). 
A patient’s total cholesterol level has consistently demonstrated a strong, 
positive, and graded relationship with cardiovascular mortality. In the MRFIT 
study of 350,000 men over a period of 12 years, the relative risk of 
cardiovascular mortality was 17% higher, and 56% higher for those whose total 
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cholesterol was between 4.1 and 5.2mmol/l and greater than 5.2 mmol/l 
respectively, when compared to those with total cholesterol less than 4.1mmol/l 
(Neaton et al., 1992). A similar trend was also observed in the 18 years of follow 
up of the Whitehall Study involving 17,718 men. In this instance, a decrease of 
1.21mmol/l in total cholesterol was associated with a 17% lower hazard of death 
as a result of CVD (Smith et al., 1992). 
In contrast, HDL cholesterol has been shown to have an inverse relationship with 
CVD. In the SCORE dataset of 96,000 individuals, significant hazard ratios for 
cardiovascular mortality of 0.60 and 0.76 in women and men respectively were 
reported per 0.5mmol/l increase in HDL cholesterol. These associations 
remained significant in subsequent analyses of smokers, non-smokers, and those 
with and without hypertensive treatments, as well as being shown to be 
independent of triglyceride levels and family history (Cooney et al., 2009). 
Despite these associations, whether HDL cholesterol is causally protective is 
controversial, with several trials of HDL-raising cholesteryl ester transfer protein 
(CETP) inhibitors failing to reduce CVD risk (Barter et al., 2007; Schwartz et al., 
2012), and another CETP inhibitor perhaps lowering CVD risk through LDL 
cholesterol reduction rather than HDL raising (Bowman et al., 2017). 
The predictive value of HDL could be as a result of its association with other 
components of the lipid profile. For example, in the Framingham Offspring 
cohort, low HDL in isolation was found to be considerably less predictive in the 
presence of elevated triglycerides or LDL cholesterol, suggesting a role of the 
ratios of components in risk prediction (Bartlett et al., 2016). Nonetheless, an 
analysis of over 300,000 individuals reported that the strength of the 
relationships with CVD were similar for non-HDL cholesterol, HDL cholesterol, 
and direct LDL cholesterol. Therefore, the authors of this analysis suggested that 
total cholesterol and one of the above should be used when estimating 
cardiovascular risk, with the addition of further components offering minimal 
additional predictive value (The Emerging Risk Factors Collaboration, 2009). This 
was further supported by our analysis of 500,000 participants in the UK Biobank, 
which found that there was no meaningful improvement in the prediction of 
events when apolipoproteins or direct or calculated LDL were included or 
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substituted in existing models utilising Total and HDL cholesterol (Welsh et al., 
2019).  
1.2.1.8 Rheumatoid Arthritis 
The presence of rheumatoid arthritis (RA) is associated with an increased risk of 
CVD. For example, one meta-analysis of observational studies found a 50% 
increase of cardiovascular mortality in those with RA, compared to those without 
(Aviña-Zubieta et al., 2008). A further meta-analysis also found a similar 
increase in the risk of experiencing cardiovascular events, with a 48% increased 
risk of CVD and a higher risk of 68% for experiencing an MI (Aviña-Zubieta et al., 
2012). However, both analyses also reported significant heterogeneity (Aviña-
Zubieta et al., 2008, 2012). 
Despite this, the estimated effect of RA is comparable to that which was 
observed in the QRESEARCH data, the data used in the development and 
validation of the QRISK2 prediction equation recommended under the National 
Institute for Health and Care Excellence (NICE) 2014 guidelines (Hippisley-Cox et 
al., 2008; NICE, 2014). In this analysis, following adjustment for other CVD risk 
factors, the effect of RA remained a significant predictor of cardiovascular 
events, with hazard ratios of 1.50 and 1.38, for women and men respectively 
(Hippisley-Cox et al., 2008). When this equation was subsequently updated in 
2017, the effect of RA was reduced to 1.24 and 1.23 in men and women 
respectively, but remained significant (Hippisley-Cox, Coupland and Brindle, 
2017). Consequently, rheumatoid arthritis is included in the QRISK2, QRISK3, and 
ASSIGN equations for risk prediction, where in the case of the latter, its effect is 
estimated to be equivalent to light smoking (ten cigarettes a day) (Hippisley-Cox 
et al., 2008; ASSIGN, 2014). 
1.2.1.9 Deprivation  
The risk of experiencing a cardiovascular event is higher in areas of greater 
socioeconomic deprivation, with one analysis finding that the increase in risk 
between the least and most deprived 20% is broadly comparable to a ten year 
increase in age or a diagnosis of diabetes (Tunstall-Pedoe and Woodward, 2006). 
Similarly, the MONICA register, which involved more than 5,000 patients in 
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Glasgow, reported that the rate of coronary events in the most deprived quarter 
was 1.7 and 2.4 times higher for men and women respectively than those in the 
least deprived. Furthermore, those in the most deprived 25% were less likely to 
be treated at the hospital and had a higher case fatality than those in less 
deprived areas (Morrison et al., 1997). 
Therefore, with socioeconomic deprivation having an important effect on 
cardiovascular event rates, primary and secondary prevention strategies have a 
greater potential to reduce the effect of deprivation than acute hospital-based 
interventions (Morrison et al., 1997). Attendance at screening appointments to 
assess cardiovascular risk may be one factor contributing to socio-economic 
inequalities. A study of 8,000 patients at practices across the UK reported that 
whilst the most deprived patients were more likely to be at high risk of an 
event, they were also considerably less likely to attend screening appointments 
(Lang et al., 2016). 
In the Scottish guidelines, the inclusion of deprivation in the ASSIGN tool is an 
attempt to adjust for the increased risk experienced by the most deprived 
(Woodward, Brindle and Tunstall-Pedoe, 2007), as well as to facilitate access to 
prevention among deprived populations (Tunstall-Pedoe and Woodward, 2006). 
This aspect of CVD risk would be ignored if the Framingham score was 
implemented in the Scottish population. Whilst the expected risk, calculated by 
the Framingham score, in Scottish patients overall is higher than the observed 
risk, there was scope for potential overtreatment of the least deprived 
populations and undertreatment of the most deprived (Tunstall-Pedoe and 
Woodward, 2006; Woodward, Brindle and Tunstall-Pedoe, 2007). Thus, there is a 
need for the Scottish-specific risk score, ASSIGN, which includes deprivation 
(ASSIGN, 2014). This did not yield substantial improvements in discriminating 
between those who will and will not experience an event but instead aims to 
improve equity in the prevention of cardiovascular events (Woodward, Brindle 
and Tunstall-Pedoe, 2007).  
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1.2.2 Default High Risk Populations 
1.2.2.1 Established Cardiovascular Disease  
Patients with established disease are widely considered to be at elevated risk of 
further cardiovascular events and consequently are excluded from most risk 
prediction algorithms (NICE, 2014; Stone et al., 2014; Piepoli et al., 2016; SIGN, 
2017; Mach et al., 2020). The rationale behind this is self-evident. If 
atherosclerotic plaques have developed to such an extent as to cause an event in 
one location, it is therefore likely that similarly advanced lesions are present 
elsewhere within the circulatory system and may lead to further cardiovascular 
events. Indeed, the rate per year of further cardiovascular events in patients not 
treated with statins has been estimated at 5.6% in those with established 
disease, compared to 1.8% in the primary prevention population (Cholesterol 
Treatment Trialists’ (CTT) Collaboration, 2010). Survival rates are also lower in 
the secondary prevention population, with the World Health Organization 
reporting a death rate six times higher than those without CVD (World Health 
Organization, 2017a).  
Therefore, risk management strategies are needed in this population, regardless 
of other risk factors. However, their exclusion from risk prediction equations 
does not mean that the co-existence of known risk factors in patients should not 
also require management. For example, additional medical therapies are 
recommended for those with established disease to effectively manage the risks 
presented by elevated lipids and blood pressure as well as the risk of clotting, as 
detailed in Chapters 1.3.1 and 1.3.2. There is also a wide consensus among 
major guidelines that other lifestyle factors, such as smoking and physical 
activity, should also be addressed to further reduce a patient’s cardiovascular 
risk (NICE, 2014; SIGN, 2017; Mach et al., 2020). 
1.2.2.2 Renal Disease 
Patients with stage 3 or higher chronic kidney disease (CKD) (defined as an 
estimated glomerular filtration rate (eGFR) <60ml/min/1.73m2) or micro- or 
macro-albuminuria (an albumin-to-creatinine ratio (ACR) >30 and 300 mg/g 
respectively) are also automatically considered to be at high risk of CVD in many 
major guidelines, and therefore should not have their cardiovascular risk 
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assessed (NICE, 2014; SIGN, 2017; Grundy et al., 2019; Mach et al., 2020). In the 
case of this patient group, studies have consistently reported that cardiovascular 
events occur more frequently in patients with CKD than in the general 
population (Chronic Kidney Disease Prognosis Consortium, 2010; Gansevoort et 
al., 2013). There is also evidence to suggest that such events occur at a greater 
severity, may go unrecognised, and be undertreated due to the additional 
presence of CKD. Furthermore, the association between CKD and CVD has been 
shown regardless of age and sex, and across many geographical regions 
(Gansevoort et al., 2013).  
CKD is a common sequela of hypertension and diabetes (Gansevoort et al., 
2013), both of which have already been discussed as significant risk factors for 
CVD (Chapters 1.2.1.3 and 1.2.1.5). However, two large meta-analyses of 
published and unpublished cohort data have shown that the association with CVD 
remains significant following adjustment for traditional risk factors. This 
association was shown using both eGFR and ACR measures, and the two measures 
additionally appeared to be independent of each other in their association with 
CVD. Moreover, thresholds used in the SIGN guidelines for the definition of the 
high-risk populations coincide with a significant increase in risk (Chronic Kidney 
Disease Prognosis Consortium, 2010, 2011). Nonetheless, whilst the association 
between CKD and CVD may be evident after adjustment for risk factors, the 
complications as a result of renal disease can make the management of the co-
existing risk factors more challenging. Consequently, this population’s risk of a 
cardiovascular event may be further elevated (Gansevoort et al., 2013).  
1.2.2.3 Duration of Diabetes and Diabetes Complications 
Diabetes as a risk factor is discussed in Chapter 1.2.1.3. For many patients with 
a diagnosis of diabetes, the associated elevated risk (through the combination of 
their age and type of diabetes) will result in them automatically being 
considered as high risk under many current guidelines. However, there is some 
discrepancy between the guidelines in terms of the criteria used to classify 
patients with diabetes as high risk. For example, some take into account the 
duration of the disease and the presence of diabetes complications such micro- 
or macro-albuminuria, proliferative retinopathy or autonomic neuropathy, or 
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other significant risk factors (NICE, 2014; SIGN, 2017; Mach et al., 2020) whilst 
others consider a diagnosis of diabetes sufficient (Grundy et al., 2019).   
Duration of disease is considered as the lifetime risk increases with longer 
exposure to diabetes and with age (Aidin Rawshani et al., 2018). Therefore, 
those who develop diabetes at a younger age, who are typically patients with 
Type 1 diabetes, have substantially higher rates of mortality and morbidity from 
CVD than the general population, and consequently their risk should be managed 
(Rawshani et al., 2017). Duration of Type 2 diabetes has also been shown to be 
associated with the likelihood of a range of cardiovascular outcomes, with its 
greatest predictive value in the prediction of stroke (Aidin Rawshani et al., 
2018).  
Typically, younger patients with diabetes would not frequently have been 
exposed for a sufficiently long period to start developing comorbidities 
associated with diabetes. However, even in younger patients, the development 
of micro-or macro-albuminuria (as discussed in Chapter 1.2.2.2) confers a 
significant cardiovascular risk regardless of a patient’s diabetes status, although 
diabetes often precedes its development (Gansevoort et al., 2013). Proliferative 
retinopathy or autonomic neuropathy is also likely an indication of uncontrolled 
diabetes and therefore suggestive of the presence of other significant 
cardiovascular risk factors that need to be addressed (Skyler et al., 2009).  
1.2.2.4 Familial Hypercholesterolaemia 
Familial Hypercholesterolaemia (FH) is a common genetic disorder that primarily 
manifests as elevated LDL cholesterol levels, ultimately resulting in an increased 
risk of premature CVD (Nordestgaard et al., 2013; Lee et al., 2019). There are 
two forms: heterozygous and homozygous. Heterozygous FH is the more common 
form with estimates of prevalence approximately 1 in 250 to 500 individuals 
(Nordestgaard et al., 2013; Akioyamen et al., 2017; Lee et al., 2019), and 
patients are likely to develop CHD before the ages of 55-60 if left untreated 
(Nordestgaard et al., 2013). Homozygous FH patients typically have more 
marked elevations of LDL cholesterol levels and are likely to develop CHD by 
their early teens, dying before the age of 20 if left untreated (Nordestgaard et 
al., 2013). Estimates of homozygous FH’s prevalence would classify it as an 
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orphan disease with it effecting between 1 in 250,000 to 1,000,000 
(Nordestgaard et al., 2013; Lee et al., 2019). However, in both cases, it is 
widely believed that FH is likely underdiagnosed in the general population 
(Nordestgaard et al., 2013; Akioyamen et al., 2017). 
Treatment with lipid-lowering medications and management of concurrent risk 
factors can attenuate some of the increased cardiovascular risk, especially 
amongst those with heterozygous FH (henceforth referred to as FH), however, 
the individuals would remain at high risk (Nordestgaard et al., 2013). Those with 
FH have considerably higher lifetime cardiovascular risk (Nordestgaard et al., 
2013; Perak et al., 2016; Akioyamen et al., 2017; Lee et al., 2019). For 
example, one meta-analysis found that the risk of MI ranged from 4.4-6.8 times 
that of the general population, depending on the particular variant of the LDL 
receptor gene (Lee et al., 2019). Meanwhile, a different meta-analysis found 
that the 30-year risk of CHD could be as high as 5.0 times that of the general 
population, with a similar estimated risk (max 4.1 times) for the risk of 
atherosclerotic CVD (ASCVD), with the hazard ratios decreasing as age increased. 
Furthermore, this analysis reported that the presence of FH accelerated a 
patient’s CHD risk 10-20 years in men and 20-30 years in women (Perak et al., 
2016). 
1.2.3 Other Cardiovascular Risk Factors  
1.2.3.1 Diet  
Various components of an individual’s diet can have important roles in their 
cardiovascular risk, as well as influencing, and being influenced by, other risk 
factors. Therefore, whilst dietary intake is not usually included within an 
individual’s risk assessment nor is its influence alone considered sufficient to 
warrant the identification of an automatically high-risk population, its impact is 
still discussed within many current guidelines for CVD risk management with 
some recommendations made (NICE, 2014; SIGN, 2017; Grundy et al., 2019; 
Mach et al., 2020).  
One recommendation, which encompasses many of the guideline’s 
recommendations for components of an individual’s diet, is that those deemed 
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to be at high risk of CVD should follow a Mediterranean diet pattern, specifically 
one that is supplemented with either extra virgin olive oil or unsalted nuts. 
Although a universal definition of a Mediterranean diet is yet to be widely 
accepted, leaving some ambiguity, this diet is often identified through its high 
vegetable and fruit, moderate fat, and low red meat intakes (NICE, 2014; SIGN, 
2017; Grundy et al., 2019; Mach et al., 2020). The association between the 
recommended diet and a reduction in cardiovascular risk has been discussed in 
both RCTs and Cochrane reviews (Rees et al., 2013, 2019; Estruch et al., 2018). 
For example, in the PREDIMED trial of nearly 7,500 high-risk patients followed up 
for an average of five years, those who received a Mediterranean diet with extra 
virgin olive oil or unsalted nuts had a 30% lower risk of a major cardiovascular 
event than those who were randomised to a control diet (Estruch et al., 2013, 
2018). 
In contrast, a recent Cochrane review of 12,500 patients from 30 RCTs suggested 
that in primary prevention a Mediterranean diet showed little to no effect on 
cardiovascular, and overall, mortality, albeit that it considered the quality of 
evidence to be low. In secondary prevention, a statistically significant reduction 
in cardiovascular, and overall, mortality was observed, although the number of 
patients included was small and the quality of evidence was also assessed to be 
low by Cochrane (Rees et al., 2019). However, there was some evidence of 
associated significant reductions in other known cardiovascular risk factors, such 
as components of the lipid panel and in blood pressure, in both primary and 
secondary prevention (Rees et al., 2019), with similar findings also reported in 
the previous larger (n>50,000) primary prevention Cochrane review (Rees et al., 
2013). Therefore, this may suggest that any effects of this diet on mortality may 
not only require research with a longer exposure or follow up but may also occur 
as a result of the effects in other established cardiovascular risk factors. 
1.2.3.2 Alcohol Intake 
The consumption of excess alcohol has been shown to have a causal relationship 
with several hundred diseases and injuries, resulting in it being implicated in an 
estimated 5% of all global deaths (World Health Organization, 2018). One of 
these relationships is with CVD where the harmful use of alcohol is a well-
established risk factor (Costanzo et al., 2010; Ronksley et al., 2011).  
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Much of the evidence supporting the association between alcohol consumption 
and risk of CVD arises from observational studies. These typically report a J-
shaped relationship i.e. that those with a low alcohol intake have lower 
cardiovascular morbidity and mortality than abstainers (Costanzo et al., 2010; 
Ronksley et al., 2011). For example, one meta-analysis of 84 prospective cohort 
studies (n>1m) found, in a dose-response analysis, that the equivalent of less 
one drink a day (2.5-14.9g/day) was associated with a significant reduction in 
CVD mortality, CHD incidence and mortality, and stroke incidence and mortality 
by between 14-25% when compared to those who consumed no alcohol. 
However, the risks for all outcomes did also increase as alcohol consumption 
increased, particularly for stroke (Ronksley et al., 2011). A similar reduction in 
cardiovascular mortality was observed in a further dose-dependent meta-
analysis, where the lowest risk was observed in patients whose daily 
consumption was 5-10g/day in both primary and secondary prevention 
populations (Costanzo et al., 2010).  
However, the shape of this relationship may be explained due to methodological 
issues arising from the use of observational data, particularly the risk of reverse 
causality. People who do not drink may not do so due to the presence of pre-
existing ill-health which may also elevate their cardiovascular risk, resulting in a 
higher observed rate of cardiovascular events in abstainers (Shaper, 
Wannamethee and Walker, 1988). Furthermore, a Mendelian randomisation 
found that some genetic variations associated with reduced alcohol intake were 
also associated with a more favourable combination of cardiovascular risk 
factors (Holmes et al., 2014). As a result, current Scottish guidelines recommend 
that all patients irrespective of their current alcohol consumption should be 
advised to reduce theirs to decrease their CVD risk (SIGN, 2017), whilst other 
guidelines suggest that consumption should not exceed recommended levels 
(NICE, 2014; Mach et al., 2020).  
1.2.3.3 Psychological Factors 
The perception that psychological stress can contribute to the development of 
CVD is prevalent amongst both cardiac patients and the general public. 
However, reasonable uncertainty exists as to the exact nature of its role in the 
development of CVD, which is likely exacerbated by a lack of universal definition 
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and measurement standards in individuals. This makes the impact of stress on a 
patient’s cardiovascular risk difficult to quantify (Bunker et al., 2003). Despite 
this, common consequences of prolonged stress are depression and anxiety 
(Bunker et al., 2003), and both have been shown to be associated with an 
increased CVD risk (Bunker et al., 2003; Batelaan et al., 2016).  
In depression, a review of systematic reviews found a dose-response relationship 
between the severity of a patient’s depression and the increased risk of 
developing CHD, independent of many conventional risk factors. Furthermore, 
social isolation, which is commonly associated with depression, also 
demonstrated a similar dose-response relationship with CHD mortality (Bunker et 
al., 2003). However, treating a patient’s depression has not been shown to 
reduce their CVD risk, and as such, it is advised that greater emphasis should be 
placed on treating the conventional risk factors for CVD that are likely to be co-
existing in these patients (Carney et al., 2004).  
Anxiety has also been shown to be an independent risk factor for CVD in a meta-
analysis of over 1.5 million individuals, with a hazard ratio of 1.52. This hazard 
ratio remained statistically significant and broadly similar following adjustment 
for suspected high publication bias, comorbid depression, and multiple CVD risk 
factors (hazard ratios: 1.41, 1.57, and 1.50 respectively). However, given that 
psychotropic medication use can also elevate an individual’s cardiovascular risk 
and few of the included studies adjusted for this, it is possible that the true 
effect of anxiety on a patient’s CVD risk may have been inflated in this analysis 
(Batelaan et al., 2016).  
Nonetheless, whilst there may not be sufficient cause to include psychological 
wellbeing indicators as part of risk score calculators, some guidelines 
recommend that a patient’s depression, anxiety, and social isolation should be 
considered in combination with this score when assessing their cardiovascular 
risk (Piepoli et al., 2016; SIGN, 2017; Mach et al., 2020).  
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1.3 Current Management of Established Cardiovascular 
Disease  
As much of this thesis will involve the analysis of a cohort derived from the NHS 
Greater Glasgow and Clyde Safe Haven (as outlined later in Chapter 1.8), all 
sections from Chapter 1.3.3 onwards will take a closer look at the current 
Scottish Guidelines. These are produced by the Scottish Intercollegiate 
Guidelines Network (SIGN), and the principal guideline of interest is the 
guideline for the risk estimation and prevention of cardiovascular disease (SIGN 
149). However, the initial subsections will focus on the medications used within 
the management of cardiovascular disease more generally.   
Regardless of their overall risk, all patients should be encouraged to make 
lifestyle changes to lower their risk of CVD further. For example, unhealthy diet, 
physical inactivity with or without increased body mass index (BMI), smoking, 
and high alcohol consumption (all discussed in Chapter 1.2) are examples of 
established lifestyle risk factors. Consequently, advice that may be given to the 
patient would therefore include a Mediterranean diet and an increase in physical 
activity, the cessation of cigarette smoking, and a reduction in alcohol 
consumption, respectively. 
1.3.1 Use of Lipid-Lowering Medication in Cardiovascular Disease  
Given the evidence of the association between LDL cholesterol and 
cardiovascular risk, lipid-lowering therapies are often prescribed to individuals 
to reduce that risk, with statins forming the principal choice in both primary and 
secondary prevention (World Health Organization, 2017b). Statins work by 
inhibiting the 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity, which 
forms an important part in the synthesis of cholesterol in the liver. This results 
in an increased LDL receptor expression in the liver, leading to a greater amount 
of LDL cholesterol being removed from the patient’s blood (Ward, Watts and 
Eckel, 2019). 
There is a strong evidence base for the use of statins to reduce the risk of 
cardiovascular events. One meta-analysis of 26 double-blinded RCTs, which 
included over 170,000 patients showed a significant reduction in many clinical 
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outcomes in those randomised to receive statins. This reduction was present 
regardless of baseline risk (including primary and secondary prevention), and a 
greater, but proportional, reduction was observed as the intensity of the statin 
was increased. When compared to those treated with placebo, those treated 
with statins were 21% (95% CI: 0.77-0.81, p<0.0001) less likely to experience a 
major vascular event per 1mmol/l reduction in LDL cholesterol. This reduction 
of cholesterol is attainable for many patients, as the average reduction in LDL 
cholesterol in the meta-analysis in the first year of statin treatment was 
1.07mmol/l (Cholesterol Treatment Trialists’ (CTT) Collaboration, 2010). 
However, as risk reductions are relative, those at a higher risk of a 
cardiovascular event have the greatest potential benefit from treatment. In 
addition, no lower limit has been identified where cholesterol lowering is not 
beneficial to CVD risk (Cholesterol Treatment Trialists’ (CTT) Collaborators, 
2012). For this reason, current and previous guidelines recommend statin 
therapy to those considered at high risk (regardless of cholesterol), with more 
intensive doses recommended for those with established disease and greatest 
overall risk (SIGN, 2007, 2017). 
One of the studies included in the above meta-analysis was the West of Scotland 
Coronary Prevention Study (WOSCOPS), the first large endpoint trial of statins in 
primary prevention. This recruited 6,500 men aged 45-64 years who were 
randomised to receive either placebo or pravastatin 40mg over an average 
follow up period of five years. All patients were considered to be in the primary 
prevention population, but 5% had been diagnosed with angina and therefore 
had established CVD (The WOSCOPS Study Group, 1995). LDL cholesterol was 
lowered by just over 1mmol/l in the pravastatin treatment group, compared to 
no change in the placebo group, putting the result in line with the other trials 
included in the Cholesterol Treatment Trialists’ meta-analysis (Shepherd et al., 
1995; Cholesterol Treatment Trialists’ (CTT) Collaboration, 2010). Furthermore, 
a 31% reduction in the risk of the composite endpoint, of non-fatal MI and death 
from coronary heart disease, was observed at five years in the treatment group. 
A significant reduction was also observed when each of the events was 
considered separately (Shepherd et al., 1995).  Following the completion of the 
trial, patients were transferred back to primary care, where those patients who 
had been in the treatment group continued to have a significantly lower risk of 
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mortality at both ten and twenty years after the end of the trial (Ford et al., 
2007, 2016), even though less than two fifths were on statins in the five years 
after the trial completion (Ford et al., 2007). 
There is strong evidence suggesting that statins are largely considered to be 
safe, with minor muscle discomfort being the most commonly reported adverse 
effect of their use, which is resolved with the discontinuation of treatment 
(Collins et al., 2016). Other adverse effects such as myopathy and haemorrhagic 
strokes are considered to be very rare. It is estimated that in 2,000 people 
treated for five years, there would be one new case of myopathy and up to two 
haemorrhagic strokes (Collins et al., 2016). One meta-analysis of RCTs also found 
that statins were associated with a small increase in absolute risk of developing 
diabetes (Sattar et al., 2010), with a second finding that this risk is associated 
with the dose intensity of the statin (Preiss et al., 2011). However, recently 
published guidelines conclude that the cardiovascular benefits of statins exceed 
this risk and therefore should continue to be prescribed as the principal lipid-
lowering therapy (SIGN, 2017; Grundy et al., 2019; Mach et al., 2020). 
Despite this, some patients will be unable to tolerate their side effects, statins 
will be contraindicated, or an insufficient reduction in LDL cholesterol will be 
observed on the patient’s maximum tolerated dose. Other lipid-lowering 
therapies are also recommended by many guidelines either to be used as an 
alternative to, or in combination with, statins. These include ezetimibe, and, 
more recently, PCSK9 inhibitors. Fibrates and nicotinic acids are no longer 
commonly routinely recommended as alternative lipid-lowering medications 
(SIGN, 2017; Grundy et al., 2019; Mach et al., 2020). 
1.3.2 Other Medications Prescribed in Cardiovascular Disease 
Further classes of medication have also been effective at reducing the incidence 
of CVD. This is due to the decrease in the impact of known risk factors, 
specifically high blood pressure and the formation of blood clots. Whilst 
hypertension can be treated in both the primary and secondary prevention of 
CVD (Piepoli et al., 2016; SIGN, 2017; Whelton et al., 2018; NICE, 2019a), 
antithrombotic treatment is typically only recommended for those with 
established disease (Piepoli et al., 2016; SIGN, 2017; Arnett et al., 2019). 
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However, unlike cholesterol where no lower limit has been identified 
(Cholesterol Treatment Trialists’ (CTT) Collaborators, 2012), it is possible to 
lower blood pressure, and thin blood, too far which can result in unwanted and 
potentially fatal adverse events. 
For hypertension, thresholds for intervention with anti-hypertensive therapies 
and treatment targets are provided by current guidelines (Piepoli et al., 2016; 
SIGN, 2017; Whelton et al., 2018; NICE, 2019a). In the UK, medications should 
be prescribed according to the British Hypertension Society algorithm (as shown 
in Figure 1.3), which provides the order that the medications should be 
considered in patients with hypertension (SIGN, 2017; NICE, 2019a). However, if 
a patient has experienced an acute MI, then they should be offered an 
Angiotensin-Converting Enzyme (ACE) inhibitor or an Angiotensin II Receptor 
Blocker (ARB) regardless of their blood pressure, in addition to a beta-blocker 
(NICE, 2013; World Health Organization, 2017b). Furthermore, in Scotland, 
patients who have had a stroke or TIA should also be offered anti-hypertensives 
even if they are not hypertensive (SIGN, 2017). 
 
Figure 1.3: British Hypertension Society Algorithm for the use of antihypertensives (NICE, 
2019b) 
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Antithrombotic therapy in established CVD consists of antiplatelets and 
anticoagulants which are not generally co-prescribed due to elevated bleeding 
risks. For most patients in this population, aspirin should be prescribed with 
clopidogrel (or other P2Y12 inhibitor) considered in patients where this is not 
tolerated or contraindicated. However, there is some variation between 
guideline bodies as to which patients with established disease should receive 
solely aspirin and which should receive dual antiplatelet therapy. There is a 
wider consensus that in patients with stroke or TIA, dual antiplatelet (such as 
clopidogrel or aspirin in combination with dipyridamole) therapy should be 
offered (Levine et al., 2016; Piepoli et al., 2016; SIGN, 2017). For those patients 
who also have atrial fibrillation, anticoagulants should be prescribed, although 
care should be taken to avoid interactions with other medications (including 
antiplatelet medications) that are co-prescribed to minimise bleeding risk (SIGN, 
2013; Levine et al., 2016). Finally, due to the associated risk of serious bleeding, 
antiplatelet therapy is not recommended in the primary prevention population 
(Piepoli et al., 2016; SIGN, 2017; Arnett et al., 2019). 
1.3.3 Management of High-Risk Individuals under Current 
Scottish Guidelines 
Regardless of their baseline plasma lipid levels, patients classified as high risk 
are typically offered drug treatment, conventionally statins, to lower this 
further, with the expectation that this will reduce non-HDL cholesterol by 
1mmol/l or 40%. However, this should not be used as a treatment target, but 
rather a measure to check a patient’s adherence following the initiation of 
treatment. In cases where the patient is also experiencing hypertension, blood 
pressure lowering therapy should also be offered (SIGN, 2017).  
Assessing and identifying those at high risk of an event is not the only aim of the 
guideline, however. Once identified, a patient should be monitored to see if 
interventions have been successful in reducing risk factors, with the aim of 
preventing such events from occurring. Patients considered at low risk should be 
reviewed every five years, with patients at high risk reviewed annually as part of 
good practice (SIGN, 2017). These annual reviews should be considered to 
“discuss lifestyle modification, medicines adherence and address CVD risk 
factors” (SIGN, 2017, p. 15). 
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Given plasma lipid levels are a known risk factor for disease, it is therefore likely 
that a clinician will recommend blood tests to ascertain the effectiveness of the 
treatment, and potentially use the results as a starting point when discussing the 
patient’s adherence to their current treatment regimen, or the potential 
introduction of further treatment. Furthermore, the guidelines subsequently 
provide an expected reduction: a 40% reduction in non-HDL cholesterol or a 1 
mmol/l reduction in non-HDL, in cases where the former is unattainable (SIGN, 
2017). As these suggested aims are provided, this could further facilitate the use 
of blood test results as part of a patient’s annual review. 
1.3.4 Comparison with Previous SIGN Guidelines 
Prior to the current (2017) guidelines, the previous SIGN guidelines were 
published in 2007. The definition of the high-risk population stayed broadly 
similar between the two. However, in 2007, patients with stage 3 or higher CKD, 
micro- or macro-albuminuria, or diabetes and under the age of 40 (with 
additional risk factors) were not considered to be automatically at high risk. 
Annual monitoring in this population was still encouraged in the prior guideline, 
as was monitoring every five years in those considered to be at low risk. Indeed, 
all recommendations for the low-risk population remained identical between the 
two guidelines, with only levels of supporting evidence altering (SIGN, 2007, 
2017).  
Recommended medications have altered slightly. With respect to statins, high-
risk patients should have been offered a statin since the 2007 guidelines. In 
2007, simvastatin 40mg was the recommended drug and dose for those at high 
risk, with more intensive therapy considered for those with established disease 
(though the specific medication is not detailed). In 2017, atorvastatin is the 
recommended drug, with 80mg for secondary prevention and 20mg for primary 
prevention patients.  
In 2007, aspirin 75mg should have been considered for all at high risk but offered 
to those with diabetes and over 50 years of age or with additional risk factors. In 
2017, aspirin is only recommended for those with established disease. The same 
medications and doses of anticoagulants are recommended for stroke patients in 
both guidelines (SIGN, 2007, 2017).   
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There are also some differences in blood pressure recommendations, but the 
target for the high-risk population remained at 140/90mmHg. In patients with 
diabetes, those with a blood pressure higher than 130/80mmHg should have 
been considered for treatment, though in the current guidelines this is revised. 
In the current guidelines, if the systolic blood pressure is above 140mmHg then 
treatment should be offered; if it is less than 140mmHg then treatment should 
be considered, with a treatment target of 135/85mmHg. The same target is 
provided for patients with CKD or micro- or macro-albuminuria, and in patients 
with a history of stroke, antihypertensives should be prescribed even if their 
blood pressure is normal (SIGN, 2007, 2017). 
1.3.5 Differences with NICE Guidelines 
These SIGN recommendations are broadly in line with the recommendations 
published by the National Institute for Health and Care Excellence (NICE). In the 
case of low-risk patients, these recommendations are similar, with both 
recommending five yearly reviews (NICE, 2014; SIGN, 2017). The identification 
of those subgroups automatically considered high risk is also similar, with only 
real differences occurring regarding individuals with diabetes mellitus. In 
patients with Type 1 diabetes, both guidelines identify people over the age of 40 
years as high risk, but under the age of 40, there are differences regarding the 
duration of disease which constitutes high risk, 10 years in the case of NICE, 
compared to 20 years in SIGN. For those patients with Type 2 diabetes, SIGN has 
the same recommendations as Type 1, but for the NICE 2014 recommendations, 
the patient’s risk should be assessed using the most recent QRISK risk calculator 
(NICE, 2014; SIGN, 2017). Perhaps the largest differences between the two 
guidelines are the recommended risk calculators and the thresholds used to 
define high risk. In Scotland, a patient’s risk is calculated using the ASSIGN tool 
and they are considered high risk if their 10 year risk of an event is greater than 
20%, whereas NICE defines a patient as being at high risk if their risk exceeds 
10% using the most recent QRISK tool (NICE, 2014; SIGN, 2017).  
When it comes to high-risk populations, lipid-lowering therapy, preferably 
statins, is also recommended by NICE, together with an annual review for each 
patient (NICE, 2014). NICE specify only that such a review should include the 
topic of the patient’s adherence to medication but go onto state that a fasting 
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non-HDL cholesterol blood result could be used to assist with this aspect. Both 
guidelines have the same anticipated reduction in cholesterol to assess the 
effectiveness and patient’s adherence to medication: a 40% reduction in non-
HDL cholesterol from a non-medicated baseline, although SIGN additionally 
provides a supplementary guide reduction of 1mmol/l, and both values are only 
expectations and not targets (NICE, 2014; SIGN, 2017).  
1.4 Adherence to Recommended Medications 
1.4.1 Approaches to Assessing Adherence 
Medication adherence has been defined by Osterberg and Blaschke (2005) as 
“the extent to which patients take medications as prescribed by their 
healthcare providers”, with methods used to assess adherence divided into two 
categories: direct and indirect (Osterberg and Blaschke, 2005). This differs from 
medication persistence, which is the duration that a medication is taken by an 
adherent patient without a break (Ho, Bryson and Rumsfeld, 2009; Ryan et al., 
2017). 
Direct methods of measuring adherence include the act of physically observing 
the patients taking the medication, as well as the measuring of the levels of 
medicine, its metabolites, or an associated biological marker in the patient’s 
blood or urine at regular intervals. In contrast, indirect methods often rely on 
patient self-reporting of their adherence, pill counting, or the use of electronic 
prescription data (Osterberg and Blaschke, 2005). None of these methods are 
without their disadvantages, though, and as a result, there is no gold standard 
method of assessing adherence (Osterberg and Blaschke, 2005; Ho, Bryson and 
Rumsfeld, 2009; Brown et al., 2016; Stephenson et al., 2018). 
Whilst direct methods are generally thought to be more robust than indirect 
methods, they cannot be implemented easily within routine clinical practice 
(Osterberg and Blaschke, 2005). This is largely due to the costs of the more 
intensive monitoring and testing, as well as the higher patient burdens (Ho, 
Bryson and Rumsfeld, 2009). Additionally, for methods involving blood samples, 
the timing of doses, especially for medications with shorter half-lives, can make 
their detection within the blood challenging (Ryan et al., 2017; Sutherland et 
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al., 2018). Furthermore, if patients are informed that such a test is going to 
occur this has been shown to result in higher adherence within the samples 
collected (Sutherland et al., 2018). This effect has also been documented within 
the literature as “white coat adherence”, whereby patients restart medications 
just before their review appointments (Brown et al., 2016; Ryan et al., 2017). 
One approach to reducing such a bias would be to introduce random blood tests 
within a population, but this would be difficult to implement in clinical practice 
and as a result has largely been confined to drugs of abuse (Ryan et al., 2017).   
Observer effects, however, are not confined to direct methods of estimation and 
are also likely when using indirect methods, specifically those involving patient-
reported adherence (Osterberg and Blaschke, 2005; Ho, Bryson and Rumsfeld, 
2009; Brown et al., 2016). For example, when pill counting methods are utilised, 
patients may discard pills to appear more adherent, and when medication 
diaries are used, both inaccurate recall and social desirability bias are likely to 
lead to overestimation (Ho, Bryson and Rumsfeld, 2009). Nonetheless, one study 
looking at the adherence of anticoagulants in non-valvular atrial fibrillation 
found that patient-reported adherence (captured through four validated 
questionnaires over a year) was lower than the adherence derived from 
electronic health records. One explanation for this discrepancy is that the 
questionnaires reflected a patient’s adherence in the recent run-up to its 
completion, whereas the electronic health record data reflected their adherence 
throughout the year. Furthermore, the associated reduction in healthcare costs 
with the adherence estimated from the health records was larger than with 
patient-reported adherence (Stephenson et al., 2018).   
Electronic prescription data, which can be divided into two distinct types 
(prescribing and dispensing), is less susceptible to the biases discussed and often 
more easily applicable to routine clinical practice or larger trial populations 
(Brown et al., 2016). Prescribing data, which is available in the Clinical Practice 
Research Datalink (CPRD), includes all prescriptions that have been written by 
healthcare professionals (Herrett et al., 2015). This allows the identification of 
patients who should be in possession of medication but does not indicate 
whether the medication was ever dispensed by the pharmacy and collected by 
the patient. Therefore, this data allows the analysis of healthcare professionals’ 
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prescribing patterns but can also result in adherence overestimation. In 
contrast, dispensing data, which is available in the Scottish National Prescribing 
Information System (PIS), includes all prescriptions that have been dispensed 
(and encashed, in the case of PIS) (Information Services Division, 2010). As a 
result, it can be inferred that the patient is in possession of the medication. 
However, like prescribing methods, adherence could be overestimated in 
patients who receive their medication but do not take it and is particularly likely 
where medication is automatically dispensed at weekly or monthly time 
intervals. Furthermore, the size of populations which may be identified through 
prescription records, such as the primary prevention population for CVD, could 
be underestimated (Sutherland et al., 2018). 
Using either type of prescription refill data, the medication possession ratio 
(MPR) and the proportion of days covered (PDC) are two of the most widely 
applied methods to estimate a patient’s adherence, with no gold standard 
method identified, and often differences in the specific calculations of the 
estimates reported (Krueger et al., 2018). The MPR is principally the total 
number of doses prescribed in a time window divided by the number of doses 
that should have been administered in a time window and can therefore give 
values greater than one if early refilling has occurred between prescriptions. In 
contrast, the PDC, whilst similar, ignores any overlaps that may occur between 
prescriptions and as a result is truncated at the value of one (Ho, Bryson and 
Rumsfeld, 2009; Krueger et al., 2018). However, these measures can only be 
applied in closed pharmacy systems (Osterberg and Blaschke, 2005; Ho, Bryson 
and Rumsfeld, 2009). Furthermore, underestimation can arise in situations 
where electronic health records are not complete. For example, one study from 
the US found that in 1,000 patients randomly sampled from routine clinical care, 
the proportion who had matching electronic health records with the medications 
detected within their blood was less than half (Sutherland et al., 2018). 
Nonetheless, these methods only allow clinicians to gauge if a patient is in 
possession of the medication and not whether they are taking it correctly or, 
indeed, at all (Ho, Bryson and Rumsfeld, 2009).  
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1.4.2 Adherence to Cardiovascular Medications 
Patients with chronic diseases are less likely to be adherent to their medication, 
especially if the disease of interest is asymptomatic, when compared to those 
receiving short-term prescriptions for symptomatic conditions. Therefore, as 
lipid-lowering medications should be prescribed to patients indefinitely and, in 
primary prevention, the patient has experienced no symptoms of high 
cholesterol, non-adherence to their medication is increasingly likely as the time 
from first administration increases (Ho, Bryson and Rumsfeld, 2009). In 
secondary prevention, adherence to all cardiovascular medications has been 
found to be significantly higher than in primary prevention (Naderi, Bestwick and 
Wald, 2012). Furthermore, two meta-analyses of prospective studies identified 
no substantial differences in adherence between the classes of medication 
prescribed to secondary prevention patients (Naderi, Bestwick and Wald, 2012; 
Chowdhury et al., 2013). This may suggest that, especially in clinical scenarios 
where polypharmacy is recommended, non-adherence may not be as a 
consequence of a specific medication, rather as a result of patient or condition 
factors. 
Estimates of the proportion of patients adhering to statin medication vary 
between 54% and 71%, with adherence rates decreasing as the length of follow 
up increases (Naderi, Bestwick and Wald, 2012; Chowdhury et al., 2013; Chen et 
al., 2019). This rate of decrease was examined more closely in over 150,000 
patients with established CVD in the Taiwan National Health Insurance database 
between 2006 and 2012. It was found that although adherence did decrease over 
the seven years, the largest decrease was in the first year after statin initiation, 
with the rate nearly plateauing between years three and six of follow up (Chen 
et al., 2019). This pattern has also been observed in secondary and primary 
prevention populations in the UK and Finland (Nordstrom et al., 2015; Lavikainen 
et al., 2016).  
Characterising patients who are likely to not adhere to their medication is not 
straightforward. However, non-adherence to cardiovascular medication has been 
consistently associated with being female (Vupputuri et al., 2016; Rodriguez et 
al., 2017; Chen et al., 2019; Hope et al., 2019) and not white (Vupputuri et al., 
2016; Rodriguez et al., 2017; Hope et al., 2019). The relationship with age is 
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also consistently observed in the literature but not a linear association. Younger 
and older patients are more likely to be non-adherent (Vupputuri et al., 2016; 
Rodriguez et al., 2017; Chen et al., 2019; Hope et al., 2019), with adherence 
peaking at approximately 65 years of age (Hope et al., 2019). Additionally, it is 
not just the patient’s characteristics that have been shown to influence a 
patient’s adherence. Statin prescriptions issued by a cardiologist and further 
appointments with a cardiologist have also been associated with increased 
adherence to medication (Vupputuri et al., 2016; Chen et al., 2019). 
The patient’s number of comorbidities or other prescriptions and their 
association with adherence is not clear (Hope et al., 2019). Patients with 
depression (Chen et al., 2019; Hope et al., 2019), renal impairment, liver 
damage, and COPD (Chen et al., 2019) are less likely to be adherent to statin 
medication, whilst patients with hypertension and diabetes are more likely 
(Hope et al., 2019). However, the use of insulin has been associated with non-
adherence (Chen et al., 2019), suggesting the relationship between adherence 
and diabetes is more complex, especially as patients with diabetes have been 
shown to be more likely to achieve the guideline-recommended cholesterol 
targets (Danese et al., 2017).  
1.4.3 Impact of Adherence on Guideline Targets and Patient 
Outcomes 
Cardiovascular medication adherence and the achieving of LDL cholesterol 
targets have been examined in CPRD, a primary care database from selected GP 
practices across the UK, by Danese et al (2017). Over 24,000 patients were 
identified following a hospitalisation with a cardiovascular event, with 
prescriptions for lipid-lowering medications (LLMs) issued in the preceding six 
months. At twelve months following the event, the percentage of patients 
achieving an LDL cholesterol result <1.8mmol/l increased from pre-event levels 
(by 5-9%), with patients with diabetes more likely to reach the target than those 
without. Adherence, defined as >80% MPR, was high, with over 70% adherent in 
the first year of follow up, although persistence (taking the medication without 
any breaks) with LLMs was considerably lower with only 50% achieving this 
(Danese et al., 2017). 
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Some of this increase in the achievement of targets is likely to be as a result of 
the increase of the intensity of the treatment following a cardiovascular event. 
Indeed, it was observed that between 12% and 16% of patients had the intensity 
of their statin therapy increased (which consisted of either a higher dose or a 
change to a more potent statin) following their event, with many others 
augmenting therapy with ezetimibe or fibrates (Danese et al., 2017). 
Nevertheless, an increase in the intensity of therapy alone is unlikely to increase 
the likelihood of achieving LDL targets in patients with poor adherence to 
medication. For example, in over 1,000 secondary prevention patients in 
Georgia, USA, those with adherence <50%, estimated with PDC, were at 88% 
greater risk of not achieving a reduction of 30% in LDL cholesterol (Vupputuri et 
al., 2016).  
However, an interaction between the intensity of therapy and adherence to 
therapy could seem plausible, particularly if the intensity of therapy is viewed as 
a surrogate measure for severity of illness. This has been found in both the 
primary and secondary prevention of CVD, with patients with higher numbers of 
comorbidities, or more severe comorbidities, likely to be adherent to LLM 
(Vupputuri et al., 2016; Danese et al., 2017; Hope et al., 2019). In contrast, in a 
primary prevention systematic review, whilst increased comorbidities were 
associated with an increased likelihood of being adherent, the intensity of statin 
was found to have a negative association, possibly as a result of the risk of 
adverse events (Hope et al., 2019). In secondary prevention populations though, 
the overall benefit of LLM may negate this. For example, Khunti et al (2018) 
used CPRD to examine 16,000 patients with established CVD and found that 
those prescribed higher intensity therapies were more likely to be adherent 
(Khunti et al., 2018).  
Furthermore, higher adherence to LLM has been associated with a decreased 
likelihood of cardiovascular events. In patients with established CVD, a 10% 
increase in adherence was found to be associated with a 5% reduction in the risk 
of the patient experiencing further events (Khunti et al., 2018). This was also 
shown in the reduction of the risk of stroke in a meta-analysis of primary and 
secondary prevention populations (n>700,000 patients), where a 20% increase in 
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adherence was associated with an 8% lower risk of any stroke (ischaemic or 
haemorrhagic) (Xu et al., 2017). 
Overall, there is some evidence to suggest that many patients who are adherent 
in the first year remain so beyond this. In one study of >60,000 established CVD 
patients in CPRD, 71.3% were adherent (MPR >80%) two years after diagnosis, 
down from 74.8% at the end of the first year (Nordstrom et al., 2015). This 
pattern has also been observed in a primary prevention population in Finland 
(n>40,000), where 63.8% of those who were adherent (PDC >80%) in the first 
year of treatment, remained so for three years. This pattern was stronger in 
non-adherers, where 73.7% of those who were non-adherent in the first year, 
were non-adherent for the three years of follow up (Lavikainen et al., 2016). 
This would suggest that few patients alternate between being adherent and non-
adherent to LLMs, with higher rates of discontinuation most likely in the first 
year of follow up. Therefore, non-adherence may pose a greater problem in 
secondary prevention populations where there is a greater risk of further 
cardiovascular events in the first year after an event (Khunti et al., 2018).  
1.5 Developments within the IT Structure in the NHS 
1.5.1 Linkage of Routine Healthcare Data 
Extensive quantities of healthcare and demographic data are collected routinely 
within various parts of the NHS. When these sources are linked together they can 
prove hugely beneficial for research, with various projects demonstrating the 
potential impact that routine linked data could have for both the patients and 
the health service (Barker et al., 2018; The Health Foundation, 2018; Lloyd et 
al., 2019). For example, when a survey of the confidence in patients to manage 
their chronic conditions was linked with primary and secondary care data, it 
revealed that those more confident had a lower usage of health services, 
including Accident and Emergency admissions (Barker et al., 2018). In a separate 
project, the identification of patients living in care homes from GP records 
facilitated the introduction of enhanced care packages which subsequently 
reduced the number of recipients’ emergency admissions to hospital (Lloyd et 
al., 2019). Routine healthcare data linkage can also facilitate longer and 
accurate follow up periods for studies relatively inexpensively, and with minimal 
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impact on the participants. Furthermore, when multiple sources of routine 
healthcare data are linked to create a patient’s electronic health record, their 
engagement with various healthcare services can also be easily followed (NHS 
Research Scotland, 2015a; Wellcome Trust, 2015).  
With these benefits identified, there is a growing aspiration to implement 
linkage between health record datasets routinely, such as through the Integrated 
Care Programmes in England. This not only aims to improve care decisions 
through the consistent sharing of health data, but also aims to enable the 
development of system interface standards, resulting in the standardisation of 
electronic health records and, consequently, improving the consistency of 
recording between partnerships (NHS Digital, 2018).  
1.5.2 Information Contained within NHS Scotland Data 
 
Figure 1.4: Health Data Captured Across the Lifespan in Scotland and the associated 
datasets (NHS Research Scotland, 2015a) 
In Scotland, data linkage between a patient’s health records from different 
services is made possible using a patient’s Community Health Index (CHI) 
number. This is entered in the capture of all health-related activities for the 
individual including prescriptions and test results, as well as all appointments 
and surgeries. The exact repositories where this information from across an 
individual’s life span is stored is shown in Figure 1.4. As a result of this linkage 
capability, rigorous anonymisation, and complete population coverage, health 
and biomedical research on this data is common (NHS Research Scotland, 
2015a). Access to such data for research purposes is usually provided through 
data safe havens, which are available for regions of Scotland and nationally. 
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These provide secure, confidential, and non-identifiable access to such datasets 
to trained researchers and allow linkages between health and non-health data 
for analysis (NHS Research Scotland, 2015b).  
For clinical practice, NHS Scotland produced an eHealth Strategy for 2014-2017, 
and developed Scotland’s Digital Health and Care Strategy in 2018 (The Scottish 
Government, 2015, 2018). This original strategy provided an update on the 
current progress and modified vision towards the streamlining of the various 
components of a patient’s electronic health record, with the goal of combining 
the information and making it available in one portal, with a parallel system 
available for patients to view their data. It is hoped that this would ultimately 
include all interactions between a patient and the health and social care 
services, and in the required level of detail for the professional accessing it. It 
was anticipated that this would be achieved by 2020 (The Scottish Government, 
2015).  
1.6 Plasma Lipid Testing   
1.6.1 Incidence and Costs of Testing 
In 2010, a review for the Department of Health estimated that tests in patients 
for chronic diseases, including CVD, accounted for 50% of all pathology work in 
the UK (Department of Health, 2010), with the number of tests requested 
increasing on an annual basis (Smellie, 2012; O’Sullivan et al., 2018). In an 
analysis of more than 250 million tests in 11 million patients from the CPRD 
database between April 2000 and March 2016, the age and sex-adjusted rate of 
laboratory testing increased by an average of 8.7% annually, with 44,847 tests 
per 10,000 person-years in 2015/16 (O’Sullivan et al., 2018). This is broadly 
comparable to an estimate from a 2004 survey of UK laboratories which reported 
an annual rise of 10% in workload over the preceding three years, with the 
majority of this rise accounted for by primary care workload (Smellie, 2012).  
The increasing number of tests cannot be completely accounted for by an 
increase in patient numbers. Indeed, in the analysis of testing patterns in CPRD, 
an increasingly greater proportion of tests were ordered for fewer patients, with 
32.7% of tests ordered for patients with more than 10 tests annually in 2015/16 
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compared to just 9.5% in 2000/01. The Quality Outcomes Framework (QOF), 
which ran between 2004/5 and 2015/6 in Scotland, but continues in other parts 
of the UK, and incentivised the monitoring of those with chronic diseases may 
partially explain this. Tests included in the QOF had a higher average annual 
percentage increase than those not included in the QOF (9.8% vs 7.4%). 
However, in terms of CVD, despite lipid tests being included in QOF, their annual 
percentage testing increase was lower than other QOF tests (6.6%). 
Furthermore, the annual rate of testing over the sixteen years showed an 
increase in testing rate which then decreased resulting in an inverted U-shaped 
temporal trend in the number of tests performed each year (O’Sullivan et al., 
2018).  
Whilst an individual test has been conservatively estimated to cost 
approximately £6 including some direct staff and processing costs (National 
Institute for Health and Care Excellence, 2015), the volume of tests being 
conducted represents a significant expenditure within the NHS, with estimates 
of £1.8 billion for all laboratory testing in 2015/16, not including administrative 
and reviewing costs (O’Sullivan et al., 2018). 
The burden of an increase in testing is not solely a financial one and will also 
have a substantial impact on primary care workload, both in terms of 
consultation time and the associated administration. For example, one study 
estimated that if each test result took two to three minutes to be reviewed, this 
would translate to up to two hours a day (O’Sullivan et al., 2018), without 
considering the time needed for any follow up consultations with patients. This 
is broadly in line with Thompson and Walter (2016) who, using data from the 
Eighth National GP Worklife Survey in 2015 (Gibson et al., 2015), estimated that 
work outside of consultation hours was responsible for an additional eight or 
more hours for an average GP a week (Thompson and Walter, 2016). 
Furthermore, the number and duration of consultations also increased 
significantly between 2007 and 2014 (by 10.5% and 6.7% respectively), leading to 
a workload increase equivalent to 16% over the seven years for GPs (Hobbs et 
al., 2016). This has led to widespread and justified beliefs that workload in 
primary care is increasing unsustainably, resulting in difficulties in the 
recruitment and retention of staff, burnout, and concerns that the problem will 
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continue to worsen as the populations grows and ages (Hobbs et al., 2016; 
Thompson and Walter, 2016). 
1.6.2 Inappropriate Lipid Testing (Over and Under) 
As numbers of laboratory tests conducted are consistently shown to be 
increasing annually and carry with them a significant associated burden on the 
health service (O’Sullivan et al., 2018), the question as to the necessity and 
appropriateness of the testing is raised. However, the definition of an 
inappropriate lipid test is not universal within the literature, and many authors 
argue that the absence of the clinical context for a test in databases used for 
such analysis may have resulted in its misclassification. As a result, estimates of 
the proportion of inappropriate testing in lipids ranges from 10-42%, with 
definitions of an inappropriate test focussing on the frequency and intervals 
between repeated tests (Doll et al., 2011; Morgen and Naugler, 2015; Chami et 
al., 2017; Hajati et al., 2018).  
Two analyses from Canada both defined a lipid test as inappropriate if it took 
place within three months of another test, in line with the recommendations in 
the Canadian guidelines, and reported similar results (Morgen and Naugler, 2015; 
Chami et al., 2017). Chami et al (2017) looked at 4.6 million lipid tests in 3.5 
million patients from the Ontario Health Insurance plan between 2006 and 2010 
and found that 10.2% of tests appeared to be inappropriate, with 9.2% of 
patients having at least one inappropriate test in the period (Chami et al., 
2017). Meanwhile, an analysis of 100,000 randomly selected patients in the 
laboratory services data in Calgary in 2010 who were followed up for a year 
reported that 10.5% of tests were inappropriately repeated within 12 weeks of 
an earlier test, and after 6.5 months a quarter of the population had been 
retested (Morgen and Naugler, 2015).  
However, in the UK, guidelines recommend monitoring cholesterol levels in high-
risk patients annually (NICE, 2014; SIGN, 2017), rather than quarterly as was 
assumed by Morgen and Naugler (2015) and Chami et al (2017). An analysis of 1.6 
million tests from a subset of the Medicare Benefits Schedule in Australia from 
2008 to 2014 defined more than one HDL cholesterol test per year to be 
unnecessary. This revealed a slight but steady decrease in the proportion of 
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over-testing during the seven years (20.8% to 16.9%) but estimated that the 
economic burden of this testing was approximately $A4.3 million each year. 
Furthermore, whilst more tests may be necessary following the commencement 
of adjustment of lipid-lowering medication, Hajati et al (2018) only included 
patients who had reported a stable prescription, and therefore tests conducted 
for these purposes are unlikely to have been included in these estimates. 
Despite this, in a sensitivity analysis where the number of tests considered 
necessary was increased to two, 6% of tests remained unnecessary (Hajati et al., 
2018).  
Nonetheless, all of these estimates are considerably lower than estimates from a 
20-year period in Oxfordshire, which defined a test as unnecessary if more than 
three tests were reported within three years (i.e. more than annual), and found 
the rate to be increasing across the two decades with the highest rate of 42% 
observed in the final period between 2005 and 2007 (Doll et al., 2011). However, 
regardless as to which estimate or definition is used, it is clear that over-
utilisation could be contributing to the burden placed in the health system as 
the demand for testing continues to grow in primary care.  
Furthermore, whilst reducing the number of tests conducted more than those 
recommended, the guidelines may reduce the impact of such testing. One 
suggestion to further mitigate this could be to scale back the number of tests 
recommended in guidelines. Indeed, there is some evidence to suggest that this 
may already be happening. In Australia, it was found that in any given year 
between 2008 and 2014, nearly half of patients on stable lipid-lowering 
medication did not have their HDL cholesterol checked, and consequently, an 
estimated $A11 million was saved in laboratory expenditure (Hajati et al., 
2018). However, the reasons for these being missed were unknown (Hajati et al., 
2018), and the long-term consequences of this could ultimately have resulted in 
a greater burden for both the patients and the health service if opportunities 
were missed to reduce the potential number of cardiovascular events (Perera et 
al., 2015).  
As a result, a careful balancing act must be performed when deciding when a 
test is necessary. Testing patients too often can lead to an increased likelihood 
of misleading results due to biological variation in cholesterol levels within an 
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individual. This could result in potentially over- or under-treating patients 
(Perera et al., 2015), in addition to the resource implications discussed in 
Chapter 1.6.1. In contrast, testing too infrequently could increase the risk of 
cardiovascular events with a significant impact on families and the health 
service (Perera et al., 2015). In balancing these scenarios, a Health Technology 
Assessment funded by the National Institute for Health Research (NIHR) found 
that, for patients considered to be at high risk of CVD, annual reviews of lipid 
levels represented the optimal benefit-risk ratio (Perera et al., 2015), in line 
with the recommendation in current national guidelines (NICE, 2014; SIGN, 
2017). 
1.6.3 Implementation of Personalising Testing Schedules 
Whilst annual reviews may be optimal for the high-risk population as a whole, it 
is likely that there is a group of patients at each annual review for whom their 
lipid test result will not result in a change in the patient’s management of their 
cardiovascular risk. Therefore, the successful identification of these patients 
would allow the overall number of tests conducted to be reduced without 
increasing the number of cardiovascular events experienced within the 
population. Routinely collected data, such as a patient’s prescription collection 
records, their demographics, and their previous test results, which all form part 
of a patient’s electronic health record (Chapter 1.5.2), could all potentially 
facilitate the accurate identification of this sub-population at any given time.  
The idea of personalising monitoring schedules is not novel, but research has, 
thus far, largely been confined to screening programmes including diabetic 
retinopathy, and cancers such as cervical and breast. In the case of cervical 
cancer screening programmes, such approaches are in the early stages of 
development: one analysis sought to develop risk scores in patients with 
abnormalities detected (Kyrgiou et al., 2016), and another has attempted to 
devise a risk-stratification for all patients (Baltzer et al., 2017). Both, however, 
recognise that further research is needed before either could be implemented 
safely, be clinically useful, or cost-effective (Kyrgiou et al., 2016; Baltzer et al., 
2017). Within breast cancer, models have shown that personalised risk-
management is cost-effective and results in more favourable harm-benefit ratios 
through the reduced likelihood of false-positives and overestimation of cancer-
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incidence (Vilaprinyo et al., 2014; Pashayan et al., 2018). However, the 
accurate determination of an individual’s risk category, and their corresponding 
risks of overdiagnosis, remain key areas for further research before any 
widespread implementation is likely to be successful (Vilaprinyo et al., 2014; 
Román et al., 2017; Pashayan et al., 2018).  
In contrast, the literature seeking to personalise screening schedules for diabetic 
retinopathy is better established and has analysed large datasets in various 
countries, including Denmark (Aspelund et al., 2011), Scotland (Looker et al., 
2013), Wales (Thomas et al., 2012), and England (Eleuteri et al., 2017). The 
largest of these studies involved data from 150,000 patients over six years from 
the Scottish Diabetic Retinopathy Screening Programme, which found that, for 
patients with Type 2 diabetes, two consecutive clear scans were sufficient to 
recommend biennial screening with minimal additional risk (Looker et al., 2013). 
This was also supported by data from nearly 50,000 patients in Wales, where a 
clear scan in patients with Type 2 diabetes was found to be adequate evidence 
to extend the screening interval beyond the standard 12 months. However, it 
also reported that patients on insulin and with a duration of disease longer than 
ten years should continue with annual scans, irrespective of their previous scan 
result (Thomas et al., 2012).  
The accurate identification of those who could benefit from reduced monitoring 
is not the sole step in this process. Consideration also needs to be given towards 
the duration of the extended intervals that could be implemented safely without 
increasing the patients’ risks of negative outcomes. For example, in cervical 
screening, the introduction of the human papillomavirus vaccines and testing has 
led to the development of models derived from national screening programmes. 
These, in turn, have suggested that those with negative results could safely 
benefit from screening at reduced intervals from current guidelines, with 
comparable risks (Dijkstra et al., 2016; Bains et al., 2019).  
Meanwhile, in diabetic retinopathy, some models have looked at the effects of 
implementing a range of intervals depending on the calculated risks. Both the 
analysis of the Danish Diabetes database (Aspelund et al., 2011) and the 
Liverpool Diabetic Eye Screening Programme (Eleuteri et al., 2017) calculated a 
patient’s risk score and offered a range of screening intervals. Aspelund et al’s 
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(2011) risk score, developed using data from 5,000 Danish patients with 20 years 
of follow up, included several clinical predictors of retinopathy: type and 
duration of diabetes, HbA1c, blood pressure, and presence and grade of 
retinopathy at the previous scan. The corresponding risk score was then used to 
output a screening interval for the patient ranging between 6 months and 5 
years, with the average recommendation for the population between 2 and 2.5 
years (Aspelund et al., 2011). Similarly, Eleuteri et al (2017) recommended 
screening intervals of 6, 12, or 24 months based on their risk score which was 
derived from a 5 year follow up of approximately 12,000 patients in Liverpool. 
This score was calculated based on the duration of disease, HbA1c, systolic 
blood pressure, age, and total cholesterol (Eleuteri et al., 2017).  
The cost-effectiveness of any reduced monitoring schedule should also be 
considered, and within diabetic retinopathy, the predicted impact of such 
methods on resourcing varies between studies. For example, the Danish risk 
score corresponded to the greatest reduction in visits, at 59% (Aspelund et al., 
2011), whilst a simulation of UK data, where a clear scan was sufficient to 
extend the screening interval to two years, yielded a 25% reduction in costs and 
went on to suggest that such a transition was also safe and cost-effective (Chalk 
et al., 2012).  
However, a systematic review published in 2016, exercised caution concerning 
extending the screening interval for diabetic retinopathy, concluding that whilst 
there was a minimal difference in clinical outcomes for annual and biennial 
screening for low-risk patients, the poor quality of the evidence due to the 
experimental designs used limited the ability to draw reliable conclusions 
(Taylor-Phillips et al., 2016). Indeed, whilst Apselund et al’s (2011) algorithm 
has now been validated in many diabetes registers, concern has also been raised 
regarding missed opportunities (Van Der Heijden et al., 2014; Soto-Pedre, Pinies 
and Hernaez-Ortega, 2015; Lund et al., 2016). This is especially true for patients 
for whom longer screening intervals were recommended, where a patient’s risk 
profile could change substantially (McGhee, Harding and Wong, 2012). 
Therefore, when Lund et al (2016) validated this algorithm, a maximum of two 
years between screenings was used and resulted in a similar risk profile to 
annual screenings and a reduction in costs of 40%. This represented a reasonable 
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and cautious compromise towards reduced screening, with the authors reasoning 
that the risks could be further minimised if linked to real-time clinical records to 
detect changes in patients’ risk profiles (Lund et al., 2016).  
Nonetheless, further steps are also needed to validate the evidence for the safe 
implementation of reduced testing with the systematic review of the evidence 
strongly advocating the need for clinical trials in this area (Taylor-Phillips et al., 
2016), and one such trial has since been designed for the Eleuteri et al’s (2017) 
Liverpool risk score (Broadbent et al., 2019).   
1.7 Overall Summary  
Risk stratification of the population, using established risk factors, forms a 
crucial component of the clinical guidelines for the management and prevention 
of CVD. For those at high risk, lipid-lowering therapies, principally statins, are 
recommended, with other classes of medication including antihypertensives, 
anticoagulants, and antiplatelets also recommended for subpopulations of those 
at high risk where clinically indicated and the benefit-risk ratio is favourable. 
This current approach is broadly similar to the previous guidelines issued ten 
years prior. Despite a difference in threshold defining high risk (20% vs 10%), the 
guidelines are also comparable to those adopted by the rest of the UK.  
Medication represents a key component of the management of those at high risk, 
but, due to the chronic nature of CVD, long-term adherence can be difficult to 
achieve. Perhaps unsurprisingly, those with established disease are more likely 
to be adherent than those without, although, as in primary prevention, many 
patients discontinue their medication within the first few years of commencing 
it, thereby reducing the potential benefits. However, adherence to LLM has 
reassuringly been linked with an increased likelihood of achieving cholesterol 
targets, as well as reducing the likelihood of cardiovascular events and 
mortality. This confirms the clinical benefits of such medication and reinforces 
the need to encourage compliance among high-risk patients.  
Annual reviews with the patient, which are likely to include a lipid test, can be 
used as a mechanism to facilitate this, as are recommended by current 
guidelines. However, the number of tests is increasing year on year, as is the 
Chapter 1  74 
 
workload for GPs. Whilst some tests are likely occurring in excess of the 
guideline’s recommendations, it is plausible that for some patients the annual 
review would not improve their adherence or alter clinical decisions for their 
risk management. As a result, being able to identify such patients accurately 
could reduce the burden of such reviews in primary healthcare, and data 
captured within a patient’s electronic health record could be utilised to enable 
this.   
1.7.1 Current Gaps in the Literature 
Whilst many of the risk factors for CVD and the use of LLMs in managing 
patients’ risks are well-established, there are some areas within their prevention 
and risk management where the evidence is less conclusive. For example, the 
use of statins to lower a patient’s cholesterol is likely to be universal worldwide, 
but there has been a lack of consensus over the use of lipid targets. 
Nonetheless, these targets may be one reason for a patient to be reviewed 
frequently, although it could also be used as an opportunity to assess a patient’s 
adherence to their medication. Increasing evidence from electronic prescribing 
records has shown that adherence to LLM decreases with treatment duration. 
However, the evidence base that such reviews translate into improved 
adherence, lipid levels, and consequently patient outcomes when considered 
together, is also minimal with often relatively short durations of follow up. 
With the exception of one simulation study (Perera et al., 2015), there is also 
little evidence for optimal testing and review schedules of such patients, and as 
a result any guideline recommendations are likely to be derived from expert 
opinion. As evidence suggesting that the burden associated with these reviews is 
growing, there is a clear need to establish a scientific basis for them and their 
frequency, as well as explore options that could safely reduce their number. 
One such option is the personalisation of a patient’s monitoring, which would 
necessitate the identification of those likely to require continued frequent 
reviews. To date, research looking to describe patients who are likely to become 
non-adherent or not achieve lipid targets have successfully identified some 
possible characteristics. Despite this, for many other potential factors, the 
associations are less clear and often contradictory, with patients’ adherence 
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behaviours likely multifactorial and possible variables confounding with each 
other. Consequently, there is still a need to pursue the identification of such 
individuals and investigate the plausibility and effectiveness of any personalised 
schedules.  
1.8 Thesis Overview 
1.8.1 Aims and Objectives 
This thesis aims to:  
1. Assess the current guidance, within international guidelines, for the 
secondary prevention population for cardiovascular disease regarding lipid-
lowering treatment, cholesterol targets (and if used), and frequency of 
monitoring as part of long-term follow-up.  
2. Understand the demographics of the post myocardial infarction population in 
Greater Glasgow and Clyde, together with their adherence to statins and 
achievements of cholesterol-lowering targets.  
3. Explore the associations between statin adherence, achievements of 
cholesterol targets, further myocardial infarctions, and mortality. 
4. Examine the associations between demographic factors, and previous statin 
adherence and lipid results, with the likelihood of statin non-adherence or 
non-target lipids.  
5. Identify patients who would not require any intervention in response to a 
lipid test obtained during the annual review process and could, therefore, 
benefit from biennial testing.  
With these aims in mind, specific objectives were also established, with each 
numbered aim corresponding to the equivalently numbered objective. 
Therefore, the objectives of this thesis are: 
1. Conduct a systematic review of international guidelines relating to the 
management of those with established cardiovascular disease to compare 
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recommendations for lipid-lowering treatments, the use of and any specific 
cholesterol targets, and long-term monitoring.  
2. Utilise linked data from the NHS Greater Glasgow and Clyde Safe Haven to 
establish a post myocardial infarction cohort, and use descriptive statistics to 
summarise their demographics, adherence to statins, and achievements of 
cholesterol targets.  
3. Utilise data from this post myocardial infarction cohort to describe and 
quantify the strength and direction of the associations between statin 
adherence, the achievement of cholesterol targets, further myocardial 
infarctions, and mortality.  
4. Utilise the post myocardial infarction cohort data to identify, describe, and 
quantify the strength and direction of the associations between demographic 
factors, previous statin adherence, and previous lipid results, with statin non-
adherence and failure to achieve cholesterol targets.  
5. Develop an algorithm, using factors identified through the earlier objectives, 
which identifies patients for whom the results of an annual lipid test would 
not require any intervention, and therefore could safely benefit from biennial 
testing. 
The aims and objectives outlined here will each be addressed within the 
subsequent chapters, as outlined in further detail in Chapter 1.8.3 below.  
1.8.2 Hypotheses 
With the aims and objectives of this thesis now outlined, the following 
hypotheses were generated: 
1. In secondary prevention populations, the use of statins as a lipid-lowering 
therapy will be universal in current guidelines due to the strong evidence 
base for their use (Chapter 1.3.1). However, there will be some variation in 
the use, and nature, of cholesterol targets, and in the frequency of 
monitoring these patients.  
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2. The demographics, statin adherence, and achievement of cholesterol targets 
of the post myocardial infarction cohort derived from data within the NHS 
Greater Glasgow and Clyde Safe Haven will be broadly similar to other post-
myocardial infarction and secondary prevention cohorts.   
3. There will be significant positive associations between statin adherence and 
the achievement of cholesterol targets, and both, in turn, will be positively 
significantly associated with further myocardial infarctions and mortality.  
4. A patient’s previous statin adherence and previous lipid results will be 
strongly positively associated with their current adherence and lipid results. 
Some demographic factors will also be significantly associated but these 
associations will be smaller than those observed with previous data.  
5. There will be a group of patients identified by an algorithm, utilising 
associations identified from earlier objectives, who could be safely 
considered for biennial lipid testing.  
1.8.3 Structure of the Thesis 
The rest of this thesis will systematically cover each of the aims, objectives, and 
hypotheses listed above. Chapter 2 addresses the first of these and contains a 
systematic review of secondary prevention guidelines published during the past 
decade and qualitatively compares the recommendations surrounding the 
management of lipids within this population. The work outlined in Chapter 3 
details the methods and the decisions implemented as part of the cleaning of 
the data from the NHS Greater Glasgow and Clyde (GGC) Safe Haven and the 
derivation of the post MI cohort. Whilst this does not directly address any of the 
specific aims listed above, this work was necessary to facilitate the remainder of 
this thesis with it all depending upon the successful derivation of this cohort. 
Using the cohort derived in the previous chapter, Chapter 4 seeks to address the 
second aim using a series of descriptive statistics to characterise the post MI 
population and includes their demographics, lipid testing frequency, lipid test 
results, and estimated statin adherence. The third aim is investigated in Chapter 
5, where the nature of any associations between statin adherence and lipid 
testing results with further MIs and mortality are elucidated. Both final two aims 
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are covered within Chapter 6, which first identifies significant predictors of non-
adherence or non-target plasma lipids (and the direction of these associations). 
These results are then used to develop an algorithm to identify patients who are 
likely to meet targets with reasonable adherence to LLM, and as such could 
safely benefit from a reduced testing schedule. Finally, Chapter 7 provides a 
general discussion and summary of the results generated as part of this thesis as 
well as outlining their key conclusions.  
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Chapter 2 Systematic Review of Clinical 
Guidelines for Lipid-Lowering in the Secondary 
Prevention of Cardiovascular Disease Events 
This chapter is reproduced from a manuscript published in Open Heart with a 
CC-BY 4.0 license in 2020 (Brown, Welsh and Logue, 2020). However, the 
supplementary materials are included within this chapter and not as a separate 
appendix, as published, and the text has been updated to reflect this. 
Therefore, the example search strategy has been added into Chapter 2.2.1.1, 
and the supplementary table of recommendations for lipid lowering drugs other 
than statins is included as Table 2.4 in Chapter 2.3.3.1. The full reference for 
the manuscript is: 
Brown, R. E., Welsh, P. and Logue, J. (2020) ‘Systematic review of clinical 
guidelines for lipid lowering in the secondary prevention of cardiovascular 
disease events’, Open Heart, 7(2), p. e001396. doi: 10.1136/openhrt-2020-
001396. 
2.1 Introduction  
In 2016, cardiovascular disease (CVD) was the leading cause of death worldwide 
and was responsible for an estimated 17.9 million deaths, with heart attacks and 
strokes accounting for 85% of these (World Health Organization, 2017b). This is 
broadly similar to the Global Burden of Disease study’s estimate for 2015 of 
17.92 million deaths, which additionally estimated that the number of cases that 
year was 422.7 million (Roth et al., 2017). With the cardiovascular death rate 
falling between 1990 and 2015 in most high-income countries (Roth et al., 2017), 
there is an increasing focus on the management and risk prevention of CVD in 
the secondary prevention setting.  
The need for risk management in secondary prevention, which encompasses 
coronary heart disease, stroke, and peripheral artery disease, is clear. The rate 
of further cardiovascular events per annum in unmedicated patients with 
previous events has been estimated to be around 5.6% and 3.7% depending on 
whether the previous event was coronary heart disease related, compared to 
1.8% in those without (Cholesterol Treatment Trialists’ (CTT) Collaboration, 
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2010). The mortality rate is also six times higher in this population (World Health 
Organization, 2017a). As a result of this elevated risk, the World Health 
Organization states that individuals with established cardiovascular disease 
should be treated with lipid-lowering therapy, aspirin, beta-blockers and ACE 
inhibitors, as well as engage in smoking cessation to reduce the risk of further 
events by up to 75% (World Health Organization, 2017b). This has led to the use 
of statins as lipid-lowering therapy being considered a cornerstone of clinical 
practice in order to manage secondary CVD risk throughout the world, due to 
their relative safety, cost, efficacy in lowering cholesterol and consequently CVD 
prevention. Additionally, there is no threshold beyond which cholesterol-
lowering is considered dangerous (Cholesterol Treatment Trialists’ (CTT) 
Collaboration, 2010).  
However, the World Health Organization has offered no specific guidance 
regarding target plasma lipid levels or the monitoring of these since the 
publication of their prevention of cardiovascular guidelines in 2007 (World 
Health Organization, 2007). Indeed, different national or international guidelines 
have contrasting recommendations. For example, the use of on-treatment 
cholesterol targets has proved controversial in recent years (Leibowitz et al., 
2017; Pallazola et al., 2018). Prescriptions of higher doses of lipid-lowering 
therapy are more likely in the pursuit of increasingly lower lipid targets with the 
aim of reducing a patient’s risk of further cardiovascular events (Allahyari et al., 
2020). However, higher doses of medication also lead to an increased likelihood 
of side effects (Cannon et al., 2006; Preiss et al., 2011), which could result in 
further costs or even non-adherence or discontinuation in patients, reducing the 
potential reduction in risk. The long-term follow-up of lipids in high-risk 
populations poses a significant burden of time to patients (Kim et al., 2014), and 
costs to healthcare. Specifically, increased biochemistry costs from expanding 
clinical demand have been flagged as a major financial burden (Smellie, 2012). 
Therefore, effectively balancing the costs of follow-up with the reduction in 
cardiovascular risk within a given population represents a significant challenge, 
with countries and regions likely to have differing approaches. 
This systematic review aimed to investigate similarities and differences in 
clinical guidelines surrounding the recommendations for the therapeutic 
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treatment, targets, and monitoring of lipid risk factors in adults who have 
established cardiovascular disease. This will help to highlight variation in the 
guidelines, thereby providing guidance for future research priorities. 
2.2 Methods  
A protocol which documented the pre-specified analysis and the inclusion 
criteria for this systematic review was first registered on PROSPERO 
(https://www.crd.york.ac.uk/prospero/) on 19th June 2018 [Ref: CRD42018098582] 
(Brown, Welsh and Logue, 2018).  
2.2.1 Literature Search 
A search of Medline, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL) and Turning Research into Practice (TRIP) databases was conducted for 
all guidelines published in the ten years prior to 31 December 2019. In addition, 
several guideline specific databases were searched: National Guideline 
Clearinghouse (USA), the National Library for Health Guidelines Finder (UK), the 
Canadian Medical Association Clinical Practice Guidelines Infobase and 
Guidelines International Network International Guideline Library. Finally, an 
additional hand search was performed to identify the most recent versions of the 
guidelines identified through the systematic search. A copy of the search 
strategy used for MEDLINE is included in Chapter 2.2.1.1 with comparable 
searching strategies employed for other searched databases.  
2.2.1.1 Example MEDLINE Search Strategy 
((Cardiovascular Diseases/) OR (exp Aortic Aneurysm/) OR (exp Myocardial 
Ischemia/) OR (exp ARTERIOSCLEROSIS/) OR (exp Cerebrovascular Disorders/) OR 
(Peripheral Vascular Diseases/) OR (exp Heart Failure/) OR ((cardiovascular adj3 
disease*).mp.) OR ((coronary adj3 disease*).mp.) OR (heart disease*.mp.) OR 
((stroke* or cerebrovasc* or cva*).mp.) OR ((aort* adj5 aneurysm).mp.) OR 
((abdominal adj5 aneurysm).mp.) OR ((thoracoabdominal adj5 aneurysm).mp.) 
OR ((arteri* adj3 occlusi*).mp.) OR ((arteri* adj3 stenosis).mp.) OR ((peripher* 
adj5 occlusi*).mp.) OR ((peripher* adj5 arteri*).mp.) OR ((peripher* adj5 
vascular).mp.) OR (heart failure.mp.) OR (atherosclerosis.mp.) OR 
(arteriosclerosis.mp.) OR (HYPERTENSION/) OR (Hyperlipidemias/) OR (Diabetes 
Chapter 2  82 
 
Mellitus/) OR (hypertension.mp.) OR (hyperlipid?emia.mp.) OR 
(dyslipid?emia.mp.) OR (cholesterol.mp.) OR (diabetes.mp.) OR (metabolic 
syndrome.mp.)) 
AND 
((Cardiovascular Diseases/pc [Prevention & Control]) OR (Secondary Prevention/) 
OR (Risk Assessment/) OR ((established adj3 disease).mp.) OR ((subsequent adj3 
event*).mp.) OR ((recurrent adj3 event*).mp.) OR ((multiple adj3 event*).mp.) 
OR ((secondary adj3 prevention).mp.) OR ((subsequent adj3 episode*).mp.) OR 
((recurrent adj3 episode*).mp.) OR ((prior adj3 cardiovascular).mp.) OR 
((previous adj3 cardiovascular).mp.) OR ((multiple adj3 episode*).mp.)) 
AND  
((Critical Pathways/) OR (exp Clinical Protocols/) OR (exp CONSENSUS/) OR (exp 
Consensus Development Conference/) OR (exp Consensus Development 
Conferences as Topic/) OR (exp GUIDELINE/) OR (Guidelines as Topic/) OR (exp 
Practice Guideline/) OR (Practice Guidelines as Topic/) OR (Health Planning 
Guidelines/) OR ((guideline or practice guideline or consensus development 
conference or consensus development conference, NIH).pt.) OR ((position 
statement* or policy statement* or practice parameter* or best 
practice*).ti,ab,kf,kw. OR (standards or guideline or guidelines).ti,kf,kw.) OR 
(((practice or treatment* or clinical) adj guideline*).ab.) OR ((CPG or CPGs).ti.) 
OR (consensus*.ti,kf,kw.) OR (consensus*.ab. /freq=2) OR (((critical or clinical or 
practice) adj2 (path or paths or pathway or pathways or protocol*)).ti,ab,kf,kw.) 
OR (recommendat*.ti,kf,kw.) OR ((care adj2 (standard or path or paths or 
pathway or pathways or map or maps or plan or plans)).ti,ab,kf,kw.) OR 
((algorithm* adj2 (screening or examination or test or tested or testing or 
assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab,kf,kw.) 
OR ((algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or 
therap* or treatment* or intervention*)).ti,ab,kf,kw.)) 
NOT ((comment.pt.) OR (letter.pt.) OR (editorial.pt.)) 
Limit results to English language 
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Limit results to yr="2010 -Current" 
2.2.2 Selection Process  
Papers were retained if they met the Institute of Medicine’s 2011 definition of a 
clinical guideline, “Clinical Practice Guidelines are statement that include 
recommendations intended to optimize patient care that are informed by a 
systematic review of evidence and an assessment of the benefits and harms of 
alternative care options” (Institute of Medicine (US), 2011). As the focus of this 
systematic review was the management of patients with established 
cardiovascular disease, guidelines were only retained within the review if their 
specific management was detailed, regardless of whether they covered 
established cardiovascular disease as a whole, or for the management of 
patients after a specific event, such as myocardial infarction or stroke. Only the 
most recent version of the guidelines was retained, with any previous versions 
removed. Finally, included guidelines had to apply to OECD countries, produced 
by a professional organisation, and have the full version of the guidelines 
available in English. 
Two reviewers (RB and JL) independently reviewed the titles and abstracts of 
the results against the eligibility criteria. The same two reviewers also 
performed the full text review, where the reason for exclusion of the guidelines 
was also documented. In both instances, any discrepancies of opinion were 
resolved through discussion. 
2.2.3 Data Extraction  
Data extraction was performed initially by one reviewer (RB) with accuracy 
checked by a second reviewer (JL). Data extracted included the target 
population, the publishing society, the country or region the guideline applied to 
and the year it was published. Recommendations specifically for the secondary 
prevention population surrounding the frequency that plasma lipid monitoring 
should be performed, therapies that should be used, and any lipid target values 
were also extracted if given within the guideline. The strength and the level of 
evidence of each recommendation were also extracted. Once extracted, the 
recommendations were compared by all authors.  
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2.2.4 Quality Assessment 
The quality of the development processes of each of these guidelines was then 
assessed using the 2009 Appraisal of Guidelines for Research and Evaluation 
(AGREE) II tool by two reviewers (RB and JL). The AGREE II tool consists of 23 
questions covering six domains (Scope and Purpose, Stakeholder Involvement, 
Rigour of Development, Clarity of Presentation, Applicability, and Editorial 
Independence) and an overall assessment of the quality of the guideline. Each of 
the items, including the overall quality assessment, is scored on a 7 point scale 
(1, Strongly Disagree; 7, Strongly Agree), with scaled domain scores then 
calculated (AGREE Next Steps Consortium, 2010). As the AGREE II tool does not 
facilitate an aggregated score across the domains nor a specific cut point for 
high or low quality, scores for all domains are presented.  
2.3 Results 
2.3.1 Results of Literature Search 
 
Figure 2.1: Selection Process of Relevant Guidelines  
Records identified 
(N = 6,948) 
Duplicate records 
(N = 117) 
Records title and abstract screened 
(N = 6,831) 
Full-text guidelines assessed for eligibility  
(N = 159) 
Guidelines included in qualitative synthesis 
(N = 22) 
Excluded 137 guidelines 
Not the most recent version (N = 51) 
Not a guideline (N = 28) 
Not a national guideline (N = 6) 
Not secondary prevention (N = 27) 
Duplicate guideline (N = 15) 
Full guideline not available in  
English (N = 9) 
Subsequent merge with another national 
guideline (N = 1) 
Records excluded 
(N = 6,672) 
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The literature search found 6,948 results (Figure 2.1), of which 117 were 
identified as duplicates. Of the 6,831 unique results, 6,672 were excluded 
following title and abstract screening. Following a full text review of the 
remaining 159 records, a further 137 were excluded. Common reasons for this 
exclusion were that a more recent version of the guideline existed (n=51), the 
record was not a guideline (n=28), the guideline did not apply to the secondary 
prevention population (n=27), or that it was a duplicate copy of another 
guideline published in a different journal (n=15). The remaining 22 guidelines 
(Bryer et al., 2010; JBS3 Board, 2014; NICE, 2014; Expert Dyslipidemia Panel of 
the International Atherosclerosis Society Panel Members, 2014; Herdy et al., 
2014; International Diabetes Federation Guideline Development Group, 2014; 
Jacobson et al., 2015; Anderson et al., 2016; Toplak et al., 2016; Chew et al., 
2016; (Australian) Stroke Foundation, 2017; SIGN, 2017; Tai et al., 2017; Wang, 
Liu and Pu, 2017; Cheung et al., 2017; Kinoshita et al., 2018; Klug et al., 2018; 
Li et al., 2018; Naylor et al., 2018; New Zealand Ministry of Health, 2018; 
Grundy et al., 2019; Mach et al., 2020) were assessed for their quality using 
AGREE II and included in the qualitative comparisons.  
2.3.2 Characteristics and Quality of Guidelines 
The guidelines included are summarised in Table 2.1 and were for 16 different 
regions. Two of the guidelines were global, with two guidelines each for the US 
and Europe. There were also two guidelines each for the UK, South Africa, 
Australia, and New Zealand including one which was applicable to both Australia 
and New Zealand. Finally, there was one guideline for the following regions: 
Austria, Canada, China, Hong Kong, Japan, South America, Scotland, Singapore, 
and Taiwan. Most of the guidelines were published in 2014 (n=7), 2016 (n=4), 





Table 2.1: Summary of Included Guidelines  
Abbrev. Development Group Title Population Region Year 
ACD American College of Cardiology, 
American Heart Association, American 
Association of Cardiovascular and 
Pulmonary Rehabilitation, American 
Association Academy of Physician 
Assistants, Association of Black 
Cardiologists, American College of 
Preventive Medicine, American Diabetes 
Association, American Geriatrics Society, 
American Pharmacists Association, 
American Society for Preventive 
Cardiology, National Lipid Association, 




NLA/PCNA Guideline on the Management of 
Blood Cholesterol (Grundy et al., 2019) 
All USA 2018 
AUSS Stroke Foundation Australian Clinical Guidelines for Stroke 
Management 2017 ((Australian) Stroke 
Foundation, 2017) 
Stroke Australia 2017 
AUST Austrian Obesity Association, Austrian 
Atherosclerosis Society, Austrian Diabetes 
Association, Austrian Society of 
Hypertension, Austrian Society for 
Internal Angiology, Austrian Society of 
Nephrology, Austrian Society of 
Cardiology, Austrian Stroke Society 
Austrian Lipid Consensus on the management 
of metabolic lipid disorders to prevent vascular 
complications: A joint position statement 
issued by eight medical societies. 2016 update 
(Toplak et al., 2016) 
All Austria 2016 
CCSG Canadian Cardiovascular Society 2016 Canadian Cardiovascular Society 
Guidelines for the Management of Dyslipidemia 
for the Prevention of Cardiovascular Disease in 
the Adult (Anderson et al., 2016) 




Abbrev. Development Group Title Population Region Year 
CSN Chinese Society of Neurology, 
Cerebrovascular Disease Group 
2014 Chinese guidelines for secondary 
prevention of ischemic stroke and transient 
ischemic attack (Wang, Liu and Pu, 2017) 
Stroke China 2014 
ESCEAS European Society of Cardiology, European 
Atherosclerosis Society 
2019 ESC/EAS Guidelines for the management 
of dyslipidaemias: lipid modification to reduce 
cardiovascular risk (Mach et al., 2020) 
All Europe 2019 
ESVS European Society for Vascular Surgery  Management of Atherosclerotic Carotid and 
Vertebral Artery Disease: 2017 Clinical Practice 
Guidelines of the European Society for Vascular 





HKCTF Hong Kong Cardiovascular Task Force 2016 Consensus statement on prevention of 
atherosclerotic cardiovascular disease in the 




IAS International Atherosclerosis Society An International Atherosclerosis Society 
Position Paper: global recommendations for the 
management of dyslipidemia (Expert 
Dyslipidemia Panel of the International 
Atherosclerosis Society Panel Members, 2014) 
All Global 2014 
IDF International Diabetes Federation Global guideline for type 2 diabetes 
(International Diabetes Federation Guideline 
Development Group, 2014) 
Diabetes Global 2014 
JAS Japan Atherosclerosis Society Japan Atherosclerosis Society Guidelines for 
Prevention of Atherosclerotic Cardiovascular 
Diseases 2017 (Kinoshita et al., 2018) 
All Japan 2017 
JBS3 Joint British Societies  Joint British Societies' consensus 
recommendations for the prevention of 
cardiovascular disease (JBS3) (JBS3 Board, 
2014) 




Abbrev. Development Group Title Population Region Year 
NHF National Heart Foundation of Australia, 
Cardiac Society of Australia and New 
Zealand 
National Heart Foundation of Australia and 
Cardiac Society of Australia and New Zealand: 
Australian clinical guidelines for the 
management of acute coronary syndromes 2016 








NLA National Lipid Association National Lipid Association recommendations for 
patient-centered management of dyslipidemia 
(Jacobson et al., 2015) 
All  USA 2014 
NICE  National Institute for Health and Clinical 
Excellence 
NICE Cardiovascular disease: risk assessment 
and reduction, including lipid modification 
(NICE, 2014) 
All UK  2014 
NZ New Zealand Ministry of Health New Zealand Cardiovascular Disease Risk 
Assessment and Management for Primary Care 




SAF South African Stroke Society South African guideline for management of 
ischaemic stroke and transient ischaemic 




SAHA South African Heart Association, Lipid 
and Atherosclerosis Society of Southern 
Africa  
South African Dyslipidaemia Guideline 





SAM Sociedade Brasileira de Cardiologia South American guidelines for cardiovascular 





SIGN Scottish Intercollegiate Guidelines 
Network  
SIGN 149: Risk estimation and the prevention 
of cardiovascular disease (SIGN, 2017) 
All Scotland 2017 
SMH Singapore Ministry of Health Singapore Ministry of Health Clinical Practice 
Guidelines: Lipids (Tai et al., 2017) 




Abbrev. Development Group Title Population Region Year 
TSC Taiwan Society of Cardiology, Taiwan 
Society of Emergency Medicine, Taiwan 
Society of Cardiovascular Interventions 
2018 Guidelines of the Taiwan Society of 
Cardiology, Taiwan Society of Emergency 
Medicine and Taiwan Society of Cardiovascular 
Interventions for the management of non ST-
segment elevation acute coronary syndrome (Li 
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ACD 89% 50% 65% 100% 63% 100% 7 
AUSS 100% 83% 90% 89% 50% 100% 6 
AUST 78% 33% 27% 61% 0% 33% 4 
CCSG 78% 39% 65% 94% 38% 100% 6 
CSN 56% 44% 48% 78% 17% 83% 4 
ESCEAS 56% 61% 63% 94% 54% 100% 7 
ESVS 78% 56% 75% 72% 13% 33% 5 
HKCTF 50% 33% 46% 78% 25% 58% 4 
IAS 44% 39% 42% 44% 25% 42% 4 
IDF 56% 33% 48% 83% 100% 83% 6 
JAS 61% 44% 71% 67% 4% 25% 4 
JBS3 56% 56% 29% 94% 25% 50% 5 
NHF 89% 50% 73% 94% 79% 67% 7 
NICE 100% 78% 94% 100% 96% 100% 7 
NLA 72% 61% 54% 94% 17% 92% 6 
NZ 83% 39% 27% 78% 17% 17% 4 
SAF 39% 56% 67% 78% 29% 92% 6 
SAHA 61% 56% 31% 72% 29% 83% 5 
SAM 33% 28% 29% 61% 33% 33% 4 
SIGN 89% 100% 96% 89% 88% 100% 7 
SMH 67% 67% 54% 94% 17% 0% 4 
TSC 67% 50% 52% 94% 8% 50% 5 
Domain 1, Scope and Purpose; Domain 2, Stakeholder Involvement; Domain 3, Rigour of 
Development; Domain 4, Clarity of Presentation; Domain 5, Applicability; Domain 6, Editorial 
Independence. 
ACD, American College of Cardiology/American Heart Association/American Association of 
Cardiovascular and Pulmonary Rehabilitation/American Association Academy of Physician 
Assistants/Association of Black Cardiologists/American College of Preventive 
Medicine/American Diabetes Association/American Geriatrics Society/American 
Pharmacists Association/American Society for Preventive Cardiology/National Lipid 
Association/Preventive Cardiovascular Nurses Association; AUSS, Australia Stroke Society; 
AUST, Austrian Obesity Association/Austrian Atherosclerosis Society/Austrian Diabetes 
Association/Austrian Society of Hypertension/Austrian Society for Internal 
Angiology/Austrian Society of Nephrology/Austrian Society of Cardiology/Austrian Stroke 
Society; CCSG, Canadian Cardiovascular Society; CSN, Chinese Society of Neurology and 
Cerebrovascular Disease Group; ESCEAS, European Society of Cardiology and European 
Atherosclerosis Society; ESVS, European Society for Vascular Surgery; HKCTF, Hong Kong 
Cardiovascular Task Force; IAS, International Atherosclerosis Society; IDF, International 
Diabetes Federation; JAS, Japan Atherosclerosis Society; JBS3, Joint British Societies; 
NHF, National Heart Foundation of Australia and Cardiac Society of Australia and New 
Zealand; NICE, National Institute for Health and Clinical Excellence; NLA, National Lipid 
Association; NZ, New Zealand Ministry of Health; SAF, South African Stroke Society; SAHA, 
South African Heart Association; SAM, Sociedade Brasileira de Cardiologia; SIGN, Scottish 
Intercollegiate Guidelines Network; SMH, Singapore Ministry of Health; TSC, Taiwan Society 
of Cardiology/Taiwan Society of Emergency Medicine/Taiwan Society of Cardiovascular 
Interventions. 
Table 2.2 contains the AGREE II scores for each of the guidelines. Reflecting 
generally high quality, eight guidelines were ranked as 4, four ranked as 5, five 
Chapter 2  91 
 
 
as 6 and five as 7. Guidelines scored highest in Domain 4 (Clarity of 
Presentation) on average, and lowest in Domain 5 (Applicability) with many 
guidelines scoring below 50%. Scores of 0% were only attained in Domains 5 and 6 
(Editorial Independence), with the latter occurring when no funding information 
or conflicts of interest were documented within the text. In terms of maximum 
values, 100% was attained in all domains by at least one guideline except for 
Domain 3 (Rigour of Development), where the highest score was 96%. This was 
the largest domain of the six and focussed on the development process of the 
guideline. Many did not document this fully or provide necessary references to 
additional material, and few detailed their update procedures.  
2.3.3 Summary of Recommendations 
Recommendations for the use of statin medication, cholesterol targets, and the 
frequency of monitoring are presented in Table 2.3.  
2.3.3.1 Treatment Recommendations  
All of the guidelines presented recommendations for the treatment of the 
secondary prevention population, with all recommending statins as the primary 
therapy. Only UK/Scottish guidelines suggested the specific drug and dose, 
namely, atorvastatin 80mg, with many instead recommending the maximally 
tolerated high-intensity doses in general, with lower doses considered when 
contraindications were present, or they were poorly tolerated by the patients. 
Few caveats were stated regarding the prescription of statins. For example, all 
stroke guidelines recommended statins only when the cause of the stroke was 
likely to be atherosclerotic, with the South African Stroke Society (SAF) 
additionally only recommending them in the case of total cholesterol 
>3.5mmol/l, and the Australia Stroke Society (AUSS) only considering them 
appropriate when the patient’s life expectancy was considered reasonable. For 
the secondary prevention population as a whole, the European Society of 
Cardiology and European Atherosclerosis Society (ESCEAS) tailored their 
recommendations for patients whose baseline low-density lipoprotein (LDL) was 
<1.4mmol/l at baseline respectively, with therapy considered rather than 
offered to these patients. Finally, the 2018 American Consensus (ACD) guidelines 
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stated that the benefit-risk ratio should be considered when offering medication 
to patients over the age of 75 years. 
For the guidelines which reported corresponding levels of evidence with their 
treatment recommendations (n=12), all considered that the level of evidence for 
statins was high, resulting in strong recommendations for their administration to 
the secondary prevention population. For situations where lower doses of 
therapy may be needed, such as in cases of contraindications or lack of 
tolerance, if specified at all, guidelines often considered the level of evidence 
supporting these changes to be lower than for the main treatment 
recommendation. Specifically, the level of evidence was typically assessed to be 
moderate (rather than high) or such alterations to medications were considered 
to be only good practice. 
Besides statins, other lipid-lowering medications were also discussed within the 
guidelines (Table 2.4). The most commonly recommended of these was 
ezetimibe (n=17), both as an additional medication (n=15), and as a 
monotherapy (n=10) predominantly for patients with statin intolerance (n=8). 
Fibrates, niacin derivatives, and omega-3 supplements were also commonly 
recommended (n=15, n=10 and n=8, respectively) though under two different 
circumstances: elevated triglyceride levels and LDL cholesterol-lowering. For the 
former, fourteen recommended fibrates, whilst five guidelines each 
recommended considering niacin derivatives and Omega-3 supplements. Three 
guidelines suggested Omega-3 as lipid-lowering therapy, although the roles of 
fibrates and niacin derivatives were more disputed. Fibrates and niacin 
derivatives were recommended routinely in five and eight guidelines, 
respectively. However, three guidelines each did not recommend the use of 
fibrates and niacin derivatives. Bile acid sequestrant use was debated in thirteen 
guidelines, with only the South African Heart Association (SAHA) discouraging 
their use. PCSK9 inhibitors were only included in six guidelines, all of which were 
published from 2016 onwards, and all recommending them as an additional 
therapy or in cases of statin intolerance. Four guidelines did not give any 
recommendations for lipid-lowering medications other than statins. Evidence 
supporting these recommendations (if stated) was generally assessed by the 
guidelines to be of lower quality than for statins, and consequently the 
Chapter 2  93 
 
 
associated strength of recommendations was typically lower. Ezetimibe and 
PCSK9 inhibitors tended to have higher levels of supporting evidence behind 
them, although the strength of recommendations for PCSK9 inhibitors was lower 





Table 2.3: Summary of Recommendations  
Guideline 
Statin Medication Cholesterol Targets Frequency of Monitoring 
Recommendation LoE SoR Recommendation LoE SoR Recommendation LoE SoR 
ACD ≤75yr: High intensity 
statins  
>75yr: Initiate moderate or 







-- -- -- Fasting lipids 4-12 
weeks after initiation, 
then every 3-12 
months 
A I 
AUSS Atherosclerotic: High 
intensity statins if 
reasonable life expectancy  
High Strong -- -- -- -- -- -- 
AUST Statins  -- -- LDL-C <1.8mmol/L 










-- -- -- 
CCSG Moderate/high intensity 
statins  
High Strong LDL-C <2.0mmol/L 


























Statin Medication Cholesterol Targets Frequency of Monitoring 
Recommendation LoE SoR Recommendation LoE SoR Recommendation LoE SoR 
CSN Ischaemic: High intensity 
statins  
A I LDL-C <1.8mmol/L  






-- -- -- 
ESCEAS Baseline LDL-C  
>1.4mmol/L: offer med 







LDL-C <1.4mmol/L  
Or LDL-C >50% 
reduction  
Further event <2yrs:  

















ESVS Statins prior to 
endarterectomy or stenting  
A I -- -- -- -- -- -- 
HKCTF High intensity statins -- -- LDL-C <1.8mmol/L  
Or LDL-C >50% 






-- -- -- 







-- -- -- 
IDF Statins -- RC Triglyceride 
<2.3mmol/L  
















Statin Medication Cholesterol Targets Frequency of Monitoring 
Recommendation LoE SoR Recommendation LoE SoR Recommendation LoE SoR 
JAS Statins  1+ A LDL-C <2.6mmol/L  
Or LDL-C >50% 
reduction if target 
cannot be met  
If additional 
conditions:  
LDL-C <1.8mmol/L  






















Regular blood testing  





JBS3 Atorvastatin, up to 80mg in 
ACS 







Annual non-fasting TC 
and HDL-C once stable  
-- -- 
NHF Highest tolerated dose of 
statins  
1A Strong LDL-C ≤1.8mmol/L  -- -- TC and LDL-C approx. 
3 months after starting  
-- -- 
NICE  Atorvastatin 80mg, lower 
dose if not tolerated.  
-- Strong Non-HDL-C >40% 
reduction 








NLA Moderate/high intensity 
statins  







4-12 months once 
achieved  
Low E 
NZ Statins  -- -- LDL-C 1.6-1.8mmol/L  -- -- Non-fasting 6-12 












Statin Medication Cholesterol Targets Frequency of Monitoring 
Recommendation LoE SoR Recommendation LoE SoR Recommendation LoE SoR 
SAF Atherosclerotic and TC 
>3.5mmol/L: Statins  








-- -- -- -- -- -- 
SAHA High-intensity statins  -- -- LDL-C <1.8mmol/L  
Or LDL-C >50% 







8(±4) weeks  






SAM Statins  -- -- LDL-C <2.6mmol/L  -- -- -- -- -- 
SIGN Atorvastatin 80mg  





-- -- -- Annual Review  -- GP 
SMH Statins  1++ A LDL-C <2.1mmol/L 1++ A Annually  -- GP 







-- -- -- 
ACD, American College of Cardiology/American Heart Association/American Association of Cardiovascular and Pulmonary Rehabilitation/American 
Association Academy of Physician Assistants/Association of Black Cardiologists/American College of Preventive Medicine/American Diabetes 
Association/American Geriatrics Society/American Pharmacists Association/American Society for Preventive Cardiology/National Lipid 
Association/Preventive Cardiovascular Nurses Association; ACS, acute coronary syndromes; AUSS, Australia Stroke Society; AUST, Austrian Obesity 
Association/Austrian Atherosclerosis Society/Austrian Diabetes Association/Austrian Society of Hypertension/Austrian Society for Internal 
Angiology/Austrian Society of Nephrology/Austrian Society of Cardiology/Austrian Stroke Society; CCSG, Canadian Cardiovascular Society; CSN, Chinese 
Society of Neurology and Cerebrovascular Disease Group; ESCEAS, European Society of Cardiology and European Atherosclerosis Society; ESVS, 
European Society for Vascular Surgery; GP, good practice; ; (non) HDL-C, (non) HDL-cholesterol; HKCTF, Hong Kong Cardiovascular Task Force ; IAS, 
International Atherosclerosis Society; IDF, International Diabetes Federation; JAS, Japan Atherosclerosis Society; JBS3, Joint British Societies ; LDL-C, 
LDL cholesterol; LoE, level of evidence; Med, medication; Mod, moderate; NHF, National Heart Foundation of Australia and Cardiac Society of Australia and 
New Zealand; NICE, National Institute for Health and Clinical Excellence; NLA, National Lipid Association; NZ, New Zealand Ministry of Health; PO, panel 
opinion; RC, recommended care; SAF, South African Stroke Society; SAHA, South African Heart Association; SAM, Sociedade Brasileira de Cardiologia; 
SIGN, Scottish Intercollegiate Guidelines Network; SMH, Singapore Ministry of Health; SoR, strength of recommendation; TC, total cholesterol; TSC, 
Taiwan Society of Cardiology/Taiwan Society of Emergency Medicine/Taiwan Society of Cardiovascular Interventions; V&Ps, values and preferences.  
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Table 2.4: Summary of Non-Statin Medication Recommendations  
Guideline 
Ezetimibe Fibrates PCSK9 Inhibitors Others 
Recom. LoE SoR Recom.  LoE SoR Recom.  LoE SoR Recom. LoE SoR 
ACD If max statins 
and LDL ≥1.8 
mmol/l, + 




IIa If max LLM, 
non-HDL ≥2.6 
or LDL ≥1.8 
mmol/l, + 
A IIa -- -- -- 
AUSS -- -- -- Not routine  Mod Weak -- -- -- -- -- -- 
AUST First-line 
option 














If trigs ≥5.6 
mmol/l 
Niacin  













CCSG If max 
statins, + 
High Strong For lowering 
LDL once 
met, + not 
recommended 
If high trigs, 















Cond For lowering 
LDL once met, 
+ niacin not 
recommended 
If max statins 
(/+ezetimibe), 













Ezetimibe Fibrates PCSK9 Inhibitors Others 
Recom. LoE SoR Recom.  LoE SoR Recom.  LoE SoR Recom. LoE SoR 













If trigs >2.3 
mmol/l and 
















If max statins, 
consider + BAS 










ESVS -- -- -- -- -- -- -- -- -- -- -- -- 








If very high 
trigs 
-- -- -- -- -- If low HDL or 
















IAS If max 
statins, LDL ≥ 
1.8mmol/l, 
consider + 




-- -- -- -- -- If max statins, 
LDL ≥1.8 
mmol/l, 
consider + BAS 
If high trigs, 
low HDL, 
target LDL, 























Ezetimibe Fibrates PCSK9 Inhibitors Others 
Recom. LoE SoR Recom.  LoE SoR Recom.  LoE SoR Recom. LoE SoR 
















-- RC -- -- -- If max statins, 

































































-- -- -- -- -- If max statins, 
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ACD, American College of Cardiology/American Heart Association/American Association of Cardiovascular and Pulmonary Rehabilitation/American 
Association Academy of Physician Assistants/Association of Black Cardiologists/American College of Preventive Medicine/American Diabetes 
Association/American Geriatrics Society/American Pharmacists Association/American Society for Preventive Cardiology/National Lipid 
Association/Preventive Cardiovascular Nurses Association; AUSS, Australia Stroke Society; AUST, Austrian Obesity Association/Austrian Atherosclerosis 
Society/Austrian Diabetes Association/Austrian Society of Hypertension/Austrian Society for Internal Angiology/Austrian Society of Nephrology/Austrian 
Society of Cardiology/Austrian Stroke Society; BAS, bile acid sequestrant; CCSG, Canadian Cardiovascular Society; Cond, conditional; CSN, Chinese 
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Society of Neurology and Cerebrovascular Disease Group; ESCEAS, European Society of Cardiology and European Atherosclerosis Society; ESVS, 
European Society for Vascular Surgery; GP, good practice; (non) HDL-C, (non) HDL-cholesterol; HKCTF, Hong Kong Cardiovascular Task Force ; IAS, 
International Atherosclerosis Society; IDF, International Diabetes Federation; JAS, Japan Atherosclerosis Society; JBS3, Joint British Societies ; LDL-C, 
LDL cholesterol; LLM, lipid-lowering medication; LoE, level of evidence; Med, medication; Mod, moderate; NHF, National Heart Foundation of Australia and 
Cardiac Society of Australia and New Zealand; NICE, National Institute for Health and Clinical Excellence; NLA, National Lipid Association; NZ, New 
Zealand Ministry of Health; PCSK9, Proprotein Convertase Subtilisin/Kexin type 9; RC, recommended care; Recom, recommendations; SAF, South African 
Stroke Society; SAHA, South African Heart Association; SAM, Sociedade Brasileira de Cardiologia; SIGN, Scottish Intercollegiate Guidelines Network; 
SMH, Singapore Ministry of Health; SoR, strength of recommendation; TC, total cholesterol; Trigs, triglycerides; TSC, Taiwan Society of Cardiology/Taiwan 
Society of Emergency Medicine/Taiwan Society of Cardiovascular Interventions; V&Ps, values and preferences; +, adding. 
Chapter 2  104 
 
 
2.3.3.2 Plasma Lipid Recommendations  
Seventeen of the guidelines provided at least one target, with all except one of 
these providing an LDL cholesterol goal. Target values ranged between 1.0 and 
2.6mmol/l, although the most frequently recommended was <1.8mmol/l (n=12). 
Many guidelines additionally suggested that a 50% reduction in LDL could be used 
as an alternative where this target may be unattainable or for patients whose 
baseline values were already <3.5mmol/l (n=7). A non-high-density lipoprotein 
(HDL) cholesterol target was also common (n=8), with target values ranging from 
2.5-3.4mmol/l, with 2.6mmol/l the most frequent (n=5). These targets were 
usually given in combination with a target for LDL cholesterol, though in the 
case of the Japan Atherosclerosis Society (JAS), the non-HDL target was 
considered only relevant when a patient’s triglycerides were elevated. 
Meanwhile, the National Institute for Health and Clinical Excellence (NICE) did 
not provide a numerical target for non-HDL, recommending a 40% reduction from 
the patient’s baseline only. Only two guidelines referred to other lipid 
parameters in their recommendations. The Canadian Cardiovascular Society 
(CCSG) provided an apolipoprotein B target as an alternative for LDL, and the 
International Diabetes Federation (IDF) provided additional targets for 
triglycerides and HDL cholesterol. There were no apparent differences in 
recommendations for stroke or diabetes specific guidelines, although some 
guidelines for all secondary prevention populations provided different targets for 
those patients with additional comorbidities (n=2), or specific cardiovascular 
events (n=2).  
For the majority of the guidelines that provided targets, the recommendations 
provided either no supporting evidence or graded it as low. Consequently, the 
associated strength of the recommendations was often either not given or was 
given as preferences and opinions of those involved in the guideline’s 
construction. There were few exceptions. Singapore’s (SMH) recommendation of 
LDL<2.1mmol/l considered the level of evidence to be high, resulting in a strong 
recommendation. The target of LDL<1.8mmol/l, when stated in some guidelines, 
was also strongly recommended, with the National Lipid Association (NLA) 
considering the supporting evidence to be high, whilst others graded it as only 
moderate (n=2). CCSG’s target for patients who have not experienced an acute 
coronary syndrome of LDL<2.0mmol/l was also given as a strong 
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recommendation, with the guideline viewing the supporting evidence for it as 
moderate. Its recommendation of LDL<1.8mmol/l for patients who have 
experienced an acute coronary syndrome cited no supporting evidence, and 
consequently was given as a preference amongst the guideline’s creators.  
2.3.3.3 Frequency of Monitoring 
Thirteen guidelines detailed recommendations regarding the ongoing monitoring 
of this population, with the specifics falling into three categories: monitoring 
following the initiation of treatment (n=5), monitoring prior to stable lipids 
(n=2), and long term follow-up (n=11), with some providing recommendations in 
more than one of these categories (n=5). Of those who detailed monitoring 
following statin initiation, all recommended a review of the patient’s lipids 
within three months. Within these, two guidelines recommended also measuring 
the patient’s alanine aminotransferase at this review (NICE, 2014; Mach et al., 
2020), one suggested this should be conducted only if symptoms were present 
(Grundy et al., 2019), and another two did not refer to this safety blood 
indicator (Chew et al., 2016; Klug et al., 2018). Furthermore, the measurement 
of creatine kinase was only considered where side effects were reported at this 
initial review, and was recommended in five of these guidelines (NICE, 2014; 
Klug et al., 2018; Grundy et al., 2019; Mach et al., 2020), and implied in the 
remaining guideline (Chew et al., 2016). Meanwhile, for the guidelines which 
recommended monitoring prior to stability, the criteria for this was not clearly 
defined. Both CCSG and New Zealand Ministry of Health (NZ) did not detail a 
specific purpose for these reviews. In terms of long term follow-up, many 
recommended reviewing the patient annually (n=9), although there was some 
variation in recommendations between 3 and 12 months.  
The majority of guidelines considered the evidence behind their frequency of 
monitoring recommendations to either be low (n=1) or gave no evidence to 
support them (n=11), sometimes referring to them as good practice points or 
clinician’s opinions or preferences (n=5). However, the ACD guidelines were the 
exception to this, which graded the evidence behind their monitoring 
recommendations of every 3-12 months as strong.  




This systematic review illustrates the variation in recommendations surrounding 
optimal on-statin lipid monitoring within secondary prevention. Specifically, 
there were considerable differences in the recommendations for cholesterol 
targets (including their use) and the ongoing monitoring of lipid levels over the 
longer term. These findings reflect the fact that no guideline identified a 
specifically designed randomised controlled trial to assess either treatment 
targets or monitoring of therapy. However, such trials are likely to be expensive, 
although in the future advances with electronic health records may facilitate the 
evidence base for this. Nonetheless, this systematic review illustrates that 
better evidence is needed to provide an optimal approach to lipid monitoring in 
order to balance safety, adherence, cost, and time burden to patients.  
All guideline committees are likely to be searching a broadly similar evidence 
base, where the efficacy and safety of statins has been well established in the 
prevention of further cardiovascular events (Cholesterol Treatment Trialists’ 
(CTT) Collaboration, 2010; Cholesterol Treatment Trialists’ (CTT) Collaborators, 
2012). Furthermore, the World Health Organisation recommends the use of 
statins as part of their secondary prevention program (World Health 
Organization, 2017b), with the increased risk widely accepted within this 
population. It is therefore not surprising that all guidelines agree that statins 
should be commenced as the lipid-lowering therapy with a high level of 
evidence, commensurate with the availability of randomised controlled trials. 
Guidelines that specify drugs or doses generally recommend high dose therapy 
and titrating down as necessary to a tolerated dose, rather than titrating up. 
This is in line with large randomised controlled trials over the preceding decades 
that have shown that higher dose statin therapy improves outcomes (Cannon et 
al., 2006). Nonetheless, despite this widespread recommendation, there is some 
evidence to suggest that statins are not consistently prescribed within the 
secondary prevention population depending on the cardiovascular events 
experienced (Tibuakuu et al., 2020). Meanwhile, recommendations for the use 
of other lipid-lowering therapies illustrate that such guidelines are likely a 
reflection of the evidence available when the guidelines were created e.g. 
PCSK9 inhibitors were only discussed in guidelines published after 2016. 
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Therefore, in clinical practice, consideration may need to be given to the timing 
of the publication where new evidence has emerged. 
The evidence that “lower is better” for LDL and non-HDL cholesterol in terms of 
secondary CVD prevention is well supported by evidence, and the recent advent 
of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors further 
supports this notion (Sabatine et al., 2017; Schwartz et al., 2018). The issue at 
hand is how to use this information clinically to support a testing regimen. In 
this regard the use of cholesterol targets for therapy is contentious, in part 
because the evidence for their use is less strong. Whilst research has shown that 
achieving targets is associated with better outcomes (Boekholdt et al., 2014; 
Sabatine et al., 2017; Schwartz et al., 2018), no specific randomised controlled 
trial has shown that randomising patients to a target improves adherence or 
event rates Indeed, it might be argued that the maximally tolerated statin 
should be initiated as the default, and therefore a hard target may be moot. 
Clearly, other lipid-lowering medications could be added to therapy. Despite the 
lack of strong evidence, many guidelines recommended specific lipid targets, 
with many choosing similar values, suggesting that guideline committees are 
likely to be examining the same evidence. However, one of the most recently 
published guidelines, the 2019 ESC/EAS Guidelines for the Management of 
Dyslipidaemias (ESCEAS) advised the lowest cholesterol targets of all the 
included guidelines (LDL<1.4mmol/l), with further lower levels for those with 
multiple recent cardiovascular events (LDL<1.0mmol/l). This was rated as being 
supported by strong and moderate levels of evidence, although the guidelines 
acknowledged that both targets are based on the LDL levels achieved in the 
trials for PCSK9 inhibitors (Sabatine et al., 2017; Schwartz et al., 2018; Mach et 
al., 2020).  
There was virtually no evidence to support any recommendations regarding the 
frequency of ongoing monitoring once lipid-lowering therapies had been 
commenced. Guidelines that recommended retesting following statin initiation 
tended to additionally recommend liver function tests were performed as a 
safety indicator, especially if hepatic symptoms were present, including those 
produced by the ACC/AHA and the ESC/EAS (Grundy et al., 2019; Mach et al., 
2020). Guidelines frequently conflate the issue of short term safety bloods with 
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longer-term lipid monitoring when reporting the strength of evidence. Despite 
this only one guideline (ACD) cited evidence that they considered to be strong in 
their recommendations. The evidence referenced would suggest that monitoring 
patients regularly is associated with improved adherence to medication, and, 
consequently, patient outcomes (Benner et al., 2004). However, this study was 
open to confounding due to its observational nature, and as far as we are aware, 
this has never been tested within a randomised controlled trial. Furthermore, 
the purpose of such follow-up testing in guidelines is seldom stated. Where 
evidence was cited, though, this would suggest that the purpose of such reviews 
is to promote adherence, but this may not be the rationale for all of the 
guidelines included, which could also include the monitoring of lipids to check if 
targets are still being achieved or of safety concerns. Regardless, the majority of 
guidelines recommended that secondary prevention patients were reviewed 
annually based purely on clinician’s opinion. However, in the UK, simulations 
have suggested that this is likely to be optimal economically as well as reducing 
the impact of any natural variation in an individual’s cholesterol levels (Perera 
et al., 2015). Nonetheless, some patients will not be optimally managed under 
these recommendations, and by integrating algorithms into electronic health 
records to aid clinical decision making, there is the potential to personalise an 
individual patient’s lipid management.  
2.4.1 Strengths and Limitations 
To our knowledge, this is the first review to compare guidelines surrounding the 
management of lipids in the secondary prevention population, as previous 
research has focussed on comparing guidelines for assessing risk and managing it 
through lifestyle interventions in the primary prevention population only (Khanji 
et al., 2016, 2018). Furthermore, following a comprehensive search, this 
identified current guidelines from 22 different professional bodies, covering 16 
different geographical regions. Nonetheless, guidelines were only included if 
their full guideline was available in English, which is likely to have resulted in a 
bias in the regions included and impacted the number of guidelines compared 
within this review. Another limitation is that the guidelines’ methodological 
quality, as assessed by the AGREE II tool, was not used to restrict their inclusion 
in this review, and no comparisons were made between either the 
recommendations given, their considered level of evidence or their strength, 
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and the AGREE scores. However, given that all included guidelines were assessed 
to be of generally high quality, such stratification is unlikely to have yielded 
meaningful differences. 
2.4.2 Conclusion 
The safe and optimal treatment of plasma lipids within the secondary prevention 
population is key to reducing the increasing burden of cardiovascular disease in 
society. However, given the paucity of evidence for the frequency of ongoing 
monitoring, there is a clear need for further research in these two key areas of 





Chapter 3 Deriving the Cohort  
3.1 Data Source 
The source data for this project consisted of an extract of all individuals in NHS 
Greater Glasgow and Clyde (NHS GGC) who had any lipid profile result or a 
prescription for a statin, ezetimibe, or PCSK9 inhibitor before 29th December 
2017 (when the data extraction occurred). Further details surrounding the 
definitions of a lipid profile result and the lipid-regulating medications of 
interest are shown in Figure 3.1 below. These medications were selected as 
statins, ezetimibe, and PCSK9 inhibitors are all recommended routinely in 
Scotland, whereas fibrate use is not routine and niacin is no longer 
recommended (SIGN, 2017). Initial data extraction from all available NHS GGC 
data was performed by Safe Haven staff and contained data for 652,441 
individuals (Project Reference: GSH/17/CA/012 PMCVD). 
 
Figure 3.1: Initial Inclusion Criteria for Data Extract 
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The extracted data for these individuals included their demographic data (such 
as their date of birth, sex, postcode sector, and deprivation quintiles), their 
laboratory results (from SCI Store), their dispensed prescriptions, their hospital 
admissions (from SMR01 records), and death records captured by the National 
Records of Scotland (NRS). If applicable, information captured regarding an 
individual’s diabetes diagnosis was also extracted from the diabetes register (SCI 
Diabetes). The number of records contained within each of these datasets 
before data cleaning are shown in Table 3.1.  
Table 3.1: Size of Datasets from Initial Extraction Performed by Safe Haven Staff.  
Dataset # Records 
Demographics 652,441 
  
Laboratory Tests (SCI Store) 256,361,353 
   Lipid Tests* 14,626,093 
  
Prescribing (Pharmacy) 40,899,219 
   Lipid-Lowering Medications† 9,812,303 
  
Hospital Admissions (SMR01) 775,172 
  
Deaths (NRS) 67,930 
  
Diabetes Register (SCI Diabetes) 82,579,801 
   Date and Type‡ 1,791,215 
*Results for Total Cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, and 
Total:HDL Cholesterol. †Prescriptions with a BNF Section Description equal to “Lipid-
Regulating Drugs”. ‡Data items with a description of Date of Diagnosis or Diabetes Mellitus 
Type. 
Records between the datasets for an individual were linked by Safe Haven staff 
using the individual’s CHI number, which was then removed, and an anonymous 
patient ID assigned. Dates of birth were also set to the fifteenth of the month 
and year applicable, and postcodes were limited to the postcode sector of the 
individual. Access to this anonymised data was granted via a secure platform 
hosted by the Robertson Centre for Biostatistics. All results included in this 
thesis were extracted in tabular and graphical form and were quality checked by 
Safe Haven staff before extraction. All data cleaning and analysis for this project 
was performed using R v3.5.0 (R Core Team, 2018) within the secure platform. 
Packages for specific analyses are referenced at the corresponding results. 
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After extraction, data cleaning occurred in two stages: first, to remove those 
with clinically implausible values, and records captured outside the period of 
interest, and second, to identify those individuals with a valid MI (determined 
using hospital admission records with ICD10 codes I21 and I22) to be included in 
the analysis. An overview of these processes is shown in Figure 3.2 below, and 
further details of the decisions and processes implemented are described in the 
remainder of this chapter. 
 
Figure 3.2: Derivation of the Post Myocardial Infarction Population; MI = Myocardial 
Infarction.  
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3.2 Initial Data Cleaning to Establish Basic Cohort 
3.2.1 Start and End Date 
In the initial data extraction, no start date was formally defined to maximise the 
data available for use. However, the earliest dates in the laboratory data did not 
suggest reliability or plausibility for the earliest records (e.g. earliest dates were 
in 1931). Therefore, a cumulative distribution plot was used to identify the first 
day that such laboratory values were likely to be collected (Figure 3.3). This 
identified two possible dates where a sharp increase in the number of records 
was reported, 25th June 2006 and 1st March 2008.  
 
Figure 3.3: Cumulative Observation Plot for Laboratory Samples within SCI Store. The total 
number of lipid profile observations contained within the data by each date between 
January 2000 and January 2018 were plotted to reveal two dates where a sharp increase 
was observed.  
The rate of new 
data in the dataset 
changes here 




Figure 3.4: Location Plot of Lipid Profile Tests. The number of tests in each postcode sector 
collected between 25th June 2006 and 1st March 2008 were plotted geographically, with 
purple and red areas indicating high and low numbers of tests respectively. Background 
map was sourced from OpenStreetMap (OpenStreetMap, 2020b) with extraction coordinates: 
latitude (55.67, 55.97), longitude (-4.75, -3.95).  
To determine which of the dates to select, the number of tests per postcode 
sector between these two dates were cross-tabulated and subsequently plotted 
in R to aid the identification of any geographical patterns (Figure 3.4). These 
were plotted using coordinates obtained from the 2019 Scottish Postcode 
Directory (National Records of Scotland, 2019), which were subsequently 
transformed using the Mercator projection (OpenStreetMap, 2020a), and plotted 
on a map sourced from OpenStreetMap (OpenStreetMap, 2020b). This revealed 
that the majority of the tests collected between the two dates were from 
individuals residing in the west of the NHS GGC region. This is likely due to not 
all laboratories in the region starting to upload results into SCI store on the same 
date, resulting in the second notable increase in the rate of observations on 1st 
March 2008. Therefore, 1st March 2008 was considered the start of reliable data 
captured within SCI store. 
However, whilst laboratory data was found to be accurate from 1st March 2008, 
concerns were raised about the completeness of the prescription records before 
2009. The cumulative incidence graph showed a relatively small increase in the 
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rate of prescribing at the start of 2009 (Figure 3.5). As a result of this, and the 
prescribing documentation recommendation regarding the CHI linkage of 
prescriptions before 2009 at the national level (Information Services Division, 
2010, p. 2), the start date for this analysis was selected as 1st January 2009.  
 
Figure 3.5: Cumulative Observation Plot for Lipid Regulating Prescriptions.  The total 
number of prescriptions contained within the data by each date between January 2008 and 
January 2018 were plotted. This revealed one date where a slight increase was observed, 
suggesting that records were becoming more complete at the start of 2009.  
 
Whilst the laboratory records were generally considered to be complete until the 
date of extraction (29th December 2017), concern was raised for complete record 
ascertainment in the prescription records and the hospital admission data 
(SMR01 file). The number of prescriptions and MI admissions appeared to taper 
off throughout 2017 (Figure 3.6), suggesting that not all the records had been 
completed at the time of extraction. When examined on a monthly basis for 
2017, it became apparent that whilst the SMR01 records appeared complete 
until the end of August 2017, the prescriptions records were only complete until 
the end of July 2017. For this reason, the end of follow up for this analysis was 
selected as 31st July 2017.  
 
A slight change of 
slope is noted here 




Figure 3.6: Bar Plots Illustrating Prescriptions and Number of MI Admissions by Month in 
2017. The decrease in the number of prescriptions appears to start in August 2017, whilst 
the decrease in the number of MI admissions is not evident until September 2017. 
3.2.2 Events Occurring Around Time of Death 
Individuals included in the analysis were followed up until their date of death or 
31st July 2017, whichever occurred first. Data cleaning efforts were therefore 
undertaken to ensure the accuracy and reliability of death records.  
The date of death was available in the NRS deaths file, together with details 
surrounding the cause and location from the individual’s death certificate. 
Firstly, those whose date of death was reported before 1st January 2009 were 
removed (n=112), and individuals who had more than one death certificate 
contained within the NRS file were removed from the cohort (n=3) as the correct 
record could not be ascertained. The date of death was also recorded in the 
separately derived demographics file, with the date being derived through a 
hospital discharge notice where the discharge occurs as a result of ‘DEATH’. A 
check was made to ensure that the dates in both sources matched, and there 
were approximately 100 individuals where this was not the case. As the NRS date 
was likely to be the more reliable, this date was used in such instances. Where 
the death certificate details were unavailable, the demographic file date was 
assumed. If an individual had no date of death recorded in either file before 31st 
July 2017, then they were assumed to still be alive at the end of follow up.  
To further assess the plausibility of such dates of death, checks for lipid profile 
results recorded after the date of death were conducted. Individuals with 
apparently posthumous blood results were also removed from the population as 
it could not be determined whether the date of the test or the date of death 
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was correct. Similarly, checks for prescriptions of lipid-regulating medications 
prescribed after the date of death were performed. However, due to the 
possibility that some individuals could have their medications automatically 
dispensed (such as those residing in care homes), a six-month time window (182 
days) was allowed. Any individuals whose prescriptions were issued more than 
six months after death were removed from the cohort, as this would suggest that 
one of the dates was inaccurate and determining where the error had occurred 
was not possible. These two checks combined removed a further 55 individuals 
from the population. 
3.2.3 Missing Causes of Death 
The number of deaths reported in the two sources also highlighted that there 
were considerably more deaths captured in the demographics file than in the 
NRS data. This meant that for many deaths, the cause of death was unknown. A 
temporal check was performed and was found not to be the cause of this 
discrepancy. A geographical check, which consisted of plotting the number of 
deaths and the number of missing deaths per postcode sector (Figure 3.7), was 
implemented. This highlighted that the areas with the highest rates of missing 
information were in postcode sectors outside the NHS GGC region. These 
individuals are likely to have travelled into the region for some aspects of their 
care, and therefore a complete representation of their health status was 
unlikely to have been obtained in this data extract. As a result, all individuals 
with postcodes completely outside the health board (NHS Greater Glasgow and 
Clyde, 2015a, p. 7), as shown in Figure 3.8, were excluded (n=56,170). 
Despite this, a moderate degree of missingness was still present, as around 25% 
of those with a recorded death did not have a cause of death available due to a 
missing death certificate. This is most likely to have occurred for patients who 
died in an NHS GGC hospital, but whose death certificate was registered outwith 
the region. This highlighted a possible bias within the data, as a patient’s 
location was only ascertained by their postcode sector at the time of their first 
lipid test or lipid-regulating prescription. Consequently, those appearing to not 
be tested or dispensed medications may have moved out of the area during the 
period of interest. As a result, the cause of death may not be missing at random 
if relocations are more common in patients who have more severe levels of 
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frailty (Scheibl et al., 2019), which may result in deaths from certain causes 
more likely.  
 
Figure 3.7: Geographical Plotting of Missing Death Certificates by Postcode Sector. Larger 
circles represent regions with higher numbers of deaths. Purple circles indicate a higher 
proportion of death certificates are missing, whilst red indicates that a lower proportion is 
missing. Background map was sourced from OpenStreetMap (OpenStreetMap, 2020b) with 
extraction coordinates: latitude (55.2, 57.0), longitude (-7.0, -3.9).  




Figure 3.8: Map of Postcode Sectors within NHS GGC Region 2015 (History & Maps, 2015) 
3.2.4 Age Restrictions 
Lipid-lowering prescriptions and lipid profile blood tests were removed from the 
records if they occurred when the individual was less than 18 years old at the 
time. The individual’s age was calculated using the following equation:  
(𝑑𝑎𝑡𝑒 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡 − 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑏𝑖𝑟𝑡ℎ)
365.25
⁄  
Equation 3.1: Calculation of Age in Years 
 
As dates of birth were provided as the fifteenth of the relevant month and year 
for the individual, this age will be an approximation. Individuals were 
subsequently removed completely if there were no prescriptions for lipid-
lowering drugs or lipid profile blood test results reported for them in the period 
of interest when they were over the age of 18 years (n=39,448). 
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3.3 Defining the Post Myocardial Infarction Population 
3.3.1 Justification of Choice of Population 
The post MI population was selected as it is widely accepted that patients who 
have previously experienced an MI are, and remain, at high risk of further MIs 
without the need to consider other risk factors. Indeed, the majority of 
cardiovascular risk assessments exclude those with established CVD from their 
use with guidelines enforcing the notion that they should be treated and 
monitored regardless (NICE, 2014; Stone et al., 2014; Piepoli et al., 2016; SIGN, 
2017), and the World Health Organisation has issued clear guidance regarding 
the treatment of such patients (World Health Organization, 2017a). For the 
purposes of this study, a post MI population would be expected to have a high 
proportion of patients with a statin prescription given the clear clinical 
guidelines, and therefore this group represents a cleaner population than 
primary prevention patients. Although the terms ‘secondary prevention’ and 
‘established cardiovascular disease’ do not exclusively refer to MIs alone, they 
form one of the key subsections of these populations (SIGN, 2017). Patients 
could also be defined with relative ease from the data available (all MIs would 
result in a hospital admission), and benefit from an easily definable start date 
for follow up (the date of their MI). 
3.3.2 Definition of New Hospital Stay 
During an inpatient stay at a hospital, multiple records are often generated in 
the SMR01 database with each transfer to a new ward (or transfer between 
hospitals) counting as a new episode and consequently generating a new record. 
Without a method of identifying which records were part of the same stay, this 
would result in the overestimation of the number of stays in a hospital made by 
a patient (and result in a single event such as an MI being counted multiple 
times). The method implemented to identify new stays was similar to that taken 
by The Health & Social Care Information Centre (HSCIC) methodology used in the 
national datasets (Health and Social Care Information Centre, 2014).  
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An episode was considered to be part of the same stay if for the same individual:  
• The admission date was on or before the previous discharge date  
OR 
• The admission date was less than or equal to two days after the previous 
discharge date  
AND  
o The previous discharge type was ‘Transfer within the same Health 
Board/ Health Care Provider’ (Code 12)  
OR  
o The previous discharge type was ‘Transfer to another Health 
Board/ Health Care Provider’ (Code 13)  
OR  
o The admission type was ‘Planned Transfers’ (Code 18) 
This is further illustrated as an example in Figure 3.9. Under these conditions, a 
new stay is the first episode which is not considered to be part of the previous 
stay for the same patient. Once identified, each new stay was numbered 
consecutively to create a hospital stay ID. 




Figure 3.9: Methodology to Determine New Hospital Stays (Schematic Example) 
3.3.3 Definition of Myocardial Infarction of Interest for Analysis 
Figure 3.10 details the number of records retained at each stage of the 
derivation process to extract the post MI population. The hospital admission 
(SMR01) file was first restricted to records where any of the six diagnosis codes 
captured contained the ICD10 codes I21 (acute myocardial infarction) or I22 
(subsequent myocardial infarction). Duplicate records were then removed (which 
occurred as a result of other episodes captured as part of the same stay) so that 
the number of unique MIs could be identified. 
The dates of admission were then used to select events where there were 
potentially three years or more of follow up data (death may occur before that, 
however), as the longer-term management of this population was the focus of 
this thesis. As the date for the end of follow up was 31st July 2017, this made the 
time window of interest for MI admissions 1st January 2009 and 31st July 2014 
(inclusive). However, it is important to note that in the absence of a reported 
death, patients are assumed to be still alive and within the NHS GGC region until 
31st July 2017, with no formal indicator to confirm that this is the case. 
Consequently, by restricting the cohort to those with the possibility of three 
years follow up, this extended time window may mean that the population has a 
higher proportion of patients who have moved out of the region than in a 
population of post MI patients without this constraint. Patient relocation could 
be due to systematic differences in their characteristics, such as frailty or 
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severity of illness, and could result in some biases in the estimation of the 
frequency of patient outcomes and behaviour.  
 
Figure 3.10: Identification of MIs for the Post MI population. A valid MI was defined as ICD10 
codes I21 or I22. An MI was non-fatal if no death occurred during admission or within 30 
days of discharge. Reliable prescribing data refers to patients where estimated adherence 
did not exceed 200% for any given year (further details given in Chapter 3.4.3). 
3.3.4 Creation of Subsequent Time Windows 
 
Figure 3.11: Annual Time Windows Constructed for each Patient (Schematic Examples). NC 
= Not Complete (year). Green and red arrows represent the start and end dates for each time 
window respectively. 
The list of relevant MIs was then restricted further to those which were non-
fatal. MIs were considered to be fatal if the patient died during the admission or 
within the first 30 days after hospital discharge, with non-fatal MIs being the 
remainder. For patients with more than one MI captured during the period, only 
Valid MIs 




31st Jul 2014 
N = 16,978 
# Pts: 12,692
Non-Fatal
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the first MI was used. The admission date for the MI was used as the start date of 
follow up for each patient. The list of patient IDs was then used to extract the 
corresponding prescribing, laboratory, and demographic data. 
For each patient in the post MI population, a set of time windows was 
constructed to capture information (such as adherence) available in each year of 
follow up since the date of admission (as illustrated in Figure 3.11). These 
windows were adjusted for leap years to ensure that each time window started 
on the same date of each year. Given the earliest date that an MI could be 
counted was 1st January 2009, the maximum number of windows available for a 
patient was nine. Any time windows starting after the end of follow up (31st July 
2017) or after the patient’s death were removed. For time windows where the 
end of follow up or death occurs, the end date for the window was adjusted 
accordingly and an indicator variable was created to highlight that this time 
window did not represent a complete year of follow up.  
3.4 Statin Prescription Data 
Statin prescription records were used to approximate a patient’s statin 
adherence through the calculation of the Medication Possession Ratio (MPR) for 
each year post MI. Prescriptions for Atorvastatin, Fluvastatin, Pravastatin, 
Simvastatin, Rosuvastatin, Simvastatin/Ezetimibe, and Simvastatin/Fenofibrate, 
where the latter two represented combination drugs, were included. Dispensed 
dates were used preferentially over prescribed dates as this was the first date 
that the patient could be in possession of the medication. If the dispensed date 
had been left blank on entry then this is automatically set as the paid date by 
the Information Services Division which is the last day of the month (Information 
Services Division, 2010). 
3.4.1 Adjusting for Concomitant Statin Use 
A prescription’s end date was calculated as day the drug was dispensed plus the 
day-coverage of statins dispensed. This model assumes that one statin tablet was 
taken per day (NHS, 2018), that the patient took their first dose on the day it 
was dispensed, and that the end date is the first day that the patient would 
have no medication. Prescriptions with an estimated end date after a patient’s 
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death had the end date revised to the date of death, and the quantity dispensed 
was updated to reflect the number of doses that could have been taken by the 
patient. Prescriptions dispensed after death were removed completely. 
 
Figure 3.12: Algorithm and Hierarchy for Multiple Prescriptions. This method was only 
implemented on cases where an individual was dispensed multiple prescriptions on the 
same date (regardless of drug or dose). For the final part, the first drug that occurs in each 
duplicate set should be kept at its highest dose e.g. if Fluvastatin 40mg, Fluvastatin 20mg 
and Rosuvastatin 5mg were all dispensed on the same day, Fluvastatin 40mg should be 
retained only.  
Before further adjustment, an algorithm was implemented to adjust for cases 
where a patient was dispensed more than one prescription for a statin on the 
Remove outright duplicates (i.e. same prescribed date, same drug, dose etc). 
For each dispensed date-drug-dose combination, calculate the total quantity dispensed 
to collapse into one entry per date-drug-dose combination. Adjusted quantity and end 
date.
Assess drugs dispensed prior to and post the duplication. 
1. If one of the drugs matches the drug dispensed after, keep this record and discard 
the others. 
2. If one of the drugs matches the prior, discard this one and keep the different ones 
(for now).
If the duplicate is within the same drug but at different doses, assume the higher dose.
For each set of duplicates, assume the following hierarchy:
1. Highest Dose Fluvastatin 
2. Highest Dose Pravastatin 
3. Highest Dose Rosuvastatin 
4. Highest Dose Atorvastatin
5. Highest Dose Simvastatin (regardless of combination or not)
6. Simvastatin Combination
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same day. This was necessary as a patient should not be assumed to be taking 
more than one statin at a time, and such duplication is likely the result of a 
delay in updating the patient’s current prescription. Therefore, inclusion of the 
multiple prescriptions in the calculation would result in an inflated and 
inaccurate estimation of the patient’s adherence. The algorithm used to handle 
such instances is detailed in Figure 3.12.  
Once this was complete, if any overlap occurred between the dates for two 
different statins (and doses) in a patient, an adjustment was made such that the 
end date for the previous prescription was the dispensed date of the new one (as 
the end date would be the first day with no medication), and quantities were 
also adjusted. Prescriptions for the combination drugs, Simvastatin/Ezetimibe 
and Simvastatin/Fenofibrate, were then merged with the Ezetimibe and Fibrate 
prescriptions respectively where a similar process was conducted to prevent any 
further overlap occurring. The adjusted dates and quantities from this process 
were then recombined with the statin prescriptions. The complete details on the 
stages of this process can be found in Appendix A. 
3.4.2 Estimating Adherence with Medication Possession Ratio 
The MPR was used to estimate a patient’s adherence to statin medication for 
each of the full year time windows constructed. Whilst concerns regarding 
overestimation of adherence using this method have been documented (Raebel 
et al., 2014), this likelihood was reduced as dispensed quantities and end dates 
of treatment had been adjusted to ensure that a patient was only dispensed one 
medication in the class at a time. However, early refilling issues within the same 
statin and dose would have remained (Raebel et al., 2014). Despite this, the 
fixed length of the time windows (at 365 or 366 days) used for this analysis does 
make MPR preferable in this scenario (Sperber, Samarasinghe and Lomax, 2017). 
Nonetheless, as with all methods used for estimating adherence using secondary 
data, MPR assumes that possession of the medication corresponds to a patient’s 
compliance, which may not be the case (Lam and Fresco, 2015). However, whilst 
possession of the medication isn’t a sufficient condition to ensure a patient’s 
adherence with the medication, it is a necessary one, and as a result, such 
methods have been extensively used in the literature (Donnan, MacDonald and 
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Morris, 2002; Donnelly et al., 2008; Wei, Fahey and MacDonald, 2008; Shetty et 
al., 2016).  
For the post MI population, the statins prescription file was first restricted to 
those only issued with an end date after the MI admission date of interest and 
with a start date before the end of follow up. Prescriptions were then matched 
to the time windows. Prescriptions which fell over two time windows were 
matched to both, and their quantities adjusted in each time window to reflect 
the number of doses that should have been available to be taken by the patient 
if they were fully compliant with the medication schedule. The MPR for each 
time window was then calculated using the formula (Raebel et al., 2014; Lam 
and Fresco, 2015; Sperber, Samarasinghe and Lomax, 2017):  
(
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑜𝑠𝑒𝑠 𝑑𝑖𝑠𝑝𝑒𝑛𝑠𝑒𝑑 𝑖𝑛 𝑡𝑖𝑚𝑒 𝑤𝑖𝑛𝑑𝑜𝑤
𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑡𝑖𝑚𝑒 𝑤𝑖𝑛𝑑𝑜𝑤⁄ ) 𝑥 100 
Equation 3.2: Medication Possession Ratio (MPR) 
 
This calculation was only made for time windows that were a full year (365 or 
366 days) in duration, and not those which were shorter due to end of follow up 
or death. The full details of this method can be found in Appendix B. 
3.4.3 Handling of Excessively High Adherers 
After this calculation, however, it was noted that some patients achieved an 
MPR higher than 100% (i.e. taking the statin as prescribed). Small increases 
above 100% would be expected if a patient was dispensed further medication 
before the previous prescription was completely used, which is a known 
limitation of MPR (Raebel et al., 2014). However, where the calculated MPR was 
considerably higher than 100%, this raised concerns regarding the accuracy and 
reliability of the dispensing records. To fully assess the scale of this, an 
individual line graph was plotted to examine trends of MPR for patients who had 
an MPR greater than 120% at any point during follow up (Figure 3.13). Patients 
with an MPR greater than 200% (n=45, 0.4% Post MI) were subsequently removed. 
A look at the prescription records for these patients found they were due to, 
sometimes persistent, human-error in the quantities dispensed variable. 




Figure 3.13: MPR Patterns for Patients with High Adherence. Patients were included if their 
estimated MPR exceeded 120% for any year during follow up. Coloured lines show some of 
the patterns in MPR for a selection of individual patients.  
3.5 Lipid Profile Results  
A lipid profile result consisted of five components (“a set”): Total Cholesterol, 
Total Cholesterol:HDL Cholesterol, HDL Cholesterol, LDL Cholesterol, and 
Triglycerides. However, not all of these components were available for each 
sample, and in some cases, multiple results for the same component were 
reported.  
3.5.1 Handling Duplicate Results 
Multiple results for one component from the same sample became problematic 
when the five components of the set were subsequently transposed from long to 
wide format and matched by the patient, sample date, and time, as shown in 
Figure 3.14. In such instances, these records needed to be simplified such that 
only one test result was reported at each time point. 
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First, complete duplicates were removed. Total Cholesterol:HDL Cholesterol and 
LDL Cholesterol values were then manually calculated, using the formulae 
detailed in the SIGN guidelines (SIGN, 2017, p. 39):  




Equation 3.3: Total Cholesterol:HDL Cholesterol 
 




𝑤ℎ𝑒𝑟𝑒 𝑎𝑙𝑙 𝑣𝑎𝑙𝑢𝑒𝑠 𝑎𝑟𝑒 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑖𝑛 𝑚𝑚𝑜𝑙/𝑙, 𝑎𝑛𝑑 𝑡𝑟𝑖𝑔𝑙𝑦𝑐𝑒𝑟𝑖𝑑𝑒𝑠 𝑎𝑟𝑒 ≤ 4.5 𝑚𝑚𝑜𝑙/𝑙. 
Equation 3.4: LDL Cholesterol 
 
 
Figure 3.14: Example of Transposition-Induced Duplication of Lipid Profiles. This example is 
included for illustration purposes only. In this case, each of the five components is 
duplicated just once, but when these are transposed 32 records are produced. 
Records where both manually calculated values matched the reported values 
(allowing for rounding error) (Goldberg, 1991) were then retained, along with 
the most complete sets. Those with triglycerides too high for an LDL result 
(>4.5mmol/l) to match were then retained if they matched on Total 
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Cholesterol:HDL Cholesterol alone. The mean values for each of the components 
for any remaining duplicates for a sample were then calculated. The full details 
of the method undertaken to handle duplicated lipid results can be found in 
Appendix C. 
3.5.2 Matching Lipid Profile Results to Time Windows 
The lipid profile results were then restricted to the post MI population and 
subsequently combined with the time window dates. Tests were matched to a 
time window if the sample was taken within the dates of the time window. In 
cases where multiple tests were obtained within a time window, the mean value 
of each of the components from all of the tests in that window was derived. 
These values could then be used to generate indicator variables to ascertain 
whether a patient met guideline specific lipid reduction criteria in any given 
time window (on average) e.g. LDL Cholesterol ≤1.8mmol/l from the 2016 
European Society of Cardiology (ESC) Guidelines (Piepoli et al., 2016).  
3.5.3 Calculating Percentage Change in Non-HDL Cholesterol 
One target of interest was the percentage reduction of non-HDL cholesterol; the 
primary focus of the current NICE guidelines (NICE, 2014). For this, a baseline 
sample where the patient was not on statin medication was required, and the 
number of the patients included at each stage of its derivation is shown in Figure 
3.15. Firstly, the lipid profile data was restricted to tests conducted before the 
MI at the start of a patient’s follow up. These tests were then combined with the 
statin prescription dates. A test was considered a suitable baseline if it was 
more than six months after the estimated end date (182 days) of a statin 
prescription or if the patient had no prescriptions for statins prior to the date of 
the MI. If multiple tests were considered to be suitable for a patient’s baseline 
result, the test closest to the date of MI was selected. If no tests were 
considered to be suitable, then a percentage reduction could not be calculated 
for any of the patient’s time windows, and the result was set to missing. 
Once a baseline test was selected and merged with the time window 
information, non-HDL Cholesterol was calculated as (SIGN, 2017, p. 39):  
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𝑛𝑜𝑛𝐻𝐷𝐿 𝐶ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 = 𝑇𝑜𝑡𝑎𝑙 𝐶ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 − 𝐻𝐷𝐿 𝐶ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙  
Equation 3.5: Non-HDL Cholesterol 
 
This was only calculated for time windows and baseline tests where both of 
these values were present. Finally, the percentage change was calculated as:  
(
(𝑡𝑖𝑚𝑒 𝑤𝑖𝑛𝑑𝑜𝑤 𝑛𝑜𝑛𝐻𝐷𝐿 − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑛𝑜𝑛𝐻𝐷𝐿)
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑛𝑜𝑛𝐻𝐷𝐿 
⁄ ) 𝑥 100 
Equation 3.6: Percentage Change in Non-HDL Cholesterol 
  
Full details of the method used can be found in Appendix D.  
 
Figure 3.15: Selection Process for Deriving the Percentage Change in Non-HDL Cholesterol. 
*On statins defined as either the result was obtained during a prescription or within 182 
days of its end date. 
Post MI 
Population  
N = 11,110 
Pre-MI Lipid Test 
N = 7,750 
Not on Statins* 
N = 5,037 
% Change Non-
HDL Calculable 
N = 3,355 
% Change Non-HDL 
Not Calculable 
N = 1,682 
On Statins* 
N = 2,713 
No Pre-MI Lipid 
Tests 
N = 3,360 
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3.5.4 Lipid Testing Rates 
The total number of tests during a patient’s follow up was also calculated, along 
with the number of tests within each time window. Within each time window, 
patients were then categorised as having no tests, recommended testing (one 
test), or over-testing (more than one test). Over the entire duration of follow 
up, a patient’s testing rate was calculated as:  
(
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑒𝑠𝑡𝑠 𝑖𝑛 𝑓𝑜𝑙𝑙𝑜𝑤 𝑢𝑝
𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑓𝑜𝑙𝑙𝑜𝑤 𝑢𝑝 (𝑑𝑎𝑦𝑠)⁄ ) 𝑥 365.25 
Equation 3.7: Rate of Lipid Testing  
 
3.6 Demographics and Covariates 
3.6.1 Age at Myocardial Infarction  
The age of the patient was calculated on the day they were first admitted with 
an MI. This was calculated as: 
(𝑑𝑎𝑡𝑒 𝑜𝑓 𝑎𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛 − 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑏𝑖𝑟𝑡ℎ) 
365.25
⁄  
Equation 3.8: Age (in years) at MI 
 
As stated earlier (Chapters 3.1 and 3.2.4), the calculated age of the patient will 
be an approximation as the dates of birth were given as the fifteenth of the 
relevant month and year in the demographics file. 
3.6.2 NHS GGC Specific Scottish Index of Multiple Deprivation 
The demographics file provided various measures of the patient’s deprivation 
status which were derived from their postcode. This included the Scottish Index 
of Multiple Deprivation (SIMD) 2012 rank and its associated quintile. These were 
derived by ranking data zones (which represent small areas) across Scotland in 
2012 from the most deprived to the least deprived. Areas in the top 20% of the 
ranks would, therefore, constitute the most deprived quintile (Scottish 
Government, 2018).   
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However, approximately 40% of the population of the NHS GGC area are 
estimated to live in areas in the most deprived quintile (NHS Greater Glasgow 
and Clyde, 2015b, chap. 1), with 30% of the 15% most deprived zones nationally 
found in Glasgow City in 2013 (Scottish Government, 2013). This meant that the 
NHS GGC population was unlikely to be representative of the overall Scottish 
population, or its post MI population. Therefore, NHS GGC specific SIMD quintiles 
were derived, so that the role of deprivation could be effectively compared 
within the post MI population of NHS GGC. For the majority of summaries, only 
these NHS GGC specific quintiles are presented. 
To generate these quintiles, a list of the data zones in the NHS GGC area was 
sourced, which showed that there were 1,473 data zones in the area in 2012 
(Scottish Government, 2015). These were ordered by rank and subsequently 
divided into quintiles, based on the number of data zones included. The cut 
points for these quintiles were then equated back to the Scottish SIMD ranks for 
2012 and are shown in Table 3.2. 
Table 3.2: NHS GGC Specific SIMD 2012 Quintiles. All cut points are inclusive, and ranks 
refer to the ISD (National) Ranks 







3.6.3 Causes of Death  
Causes of death were available for all individuals with a death certificate 
recorded. These were first formatted to the shortened ICD10 codes (retaining 
only the letter and the first two numbers). A series of consecutively numbered 
cause of death variables were included, with the primary cause of death coded 
with zero, and the underlying cause of death given in a separate non-numerically 
coded variable. Primary and antecedent causes of death were then extracted 
and separated from other significant conditions. The primary cause and 
antecedent causes were also referred to as contributory causes when considered 
together. The process of extraction was derived to reflect how such information 
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would have been captured and structured on the paper version of a death 
certificate, as shown in Figure 3.16 (National Records Scotland, 2014a). 
 
Figure 3.16: Annotated Death Certificate. Annotations indicate assumed source of the 
causes of death definitions. Example death certificate was taken from National Records 
Scotland, 2014. 
3.6.4 Diabetes Type and Duration 
Diabetes type and the date of diagnosis were extracted from the SCI Diabetes 
data, which contains health and treatment data for all diabetes patients in 
Scotland (Scottish Care Information Diabetes Collaboration, 2015). The date of 
diagnosis is captured in the ‘date of entry’ column for the ‘Type of Diabetes’ 
observations within the data, and therefore all of these observations were 
extracted. Multiple records were available for each patient by visit. Dates of 
entry before the patient’s date of birth were considered to be invalid and were 
excluded. The first valid date for each patient was then assumed to be the date 
of diagnosis of diabetes. For patients with no valid dates of diagnosis, the date 
of diagnosis and consequently the duration of disease was set to missing. 
However, diabetes type could still be ascertained. Some discrepancy was 
present for some patients with the type of diabetes often listed differently at 
each visit, or simply listed as unknown. As a result, an algorithm was 
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implemented to determine the type of diabetes for each patient (as shown in 
Figure 3.17). Full details of the method used can be found in Appendix E. 
 
Figure 3.17: Type and Date of Diagnosis of Diabetes Algorithm. This algorithm was used for 
patients included in the SCI Diabetes database using the information captured in all 
observations with the description ‘Type of Diabetes’.  
Once a date of diagnosis and type of diabetes was determined, this was 
restricted to only members of the post MI population, and those diagnosed 
before the end of follow up. This was combined with the demographic and time 
window data. The duration of disease (in years) at the time of MI was calculated 
using the formula below. The minus one was included to identify those whose 
diabetes status was confirmed before their admission with an MI (as it could 
have been confirmed at the visit). This also prevented any discrepancy when 
identifying patients diagnosed during follow up, as the date of MI forms the start 
date of the first window. 
(𝑑𝑎𝑡𝑒 𝑜𝑓 𝑀𝐼 − 1 − 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠)
365.25
⁄  
Equation 3.9: Diabetes Duration Prior to MI 
 
In the time window data, a similar calculation was used to determine the 
duration of disease at the end of the time window. A minus one adjustment was 
not necessary for this instance as the start and end dates of the time windows 
were inclusive.  
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(𝑒𝑛𝑑 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑡𝑖𝑚𝑒 𝑤𝑖𝑛𝑑𝑜𝑤 − 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠)
365.25
⁄  
Equation 3.10: Diabetes Duration in Time Windows 
 
An indicator variable was also derived to highlight time windows where the 
diagnosis of diabetes was new.  
3.6.5 Duration of Follow Up  
Each patient was followed up from the day of the admission with their first MI 
(on or after 1st January 2009) until death (or 31st July 2017), whichever occurred 
first. Therefore, a patient’s time at risk, or duration of follow up, was 
calculated using the equation below. The plus one adjustment is included to 
allow the inclusion of both the start and end date in the time at risk. Though the 
equation below would yield the duration of follow up in days, it can be 
converted into years by dividing by 365.25. 
𝑃𝑎𝑡𝑖𝑒𝑛𝑡′𝑠 𝑇𝑖𝑚𝑒 𝑎𝑡 𝑅𝑖𝑠𝑘 = 𝑃𝑎𝑡𝑖𝑒𝑛𝑡′𝑠 𝐸𝑛𝑑 𝐷𝑎𝑡𝑒 − 𝑃𝑎𝑡𝑖𝑒𝑛𝑡′𝑠 𝑆𝑡𝑎𝑟𝑡 𝐷𝑎𝑡𝑒 + 1 
Equation 3.11: Patient's Duration of Follow Up (days). A patient’s end date was defined as 
31st July 2017 if death did not occur earlier. A patient’s start date was the first day of their 
admission with an MI on or after 1st January 2009. 
3.6.6 Duration of Stay  
The duration of the hospital stay was defined similarly (Equation 3.12). The plus 
one adjustment is included so that if a patient was admitted and discharged on 
the same day, the duration of stay would be equal to one day. Therefore, the 
duration of stay does not reflect the number of nights admitted, but the number 
of partial days in the hospital.  
𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑆𝑡𝑎𝑦 = 𝑉𝑖𝑠𝑖𝑡 𝐷𝑖𝑠𝑐ℎ𝑎𝑟𝑔𝑒 𝐷𝑎𝑡𝑒 − 𝑉𝑖𝑠𝑖𝑡 𝐴𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛 𝐷𝑎𝑡𝑒 + 1 
Equation 3.12: Duration of Hospital Stay (days) 
3.6.7 Time Since MI (Prior) 
MIs documented in the ten years prior to the first non-fatal MI of interest were 
also captured. If an individual had multiple previous MIs, then all were retained, 
and the number of them captured in a separate variable. The time elapsed 
Chapter 3  137 
 
 
between the prior MI and the MI of interest was calculated for all patients with a 
prior MI using a similar method to the other duration variables previously 
discussed (Equation 3.13). Values were converted into years by dividing by 
365.25. 
𝑇𝑖𝑚𝑒 𝑆𝑖𝑛𝑐𝑒 𝑃𝑟𝑖𝑜𝑟 𝑀𝐼 = 𝐷𝑎𝑡𝑒 𝑜𝑓 𝐴𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛 − 𝑃𝑟𝑖𝑜𝑟 𝐷𝑎𝑡𝑒 𝑜𝑓 𝐴𝑑𝑚𝑖𝑠𝑠𝑖𝑜𝑛 + 1 
Equation 3.13: Time Since Prior MI (days). Date of Admission refers to the date the patient 
was first admitted with the non-fatal MI of interest on or after 1st January 2009 (the patient’s 
start of follow up date). Prior Date of Admission is the visit start date for the most recent MI 
in the ten years before this start date. 
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Chapter 4 Describing the Post Myocardial 
Infarction Population 
4.1 Introduction 
NHS GGC is formed from six local authorities: Glasgow City, Renfrewshire, East 
Dunbartonshire, East Renfrewshire, West Dunbartonshire, and Inverclyde. In 
2013, its population was estimated to represent 21.4% of the Scottish population 
with over 1.1 million individuals, with a slightly higher percentage of females 
(51.4%) (NHS Greater Glasgow and Clyde, 2015b). This gender divide was similar 
to the overall Scottish population (National Records Scotland, 2014b). The age 
distribution is also comparable, with similar numbers of those under the age of 
20 (NHS GGC: 21.6%, Scotland: 21.9%), although there was a slightly lower 
percentage of those over the age of 65 in NHS GGC (16.2% vs 17.8%). There was 
also some regional variation in the age distribution within NHS GGC, with 13.9% 
in the Glasgow City local authority over the age of 65, compared to 20.8% in East 
Dunbartonshire (NHS Greater Glasgow and Clyde, 2015b).  
The population of interest in the remainder of this thesis, namely those who 
have experienced a non-fatal MI, however, is not the entire population of NHS 
GGC region as the presence of the risk factors identified in Chapter 1.2 will 
impact on an individual’s likelihood of experiencing a cardiovascular event. 
Consequently, the prevalence of, as well as the interactions between, these will 
all influence the prevalence of CVD within the NHS GGC population, and 
therefore the size of the population of interest for this thesis. For example, a 
higher proportion than expected live in areas within the most deprived quintile 
(35.9%) (NHS Greater Glasgow and Clyde, 2015b), and the Scottish Health Survey 
in 2015 found higher rates of smoking and exceeding recommended alcohol 
limits than the national average (NHS Greater Glasgow and Clyde, 2015c).  
Furthermore, the prevalence of diabetes mellitus was estimated to be 5.5% in 
the 2016 Scottish Diabetes Survey, which was broadly in line with the national 
average (5.4%), and 4.7% in the Quality and Outcomes Framework (QOF) 
registers for 2015/16, which was lower than the national average (5.0%) 
(ScotPHO, 2016). For several comorbidities and types of established CVD, the 
QOF estimates for prevalence were: 12.7% for hypertension, 2.8% for CKD, 4.0% 
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for CHD, and 2.1% for stroke. Except for hypertension, where this rate was 
slightly lower than the national average (13.9%), all of these estimates were 
approximately similar to national averages (Information Services Division, 2016). 
Nonetheless, the British Heart Foundation statistics for 2020 report that the 
premature death rate from CVD in Glasgow is the highest in the UK, with rates in 
Scotland also higher than the other nations. This is likely the consequence of 
combinations of many risk factors, with deprivation often demonstrating large 
variations in the rates of CVD, hypertension, and diabetes within Scotland, with 
all approximately twice as prevalent in areas that are more deprived than least 
deprived (British Heart Foundation, 2020a).   
However, research has also shown that many of the risk factors associated with 
CVD are also associated with a patient’s adherence to medication and 
subsequently their achievement of target lipid levels, as discussed in Chapters 
1.4.2 and 1.4.3. For example, those with a diagnosis of diabetes are more likely 
to be adherent (Hope et al., 2019) and meet guideline-recommended lipid 
targets (Danese et al., 2017).  
This chapter, therefore, aims to understand the post MI population in NHS GGC. 
To achieve this, descriptive statistics of the cohort derived in Chapter 3 will 
summarise their demographics, their adherence to LLM, their achievements of 
lipid-lowering targets from clinical guidelines, and the frequency and patterns of 
the testing of their lipid levels. It is hypothesised, that this population will be 
broadly similar to other post MI and secondary prevention cohorts within the 
literature. 
4.2 Population Summary 
4.2.1 Baseline Demographics 
Baseline demographics for the post MI population in NHS GGC are shown in Table 
4.1. There were 11,110 patients who experienced at least one non-fatal MI 
(ICD10: I21, I22) between 1st January 2009 and 31st July 2014 (inclusive), without 
an annual MPR greater than 200%.  
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Table 4.1: Baseline Demographics of NHS GGC’s Post MI Population 
 Post MI 
N = 11,110 
Gender   
   Male 6,732 (60.6%) 
   Female 4,378 (39.4%) 
  
Age at MI (years)  
   Mean (SD) 66.9 (13.9) 
   Median 67.4 
   IQR 56.1 – 77.9 
   Range 19.3 – 102.6 
  
SIMD 2012 Quintile (Scotland) 
   1 (Most) 4,760 (43.2%) 
   2 2,023 (18.3%) 
   3 1,393 (12.6%) 
   4 1,305 (11.8%) 
   5 (Least) 1,550 (14.1%) 
   Missing 79 
  
SIMD 2012 Quintile (NHS GGC) 
   1 (Most) 2,650 (24.0%) 
   2 2,528 (22.9%) 
   3 2,294 (20.8%) 
   4 1,877 (17.0%) 
   5 (Least) 1,682 (15.2%) 
   Missing 79 
  
Diabetes at MI 2,099 (18.9%) 
   Type 1 120 (1.1%) 
   Type 2 1,979 (17.8%) 
  
Prior MI 714 (6.4%) 
   1  558 (5.0%) 
   >1 156 (1.4%) 
Numbers are N (%) unless otherwise specified. SD = Standard Deviation; IQR = Interquartile 
Range. Population summarised is the Post MI cohort derived for this thesis; specifically, 
patients who experienced a non-fatal MI in NHS GGC between 2009 and 2014, as outlined in 
Chapter 3. 
This population was predominantly male (60.6%) and had an average age at their 
baseline MI admission of 67 years. Examination of the Scottish SIMD quintiles 
would suggest that a larger percentage of the population reside in the most 
deprived quintile of Scotland, with non-fatal MIs less prevalent in the least 
deprived areas (most vs least deprived quintile: 43.2% vs 14.1%). However, this 
does not take account of the high proportion of the most deprived regions of 
Scotland being within the NHS GGC area. When the NHS GGC specific SIMD 
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deprivation quintiles were used, this trend, whilst still present, is attenuated 
(24.0% vs 15.2%). Finally, approximately one fifth (18.9%) of the population was 
diagnosed with diabetes before their MI, and 6.4% had experienced a prior MI in 
the ten years before the start of follow up. 
4.2.2 Duration of Follow Up 
Details surrounding the duration of follow up and the number of years available 
per patient are shown in Table 4.2. The average duration of follow up per 
patient was approximately four years and six months, with the maximum follow 
up of eight years and seven months (as expected given the dates used for 
extraction).  
Table 4.2: Summary of Duration of Follow Up  
 Summary Statistic 
Duration of FU (days) (years) 
   Mean (SD) 1,646.0 (807.7) 4.5 (2.2) 
   Median 1,653.0 4.5 
   IQR 1,155.0 – 2,278.0 3.2 – 6.2 
   Range 35.0 – 3,134.0 0.1 – 8.6 
   
Complete Years Available 
   0 years 1,028 (9.3%) 
   1 years 767 (6.9%) 
   2 years 643 (5.8%) 
   3 years 2,115 (19.1%) 
   4 years 1,802 (16.2%) 
   5 years 1,619 (14.6%) 
   6 years 1,452 (13.1%) 
   7 years 1,117 (10.1%) 
   8 years 567 (5.1%) 
Numbers are N (%) unless otherwise specified. FU = Follow Up; SD = Standard Deviation; 
IQR = Interquartile Range. Post MI population was followed up from the date of their first 
non-fatal MI between 1st January 2009 and 31st July 2014, until 31st July 2017 or death, 
whichever occurred first. 
However, for much of the analysis, a patient’s follow up is divided into year-long 
time windows to allow the capture of time-varying variables such as their 
estimated adherence and lipid profile results. Therefore, the latter half of Table 
4.2 categorises patients by the number of complete (full) years of follow up that 
they had before death or the end of follow up occurred. Within these numbers, 
patients with less than three complete years of follow up, were all patients who 
died; for example, this means that just over 1,000 patients (9.3%) died in the 
Chapter 4  142 
 
 
year following their MI. This is because the cohort was set up to allow at least 
three years of follow up before censoring occurred. Therefore, those with 
greater than or equal to three full years of follow up represent those alive at 
end of follow up (31st July 2017) as well as individuals who had died, thus 
explaining the marked increase in the number of patients observed from the 
three complete years of follow up onwards.  
4.2.3 Myocardial Infarctions Prior to Period of Interest 
There were 714 (6.4%) patients who had a documented MI in the ten years 
before their start of follow up, with 156 (1.4%) experiencing more than one. 
Using just the patient’s most recent prior MI, the average time since their 
previous MI to the start of follow up was 5 years (Table 4.3). However, this 
ranged from 6 days to 10 years (maximum length of the lookback period). 
Table 4.3: Time Since Prior MI in Post MI Population with a Prior MI 
 Time Since MI (days) Time Since MI (years) 
Mean (SD) 1,851.0 (1,003.8) 5.1 (2.7) 
Median 1,835.0 5.0 
IQR 1,057.0 – 2,674.0 2.9 – 7.3 
Range 6.0 – 3,653.0 0.0 – 10.0 
SD = Standard Deviation; IQR = Interquartile Range. Only the time since the most recent 
prior MI is included, and only calculated for patients with a prior MI. Prior MIs were only 
included if the admission occurred in the ten years before the patient’s start of follow up.  
4.3 Baseline Admission for Myocardial Infarction 
Details surrounding the MIs which defined the start of a patient’s follow up are 
presented in Table 4.4 and include the year of admission, the first hospital of 
admission, and the duration of their stay.  
The number of MIs in each year was calculated for each calendar year. The 
numbers recorded increased from around 1,700 in 2009 to approximately 2,000 
per year by 2011 which then remained reasonably consistent for the remainder 
of the period. The decrease observed in 2014 occurs as a result of the fact that a 
full year’s worth of data was not included (until 31st July only).  
The hospital admitted was the first hospital that the patient was admitted to 
with the MI. This does not, therefore, allow for any transfers that may have 
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occurred subsequently, or prior, to the diagnosis of the MI. The Golden Jubilee 
National Hospital had the most admissions, and given that it is the location of 
the national and regional heart and lung services (Golden Jubilee National 
Hospital, 2019), this was in line with expectations. 
There was some apparent skewing in the duration of stay data, with several long 
stays likely to lead to an elevated mean average stay, which is further reflected 
in the wide range of values. The maximum length of stay was 1,043 days, which 
is equivalent to 2.9 years. Many of those with longer durations of stays were for 
patients who went on to be transferred to long-stay geriatric medicine units or 
rehabilitation wards, with these stays considered to be part of the same visit 
under the continuous visit methodology implemented (Chapter 3.3.2). 
Table 4.4: Details of Baseline MIs for the Post MI Population 
Summary Statistic 
Year of MI  
   2009 1,733 (15.6%) 
   2010 1,994 (17.9%) 
   2011 2,080 (18.7%) 
   2012 2,114 (19.0%) 
   2013 2,029 (18.3%) 
   2014 1,160 (10.4%) 
  
Hospital Admitted  
   Golden Jubilee National Hospital 3,764 (33.9%) 
   Glasgow Royal Infirmary 1,657 (14.9%) 
   Royal Alexandra Hospital 1,334 (12.0%) 
   New Victoria Hospital 1,197 (10.8%) 
   West Glasgow 1,179 (10.6%) 
   Queen Elizabeth University Hospital 706 (6.4%) 
   Inverclyde Royal Hospital 437 (3.9%) 
   Stobhill Hospital 317 (2.9%) 
   Hairmyres Hospital  243 (2.2%) 
   Vale of Leven General Hospital 147 (1.3%) 
   Other 129 (1.2%) 
  
Duration of Stay (days)  
   Mean (SD) 9.5 (17.8) 
   Median 5.0 
   IQR 4.0 – 9.0 
   Range 1.0 – 1,043.0 
Year totals are for each calendar year. Statistics are N (%) unless otherwise stated. SD = 
Standard Deviation; IQR = Interquartile Range. Information is given for baseline admissions 
only, and not subsequent events. Hospital admitted is the first hospital patient was admitted 
to as part of the hospital admission, so subsequent transfers may have occurred. Numbers 
are lower for 2014 as baseline MIs were only included up until 31st July 2014.  
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4.4 Plasma Lipid Testing 
4.4.1 Frequency of Lipid Testing 
There were 63,940 plasma lipid concentration tests recorded on or after the day 
of admission with the first MI of interest. These were obtained in 10,428 
individuals (93.9%). The number of tests per patient and testing rates is shown 
below in Table 4.5. The average number of tests per individual was between five 
and six, with some individuals receiving considerably more than this. On a crude 
level, given the mean follow up in years was four and a half years, this would 
suggest that individuals in this population may be being tested more frequently 
than the recommended annual testing. This is confirmed in the categorisation of 
testing rates, where nearly half of the patients had a testing rate higher than 
would be expected if a patient was being tested annually. Nonetheless, only a 
third of patients had a testing rate in line with guideline recommendations, with 
around one fifth having a lipid sample taken less frequently.  
Table 4.5: Number of Lipid Plasma Tests (per patient) in the Post MI Population 
 # Tests per Patient Tests/Year Rate (r) 
Mean (SD) 5.8 (4.2) 1.4 (1.7) 
Median 5.0 1.2 
IQR 3.0 – 8.0 0.8 – 1.6 
Range 0.0 – 56.0 0.0 – 51.1 
   
r=0 -- 682 (6.1%) 
0<r≤0.75 -- 1,710 (15.4%) 
0.75<r≤1.25 -- 3,642 (32.8%) 
r>1.25 -- 5,076 (45.7%) 
SD = Standard Deviation; IQR = Interquartile Range. r = rate of tests per year, calculated by 
the total number of tests during follow up divided by the length of follow up.  
 




Figure 4.1: Lipid Testing per Patient by Year of Follow Up in the Post MI Population. Only 
complete years of follow up are included. Partial years of follow up were excluded as tests 
could have subsequently occurred/or been scheduled to occur before the end of the full 
year but after the end of follow up (31st July 2017). 
When considering the complete years of follow up separately (Figure 4.1, Table 
4.6), patients were more likely to have more than one test in the first year after 
an MI, with 60% of patients having more than one test in year 1. This could be 
expected as LLMs are likely to be initiated or altered after an MI and clinicians 
may need to review the patient more frequently to assess if sufficient reductions 
in cholesterol occur. However, 10% of patients did not have their lipids checked 
at all in the first year after their MI. The number of patients who were not 
tested increased to 20% in the second year of follow up, and gradually increased 
to nearly 30% by the eighth year. Conversely, the percentage of patients having 
more than one test per year decreased sharply to 27% in the second year of 
follow up and tapered to 17% by the last year. Thirty percent received one lipid 
test in their first year, in line with guideline recommendations (SIGN, 2017), 
which subsequently increased to over 50% in the second year and remained 
reasonably stable for the duration of follow up. This trend is also reflected in 
the summary statistics for each year. The median number of tests in the first 
year was two, and one test for all subsequent years. However, this analysis does 
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not show patterns within each patient, and patients may switch between each of 
these categories throughout their follow up (Figure 4.2).  
Figure 4.2 attempts to elucidate the testing patterns within patients during 
follow up, both as a whole and within those who died during follow up. This 
confirmed that over-testing was more common within the first year of follow up 
(even when incomplete years were included), though to a lesser extent in 
patients who died. This difference may be partly explained by the fact that a 
significant number of deaths occurred in the first year, and therefore there was 
reduced available time to have multiple tests. Indeed, of those who died in the 
first year, most had no lipid tests post MI. This pattern was also observed 
throughout follow up where many patients had no tests in the year that they 
died. In both graphs, of those who did not have lipid tests in their first year, a 
significant proportion did not receive lipid tests throughout their follow up. This 
was not the case for those who had more than one test in their first year, with 
many having only one test in their second year and throughout the remainder of 
their follow up. Furthermore, most changes in the frequency of lipid testing 
occurred in the first couple of years, with many of these changes representing a 




Table 4.6: Number of Tests per Patient by Year of Follow Up in the Post MI Population 
 Year 1 
10,082 
Year 2  
9,315 
Year 3  
8,672 
Year 4  
6,557 
Year 5  
4,755 
Year 6  
3,136 




Mean (SD) 2.1 (1.5) 1.2 (1.0) 1.1 (0.9) 1.0 (0.9) 1.0 (0.9) 1.0 (0.9) 1.0 (0.9) 1.0 (0.9) 
Median 2.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
IQR 1.0 – 3.0 1.0 – 2.0 1.0 – 1.0 1.0 – 1.0 0.0 – 1.0 0.0 – 1.0 0.0 – 1.0 0.0 – 1.0 
Range 0.0 – 15.0 0.0 – 13.0 0.0 – 19.0 0.0 – 8.0 0.0 – 10.0 0.0 – 13.0  0.0 – 10.0 0.0 – 9.0 
         
















































Only complete years of follow up are included in summary statistics, as incomplete years may lead to underestimation of testing patterns (e.g. follow up 
may have ended before further tests being conducted within that year). Numbers included are for the number of patients with a complete year of follow up 






Figure 4.2: Individual Line Plots of Individual Testing Patterns During Follow Up (Overall and Patients who Died) including incomplete time windows. 
Patient numbers differ between the two graphs, i.e. patient 100 in the overall graph will not be patient 100 in the patients who died graph. Therefore, for 
both graphs, the patient number is arbitrary, and patients were sorted by their testing pattern before plotting. 
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4.4.2 Plasma Lipid Concentrations  
Just under half of the patients had a baseline lipid measurement when they 
were not receiving statin therapy (5,037, 45.3%), with 3,360 (30.2%) patients 
having no pre-MI lipid measurement, and 2,713 (24.4%) with tests obtained only 
whilst already receiving statin medication. As only one baseline sample was 
required and extracted where it was available for a patient, the number of tests 
before the MI per individual was not investigated. Both the baseline (pre-MI 
statin-naïve) and post MI lipid plasma concentrations are summarised in Table 
4.7. 
There were no substantial differences identified in the post MI lipid plasma 
results between those with and without a baseline result (Table 4.7). However, 
the converse was not the case; some differences were present in the baseline 
lipid plasma results between those with and without post MI results. Whilst the 
numbers were small, those with a baseline result but no post MI result tended to 
have more favourable lipid concentrations (e.g. lower total and LDL cholesterol, 
and slightly higher HDL cholesterol). Comparisons of the baseline and post MI 
plasma lipid concentrations within the same patients suggested that the lipids in 
this population were subsequently reasonably well controlled following an MI, 
with the mean total cholesterol lower by over one mmol/l (5.4 vs 4.2mmol/l). As 
the HDL cholesterol stays broadly similar, changes in the Total:HDL cholesterol 
ratio are, therefore, likely the result of the reduction of the total cholesterol 
rather than an increase in HDL cholesterol. The mean values for LDL cholesterol 
and triglycerides also show some evidence of reduction post MI. However, given 
that there are often multiple tests per person in the post MI results compared to 
just one baseline result per person, such comparisons between the summary 
statistics should be interpreted with caution. 
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Table 4.7: Plasma Lipid Summary Statistics Comparing Pre and Post MI Concentrations 
 Pre MI 
















   Mean (SD) 5.4 (1.4) 4.2 (1.4) 4.9 (1.3) 4.1 (1.3) 
   Median 5.3 4.1 4.8 4.0 
   IQR 4.5 – 6.3 3.4 – 4.9 4.0 – 5.7 3.4 – 4.7 
   Range 0.0 – 14.6 0.0 – 16.0 0.0 – 9.3 0.0 – 18.6 
   Missing (%) 2 (<0.1%) 23 (0.1%) 0 (0.0%) 37 (0.1%) 
     
Total:HDL Cholesterol 
   Mean (SD) 4.8 (1.7) 3.8 (1.5) 4.1 (1.5) 3.8 (1.5) 
   Median 4.6 3.6 3.9 3.6 
   IQR 3.6 – 5.7 2.9 – 4.5 3.0 – 4.9 3.0 – 4.5 
   Range 0.0 – 15.7 0.0 – 25.0 0.0 – 11.6 0.0 – 30.8 
   Missing (%) 1,152 (24.4%) 9,314 (32.2%) 95 (30.4%) 11,305 (32.3%) 
     
HDL Cholesterol 
   Mean (SD) 1.2 (0.4) 1.1 (0.4) 1.3 (0.4) 1.1 (0.4) 
   Median 1.1 1.1 1.2 1.1 
   IQR 1.0 – 1.4 0.9 – 1.3 1.0 – 1.5 0.9 – 1.3 
   Range 0.0 – 3.9 0.0 – 4.4 0.0 – 2.9 0.0 – 4.4 
   Missing (%) 1,142 (24.2%) 9,246 (32.0%) 95 (30.4%) 11,246 (32.1%) 
     
LDL Cholesterol 
   Mean (SD) 1.7 (1.9) 1.5 (1.3) 1.3 (1.6) 1.4 (1.3) 
   Median 1.6 1.7 0.0 1.6 
   IQR 0.0 – 3.4 0.0 – 2.3 0.0 – 2.6 0.0 – 2.3 
   Range 0.0 – 9.3 0.0 – 10.2 0.0 – 5.9 0.0 – 8.1 
   Missing (%) 1,208 (25.6%) 9,414 (32.6%) 97 (31.1%) 11,398 (32.5%) 
     
Triglycerides 
   Mean (SD) 2.0 (1.5) 1.8 (1.5) 1.7 (1.1) 1.8 (1.5) 
   Median 1.7 1.5 1.4 1.5 
   IQR 1.2 – 2.4 1.1 – 2.2 1.0 – 2.2 1.1 – 2.2 
   Range 0.0 – 25.3 0.0 – 54.3 0.0 – 9.2 0.0 – 57.8 
   Missing (%) 199 (4.2%) 342 (1.2%) 16 (5.1%) 559 (1.6%) 
All measurements are in mmol/l, except for the ratio where no units are given. Missing % 
calculated from the number of tests. Pts = Patients; SD = Standard Deviation; IQR = 
Interquartile Range. Pre MI (w/ Post MI) are pre MI tests obtained in patients with post MI 
test results available. Similarly, Post MI (with Pre MI) are post MI results in patients with a 
baseline lipid test. The remaining columns are pre MI test results where patients had no 
post MI tests and post MI results for patients with no pre MI baseline tests. Only one pre MI 
statin-naïve test per patient was included. Multiple post MI tests per patients were included. 
4.4.3 Achieving Target Values Post Myocardial Infarction 
Two lipid concentration targets were examined. The percentage reduction of 
non-HDL cholesterol, which is the focus of the NICE guidelines (NICE, 2014), 
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targets ≥40% reduction, whilst in the 2016 ESC guidelines, a target value of ≤1.8 
mmol/l for LDL cholesterol is recommended (Piepoli et al., 2016). For 
population comparisons, if a patient had achieved one of the targets in any of 
their time windows, then they were considered to have met that target, 
regardless of the consistency of this achievement. 
There were 10,700 time windows (complete or partial years of follow up) where 
the percentage of non-HDL reduction could be calculated, occurring in 3,355 
individuals. There were 3,835 (35.8%) time windows where the average 
reduction in non-HDL was ≥40% from their baseline, which occurred in 1,721 
individuals. In 6,865 (64.2%) windows, this target was not met.  
There were 30,319 windows where LDL values were reported in 9,504 
individuals. Of these, 16,336 (53.9%) reported LDL to be ≤1.8mmol/l, with the 
remainder (13,983, 46.1%) not achieving this. The 16,336 windows where this 
target was achieved occurred in 7,215 individuals. 
4.4.4 Demographics by Plasma Lipid Concentration Targets  
The demographics summarising those who met and did not meet the lipid 
cholesterol targets are shown in Table 4.8. Males were more likely to achieve 
the percentage reduction in non-HDL and LDL targets, with a similar gender split 
observed in both groups (non-HDL: 64.6% vs 35.4%; LDL: 63.7% vs 36.3%). 
However, a slightly higher percentage of females did not achieve the percentage 
non-HDL reduction target compared to the LDL cholesterol target (43.9% vs 
40.9%). Patients who achieved the target percentage non-HDL reduction were 
typically younger than those who did not (63.6 vs 67.1 years), but no age 
differences were identified when comparing patients who met and did not meet 
the LDL cholesterol recommendation. For the LDL target, a broadly U-shaped 
relationship appeared to exist between deprivation and those who met such 
targets with those in the most and least deprived areas more likely to meet it. 
This is not the case for the non-HDL target where no differences by deprivation 
quintile were evident. Whilst patients with a diagnosis of diabetes were more 
likely to achieve the LDL target (20.1% vs 13.8%), they were less likely to meet 
the percentage non-HDL reduction target (16.7% vs 22.8%). This pattern was also 
present amongst those patients with a prior MI. 
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Table 4.8: Demographics by Lipid Plasma Targets (from NICE and ESC Recommendations) 
 Target:  
≥40% Reduction non-HDL* 
Target:  
LDL ≤1.8mmol/l 








Gender     
   Male 1,111 (64.6%) 917 (56.1%) 4,593 (63.7%) 1,352 (59.1%) 
   Female 610 (35.4%) 717 (43.9%) 2,622 (36.3%) 937 (40.9%) 
     
Age at MI (years)    
   Mean (SD) 63.6 (12.5) 67.1 (13.6) 65.4 (13.2) 65.5 (14.0) 
   Median 62.7 67.8 65.4 65.2 
   IQR 53.9 – 73.8 56.4 – 77.5 55.2 – 75.9 54.8 – 76.6 
   Range 30.0 – 96.4 23.4 – 99.3 19.3 – 102.2 22.5 – 98.1 
     
SIMD 2012 Quintile (NHS GGC)  
   1 (Most) 398 (23.3%) 381 (23.5%) 1,824 (25.4%) 412 (18.2%) 
   2 389 (22.8%) 363 (22.4%) 1,620 (22.6%) 551 (24.3%) 
   3 349 (20.4%) 349 (21.5%) 1,438 (20.1%) 535 (23.6%) 
   4 284 (16.6%) 283 (17.5%) 1,140 (15.9%) 454 (20.0%) 
   5 (Least) 289 (16.9%) 244 (15.1%) 1,149 (16.0%) 317 (14.0%) 
   Missing 12 14 44 20 
     
Diabetes at MI 288 (16.7%) 373 (22.8%) 1,447 (20.1%) 315 (13.8%) 
   Type 1 12 (0.7%) 29 (1.8%) 73 (1.0%) 32 (1.4%) 
   Type 2 276 (16.0%) 344 (21.1%) 1,374 (19.0%) 283 (12.4%) 
     
Prior MI  34 (2.0%) 99 (6.1%) 473 (6.6%) 115 (5.0%) 
   1 28 (1.6%) 80 (4.9%) 361 (5.0%) 95 (4.2%) 
   >1 6 (0.3%) 19 (1.2%) 112 (1.6%) 20 (0.9%) 
*refers to the percentage reduction in non-HDL cholesterol from the pre-MI baseline. 
Numbers are N (%) unless otherwise specified. Percentages are calculated within columns, 
except for the header where percentages are calculated from total with information 
available. SD = Standard Deviation; IQR = Interquartile Range. Patients only included if the 
necessary test results were available to determine whether the target was met. 
4.5 Estimated Statin Adherence  
4.5.1 Achieving Targets for Adherence 
Estimated adherence, using MPR, was not calculated for time windows where 
the death occurred before the end of the window, or the end of follow up (31st 
July 2017). In total, there were 55,866 time windows, with 11,098 (19.9%) 
representing an incomplete year (i.e. there were 44,768 complete years of 
follow up). 
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Two adherence targets were used, 50% and 80%. There were 7,127 (7127/44768, 
15.9%) time windows where a patient’s adherence was <50%, occurring in 2,798 
patients. For 80%, there were 13,546 (13546/44768, 30.3%) time windows where 
the threshold was not achieved, which occurred in 5,532 patients. 
For demographic comparisons, a patient’s adherence was (mean-)averaged over 
their available time windows with the average value used to classify a patient as 
adherent or non-adherent depending on the threshold used (i.e. not everyone 
who ever had an adherence of lower than 50% will fall under the <50% category). 
Using these averages, the majority of patients had an average MPR greater than 
the conventional adherence threshold of 80% (68.9%), with a higher percentage 
achieving the lower threshold of 50% (84.5%).  
4.5.2 Other Lipid Lowering Medications in Non-Adherent Patients 
There were 434 (4.3%) patients who had an average estimated statin adherence 
equal to zero (i.e. were never dispensed any statins post MI). Of these, 37 
patients were prescribed different LLMs at any point during their follow up. The 
most common of these was Ezetimibe, where 349 prescriptions were dispensed 
to 23 patients. A further 331 fibrate prescriptions, specifically for Bezafibrate 
and Fenofibrate, were dispensed to 14 patients, with two patients prescribed 
omega 3 ethyl esters. Very few patients were dispensed more than one LLM that 
was not a statin during follow up.  
4.5.3 Demographics by Statin Adherence 
For both adherence thresholds (MPR 50% and 80%), males were more likely to be 
classified as adherent (50%: 63.1% vs 53.6%; 80%: 63.4% vs 57.7%). In the case of 
the lower threshold, those with an average adherence <50% were several years 
older than those with average adherence ≥50% (68.1 vs 65.3 years). This was less 
evident when the threshold of 80% was used, with only a difference of a year 
(66.4 vs 65.4 years). Those in the more deprived areas were more likely to 
achieve the 50% threshold for adherence (24.3% vs 22.4%), but this was less 
evident for the 80% threshold, where the greatest difference was in the second 
most deprived quintile (23.6% vs 21.6%). Patients who were diagnosed with Type 
2 diabetes before their MI were more likely to meet the adherence thresholds 
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(50%: 17.2% vs 15.1%; 80%: 17.2% vs 16.1%), particularly in the case of the 50% 
threshold. In contrast, patients with Type 1 diabetes were more likely to have 
lower adherence (50%: 0.9% vs 1.7%; 80%: 0.9% vs 1.4%). The proportion of 
patients with prior MIs was similar between those with average adherence above 
and below both thresholds (50%: 6.2% vs 5.5%; 80%: 6.1% vs 6.1%).  
Table 4.9: Demographics by Average Statin Adherence Thresholds (50% and 80%) 








Gender    
   Male 5,375 (63.1%) 836 (53.6%) 4,400 (63.4%) 1,811 (57.7%) 
   Female 3,147 (36.9%) 724 (46.4%) 2,542 (36.6%) 1,329 (42.3%) 
     
Age at MI (years)    
   Mean (SD) 65.3 (13.2) 68.1 (15.9) 65.4 (13.0) 66.4 (15.2) 
   Median 65.2 69.9 65.4 67.1 
   IQR 55.1 – 75.8 55.9 – 81.1 55.4 – 75.6 54.5 – 78.6 
   Range 21.9 – 101.0 19.3 – 102.2 21.9 – 101.0 19.3 – 102.2 
     
SIMD 2012 Quintile (NHS GGC)   
   1 (Most) 2,058 (24.3%) 347 (22.4%) 1,652 (24.0%) 753 (24.2%) 
   2 1,979 (23.4%) 318 (20.5%) 1,625 (23.6%) 672 (21.6%) 
   3 1,750 (20.7%) 338 (21.8%) 1,389 (20.1%) 699 (22.4%) 
   4 1,395 (16.5%) 289 (18.7%) 1,153 (16.7%) 531 (17.0%) 
   5 (Least) 1,279 (15.1%) 256 (16.5%) 1,075 (15.6%) 460 (14.8%) 
   Missing 61 12 48 25 
     
Diabetes at MI 1,547 (18.2%) 261 (16.7%) 1,258 (18.1%) 550 (17.5%) 
   Type 1 80 (0.9%) 26 (1.7%) 63 (0.9%) 43 (1.4%) 
   Type 2 1,467 (17.2%) 235 (15.1%) 1,195 (17.2%) 507 (16.1%) 
     
Prior MI 532 (6.2%) 86 (5.5%) 426 (6.1%)  192 (6.1%) 
   1 415 (4.9%) 69 (4.4%) 331 (4.7%) 153 (4.9%) 
   >1 117 (1.4%) 17 (1.1%) 95 (1.4%) 39 (1.2%) 
Numbers are N (%) unless otherwise specified. Percentages are calculated within columns, 
except for the header where percentages are calculated from total with information 
available. SD = Standard Deviation; IQR = Interquartile Range. Patients were only included if 
at least one complete year of follow up was available and then classified by average statin 
adherence across the course of their complete years of follow up available.  
However, some of these differences are likely due to confounding, for example, 
females were typically older, and therefore any associations with adherence are 
unlikely to be straightforward. For this reason, models adjusting for 
confounders, which are covered in later chapters, are perhaps better suited to 
understanding the relationships between a patient’s demographics and their 
statin adherence. 
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4.5.4 Statin Adherence and Lipid Plasma Concentrations 
Table 4.10 shows the proportion of patients meeting lipid plasma concentration 
targets recommended by guidelines by their average statin adherence during 
their follow up. As anticipated, given the mechanism of action of statin 
medication, those with higher average statin adherence were more likely to 
achieve the recommended cholesterol targets from the guidelines. This was most 
evident when looking at the percentage reduction of non-HDL cholesterol, where 
the proportion of those who achieved the target was more than double in those 
with an MPR ≥50% than those who did not (58.5% vs 22.9%). A similar pattern was 
observed when the 80% threshold for adherence was used (61.1% vs 34.2%).  
Table 4.10: Average Statin Adherence and Lipid Plasma Concentrations (Adherence: 50% 
and 80%; Lipids: NICE and ESC Recommendations) 
 MPR ≥50% MPR <50% MPR ≥80% MPR <80% 
≥40% non-HDL* 1,546 (58.5%) 131 (22.9%) 1,312 (61.1%) 365 (34.2%) 
<40% non-HDL* 1,095 (41.5%) 442 (77.1%) 835 (38.9%) 702 (65.8%) 
   Total 2,641 573 2,147 1,067 
LDL ≤1.8 mmol/l 6,097 (78.0%) 816 (64.2%) 5,053 (78.7%) 1,860 (69.7%) 
LDL >1.8 mmol/l 1,719 (22.0%) 455 (35.8%) 1,367 (21.3%) 807 (30.3%) 
   Total 7,816 1,271 6,420 2,667 
*refers to the percentage reduction in non-HDL cholesterol from the pre-MI baseline. 
Numbers are N (%). Patients were only included if at least one complete year of follow up 
was available and then classified by average statin adherence across the course of their 
complete years of follow up available. Patients were also only included if the necessary test 
results were available to determine whether the target was met. The number of patients in 
each group for each target and with adherence data are included on the total line of each set 
of information, e.g. 2,641 patients had calculable non-HDL cholesterol and MPR ≥50%. 
4.5.5 Statin Adherence and Lipid Testing  
To examine the association between a patient’s adherence and the frequency of 
lipid testing in a given year, the two were cross-tabulated (Table 4.11 and Table 
4.12). Due to the different testing pattern in the first year of follow up (Chapter 
4.4.1), only years two to eight of follow up were tabulated. This highlighted that 
there may be some association between the two, with those with higher 
adherence more likely to have the guideline-recommended one lipid test, and 
those with lower adherence more likely to have had no lipid tests that year. 
There were no differences between over-testing and a patient’s adherence when 
the 80% threshold was used, though those with higher adherence were slightly 
more likely to have more than one test when the 50% cut point was used. 
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Nonetheless, despite some differences observed, a patient’s adherence does not 
appear to be substantially explained by the frequency of their lipid testing. 
Table 4.11: Adherence and Number of Lipid Tests by Year of Follow Up (50% MPR) 
 
Year of FU 
MPR≥50% MPR<50% 
N row % col % N row % col % 
Year 2       
  0 Tests 1,515 75.3% 19.2% 498 24.7% 35.3% 
  1 Test 4,260 88.8% 53.9% 540 11.3% 38.3% 
  >1 Test 2,130 85.1% 26.9% 372 14.9% 26.4% 
       
Year 3       
  0 Tests 1,480 72.7% 20.5% 555 27.3% 38.2% 
  1 Test 4,057 86.8% 56.2% 615 13.2% 42.4% 
  >1 Test 1,684 85.7% 23.3% 281 14.3% 19.4% 
       
Year 4       
  0 Tests 1,158 71.3% 21.5% 466 28.7% 40.0% 
  1 Test 3,071 86.1% 57.0% 497 13.9% 42.7% 
  >1 Test 1,163 85.2% 21.6% 202 14.8% 17.3% 
       
Year 5       
  0 Tests 914 73.5% 23.2% 330 26.5% 40.4% 
  1 Test 2,199 86.6% 55.8% 341 13.4% 41.8% 
  >1 Test 826 85.1% 21.0% 145 14.9% 17.8% 
       
Year 6       
  0 Tests 633 73.4% 24.5% 229 26.6% 41.3% 
  1 Test 1,427 85.7% 55.3% 239 14.3% 43.1% 
  >1 Test 521 85.7% 20.2% 87 14.3% 15.7% 
       
Year 7       
  0 Tests 340 71.1% 24.4% 138 28.9% 47.9% 
  1 Test 791 86.6% 56.7% 122 13.4% 42.4% 
  >1 Test 265 90.4% 19.0% 28 9.6% 9.7% 
       
Year 8       
  0 Tests 115 70.6% 24.5% 48 29.4% 49.0% 
  1 Test 268 87.3% 57.1% 39 12.7% 39.8% 
  >1 Test 86 88.7% 18.3% 11 11.3% 11.2% 
FU = Follow Up. Complete years of follow up included only. Patients classified by adherence 
in the year of follow up, so individual patients may move between adherence categories and 
testing frequencies between follow up years. Patients were defined as having a test if at 
least one component of the lipid panel was reported. Percentages are calculated by row and 
column separately but within each year of follow up.  
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Table 4.12: Adherence and Number of Lipid Tests by Year of Follow Up (80% MPR) 
 
Year of FU 
MPR≥80% MPR<80% 
N row % col % N row % col % 
Year 2       
  0 Tests 1,260 62.6% 19.0% 753 37.4% 28.1% 
  1 Test 3,631 75.6% 54.7% 1,169 24.4% 43.7% 
  >1 Test 1,749 69.9% 26.3% 753 30.1% 28.1% 
       
Year 3       
  0 Tests 1,220 60.0% 19.8% 815 40.0% 32.6% 
  1 Test 3,564 76.3% 57.8% 1,108 23.7% 44.3% 
  >1 Test 1,386 70.5% 22.5% 579 29.5% 23.1% 
       
Year 4       
  0 Tests 972 59.9% 21.1% 652 40.1% 33.5% 
  1 Test 2,669 74.8% 57.9% 899 25.2% 46.1% 
  >1 Test 967 70.8% 21.0% 398 29.2% 20.4% 
       
Year 5       
  0 Tests 783 62.9% 23.3% 461 37.1% 33.2% 
  1 Test 1,881 74.1% 55.9% 659 25.9% 47.5% 
  >1 Test 703 72.4% 20.9% 268 27.6% 19.3% 
       
Year 6       
  0 Tests 529 61.4% 24.0% 333 38.6% 35.8% 
  1 Test 1,239 74.4% 56.2% 427 25.6% 45.9% 
  >1 Test 437 71.9% 19.8% 171 28.1% 18.4% 
       
Year 7       
  0 Tests 290 60.7% 24.4% 188 39.3% 38.0% 
  1 Test 681 74.6% 57.3% 232 25.4% 46.9% 
  >1 Test 218 74.4% 18.3% 75 25.6% 15.2% 
       
Year 8       
  0 Tests 98 60.1% 23.8% 65 39.9% 41.7% 
  1 Test 240 78.2% 58.4% 67 21.8% 42.9% 
  >1 Test 73 75.3% 17.8% 24 24.7% 15.4% 
FU = Follow Up. Complete years of follow up included only. Patients classified by adherence 
in the year of follow up, so individual patients may move between adherence categories and 
testing frequencies between follow up years. Patients were defined as having a test if at 
least one component of the lipid panel was reported. Percentages are calculated by row and 
column separately but within each year of follow up. 
4.6 Diagnosis of Diabetes  
4.6.1 Diagnosis Prior to Myocardial Infarction 
There were 2,099 (18.9%) patients diagnosed with diabetes before their baseline 
MI admission, the majority of whom had Type 2 Diabetes (1979/2099, 94.3%), as 
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shown in Table 4.13. The average duration of disease was substantially different 
between the two types of diabetes. This would be expected given the average 
age of patients at the time of diagnosis for Type 1 diabetes compared to Type 2, 
and the average age of patients when they experience an MI.  
Table 4.13: Duration of Diabetes at Baseline MI Admission 
 Type 1 
N = 120 
Type 2 
N = 1,979 
Total 
N = 2,099 
Duration of Diabetes (years)   
   Mean (SD) 30.1 (16.6) 10.5 (7.8) 11.6 (9.7) 
   Median 30.4 9.2 9.7 
   IQR  17.2 – 42.2 4.4 – 14.8 4.7 – 15.7 
   Range 0.3 – 75.1 0.0 – 45.7 0.0 – 75.1 
SD = Standard Deviation; IQR = Interquartile Range. Duration of diabetes calculated using 
the date of diagnosis and date of admission with baseline MI.  
4.6.2 Diagnosis Post Myocardial Infarction  
Table 4.14 contains the number of patients subsequently diagnosed with 
diabetes in follow up (i.e. the day of admission with MI onwards). There were 
733 further patients diagnosed with diabetes, the majority with Type 2 
(727/733, 99.2%), and within the first year of follow up (236/733, 32.2%). 
However, some of the decreases in the number of those being newly diagnosed 
per year are as a result of the few patients remaining in follow up in each year. 
Two patients had an unknown date of diagnosis, so it could not be ascertained 
whether this occurred prior to or after the start of follow up and are therefore 
not included in these summaries.  
Table 4.14: Diagnosis of Diabetes in Follow Up by Year of Follow Up  
 Type 1 
N = 6 
Type 2 
N = 727 
Total 
N = 733 
Year of FU     
   1 3 233 236 
   2 0 133 133 
   3 0 122 122 
   4 0 97 97 
   5 2 66 68 
   6 1 42 43 
   7 0 24 24 
   8 0 10 10 
   9 0 0 0 
Numbers are N. FU = Follow Up. Year of follow up where diagnosis occurred was obtained 
from dates of diagnosis and start and end dates of years of follow up. 
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4.6.3 Demographics by Diabetes Diagnosis at MI 
Table 4.15: Demographics by Diabetes Diagnosis at Baseline MI Admission 








Gender      
   Male 63 (52.5%) 1,138 (57.5%) 1,201 (57.2%) 5,531 (61.4%) 
   Female 57 (47.5%) 841 (42.5%) 898 (42.8%) 3,480 (38.6%) 
     
Age at MI (years)    
   Mean (SD) 59.7 (13.9) 70.0 (11.9) 69.4 (12.2) 66.3 (14.2) 
   Median 60.6 71.1 70.7 66.4 
   IQR 49.6 – 69.9 62.4 – 78.6 61.7 – 78.3 55.2 – 77.7 
   Range 28.1 – 90.8 30.0 – 101.0 28.1 – 101.0 19.3 – 102.6 
     
SIMD 2012 Quintile (NHS GGC)   
   1 (Most) 26 (21.7%) 497 (25.3%) 523 (25.1%) 2,127 (23.8%) 
   2 26 (21.7%) 450 (22.9%) 476 (22.9%) 2,052 (22.9%) 
   3 28 (23.3%) 441 (22.4%) 469 (22.5%) 1,825 (20.4%) 
   4 27 (22.5%) 336 (17.1%) 363 (17.4%) 1,514 (16.9%) 
   5 (Least) 13 (10.8%) 237 (12.1%) 250 (12.0%) 1,432 (16.0%) 
   Missing 0 18 18 61 
     
Prior MI 14 (11.7%) 205 (10.4%) 219 (10.4%) 495 (5.5%) 
   1 12 (10.0%) 161 (8.1%) 173 (8.2%) 385 (4.3%) 
   >1 2 (1.7%) 44 (2.2%) 46 (2.2%) 110 (1.2%) 
Numbers are N (%). Percentages are calculated within columns, except for the header where 
percentages are calculated from total with information available. SD = Standard Deviation; 
IQR = Interquartile Range. Patients diagnosed during follow up are included in the no 
diabetes group, as demographics are presented by diabetes status at baseline MI 
admission. 
The demographics for those diagnosed with Type 1, Type 2, either and no 
diabetes before their baseline MI admission are summarised in Table 4.15. There 
was a higher proportion of females with a diagnosis of diabetes, especially Type 
1 diabetes (47.5%), than in the population without diabetes (42.8% vs 38.6%, 
respectively). Patients diagnosed with Type 1 diabetes were also, on average, 
around five years younger at their baseline MI admission compared to those 
without (60.6 vs 66.4 years), whereas those with Type 2 diabetes were on 
average around four years older at their baseline MI (71.1 years). When looking 
at differences in deprivation, in the case of patients with Type 1 diabetes, the 
relationship did not appear to be straightforward. However, in the case of 
patients with Type 2 diabetes, there was a slightly higher proportion of patients 
diagnosed who resided in an area in the most deprived quintile compared with 
those with no diagnosis of diabetes before their baseline MI admission (25.3% vs 
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23.8%). Patients with diabetes were also more likely to have experienced an MI 
prior to the one occurring at the start of follow up (10.4% vs 5.5%). 
4.7 Discussion  
This chapter sought to describe the post MI population of the NHS GGC region 
between 2009 and 2017 and specifically summarises their demographics, lipid 
results, testing patterns, and statin adherence following an MI.  
4.7.1 Overall Post Myocardial Infarction Population  
The post MI population was not a representative sample of the NHS GGC 
population and, instead, was characterised by the presence of the known risk 
factors for CVD. Indeed, patients within this cohort were more likely to be male, 
have a diagnosis of diabetes, be over the age of 65, and live in more deprived 
areas than in the NHS GGC overall population.  
However, this population is broadly comparable to other secondary prevention 
cohorts. These included one high-risk cohort from an insurance database in 
Georgia, USA who initiated statins in 2011 (n=1066) (Vupputuri et al., 2016), and 
three cohorts derived from UK CPRD data: a secondary prevention cohort from 
2006 and 2012 with at least two statin prescriptions before their event 
(n=24,093) (Danese et al., 2017), a cohort with documented CVD and newly 
initiated statins or ezetimibe between 2010 and 2013 (n=16,701) (Khunti et al., 
2018), and a high-risk cohort formed of those newly diagnosed with documented 
disease or diabetes from 2008 to 2011 (n=131,603) (Nordstrom et al., 2015).  
A higher proportion of males is reported in established CVD populations (Danese 
et al., 2017; Khunti et al., 2018), although is less evident in broader high-risk 
populations (Nordstrom et al., 2015; Vupputuri et al., 2016). The age profiles 
are also similar with average ages consistently over 65 years (Nordstrom et al., 
2015; Danese et al., 2017; Khunti et al., 2018). There is some discrepancy in the 
prevalence of diabetes reported within secondary prevention cohorts, with 
percentages ranging from 6% to 36% (Nordstrom et al., 2015; Danese et al., 
2017; Khunti et al., 2018). This is possibly a consequence of the different 
inclusion criteria for each of the cohorts. In the NHS GGC population, the 
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proportion of patients diagnosed with diabetes (including those diagnosed during 
follow up) is closer to the upper bound of this range and is closest to the 
estimated prevalence in patients who have been hospitalised with an acute 
cardiovascular event (Danese et al., 2017).   
4.7.2 Frequency and Patterns of Lipid Testing  
The frequency of testing within this population showed that, excluding the first 
year post MI, just over half of the cohort received one test in any given year, in 
line with current (and previous) Scottish guidelines (SIGN, 2007, 2017). However, 
the consistency of the annual test (an overall testing rate over follow up close to 
one) was only met by approximately a third of patients, with the highest 
proportion of patients reporting a much higher, rather than lower, rate. 
Nonetheless, when each year was considered individually, under-testing became 
more common than over-testing as follow up duration increased. In the first year 
of follow up, over-testing was the most common and therefore may explain the 
discrepancy between the two measures. Long-term trends in testing have also 
been shown in an analysis of 1.6 million patients at high risk of CVD on stable 
statin prescriptions, where 33% received annual testing (33%) between 2008 and 
2014 (Hajati et al., 2018). This was consistent with the overall rates in the post 
MI population but lower than the proportions observed in their individual years 
of follow up. Furthermore, in Hajati et al’s (2018) analysis, under-testing 
occurred twice as often as over-testing; a pattern that was not observed in this 
post MI cohort, possibly due to more frequent monitoring in those with 
established CVD.  
The higher rate of over-testing in the first year could be driven by two factors: 
medication initiation or alteration and further cardiovascular events. Following 
the MI at the start of their follow up, many patients are likely to either initiate 
LLM for the first time or increase its intensity (Danese et al., 2017). As such, 
extra testing may occur to assess whether targets have been achieved, as 
suggested by some major guidelines (NICE, 2014; Stone et al., 2014; Catapano et 
al., 2016). Secondly, the greatest risk of further cardiovascular events is in the 
first year after an initial event (Khunti et al., 2018). Such events occurred in this 
cohort and could have led to extra testing through hospital admissions or 
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subsequent interactions with primary care as medications are further adjusted 
or intensified (Danese et al., 2017).  
4.7.3 Achievement of Guideline-Recommended Lipid Targets  
The average post MI plasma lipid results showed a more favourable lipid profile 
when contrasted with statin-naïve results before the start of follow up. 
Specifically, reductions were observed in total cholesterol, as a consequence of 
decreases in LDL cholesterol, which in turn result in an improved Total:HDL 
cholesterol ratio. This pattern is similar to UK derived secondary prevention 
populations, although average baseline LDL levels in this population were 
considerably lower than values reported in secondary prevention populations in 
CPRD data (Danese et al., 2017; Khunti et al., 2018).  
When translated into the achievement of guideline-recommended targets, 76% 
achieved the 2016 ESC target of LDL cholesterol ≤1.8mmol/l (Piepoli et al., 
2016) during their follow up. This is higher than has been observed in other 
secondary prevention cohorts, with estimates in various high-risk populations 
ranging between 23% and 42% (Nordstrom et al., 2015; Danese et al., 2017). This 
difference may, in part, be accounted for by population differences. However, 
many analyses have focussed on the achievement of targets at a specific time 
point during follow up, e.g. one (Danese et al., 2017), or two years (Nordstrom 
et al., 2015). In contrast, patients in this population were classified as achieving 
the target if they achieved it in any year of follow up. Around 50% achieved the 
NICE recommended ≥40% reduction in non-HDL cholesterol (NICE, 2014). This is 
also higher than percentages achieving a 30% reduction in LDL cholesterol in a 
high-risk USA population (Vupputuri et al., 2016).  
Differences observed in the baseline demographics by LDL target achievement 
were not all reflected for the non-HDL cholesterol target. This may be due to 
the need for a suitable baseline to calculate the percentage reduction, causing a 
selection bias. Many patients with test results available before their MI are likely 
to have already been identified as being at high risk, either by default or using 
the ASSIGN risk prediction tool. Consequently, they should have been prescribed 
statins, making it less likely that a suitable (statin-naïve) baseline result was 
available. For example, those with prior MIs should have, and those with a 
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diagnosis of diabetes are likely to have, been on statins before their start of 
follow up (SIGN, 2007, 2017). Patients may also have no prior test results 
available because no CVD risk assessment had been performed before their MI, 
whilst others may have no post MI results due to a pre-existing concurrent 
illness, resulting in both low pre-MI lipids and an absence of lipid tests following 
their baseline MI (also preventing the calculation of a percentage reduction). As 
a result, patients included in the non-HDL cholesterol comparisons may not be 
representative of the overall post MI population. However, the LDL cholesterol 
target used in this analysis does not encounter this, as this is based on its 
absolute value (Piepoli et al., 2016).  
Despite this, some differences noted in baseline demographics by the 
achievement of the LDL target may have arisen due to confounding. For 
example, those residing in the least deprived areas were more likely to meet the 
non-HDL target, whereas those residing in the most and least deprived areas 
were more likely to meet the LDL target. This U-shaped relationship for LDL may 
have arisen due to higher rates of multimorbidity in more deprived areas, where 
these conditions may also be associated with the greater achievement of lipid 
levels and a decreased likelihood of statin naivety before their baseline MI (thus 
excluding them from non-HDL comparisons). For example, in this cohort, 
patients with a diagnosis of diabetes were more likely to reside in the most 
deprived areas (Chapter 4.7.5), as well as being more likely to achieve 
recommended LDL levels. The observations in this cohort that those with 
diabetes and those with prior MIs were more likely to achieve LDL ≤1.8mmol/l 
are also consistent with findings from another secondary prevention cohort 
within the UK (Danese et al., 2017).  
Furthermore, females were less likely to achieve the LDL cholesterol target; an 
observation that has been observed within the literature (Reiner et al., 2016; 
Leskelä et al., 2020), despite evidence to suggest that the absolute reduction in 
cardiovascular events from statins is equivalent in both sexes (Gutierrez et al., 
2012). Confounding may offer one potential explanation. For example, women 
who experience MIs are typically older than men (Smolina et al., 2015), and 
adherence to statin medication has also been shown to decrease with age over 
70 years (Hope et al., 2019), which would influence a patient’s LDL levels. 
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However, whilst adherence did decrease with age in this population, this did not 
translate into age differences between those who achieved and did not achieve 
the LDL target. Nonetheless, the management of females who experience MIs 
may explain the differences observed in both lipid target achievement and 
adherence. Several studies have reported that women are more likely to be 
undertreated following an MI (Smolina et al., 2015; Eindhoven et al., 2018), with 
the largest differences for statin use in NSTEMIs (Eindhoven et al., 2018). 
Consequently, undertreated patients could be classified as non-adherers when 
adherence is captured through dispensing prescription data, as well as being less 
likely to achieve lipid targets.   
4.7.4 Medication Adherence  
A third of the NHS GGC post MI population had an average statin adherence <80% 
which is slightly higher than estimates from other similar cohorts which utilised 
MPR or PDC as estimation methods (Nordstrom et al., 2015; Danese et al., 2017; 
Khunti et al., 2018). However, this may be due to length of follow up where 
calculations are often confined to the first few years of follow up, where 
adherence is likely to be the highest (Khunti et al., 2018). Although there is 
some evidence to suggest that the greatest decrease occurs in the first year of 
follow up (Chen et al., 2019), some decline is still present beyond this, and 
likely to affect a patient’s long-term average adherence (Naderi, Bestwick and 
Wald, 2012; Chowdhury et al., 2013; Khunti et al., 2018; Chen et al., 2019). In 
contrast, the proportion of patients with average adherence <50% (16%) was 
lower than observed in another high-risk cohort, where 36% reported a PDC <50% 
in the first year of statin initiation in Georgia, USA (Vupputuri et al., 2016). This 
could be due to differences within the populations, where those who have 
experienced an event are more likely to remain adherent to their medication 
(Naderi, Bestwick and Wald, 2012) than the overall high-risk population. 
Prescription charges could also offer some explanation for this, with their costs 
associated with lower adherence to medications (Leslie, McCowan and Pell, 
2018). Therefore, the lack of prescription charge in Scotland since 2011 (NHS 
Inform Scotland, 2020) could have resulted in fewer patients with adherence 
<50%. 
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Despite this, in line with adherence to cardiovascular medications research, 
females and older-aged patients were less likely to be adherent (Hope et al., 
2019), whilst those with a prior MI (Vupputuri et al., 2016; Danese et al., 2017) 
were more likely. This would suggest that the factors associated with adherence 
to statins in both primary and secondary prevention are universal. In this 
population, those with a diagnosis of diabetes were also more likely to be 
adherent. This association has been identified through a meta-analysis in 
primary prevention (Hope et al., 2019), but within secondary prevention has 
either been shown to have no association with adherence (Danese et al., 2017) 
or patients with diabetes are just as likely to have low adherence as they are 
high, but not intermediate (50-80%) (Vupputuri et al., 2016).  
Those with higher average adherence were also more likely to have achieved 
guideline-recommended lipid targets. This is consistent with the rationale of 
prescribing and mechanism of action LLMs, and findings in other high-risk cohorts 
(Nordstrom et al., 2015; Vupputuri et al., 2016). However, not all patients who 
had high adherence achieved the lipid targets, and therefore meeting these 
targets cannot be due to adherence alone. Indeed, treatment intensity may also 
be a factor. In one high-risk cohort, patients receiving a high-intensity statin 
were more likely to achieve a lower LDL cholesterol result (Nordstrom et al., 
2015). This concurs with findings in a different high-risk cohort, but which also 
highlighted that adherence decreases as intensity increases (Vupputuri et al., 
2016), suggesting that adherence and intensity should be balanced carefully. 
Regardless, in both analyses, not all patients receiving high-intensity LLM met 
cholesterol targets (Nordstrom et al., 2015; Vupputuri et al., 2016), and 
therefore, achieving these involves factors beyond medication. 
The frequency of testing was also shown to have some influence and may impact 
the association described above. Patients with higher adherence were more 
likely to have an annual lipid test and those with lower adherence less likely. 
Therefore, for patients with lower adherence, it was less likely that it could be 
ascertained whether a lipid target had been met. Given LLMs lower cholesterol, 
this may mean that the number of patients with lower adherence who did not 
achieve the target is far higher, and the association is underestimated.  
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4.7.5 Diabetes Mellitus 
Around one in four patients in this cohort were diagnosed with diabetes before 
their baseline MI or during follow up. This percentage diagnosed before their 
start of follow up is similar to findings for the whole of Scotland, which reported 
that 19% of patients who experienced an MI (including fatal MIs), angina, or 
revascularisation between 2006 and 2015 had a diagnosis of Type 2 diabetes at 
the time (Read et al., 2019). For those diagnosed during follow up, this was most 
likely to occur within the first-year post MI and is likely to have been detected 
during or shortly after their admission with their baseline MI (and was therefore 
likely present but undocumented at the time of the event). 
In line with a secondary prevention cohort, there was a higher proportion of 
females with a diagnosis than without, although this difference was more 
pronounced in this post MI population (Danese et al., 2017). Surprisingly, and in 
contrast to Danese et al’s (2017) established CVD population, which found 
minimal differences in age at the time of their index event, patients diagnosed 
with diabetes were also more likely to be older than those without at the time 
of their baseline MI. For those diagnosed with Type 2 diabetes (the majority of 
diagnoses in this cohort), this may in part be explained by the increased risk of 
diabetes with age (Read et al., 2016), and hence patients would need to be 
older to have diabetes and an MI concurrently. Nonetheless, there is also a 
larger variation in the age range of those experiencing MIs without a diagnosis of 
diabetes, suggesting that there may be subpopulations within this group with 
different risk factor profiles. Consistent with analysis of the diabetes register 
(SCI Diabetes) for Scotland in 2016, patients with a diagnosis of Type 2 diabetes 
were also more likely to live in deprived areas (Whittaker et al., 2020). 
Furthermore, a separate analysis of SCI Diabetes demonstrated an increased risk 
of acute MI as a result of a significant interaction between deprivation and 
diabetes (Read et al., 2019).  
The majority of patients with a diagnosis of diabetes in this population were 
diagnosed with Type 2, with approximately 5% diagnosed with Type 1, which is 
broadly similar to an established CVD cohort in CPRD (Danese et al., 2017). As a 
result of this, many of the differences observed in the demographics are the 
result of differences between those with a Type 2 diagnosis and those without a 
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diagnosis of diabetes, and consequently, the Type 1 population could be 
overlooked. Those diagnosed with Type 1 diabetes were considerably younger at 
the time of their baseline MI: around ten years younger than those with a Type 2 
diagnosis, and six years younger than those without. This, in combination with 
the greater duration of disease at the time of their MI and the higher rates of 
prior MIs reported, demonstrates the increased cardiovascular risk experienced 
by this population, which was also highlighted by findings from the Swedish 
National Diabetes Register (Araz Rawshani et al., 2018). Furthermore, in this 
cohort, those with a diagnosis of Type 1 diabetes were also less likely to achieve 
average adherence thresholds of 50% and 80%, and less likely to achieve 
guideline-recommended lipid targets, suggesting that risk management of this 
population could be improved. 
4.7.6 Strengths and Limitations  
One of the strengths of this analysis is the size and coverage of this cohort. This 
population includes over 11,000 survivors of MIs and follows them up for at least 
three years (unless death occurred), with an average follow up of four and a half 
years. This cohort was derived from hospital admission records for all patients 
across NHS GGC who had ever had a lipid test or prescription for LLM, making it 
representative of the post MI population in this area. Furthermore, the length of 
follow up is also a strength. Many similarly derived cohorts from national 
datasets often focus on shorter average periods of follow up (Nordstrom et al., 
2015; Vupputuri et al., 2016; Danese et al., 2017), whereas this data allows 
longer-term trends in adherence, lipid levels, testing patterns, and further 
cardiovascular events to be examined in later chapters.  
Nonetheless, this data is observational and thus open to confounding. This is the 
main limitation of these descriptive summaries as no adjustment for these has 
been performed. For example, those with a diagnosis of diabetes and who had 
experienced a prior MI were each more likely to be adherent, but those with a 
prior MI were also more likely to have a diagnosis of diabetes. Such interactions 
are likely to be common, leading to complex and multifactorial relationships 
with adherence or achievement of lipid targets. Likewise, the direction of an 
association may be difficult to determine, such as with the association between 
the frequency of tests and adherence. In a review of systematic reviews for 
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factors associated with adherence to CVD medications, lower adherence has 
been associated with a reduced likelihood of attending appointments (Leslie, 
McCowan and Pell, 2018), thereby reducing the potential for testing. However, 
as annual reviews should include discussions to address a patient’s adherence 
(SIGN, 2007, 2017), those who do not attend appointments are also less likely to 
become adherent in the future (Leslie, McCowan and Pell, 2018). Finally, due to 
the observational nature of this cohort, no conclusions regarding causality can 
be made. 
4.7.7 Conclusions 
This chapter summarised the demographics, lipid tests, testing frequency, and 
statin adherence of over 11,000 patients within the NHS GGC post MI population 
and found them to be broadly in line with similar secondary prevention cohorts. 
However, due to the observational nature of the data and the consequential 
likelihood of confounding, further analysis is needed to fully understand the 
associations between them. This will be addressed in later chapters.
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Chapter 5 Consequences of Non-Adherence and 
Non-Target Lipids 
5.1 Introduction  
For those with established CVD, the rationale for managing their risk has been 
outlined in Chapter 1.2.2.1. In one meta-analysis of RCTs, for patients not 
treated with statins, the rate of further events in those with a previous 
cardiovascular event has been estimated to be more than double the rate in 
patients with no previous events (Cholesterol Treatment Trialists’ (CTT) 
Collaboration, 2010). For all-cause mortality, the rate per year has been 
estimated to be six times greater in survivors of MIs than those without CVD 
(World Health Organization, 2017a). Furthermore, the associated healthcare 
costs of CVD to the UK economy are nearly £9bn per year (British Heart 
Foundation, 2018).  
However, managing and monitoring risk factors within this population can be a 
highly effective strategy to reduce the burdens of CVD. One of the cornerstones 
of this risk-management is the prescribing of LLMs to these patients, with statins 
as the primary therapy (as described in Chapter 1.3.1). The evidence for this is 
strong, with the Cholesterol Treatment Triallists’ Collaboration meta-analysis of 
21 RCTs comprising 129,526 participants reporting a 21% reduction in the risk of 
further events per 1mmol/l reduction in LDL cholesterol (Cholesterol Treatment 
Trialists’ (CTT) Collaboration, 2010). Furthermore, no adverse safety limit for 
cholesterol lowering has been identified, and absolute risk reductions are 
greater for those at the highest risk (Cholesterol Treatment Trialists’ (CTT) 
Collaborators, 2012).   
With this strong evidence base for therapies to reduce a patient’s cardiovascular 
risk, a patient’s adherence to these medications and their corresponding lipid 
levels become key components of a patient review (SIGN, 2017). Higher patient 
adherence and the achievement of target lipid levels (set by clinical guidelines) 
have both been associated with a reduced likelihood of further events and 
mortality (Chapters 1.3 and 1.4.3) with evidence for latter the result of the 
supporting evidence for the use of statins. The association between adherence 
and the risk of cardiovascular events has been shown in both primary and 
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secondary prevention (Xu et al., 2017; Khunti et al., 2018). For example using 
CPRD data, in patients with CVD, a 10% increase in statin adherence was 
associated with a 5% reduction in further cardiovascular events (Khunti et al., 
2018). However, as electronic prescribing records in CPRD are prescribing data 
(Herrett et al., 2015), the extent of this association may have been 
underestimated as not all included prescriptions will have been dispensed. 
Adherence to medication in secondary prevention settings is generally higher 
than observed in primary prevention (Naderi, Bestwick and Wald, 2012), and 
several analyses of secondary prevention cohorts have found levels of adherence 
to be reasonable; with between 67.9% and 74.8% of participants with statin 
adherence ≥80% in the 12 months following an event (Nordstrom et al., 2015; 
Danese et al., 2017). However, this does not fully translate into achievements of 
target lipid levels, with less than half of patients achieving them in the year 
following an event (Danese et al., 2017). Therefore, there superficially appears 
to be a disconnect between adherence to LLMs and achievement of lipid targets 
stated in guidelines, as discussed in Chapter 1.4.3. These issues require further 
study. 
Consequently, this chapter aims to investigate the association between statin 
adherence, and achievement of lipid-lowering targets, with cardiovascular 
outcomes separately. The two cardiovascular events of interest are further 
hospital admissions for MIs and death (all-cause and circulatory), with the 
relationships examined in separate analyses. 
5.2 Statistical Methods 
As a patient may experience multiple further hospital admissions for MIs in 
follow up, but death occurs only once, different statistical methods were used 
for each of these outcomes. Descriptive analyses and logistic regression were 
used to understand the associations between average adherence and the 
achievement of lipid targets, and both separately with further MIs. For mortality 
outcomes, descriptive analyses, Kaplan-Meier curves and Cox regression 
modelling was conducted. For both the logistic and Cox regression, unadjusted 
and adjusted (for age at MI, sex, deprivation quintile, and year of MI) models 
were generated using available case analysis. Cohen’s kappa statistic was also 
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calculated to determine the level of agreement between the two lipid targets to 
be considered: ≥40% reduction in non-HDL from a statin-naïve baseline (NICE, 
2014), LDL ≤1.8mmol/l (Piepoli et al., 2016). 
5.2.1 Descriptive Statistics, Confounding, and Reverse Causality 
Initially, descriptive statistics are presented to simply illustrate potential 
associations between exposures (adherence and lipid targets) with outcomes 
(further hospital MIs and death). For continuous variables, such as age at the 
start of follow up, several such statistics are presented: mean, standard 
deviation, median, interquartile range (the 25th and 75th percentiles), minimum 
and maximum. For categorical variables, such as deprivation quintiles, the 
number of observations (N) and percentages are provided. For each descriptive 
summary, the Ns are the numbers of observations with the necessary data 
available, unless stated otherwise and labelled as missing. Likewise, the 
summaries of continuous variables are calculated using only those with the data 
available.  
However, whilst descriptive statistics are useful for summarising the data, any 
associations highlighted by them will require further analytical investigation. 
This is particularly the case within observational cohorts, such as this one, where 
confounding variables are uncontrolled for, and therefore true associations may 
be masked or inflated, as illustrated in Figure 5.1. Adjusting for such 
confounders using other statistical methods may generate a clearer picture of 
the extent of associations (McNamee, 2003; Catalogue of Bias Collaboration et 
al., 2018). In observational data, though, this is seldom sufficient to establish 
causality due to the possibility of unmeasured confounders which could explain 
the presence or absence of such a relationship (Catalogue of Bias Collaboration 
et al., 2018). Consequently, causal relationships can be difficult to establish 
reliably using observational data (Catalogue of Bias Collaboration et al., 2018; 
Coscia Requena, Muriel and Peñuelas, 2018; Sheetz and Nathan, 2020).  
Nevertheless, some methods can facilitate causal inferences in observational 
settings, including propensity scoring and instrumental variable analysis, which 
are commonly utilised. Propensity scores allow the estimation of the probability 
of treatment assignment based on the patient’s characteristics, and these scores 
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can then be matched, stratified, used as a covariable in models, or used to 
calculate the inverse probability treatment weighting (Coscia Requena, Muriel 
and Peñuelas, 2018). This facilitates a structure to the data similar to that of a 
clinical trial by balancing the exposure groups. However, matching can result in 
the exclusion of unmatched patients from the study, and the correct selection of 
the variables for inclusion in the study is crucial to minimise bias and impact on 
variance (Coscia Requena, Muriel and Peñuelas, 2018; Sheetz and Nathan, 2020). 
Although the identification of strong, suitable variables is its principal limitation, 
instrumental variable analysis, which uses variables that predict exposure but 
not the outcome, offers the advantage of removing the effects of both measured 
and unmeasured confounders. If such a variable can be identified, though, 
patients are then compared by their likelihood of exposure, similar to intention-
to-treat analyses in RCTs (Sheetz and Nathan, 2020). However, neither of these 
methods were employed within the analysis in this chapter, and therefore no 
causal inferences are made regarding the associations observed.  
Within the descriptive statistics and the subsequent statistical models 
performed, there is also the possibility of reverse causality. This is where one 
may assume that the exposure causes the disease, but the opposite is true. 
Whilst particularly likely in cross-sectional studies (where temporal relationships 
are hard to ascertain), reverse causality can also occur in longitudinal analyses. 
Underlying processes for the disease may have already commenced and caused 
the exposure to be more likely and lead to the outcome in question (Katz, 2006; 
Wanberg, 2012). Unlike confounding, there is no standard approach for 
addressing such situations. Methods used by researchers typically involve 
sensitivity analyses which may involve the exclusion of those unwell at baseline, 
stratification by potential markers of underlying processes (such as age), or the 
exclusion of those who experience the outcome early on in follow up (Sattar and 
Preiss, 2017).  




Figure 5.1: Criteria for Confounding Variable. The diagram is taken from the Catelogue of 
Bias Collaboration et al (2018), with the criteria for confounding taken from McNamee 
(2003). 
5.2.2 Cohen’s Kappa Statistic 
Cohen’s kappa statistic is used to determine the level of agreement between 
two categorical variables. It is calculated as a ratio, as illustrated in Equation 
5.1. The numerator represents the proportion of disagreements between the two 
variables that were observed beyond those which would have been expected, 
whilst the denominator is the proportion of disagreements that would have been 
expected. The expected number of disagreements represents the number that 
would be anticipated if the two variables were allocated randomly by chance 
(Cohen, 1960).  
𝜅 =  
𝑝0 − 𝑝𝑒
1 −  𝑝𝑒
,  
𝑤ℎ𝑒𝑟𝑒 𝑝0 = 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠 𝑤ℎ𝑒𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑠 𝑎𝑔𝑟𝑒𝑒𝑑, 𝑎𝑛𝑑  
𝑝𝑒 = 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠 𝑤ℎ𝑒𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑠 𝑤𝑒𝑟𝑒 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑡𝑜 𝑎𝑔𝑟𝑒𝑒 𝑏𝑦 𝑐ℎ𝑎𝑛𝑐𝑒.  
Equation 5.1: Cohen’s Kappa Statistic for Agreement (Cohen, 1960) 
Using this value, the level of agreement could then be assessed using the 
arbitrary thresholds provided in Table 5.1, as first outlined by Landis and Koch 
(1977). In this chapter, for patients where it could be ascertained whether a 
≥40% reduction in non-HDL from a pre-MI baseline and an LDL ≤1.8mmol/l at any 
point during follow up was achieved, a Cohen’s kappa statistic for agreement 
was calculated. 
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Table 5.1: Agreement Thresholds for Cohen's Kappa Statistic from (Landis and Koch, 1977) 






0.81-1.00 Almost Perfect 
 
5.2.3 Logistic Regression 
Logistic regression is a method used to investigate the associations between one 
or more exposure variables with the binary outcome variable, where p is the 




is (natural) log-transformed to form the logit function, and the general form of 




) = 𝛽0 + 𝛽1𝑥1 + 𝛽2𝑥2 + ⋯ 
Equation 5.2: General Form of a Logistic Regression Model (Kirkwood and Sterne, 2003) 
Within the model, 𝛽0, represents the baseline odds, whilst all subsequent 
parameters (𝛽𝑖) indicate the odds associated with the corresponding exposure 
variables (𝑥𝑖). Following exponentiation, these parameters become the odds 
ratio (OR) associated with that exposure (Kirkwood and Sterne, 2003).  
In this chapter, logistic regression is performed for the outcome variables: 
further hospital admissions for MIs (yes, no), and the achievement of lipid 
targets (yes, no), with odds ratios and confidence intervals, plotted using the 
‘forestplot’ package in R (Gordon and Lumley, 2020). For each, the exposure 
variable is average adherence (of a patient’s complete year-long time windows), 
with cut-offs 50% and 80%, and as a continuous measure. Where adherence is 
categorised with the cut-offs, the reference group is those whose average 
adherence was above it, so the odds are for those who are less adherent. When 
continuous adherence is used, the odds are calculated per 10% decrease, which 
can be obtained by inverting the parameter and raising it to the power of ten. 
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This approach was also taken in a sensitivity analyses where a patient’s average 
adherence was calculated including time windows which were shorter than one 
year. The achievement of lipid targets is also used as an exposure variable for 
further hospital admissions for MIs, where, similar to models with adherence as 
the exposure, the achievement of each target is the reference category.  
5.2.4 Kaplan-Meier Curves 
Survival analysis methods are used when the outcome of interest is the time to a 
defined event, as not all individuals have experienced the event and their length 
of follow up, or ‘time at risk’, is different for each individual. Using these 
methods, individuals are censored at the last time point that it is known that 
they had not experienced the event, which is usually the end of their follow up 
(Bull and Spiegelhalter, 1997; Kirkwood and Sterne, 2003; Harrell, 2015b).  
𝐿𝑒𝑡 𝑛𝑡 = 𝑛𝑜. 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑎𝑡 𝑟𝑖𝑠𝑘, 𝑎𝑛𝑑 ⅆ𝑡 =  𝑛𝑜. 𝑒𝑣𝑒𝑛𝑡𝑠 𝑜𝑐𝑐𝑢𝑟𝑖𝑛𝑔 𝑒𝑥𝑎𝑐𝑡𝑙𝑦, 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡. 
𝑇ℎ𝑒𝑛 𝑡ℎ𝑒 𝑟𝑖𝑠𝑘 𝑜𝑓 𝑎𝑛 𝑒𝑣𝑒𝑛𝑡 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡,  
 𝑟𝑡 =  
ⅆ𝑡
𝑛𝑡
,   
𝑆𝑜, 𝑡ℎ𝑒 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦,  




𝐿𝑒𝑡 𝑡𝑖 𝑏𝑒 𝑡ℎ𝑒 𝑡𝑖𝑚𝑒 𝑤ℎ𝑒𝑟𝑒 𝑡ℎ𝑒 𝑖𝑡ℎ 𝑒𝑣𝑒𝑛𝑡 𝑜𝑐𝑐𝑢𝑟𝑠, 𝑡ℎ𝑒𝑛,  






Equation 5.3: Cumulative Survival Probability at time t The number at risk is the number of 
individuals who have not experienced the event, or been censored, prior to time t, but 
includes those who experience the event or are censored at time t.(Kirkwood and Sterne, 
2003; Harrell, 2015b) 
Kaplan-Meier curves are a non-parametric method of survival analysis which does 
not assume the shape of the survival distribution and plots the estimated 
cumulative survival probability, S(t), against time as a step function (Bull and 
Spiegelhalter, 1997; Kirkwood and Sterne, 2003; Harrell, 2015b). The calculation 
of S(t) is in two stages. First, for each time t, that an event occurs within the 
dataset, the survival probability at that time is calculated. These instantaneous 
survival probabilities are then used to generate the cumulative survival 
probability S(t), as shown in Equation 5.3 (Kirkwood and Sterne, 2003; Harrell, 
2015b). 




Figure 5.2: Example of Kaplan-Meier Curve. Graph taken from R-Bloggers (R-Bloggers, 
2016b), generated using data available in the ‘survival’ R package (Therneau, 2020), and 
plotted using the ‘survminer’ package (Kassambara et al., 2020). 
These estimates are plotted against time (Bull and Spiegelhalter, 1997; Kirkwood 
and Sterne, 2003; Harrell, 2015b), as shown in Figure 5.2. Typically, Kaplan-
Meier curves are used to compare the survival rates between two or more 
discrete groups, with larger differences between the lines indicating higher 
survival in one group (Bull and Spiegelhalter, 1997). Quantiles can also be 
estimated from these graphs or from the table of calculated cumulative survival 
probabilities. Censored observations (usually denoted by a ‘+’) and confidence 
intervals can be included on the graphs to illustrate where greater uncertainty 
may lie and indicate the strength of any differences between groups (Bull and 
Spiegelhalter, 1997; Harrell, 2015b). In the R package used for this analysis, 
these are constructed using the Normal approximation on the log scale and then 
exponentiated (Therneau, 2020). 
For this analysis, Kaplan-Meier curves were produced for the mortality (all-cause 
and circulatory) outcome only and were plotted for overall survival, and by 
average adherence (with 50% and 80% cut-offs), and achievement of lipid targets 
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during follow up. In a sensitivity analysis, the 50% and 80% cut-offs were also 
applied to average adherence calculated including incomplete years of follow 
up. Due to the number of censored observations, these were not marked on the 
graphs but the number at risk and number of events at the end of each year of 
follow up are tabulated below each graph. They were generated using the 
‘survival’ (Therneau, 2020) and ‘survminer’ (Kassambara et al., 2020) packages 
within R v3.5.0 (R Core Team, 2018). Corresponding baseline hazards were 
plotted using the ‘muhaz’ package (Hess, Gentleman and Winsemius, 2019). 
5.2.5 Cox Regression 
The Cox Proportional Hazard Model consists of a baseline hazard and a collection 
of predictor variables with their estimated parameters, as shown in Equation 
5.4. This model is semi-parametric as although the regression of the predictor 
variables is fully parameterised, there are no assumptions made regarding the 
form of the baseline hazard (Cox, 1972; Kleinbaum and Klein, 2012; Harrell, 
2015a). 
log(ℎ(𝑡)) = log(ℎ0(𝑡)) + 𝛽1𝑥1 + 𝛽2𝑥2 + ⋯,              (1)  
𝑤ℎ𝑒𝑟𝑒 ℎ(𝑡) 𝑖𝑠 𝑡ℎ𝑒 ℎ𝑎𝑧𝑎𝑟𝑑 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡, 𝑎𝑛𝑑 ℎ0(𝑡) 𝑖𝑠 𝑡ℎ𝑒 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 ℎ𝑎𝑧𝑎𝑟𝑑.  
𝐵𝑦 𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡𝑖𝑎𝑡𝑖𝑛𝑔 𝑏𝑜𝑡ℎ 𝑠𝑖𝑑𝑒𝑠, (1) 𝑏𝑒𝑐𝑜𝑚𝑒𝑠:  
ℎ(𝑡) =  ℎ0(𝑡) ∗ exp(𝛽1𝑥1 + 𝛽2𝑥2 + ⋯ ),                       (2) 
Equation 5.4: Hazard Function of the Cox Proportional Hazards Model (Cox, 1972; Kirkwood 
and Sterne, 2003; Kleinbaum and Klein, 2012; Harrell, 2015a) 
As with logistic regression, the 𝛽𝑖 are the estimated parameters associated with 
the covariates or predictor variables, 𝑥𝑖, where the exponentiated parameter 
(exp(𝛽𝑖)) yields the hazard ratio for that covariate. This estimated effect of the 
covariate is independent of the time t and emphasises the proportional hazards 
assumption of the Cox model (Cox, 1972; Kirkwood and Sterne, 2003; Kleinbaum 
and Klein, 2012; Harrell, 2015a).  




Figure 5.3: Schoenfeld Residual Plot to Check the Proportional Hazards Assumption (R-
Bloggers, 2016a) 
In this chapter, this assumption was checked using the partial Schoenfeld 
residuals for each covariate (Harrell, 2015a). These residuals are defined as the 
observed value of the covariates minus its expected (or mean) value given the 
number at risk at that time (Schoenfeld, 1982), which are then scaled (Harrell, 
2015a; Therneau, 2020). If the proportional hazards assumption holds, then 
when plotted against time, there should be no pattern between the residuals 
and time (Harrell, 2015a). In the ‘survival’ package, an accompanying formal 
test can also be implemented, both for an individual covariate and the overall 
model (Harrell, 2015a; Therneau, 2020). This takes the form of a score test, 
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which calculates the correlation between the residuals and the order of the 
failure times (Grambsch and Therneau, 1994; Harrell, 2015a). When plotted 
using the ‘survminer’ package, the p-values corresponding to these tests are 
included as part of the graphs by default (Kassambara et al., 2020), as shown in 
Figure 5.3. 
Mortality (all-cause and circulatory) was the only outcome considered in the 
analysis, with its relationship with average adherence (continuous, 50% and 80% 
cut-offs), and achievement of lipid targets investigated. In line with the logistic 
models, hazard ratios reported for continuous adherence are per 10% decrease in 
average adherence, and in a sensitivity analysis, hazard ratios were also 
calculated for average adherence estimated using incomplete, as well as 
complete, year-long time windows. Hazard ratios and their 95% confidence 
intervals were plotted using the ‘forestplot’ package in R (Gordon and Lumley, 
2020). 
5.3 Recurrent Hospital Admissions for Myocardial 
Infarctions  
All further MI admissions to hospital were included irrespective of the patient’s 
mortality status following them. However, this number is likely to be an 
underestimate of the number of recurrent MIs experienced as not all fatal MIs 
will have resulted in hospital admission. Consequently, deaths due to circulatory 
conditions are examined separately within the subsequent sections focussing on 
mortality within this population (Chapter 5.4). Nonetheless, fatal recurrent MIs 
were still included in this analysis as the economic costs to the healthcare 
system of non-fatal and fatal MIs resulting in a hospital admission are likely to be 
similar. 
There were a further 4,209 hospital admissions for MIs in the post MI population 
before 31st July 2017, which occurred in 3,038 patients (3038/11110, 27.3%). The 
number of further MIs resulting in a hospital admission that a patient had (i.e. 
excluding the first non-fatal one defining the start of follow up) is shown in 
Table 5.2. The majority of those with further hospital admissions for an MI had 
only one, but some patients had a substantially higher number of MI admissions 
recorded, with the maximum number being 16. The higher number of individuals 
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with MI admissions in follow up compared to those with MIs before their baseline 
date was not unexpected. To be included in this population, patients would have 
had to have survived not only the MI of interest but also the MIs that had 
occurred in the prior ten years and the years in between. This makes the those 
with prior MIs and those with subsequent MIs subtly distinct. However, the 
higher number could also be partially as a result of changes in MI definition over 
the lookback period and during follow up (Thygesen et al., 2007, 2012) or 
incomplete early reporting in hospital records. 
Table 5.2: Number of Further Hospital Admissions for MIs experienced in each patient who 
had at least one after the index admission. 
No. Further MIs N (%) 
1 2,290 (75.4%) 
2 502 (16.5%) 
3 160 (5.3%) 
4 49 (1.6%) 
5 21 (0.7%) 
>5 16 (0.5%) 
Numbers exclude MIs which defined the patient’s start date. Numbers are N (%) of those 
with Further Hospitalised MIs. 
Figure 5.4 details the individual patterns of further hospital admissions for MIs 
throughout follow up. From this, and Table 5.3, it is clear that the greatest risk 
of experiencing a further MI admission was in the first year after an MI 
admission, with the risk decreasing as follow up duration increases. Indeed, over 
half of the subsequent hospital admissions for MIs occurred in the first year 
(59.3%), and in nearly three quarters (70.6%) of the patients who experienced 
further MI admissions. A decrease in the number of patients with data available 
at each year of follow up (due to follow up ending 31st July 2017) may account 
for some of the apparent decreasing risk, but in the first three years, the 
number of patients available only decreases due to patient deaths. Furthermore, 
as shown in Figure 5.4, this pattern was not confined to the patient’s baseline 
MI, but with all subsequent MI admissions. Moreover, as Table 5.3 illustrates, 
some patients experienced multiple further MI admissions within a year of follow 
up, with only the ninth year reporting the same number of hospitalised MIs as 
patients being admitted with them.  




Figure 5.4: Individual Patterns of Further Hospitalised MIs During Follow Up. Each time 
window was categorised by whether further MI admissions occurred during it, with red 
indicating patients had an admission that year and grey indicating they did not. Patients 
were sorted by their further MI admission patterns before plotting, with lower patient 
numbers assigned to those with a longer period before their first recurrent MI admission. 
Only patients with a recurrent MI admission during their follow up were included (N = 3,038). 
Table 5.3: Hospitalised MIs by Year of Follow Up  
 Year of Follow Up 
 1 2 3 4 5 6 7 8 9 
# MIs 2,496 525 359 308 231 159 88 35 8 
# Pts 2,144 418 311 250 191 133 72 32 8 
# At Risk 11,110 10,082 9,316 8,675 6,558 4,753 3,136 1,684 567 
Patients may have more than one MI in any given year of follow up. # at risk is the number 
of patients still alive and not reached the end of follow up at the start of that year.  # = 
Number; Pts = Patients. 
When comparing the population of those with and without further hospital 
admissions for MIs (Table 5.4), the gender split was broadly similar between the 
two groups. There was also no substantial difference in age, with those who did 
not have a subsequent MI admission just half a year older than those who did 
(67.0 vs 66.5 years) on average. In terms of deprivation, patients who had a 
further MI admission were more likely to reside in more deprived areas (by 
quintile). However, the biggest differences between the two groups were 
observed in the presence of a diagnosis of diabetes, and the number of MIs prior 
to the start of follow up. In patients who had been diagnosed with diabetes 
approximately 6% more went on to have an MI admission than in patients without 
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diabetes (23.1% vs 17.3%). Higher proportions were observed in both Type 1 and 
Type 2 diabetes. For prior MIs, the percentage was nearly double in those with 
further MI admissions than those without (9.3% vs 5.4%).  
Table 5.4: Demographics by Further Hospitalised MIs During Follow Up  




Gender    
   Male 4,897 (60.7%) 1,835 (60.4%) 
   Female 3,175 (39.3%) 1,203 (39.6%) 
   
Age at MI (years) 
   Mean (SD) 67.0 (14.0) 66.5 (13.8) 
   Median 67.4 67.2 
   IQR 56.2 – 77.9 55.8 – 77.5 
   Range 19.3 – 102.6 20.5 – 97.9 
   
SIMD 2012 Quintile (NHS GGC) 
   1 (Most) 1,883 (23.5%) 767 (25.4%) 
   2 1,829 (22.8%) 699 (23.1%) 
   3 1,659 (20.7%) 635 (21.0%) 
   4 1,404 (17.5%) 473 (15.7%) 
   5 (Least) 1,236 (15.4%) 446 (14.8%) 
   Missing 61 18 
   
Diabetes at MI 1,397 (17.3%) 702 (23.1%) 
   Type 1 71 (0.9%) 49 (1.6%) 
   Type 2 1,326 (16.4%) 653 (21.5%) 
   
Prior MI 432 (5.4%) 282 (9.3%) 
   1 337 (4.2%) 221 (7.3%) 
   >1 95 (1.2%) 61 (2.0%) 
Numbers are N (%) unless otherwise specified. Percentages are calculated within columns, 
except for the header where percentages are calculated from the total with information 
available. SD = Standard Deviation; IQR = Interquartile Range. 
5.4 Deaths 
5.4.1 Underlying Causes of Death 
For those who died before the end of follow up, the underlying causes of death 
are presented in Table 5.5. There were 3,768 (33.9%) deaths, of which 2,894 
patients (76.8%) had the cause of death data available. Causes of death were 
grouped by the ICD10 chapters (World Health Organization, 2016), with only the 
underlying causes of death presented. Of those with the cause of death data 
available, the most common causes of death were diseases of the circulatory 
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system (I00–I99), with more than twice as many deaths than any other ICD10 
chapter. The next two biggest underlying causes of death were neoplasms (C00-
C97, D00-D48) and respiratory diseases (J00-J99), representing 19.0% and 16.4% 
of deaths respectively. All other ICD10 chapters were responsible for fewer than 
150 deaths each, with many responsible for fewer than 100. 
Table 5.5: Distribution of Underlying Causes of Death (by ICD10 Chapter) 
Cause of Death  N (%) 
Diseases of the Circulatory System 1,207 (41.7%) 
Neoplasms 551 (19.0%) 
Diseases of the Respiratory System 476 (16.4%) 
Mental and Behavioural Disorders 142 (4.9%) 
Diseases of the Digestive System 138 (4.8%) 
Other 380 (13.1%) 
Missing 874 
Numbers are N (%) of those with the cause of death available. 
Table 5.6: Distribution of Circulatory Underlying Causes of Death (by ICD10 Subchapter) 
Circulatory Causes of Death  N (%) 
Ischaemic Heart Disease (I20-I25) 836 (69.3%) 
Cerebrovascular Diseases (I60-I69) 173 (14.3%) 
Other Forms of Heart Disease (I30-I52) 128 (10.6%) 
Other Circulatory Deaths* 70 (5.8%) 
Total (I00-I99) 1,207 
Numbers are N (%) of those with a circulatory cause of death (defined by ICD10 codes I00-
I99). *including Chronic Rheumatic Heart Diseases (I05-I09); Hypertensive Diseases (I10-
I15); Pulmonary Heart Disease and Diseases of Pulmonary Circulation (I26-I28); Diseases of 
Arteries, Arterioles and Capillaries (I70-I79); Diseases of Veins, Lymphatic Vessels and 
Lymph Nodes, Not Elsewhere Classified (I80-I89). No circulatory deaths were recorded for 
Acute Rheumatic Fever (I00-I02) or Other and Unspecified Disorders of the Circulatory 
System (I95-I99).  
An examination of the ICD10 subchapters for those who died due to diseases of 
the circulatory system (Table 5.6) revealed that over half of the circulatory 
deaths were due to ischaemic heart disease (I20-I25), including MIs. 
Cerebrovascular diseases (I60-I69), principally strokes, and other forms of heart 
disease (I30-I52), including heart failure, were also responsible for over 100 
deaths within this population. No other subchapters in this group were 
responsible for more than 50 deaths.  
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5.4.2 Time to Death 
When looking at the number of deaths by year of follow up (Table 5.7), it is 
evident that more deaths occurred nearer the beginning of follow up (i.e. closer 
to the MI). This trend is also present in the numbers of deaths due to circulatory 
diseases, although the percentage of deaths due to circulatory disease does 
slightly increase between years two and six, before subsequently decreasing. It 
is also important to note that the number of circulatory deaths is likely to be 
underestimated, with patients missing a cause of death conservatively assigned 
to non-circulatory causes for much of the subsequent analyses unless otherwise 
specified.  
Table 5.7: Deaths by Year of Follow Up  
 Year of Follow Up 
 1 2 3 4 5 6 7 8 9 
# Deaths 1,028 767 643 540 358 221 157 44 10 
# Circ.  309 225 205 191 130 81 46 18 2 
# At Risk 11,110 10,082 9,316 8,675 6,558 4,753 3,136 1,684 567 
# at risk is the number of patients still alive and not reached the end of follow up at the start 
of that year. Circulatory (Circ.) cause of death defined by ICD10 codes I00-I99 as the 
underlying cause of death. 
Using the dates of death, the Kaplan-Meier plots (Figure 5.5) also show a slightly 
sharper decrease in the first couple of years of follow up before maintaining a 
shallower decline. This was less evident in the circulatory deaths plot, though 
this is likely largely due to the smaller number of events in this population. 
Furthermore, whilst there was no censoring during the first three years of follow 
up by the design of the cohort, there was a high number of censored 
observations after this time point (not marked in Figure 5.5). For both plots, the 
data was not mature enough to estimate the median survival time. However, for 
all-cause mortality only, there were enough events to estimate the lower 




Figure 5.5: Kaplan-Meier Curves of Mortality (Overall and Circulatory Deaths) (with 95% CI). Numbers are Number at Risk (Number of Events). Circulatory 















Gender       
   Male 4,800 (65.4%) 1,932 (51.3%) 656 (54.3%) 860 (51.0%) 416 (47.6%) 
   Female 2,542 (34.6%) 1,836 (48.7%) 551 (45.7%) 827 (49.0%) 458 (52.4%) 
      
Age at MI (years)      
   Mean (SD) 62.0 (12.5) 76.5 (11.3) 76.3 (11.4) 76.2 (11.1) 77.2 (11.7) 
   Median 61.3 78.1 78.0 77.5 79.5 
   IQR 52.7 – 71.6 69.8 – 84.8 69.4 – 84.5 69.7 – 84.3 70.5 – 85.9 
   Range 19.3 – 98.1 26.5 – 102.6 36.2 – 102.6 30.6 – 102.4 26.5 – 100.7 
      
SIMD 2012 Quintile (NHS GGC)      
   1 (Most) 1,760 (24.2%) 890 (23.7%) 280 (23.3%) 399 (23.8%) 211 (24.2%) 
   2 1,638 (22.5%) 890 (23.7%) 288 (24.0%) 412 (24.6%) 190 (21.8%) 
   3 1,470 (20.2%) 824 (22.0%) 262 (21.8%) 365 (21.8%) 197 (22.6%) 
   4 1,219 (16.7%) 658 (17.6%) 215 (17.9%) 283 (16.9%) 160 (18.4%) 
   5 (Least) 1,196 (16.4%) 486 (13.0%) 155 (12.9%) 218 (13.0%) 113 (13.0%) 
   Missing 59 20 7 10 3 
      
Diabetes at MI 1,045 (14.2%) 1,054 (28.0%) 364 (30.2%) 445 (26.4%) 245 (28.0%) 
   Type 1 61 (0.8%) 59 (1.6%) 16 (1.3%) 31 (1.8%) 12 (1.4%) 
   Type 2 984 (13.4%) 995 (26.4%) 348 (28.8%) 414 (24.5%) 233 (26.7%) 
      
Prior MI 344 (4.7%) 370 (9.8%) 122 (10.1%) 139 (8.2%) 109 (12.5%) 
   1 266 (3.6%) 292 (7.7%) 94 (7.8%)  114 (6.8%) 84 (9.6%)  
   >1 78 (1.1%) 78 (2.1%) 28 (2.3%) 25 (1.5%) 25 (2.9%) 
Numbers are N (%) unless otherwise specified. Percentages are calculated within columns, except for the header where they are calculated from total with 
information available. SD = Standard Deviation; IQR = Interquartile Range; Circulatory (Circ.) cause of death defined by ICD10 I00-I99 as underlying cause. 
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5.4.3 Demographics by Mortality 
The demographics of those who had died and those who were alive at the end of 
follow up are compared in Table 5.8. A higher proportion of those who died were 
female (48.7% vs 34.6% in survivors). Additionally, compared to those who were 
alive at the end of follow up, those who died were typically around 15 years 
older (76.5 vs 62.0 years), were twice as likely to have a diagnosis of diabetes 
before the start of follow up (28.0% vs 14.2%), and the percentage who had 
experienced a prior MI was also more than double (9.8% vs 4.7%). There did not 
appear to be any substantial differences in the patient’s deprivation quintile 
between the groups.  
When differences between circulatory and non-circulatory causes of death were 
compared (Table 5.8), there were no differences in age or deprivation. Those 
who died due to a circulatory disease were slightly more likely to be male (54.3% 
vs 51.0%), as well as having had a prior MI (10.1% vs 8.2%). Those with a 
circulatory cause of death were also more likely to have had a diagnosis of 
diabetes before the start of follow up (30.2% vs 26.4%), although there were 
some differences by the type of diabetes. There was a higher prevalence of Type 
2 diabetes (28.8% vs 24.5%) and a lower prevalence of Type 1 diabetes (1.3% vs 
1.8%), in those with a circulatory cause of death, compared to those who died 
due to other causes.  
5.5 Plasma Lipid Levels and Subsequent Outcomes 
Two lipid targets were considered: a non-HDL target in line with NICE 
recommendations, where ≥40% reduction from a pre-MI non-medicated baseline 
was targeted (NICE, 2014), and an LDL target of ≤1.8mmol/l from the ESC 
guidelines (Piepoli et al., 2016). Patients were classified as achieving the target 
if they achieved it in any of the years of follow up available for them, otherwise, 
they were defined as not achieving the target. It is important to note that the 
at-risk group for the non-HDL target is smaller as many patients did not have an 
available pre-MI statin-naïve baseline to facilitate the calculation of the 
percentage reduction. Further information surrounding the derivation of these 
targets within the data and descriptive statistics for those who met and did not 
meet these targets is given in Chapters 3.5 and 4.4 respectively.  
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Table 5.9: Events Stratified by Lipid Plasma Targets (NICE and ESC Recommendations) 
 Target:  
≥40% Reduction non-HDL* 
Target:  
LDL ≤1.8mmol/l 








Further Hospitalised MI    
   Yes 477 (27.7%) 499 (30.5%) 2,063 (28.6%) 635 (27.7%) 
   No 1,244 (72.2%) 1,135 (69.5%) 5,152 (71.4%) 1,654 (72.3%) 
     
Death     
   Yes  287 (16.7%) 518 (31.7%) 1,893 (26.2%) 663 (29.0%) 
   No 1,434 (83.3%) 1,116 (68.3%) 5,322 (73.8%) 1,626 (71.0%) 
     
Cause of Death†  243  433 1,526 524 
   Circulatory‡ 94 (38.7%) 177 (40.9%) 632 (41.4%) 224 (42.7%) 
   Neoplasms 64 (26.3%) 86 (19.9%) 312 (20.4%) 110 (21.0%) 
   Respiratory‡ 33 (13.6%) 84 (19.4%) 247 (16.2%) 72 (13.7%) 
   Digestive‡ 14 (5.8%) 17 (3.9%) 75 (4.9%) 26 (5.0%) 
   Other 38 (15.6%) 69 (15.9%) 260 (17.0%) 92 (17.6%) 
   Missing 44 85 367 139 
*refers to the percentage reduction in non-HDL cholesterol from the pre-MI baseline. †where 
underlying cause of death information is available. ‡ refers to the ICD10 chapter with the 
title ‘Diseases of the ‘X’ system’. Patients were classified as meeting a target if they 
achieved the target in any year of their follow up, and not meeting a target if they did not 
achieve it in every year of their follow up. Numbers are N (%). Percentages are calculated 
within columns, except for the header where percentages are calculated from total with 
information available. Percentages for specific causes of death are calculated based on 
those with the information available. 
On examination of the raw frequencies of further MI admissions and deaths by 
the achievement of these lipid targets (Table 5.9), some differences were clear. 
Those who did not meet the non-HDL target were more likely to have had a 
further MI admission (30.5% vs 27.7%). The proportion of people in this group 
who died was nearly double that of those who did achieve the target (31.7% vs 
16.7% respectively). There were also higher proportions of deaths from 
circulatory (40.9% vs 38.7%) and respiratory causes (19.4% vs 13.6%) amongst 
those who did not meet the non-HDL target than those who did meet the target. 
In contrast, there were no major differences in the proportion of patients who 
experienced a further hospital admission for MI between those who did and did 
not achieve the LDL target (28.6% vs 27.7%). However, as with the non-HDL 
target, a greater percentage of patients who did not meet the LDL target died 
(29.0% vs 26.2%), although this difference was less pronounced. The percentage 
of deaths due to circulatory diseases was also only slightly higher in those who 
did not meet the target (42.7% vs 41.4%). In contrast to what was observed with 
the non-HDL target, the proportion of deaths due to respiratory diseases was 
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higher in those that did meet the LDL target compared to those who did not 
(16.2% vs 13.7%).  
These discrepancies in outcomes between the two targets may have been 
because there was only a slight agreement between the two targets, with a 
Cohen’s kappa statistic for agreement of 0.16 (95% CI: 0.13, 0.20). In the group 
of 1,413 individuals that met both targets (compared to those who met only one 
or none of the targets), the differences observed were similar to those observed 
in the achievement of the non-HDL target; those who met both targets were less 
likely to have further MI admissions (28.3% vs 29.7%) or to die from any cause 
(16.6% vs 29.3%) or circulatory causes (5.7% vs 9.7%), than those who did not. 
5.5.1 Association Between Targets and Recurrent Hospital 
Admissions for Myocardial Infarctions 
 
Figure 5.6: Odds Ratios of Further Hospitalised MIs by Achievement of Plasma Lipid Targets  
(unadjusted and adjusted for age, sex, year of MI, and SIMD quintile). Non-HDL target is 
≥40% non-HDL reduction from a pre-MI baseline (NICE, 2014) and the LDL target is 
≤1.8mmol/l (Piepoli et al., 2016). Patients only included in analyses where all needed 
information was available. Patients were classified as meeting a target if they achieved the 
target in any year of their follow up, and not meeting a target if they did not achieve it in 
every year of their follow up. 
In unadjusted and adjusted logistic regression models (Appendix G), there were 
no statistically significant associations, at the 5% level, between not achieving 
lipid targets and experiencing further MI admissions during follow up (Figure 
5.6). Nonetheless, the non-HDL target did show trends towards associations; not 
achieving the non-HDL target during follow up was associated with a borderline 
significant 15% higher odds of a patient experiencing a further MI admission. In 
contrast, not achieving the LDL target was associated with a non-significant 4% 
lower odds. Furthermore, adjustment for age, sex, deprivation, and year of MI 
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resulted in minimal impact on the estimated odds ratios, with the odds 
increasing to 16% higher for the non-HDL target, and decreasing to 5% for LDL. In 
a sensitivity analysis (not presented), where the association with LDL was 
investigated amongst those with a non-HDL result, the odds ratio decreased to 
15% lower odds of a further hospital admission for an MI, but this was not 
statistically significant in the adjusted model.  
5.5.2 Association Between Targets and Mortality 
Kaplan-Meiers for both targets and both overall mortality and circulatory causes 
(Figure 5.7 and Figure 5.8) show some separation in the survival probabilities 
between those who achieved and did not achieve the lipid targets, with the 
differences established early on in follow up and non-achievers faring worse. For 
the LDL target and all-cause mortality, this difference is established early and 
maintained throughout, with confidence intervals only overlapping at the 
maximal follow up, likely due to greater uncertainty. For circulatory causes, this 
difference is less pronounced, with the two lines similar throughout follow up 
and non-achievers faring marginally worse. For the non-HDL target, the 
difference is evident early on for both all-cause and circulatory causes, with the 
distance between the lines increasing as the length of time post MI increases.  
As with the overall mortality Kaplan-Meier (Figure 5.5), only the lower quartile 
for each of the all-cause curves could be estimated. For both targets, the 
estimated lower quartile for not meeting the specific target was 4.2 years, 
although due to smaller numbers included for the non-HDL analysis, the 
corresponding confidence interval was slightly wider than the LDL target analysis 
(95% CI: 3.8–4.6 years vs 95% CI: 3.9–4.5 years). However, there was a bigger 
difference in the estimated lower quartiles for those who did achieve the 
targets. For those who achieved the LDL target, the lower quartile was 
estimated as 5.5 years (95% CI: 5.3–5.8 years), whereas the lower quartile for 
meeting the non-HDL target was 7.7 years, and the corresponding upper bound 
of the confidence interval inestimable (95% CI: 7.4–NA years). No other quartiles 
could be estimated from the graphs, except the median survival for those who 
did not meet the non-HDL target, which was 8.0 years (95% CI: 7.8–NA years), 
with the upper bound of the confidence interval also inestimable. No quartiles 




Figure 5.7: Kaplan-Meier Curves of Overall Mortality by Plasma Lipid Targets (with 95% Confidence Intervals). Numbers are Number at Risk (Number of 
Events). Non-HDL target is ≥40% non-HDL reduction from a pre-MI baseline (NICE, 2014) and the LDL target is ≤1.8mmol/l (Piepoli et al., 2016). Patients only 
included in analyses where information was available. Patients were classified as meeting a target if they achieved the target in any year of their follow up, 





Figure 5.8: Kaplan-Meier Curves of Circulatory Mortality by Plasma Lipid Targets (with 95% Confidence Intervals). Numbers are Number at Risk (Number of 
Events). Circulatory cause of death defined by ICD10 I00-I99 as underlying cause. Non-HDL target is ≥40% non-HDL reduction from a pre-MI baseline (NICE, 
2014) and the LDL target is ≤1.8mmol/l (Piepoli et al., 2016). Patients only included in analyses where information was available. Patients were classified as 
meeting a target if they achieved the target in any year of their follow up, and not meeting a target if they did not achieve it in every year of their follow up.
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A – Overall Mortality
 
B – Circulatory Causes
 
Figure 5.9: Hazard Ratios of Mortality by Achievement of Plasma Lipid Targets (unadjusted 
and adjusted for age, sex, year of MI, and SIMD quintile). A = all-cause mortality; B = 
circulatory cause of death (defined by ICD10 I00-I99 as the underlying cause). Non-HDL 
target is ≥40% non-HDL reduction from a pre-MI baseline (NICE, 2014) and the LDL target is 
≤1.8mmol/l (Piepoli et al., 2016). Patients only included in analyses where all needed 
information was available. Patients were classified as meeting a target if they achieved the 
target in any year of their follow up, and not meeting a target if they did not achieve it in 
every year of their follow up. 
Cox regression showed that not achieving the non-HDL target was associated 
with 2.2 times greater hazard of all-cause mortality compared to those who did 
achieve the target and that not meeting the LDL target was associated with 1.3 
times greater hazard, before any adjustment for other variables (Figure 5.9a). 
Nearly identical hazards were also observed when circulatory causes alone were 
considered (Figure 5.9b). When adjusted for age, sex, deprivation quintile, and 
year of MI, this did not attenuate the elevated hazard associated with not 
meeting the LDL target for either cause but did reduce the hazard associated 
with failure to achieve the non-HDL target to 1.8 times higher for both all-cause 
and circulatory causes. This result, along with all others, remained statistically 
significant at the 5% level. Full details of the models, including Schoenfeld 
residual plots, are included in Appendix I. As with earlier models, a sensitivity 
analysis of the LDL association in the non-HDL at-risk group (not presented), the 
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associations with all-cause and circulatory mortality remained statistically 
significant and the hazard ratios increased marginally. 
5.6 Statin Adherence and Subsequent Outcomes 
Patient statin adherence was assessed using the MPR and was calculated for each 
complete year of follow up that the individual patient had available. For each 
patient, their mean adherence was then derived. As this value needed at least 
one complete year of follow up, only patients who were alive at the end of the 
first year post MI were included in these analyses (9.3% died in the first year). 
Additionally, patients were then classified as adherent or non-adherent, using 
two different thresholds, 50% and 80% (Chapter 4.5.1). The derivation of a 
patient’s statin adherence and further descriptive statistics can be found in 
Chapters 3.4 and 4.5 respectively.  
Table 5.10: Events by Statin Adherence Thresholds (50% and 80%) 








Further Hospitalised MI    
   Yes 2,366 (27.8%) 399 (25.6%) 1,875 (27.0%) 890 (28.3%) 
   No 6,156 (72.2%) 1,161 (74.4%) 5,067 (73.0%) 2,250 (71.7%) 
     
Death     
   Yes  2,175 (25.5%) 565 (36.2%) 1,666 (24.0%) 1,074 (34.2%) 
   No 6,347 (74.5%) 995 (63.8%) 5,276 (76.0%) 2,066 (65.8%) 
     
Cause of Death*  1,808 469 1,396 881 
   Circulatory†  712 (39.4%) 186 (39.7%) 561 (40.2%) 337 (38.3%) 
   Neoplasms 375 (20.7%) 71 (15.1%) 282 (20.2%) 164 (18.6%) 
   Respiratory† 301 (16.6%) 102 (21.7%) 233 (16.7%) 170 (19.3%) 
   Men.&Beh.‡ 95 (5.3%) 29 (6.2%) 64 (4.6%) 60 (6.8%) 
   Digestive† 82 (4.5%) 20 (4.3%) 67 (4.8%) 35 (4.0%) 
   Other 243 (13.4%) 61 (13.0%) 189 (13.5%) 115 (13.1%) 
   Missing 367 96 270 193 
*where the underlying cause of death information is available. †refers to the ICD10 chapter 
with the title ‘Diseases of the ‘X’ system’. ‡refers to the ICD10 Chapter ‘Mental and 
Behavioural Disorders’. MPR = Medication Possession Ratio. NF/F-MI = Non-Fatal/Fatal 
Further Myocardial Infarction. Numbers are N (%). Percentages are calculated within 
columns, except for the header where percentages are calculated from total with 
information available. Percentages for specific causes of death are calculated based on 
those with information available. 
The relationship between adherence thresholds and further hospital admissions 
for MIs was not consistent (Table 5.10). For the 50% adherence threshold, those 
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with an average adherence above the cut-off were more likely to have further MI 
admissions than those with adherence below it (27.8% vs 25.6%). However, when 
the 80% cut-off is considered, there was little difference in the percentages of 
patients with further hospital admissions for MIs, with those whose adherence 
was lower slightly more likely to have further admissions (28.3% vs 27.0%). 
For mortality, those with average adherence lower than both thresholds were 
more likely to die during follow up (50%: 36.2% vs 25.5%, 80%: 34.2% vs 24.0%). 
When the cause of death was considered, at the 50% cut-off there was no 
difference in the percentage who died due to circulatory disease (<50%: 39.7% vs 
≥50%: 39.4%). Those whose average adherence was ≥80% were slightly more 
likely to have a circulatory cause of death than those whose adherence was 
below the threshold (40.2% vs 38.3%). Additionally, for both thresholds, the 
proportion of deaths due to respiratory diseases was greater in those whose 
adherence was lower than the threshold compared to those who exceeded it 
(50%: 21.7% vs 16.6%, 80%: 19.3% vs 16.7%).  
5.6.1 Association Between Statin Adherence and Recurrent 
Hospital Admissions for Myocardial Infarctions 
 
Figure 5.10: Odds of Further Hospitalised MIs by Average Statin Adherence During Follow 
Up (unadjusted and adjusted for age, sex, year of MI, and SIMD quintile). Achieving an 
adherence threshold defined as an average adherence, measured using MPR, with 
thresholds ≥ 50 or 80%. Average adherence calculated for patients with at least one full year 
of follow up. Patients only included in analyses where all information needed was available. 
The associations between average statin adherence and further hospital 
admissions for MIs, when modelled using logistic regression, were all non-
significant at the 5% level (Figure 5.10). Indeed, when modelled continuously, a 
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10% decrease in average statin adherence was associated with no difference in 
the odds of experiencing a further MI admission, with an estimated odds ratio of 
one. When the cut-offs of 50% and 80% were used, the odds ratios reflected the 
inconsistencies observed in Table 5.10, with adherence <50% associated with an 
11% decrease in odds of a further MI admission, and adherence <80% associated 
with a 7% increase in odds. The differences in the directions with these cut-offs 
may be suggestive that the relationship between adherence and further MI 
admissions is not linear, but equally, as neither reached significance, this could 
have occurred randomly. Additionally, adjusting for age, sex, deprivation and 
year of MI did not alter the lack of associations observed between adherence and 
further MI admissions in follow up. All associations remained consistent when 
incomplete years of follow up were included in the average adherence 
calculation (results not presented).   
5.6.2 Association Between Statin Adherence and Mortality 
The Kaplan-Meier plots by average adherence showed that those whose average 
adherence was below 50% or 80% have lower overall and circulatory survival 
probabilities than those whose adherence was above these thresholds (Figure 
5.11 and Figure 5.12). For both thresholds and causes, differences appear soon 
after the first year of follow up and are maintained throughout, although given 
there were fewer circulatory deaths, the differences are less pronounced in this 
instance. For all-cause mortality, the similar shape of the two graphs is also 
reflected in the estimates of the lower survival time quartiles. For patients 
whose average adherence was ≥50%, the lower quartile was 5.5 years (95% CI: 
5.3–5.8 years), whilst for adherence ≥80%, the lower quartile was 5.8 years (95% 
CI: 5.6–6.1 years). The estimated lower quartiles were around two years earlier 
for those whose adherence was below the thresholds. The lower quartiles were 
3.6 years (95% CI: 3.2–4.0 years) and 3.8 years (95% CI: 3.6–4.1 years), for <50% 
and <80% respectively. There was an insufficient number of events to estimate 
the median or upper quartile survival times, and no quartiles could be estimated 




Figure 5.11: Kaplan-Meier Curves of Overall Mortality by Statin Adherence Thresholds (with 95% Confidence Intervals). Numbers are Number at Risk 
(Number of Events). Patients classified by average statin adherence during follow up, measured using MPR, with thresholds ≥ 50 or 80%. Average 






Figure 5.12: Kaplan-Meier Curves of Circulatory Mortality by Statin Adherence Thresholds (with 95% Confidence Intervals). Numbers are Number at Risk 
(Number of Events). Circulatory cause of death defined by ICD10 I00-I99 as underlying cause. Patients classified by average statin adherence during follow 
up, measured using MPR, with thresholds ≥ 50 or 80%. Average adherence calculated for patients with at least one full year of follow up. Patients only 
included in analyses where information was available. 
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A – Overall Mortality
 
B – Circulatory Causes
 
Figure 5.13: Hazard Ratios of Mortality by Average Statin Adherence (unadjusted and 
adjusted for age, sex, year of MI, and SIMD quintile). A = all-cause mortality; B = circulatory 
cause of death (defined by ICD10 I00-I99 as the underlying cause). Achieving an adherence 
threshold defined as an average adherence, measured using MPR, with thresholds ≥ 50 or 
80%. Average adherence calculated for patients with at least one full year of follow up. 
Patients only included in analyses where all information needed was available. 
These differences are also reflected in the estimated hazard ratios for all-cause 
and circulatory mortality from the Cox regression (Figure 5.13). Statistically 
significant increases were observed in the hazards of all-cause and circulatory 
mortality for those not meeting adherence thresholds, both in unadjusted 
analyses and when adjusted for age, sex, deprivation, and year of MI. In 
unadjusted analyses, average adherence <50% was associated with a hazard of 
all-cause mortality 1.6 times that of average adherence ≥50%, with estimates 
similar for circulatory causes. Patients with an average adherence <80% had a 
hazard of all-cause mortality 1.5 times that of those who exceeded this 
threshold, and 1.4 times for circulatory causes. Following adjustment, the 
hazard ratio slightly attenuated for the 80% threshold to a hazard ratio of 1.4 
and 1.3 for all-cause and circulatory mortality respectively. Additionally, 
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adjustment reduced the hazard ratios to 1.2 for both causes when the 50% 
threshold was considered. On a continuous scale, a 10% decrease in a patient’s 
average adherence was associated with a 7% and 6% increase in the risk of all-
cause and circulatory mortality respectively, which reduced to 3% in the 
adjusted analyses. However, despite this comparatively small increase in risk, 
both results were statistically significant at the 5% level. Full details of these 
models and plots of the Schoenfeld residuals are available in Appendix L. Finally, 
the inclusion of incomplete years of follow up in the average adherence 
calculation resulted in marginally larger effect sizes in all associations with 
mortality and cardiovascular mortality, especially following adjustment (results 
not presented). 
5.7 Association Between Adherence and Achievement of 
Lipid Targets 
Finally, an analysis of the association between average adherence and achieving 
lipid targets was performed. An initial cross-tabulation in Chapter 4.5.4 (in Table 
4.10) showed that those with higher average statin adherence were more likely 
to have achieved a lipid target during follow up than those who did not. This is 
confirmed with the odds ratios shown in Figure 5.14, which show that those who 
had lower adherence had greater associated odds of not achieving both lipid 
targets individually, with the greatest odds observed when the 50% threshold 
was used. However, the reported odds ratios were also statistically significant in 
the analyses when the 80% threshold, and when continuous adherence was 
considered. Full details of the logistic regression models are included in 
Appendix M (non-HDL) and Appendix N (LDL). 
For the non-HDL target (Figure 5.14a), those with adherence <50% had 4.8 times 
greater odds of not achieving the recommended reduction than those with 
adherence ≥50%, which slightly reduced to 4.5 when adjusted for age, sex, 
deprivation, and year of MI. Meanwhile, when the 80% threshold was used, 
patients had 3 times higher odds of not achieving the target if their adherence 
was lower, with adjustment for other factors not impacting on this estimate. 
Adjusting for these potential confounders also had limited effect when 
adherence was measured continuously, with both models finding that a 10% 
decrease in statin adherence was associated with a 20% increase in odds of not 
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achieving a 40% reduction in non-HDL levels. These associated increased odds 
were slightly lower when incomplete years of follow up were included in the 
average adherence calculation, although the overall conclusions remained the 
same (results not presented). 
A – Non-HDL Target 
  
B – LDL Target 
 
Figure 5.14: Odds Ratios of Not Achieving Lipid Targets During Follow Up (unadjusted and 
adjusted for age, sex, year of MI, and SIMD quintile). A = Odds of Not Achieving Non-HDL 
Target; B = Odds of Not Achieving LDL Target. Non-HDL target is ≥40% non-HDL reduction 
from a pre-MI baseline (NICE, 2014) and the LDL target is ≤1.8mmol/l (Piepoli et al., 2016). 
Patients were classified as meeting a target if they achieved the target in any year of their 
follow up, and not meeting a target if they did not achieve it in every year of their follow up. 
Achieving an adherence threshold was defined as an average adherence, measured using 
MPR, ≥50% or ≥80%. Average adherence was calculated for patients with at least one full 
year of follow up. Patients only included in analyses where all information needed was 
available.  
The associated odds ratios were, overall, lower for the odds of not meeting the 
LDL target than they were observed for the non-HDL target (Figure 5.14b). As 
before, the 50% threshold yielded the greatest increase in odds, with adherence 
below this resulting in double the odds of not achieving LDL≤1.8mmol/l, 
compared to average adherence ≥50%. When 80% was used, the associated odds 
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of not achieving this target were 1.6 times that of those with adherence ≥80%. 
Adjustment for confounders did not alter the odds ratio at the 50% level but did 
result in a minor increase of the odds ratio to 1.7 when 80% was used. 
Considering age, sex, deprivation, and year of MI did not alter the model when 
adherence was used as a continuous variable, where a 10% decrease in average 
statin adherence was associated with 10% higher odds of not achieving the LDL 
target, in both the unadjusted and adjusted models. Utilising incomplete years 
of follow up in the adherence calculation, as seen with the non-HDL target, 
resulted in slightly lower associated odds ratios, but the overall conclusions 
remained unaltered (results not presented). 
5.8 Discussion 
5.8.1 Associations Between Lipid Targets, Average Adherence, 
Recurrent Myocardial Infarctions, and Mortality 
In this Scottish secondary prevention population, 51% achieved ≥40% reduction in 
non-HDL from a pre-MI baseline, 76% achieved LDL ≤1.8mmol/l, and 85% and 69% 
had an average statin adherence above 50% and 80% respectively. Furthermore, 
one third of patients had died and just over a quarter experienced a further MI 
requiring hospitalisation during a median follow up of 4.5 years. Both lower 
average statin adherence, and failure to achieve guideline-recommended lipid 
targets, were strongly associated with a higher risk of all-cause mortality, as 
well as being significantly associated with each other. In particular, when 
adjusted for age, sex, deprivation, and year of MI, those not achieving 80% 
adherence were 40% more likely to die, and those not achieving the non-HDL 
target were 2-fold more likely to die, with similar patterns observed when 
circulatory causes were considered.  
Therefore, in addition to clearly illustrating that lipid levels and statin 
adherence are important predictors of death, these results confirm and expand 
on previous data. The length of follow up, which commenced on the date of MI, 
builds on previous research which has often focussed on the initial year (or two 
years) following an event or statin initiation. Instead, this analysis allowed for a 
longer-term average statin adherence to be estimated, and a larger period for 
target lipid levels to have been achieved. Furthermore, the associations with 
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mortality and recurrent MI admissions were also investigated and compared 
between continuous adherence and two different adherence thresholds, and 
between two lipid targets from national and international guidelines. 
Additionally, they also suggest that there may be a cohort of patients where 
personalised testing regimens would be advantageous but highlight that the 
identification of these patients needs to be accurate.  
As expected, this cohort had a higher proportion of patients dying due to CVD 
than in the general population in Scotland in 2017, where CVD accounted for 26% 
of deaths (vs 42% in this cohort). Among those dying of CVD, deaths due to 
ischaemic heart disease in this cohort also accounted for a higher proportion in 
this population than in the general population (69% vs 45% respectively) 
(National Records of Scotland, 2017). However, given the moderate degree of 
missingness for cause of death (as discussed in Chapter 3.2.3), these figures for 
death due to CVD may be an underestimate of the true percentage, as the cause 
was conservatively assumed not to be as a result of CVD for those where this was 
unknown. Additionally, as missingness is possibly due to systematic differences 
within the population, such as patient frailty following their baseline MI leading 
to their relocation, some subchapters within deaths due to CVD may also be 
under- or over-represented.   
Nevertheless, for both further MI admissions and deaths, the highest numbers of 
these events were reported in the first year of follow up. Indeed, 75% of patients 
who experienced at least one further MI during follow up experienced one during 
their first year, and 27% of deaths that occurred during follow up were within 
one year. These proportions were fairly similar to the rate of cardiovascular 
events reported in those with established disease in a CPRD cohort, with the 
decreasing pattern throughout follow up also present (Khunti et al., 2018). 
Nonetheless, these numbers were higher than those reported within clinical 
trials for statins (Cholesterol Treatment Trialists’ (CTT) Collaboration, 2010), 
although this is likely to be due to lower statin adherence outside of trial 
settings and differences between trial populations and these observational 
cohorts.  
There were no significant associations between average statin adherence nor the 
achievement of lipid targets with experiencing further MI admissions. This 
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second observation is consistent with findings from a cohort of 25,000 patients in 
Sweden where post MI LDL demonstrated poor predictive performance for 
recurrent ASCVD events (Ohm et al., 2019). Similar findings were also reported 
in a Finnish cohort (n=25,000), where despite LDL reaching statistical 
significance for its association with further cardiovascular events, its effect size 
was small following a multivariable adjustment, with an increased hazard ratio 
of 3%. However, within this study, statin non-adherence did demonstrate a 
stronger, and intensity-dependent, association with further events, contrary to 
findings in this analysis (Lassenius et al., 2020). One explanation for this could 
be that the average statin adherence variables and those used for determining 
the achievement of lipid targets, captured information from before and after 
the further hospital admissions for MIs were experienced. With many 
experiencing these early on in their follow up, however, much of the data used 
to derive these variables will likely reflect a patient’s behaviour following 
multiple MIs, rather than the intervening time between them. For example, 
patients may initially increase their statin adherence after they have 
experienced an event (Lassenius et al., 2020) or have only achieved lipid targets 
after a further MI admission. This latter possibility has been shown in CPRD data 
by Danese et al (2017), although a comparatively small increase (5%) in the 
proportion of patients meeting the target was observed (Danese et al., 2017). An 
increase in treatment intensity could also have occurred, which may increase 
the likelihood of patients achieving target values. In the same CPRD cohort, this 
occurred in 7% of patients after their second cardiovascular event (Danese et 
al., 2017).  
Confounding comorbidities could also mask any association. Adherence in 
secondary prevention populations is higher in those with a greater number of 
comorbidities (Vupputuri et al., 2016; Danese et al., 2017), which may also 
increase the risk of further events. Indeed, within this population, those 
experiencing further events were more likely to have a diagnosis of diabetes or 
have experienced a prior MI, both of which have been associated with higher 
adherence (Danese et al., 2017; Hope et al., 2019).  
This latter confounding problem could also have occurred in the mortality 
analysis, although the timing of the achievement of lipid targets or changes in 
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adherence cannot be disputed. Additionally, in the adherence models, only 
those who survived at least one year of follow up were included which reduced 
the potential for reverse causality, although sensitivity analyses including 
incomplete years of follow up did not yield substantially different results. 
However, those who died also had a shorter duration of follow up and therefore 
had reduced opportunity to achieve lipid targets and to change their adherence 
behaviour.  
Nonetheless, the significant and consistent associations reported with mortality 
are similar to findings observed in other cohorts (Cholesterol Treatment 
Trialists’ (CTT) Collaboration, 2010; Xu et al., 2017; Khunti et al., 2018). In an 
analysis of high-risk patients in CPRD, adherence less than 80% was associated 
with 50% greater hazard of all cardiovascular events following adjustment for 
demographic factors and co-morbidities (Khunti et al., 2018). This is slightly 
higher than the observed hazard ratios of 1.4 in this population for all-cause and 
circulatory mortality, but this CPRD cohort considered all cardiovascular events 
and not mortality outcomes only. Furthermore, whilst the use of lipid targets is 
controversial (Leibowitz et al., 2017; Pallazola et al., 2018), and there is a lack 
of robust evidence to support their use in guidelines (as documented in Chapter 
2 (Brown, Welsh and Logue, 2020)), lowering LDL has consistently been shown to 
significantly reduce mortality within those with established disease (Cholesterol 
Treatment Trialists’ (CTT) Collaboration, 2010). 
The significant associations observed between statin adherence and the 
achievement of lipid targets also expand on associations with mortality. This was 
expected given the mechanism of action of statins and the extensive literature 
supporting their use (as outlined in Chapter 1.3.1). These associations have also 
been observed in similar observational cohorts. For example, in 1,000 secondary 
prevention patients in Georgia, USA, those with adherence <50%, were at 88% 
greater risk of not achieving a 30% reduction in LDL (Vupputuri et al., 2016). 
However, in Danese et al’s (2017) analysis, in the first year following a 
cardiovascular event, the proportion of patients achieving at least 80% statin 
adherence was estimated to be approximately 70%, despite much higher 
numbers failing to meet the LDL target. This suggested that whilst adherence 
may be associated with cholesterol levels, it is not the only contributing factor 
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(Danese et al., 2017). This pattern is also observed within this cohort, and there 
is little evidence of any strong confounding factors.  
Additionally, the associations with the non-HDL target were much stronger than 
the associations with the LDL target. This is likely to have arisen due to the 
differing nature of the targets e.g. percentage change (non-HDL) vs absolute 
value (LDL), rather than the lipid profile components themselves. For example, 
associations between absolute values of non-HDL and LDL with a composite 
endpoint of further non-fatal and fatal cardiovascular endpoints have been 
shown to be approximately equivalent (Welsh et al., 2019). Nonetheless, the use 
of percentage change targets within secondary prevention populations could 
prove problematic, with many patients unlikely to have a suitable baseline for 
the calculation to be performed. This was evident in this population where 
percentage change could only be calculated for 30% of the cohort. 
5.8.2 Strengths and Limitations 
This is a contemporary, large data set from a real-world population. 
Generalisability of these findings, particularly to the Scottish population, is 
therefore good. One key limitation is the lack of assessment or adjustment for 
the consistency of meeting lipid targets in the models, which is likely to be an 
important factor in their association with further events. Similarly, the use of 
average adherence does not reflect fluctuations in adherence throughout follow-
up, although there is some evidence to suggest that this may be minimal after 
the first year (Nordstrom et al., 2015). Nonetheless, when prediction models of 
adherence and lipid levels are developed in the subsequent chapter, these 
models will need to allow for time-varying covariates. The measure of adherence 
used is arguably stronger evidence of medication taking than data from CPRD, 
due to prescriptions being encashed. 
Another limitation is the use of logistic regression to investigate associations 
with further hospital MI admissions, where statin adherence and lipid target 
variables involved components from before and after the admissions took place. 
To further investigate these associations, adherence and target variables using 
only data collected before the event could be derived. However, this time 
window is likely to be small for many patients as most further admissions 
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occurred during the first year of follow up, and therefore the potential for 
reverse causality is increased. This difficulty would also be faced when 
considering a time-to-first-event analysis, where competing risks, such as 
mortality, would additionally need to be accounted for. This could be conducted 
using either cause-specific, which estimates the instantaneous rate of a 
recurrent MI in event-free patients, or subdistribution hazards, which estimates 
the instantaneous rate of a recurrent MI in patients who are event-free or have 
died. In this instance, the former method would be preferable given the 
aetiological nature of the question being investigated (Austin, Lee and Fine, 
2016). Finally, a recurrent analysis could be considered, although given 75% of 
patients with a further admission experienced only one event, this is unlikely to 
substantially alter any observed associations.  
The models presented in this chapter showed both unadjusted and adjusted 
analyses, and in all cases, the adjustment did not result in substantial 
alterations to the estimated effect size or its significance. However, only a few 
demographic variables were accounted for, with no interactions between them 
considered. For example, significant interactions between sex and other 
covariates were likely to be present. Females typically experience MIs at a later 
age compared to males, and as cholesterol also increases with age, this further 
increases the risk of mortality (Jousilahti et al., 1999; Mosca, Barrett-Connor 
and Kass Wenger, 2011). It has also been shown that females are less likely to be 
prescribed statins following an MI, reducing their adherence, and increasing 
their cardiovascular risk (Eindhoven et al., 2018). Consequently, future analysis 
should consider stratifying models presented by sex. Furthermore, the variables 
considered are not comprehensive, and other confounders, such as other 
comorbidities, are likely to remain, as discussed earlier. As a result of this, the 
methodology employed in this chapter, and the observational nature of these 
data, no causal inferences regarding these associations are drawn.  
Nevertheless, the strength of the associations between adherence and lipid 
targets, and them both separately with mortality in this post MI population are 
consistent with, and expand upon, current literature, and therefore demonstrate 
the external validity of this cohort.  
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5.8.3 Conclusions  
This analysis has highlighted that a significant proportion of the population 
achieves lipid targets and reasonable average statin adherence and that both are 
associated with reduced mortality. No significant associations were observed 
with the likelihood of experiencing further hospitalised MIs, but this is likely due 
to a combination of confounding and the definitions of lipid target achievement 
and the use of average adherence. Despite this, the associations observed with 
mortality and between lipids and adherence are consistent and in line with the 
evidence base for statins. We also broadly validate the existing Scottish SIGN 
non-HDL guidance as clinically relevant, however low coverage for percentage 
change variables in secondary prevention populations may prevent its practical 
use in these settings. 
These results also have implications for the potential use of personalised plasma 
lipid testing schedules within this population. Specifically, these associations 
highlight the importance of the accurate identification of patients for whom less 
frequent monitoring is considered. If reduced testing schedules are to be 
effective and safe, then this successful identification is crucial to avoid the risk 




Chapter 6 Identifying Patients for Reduced Lipid 
Monitoring 
6.1 Introduction  
In an earlier chapter (Chapter 2), a systematic review of clinical guidelines for 
the established disease population found that many guidelines (n=17/22) 
specified a lipid target for these patients, but that evidence to support the use 
of these was limited (Brown, Welsh and Logue, 2020). Furthermore, when it 
came to monitoring these patients, half of the included guidelines gave 
recommendations for their long term follow up, although there was often no 
evidence to support these suggestions beyond expert opinion. In Scotland, 
current and previous guidelines have both recommended that annual reviews are 
conducted as part of good practice for those at high risk of CVD (SIGN, 2007, 
2017). 
However, the monitoring of chronic diseases is a significant and growing burden 
to primary care, as discussed in Chapter 1.6.1, especially as the population 
continues to grow and age (Thompson and Walter, 2016). The number of 
laboratory tests requested has increased each year since 2000 and cannot be 
solely attributed to increased patient numbers (O’Sullivan et al., 2018). This has 
also led to a greater workload for primary care, with a survey of GPs reporting 
an increase in time taken for both consultations and the associated 
administration outside of it (Hobbs et al., 2016; Thompson and Walter, 2016).  
The purpose of the lipid test at a review is also unclear; both addressing 
patient’s adherence and monitoring risk factors are listed as possible discussion 
points for the annual review in current Scottish guidelines (SIGN, 2017). For 
adherence, several analyses, including those in CPRD, have demonstrated 
reasonable, and sustained, statin adherence in both primary and secondary 
prevention populations (Nordstrom et al., 2015; Lavikainen et al., 2016; Danese 
et al., 2017). Furthermore, a lower, but reasonable, proportion of patients with 
established disease has been shown to achieve lipid targets in the years 
immediately following an event (Nordstrom et al., 2015; Danese et al., 2017). 
Both of these findings have also been demonstrated in this post MI population of 
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NHS GGC in Chapter 4, with adherence rates and achievement of the LDL target 
of ≤1.8mmol/l slightly higher than those in the literature.  
Therefore, with reasonable numbers of patients achieving lipid targets and 
acceptable adherence, it is plausible that there is a subgroup within this 
population whose lipid test as part of their annual review could be considered 
unnecessary. However, such an approach would need to accurately identify 
these patients to be considered safe, due to the elevated risks of mortality in 
those non-adherent or failing to meet lipid targets, as shown in Chapter 5. Such 
an approach has been attempted before in the context of other screening 
programmes (as described in Chapter 1.6.3). This has been most successful in 
diabetic retinopathy where one risk score has been tested in an RCT which 
reported no significantly increased risk as a consequence of reduced frequency 
of screening and a reduction of 40% in required appointments (Broadbent et al., 
2020).  
However, for a similar approach to be considered in cardiovascular prevention, 
patients who could safely receive fewer lipid tests need to be accurately 
identified. Therefore, this chapter has two aims. Firstly, it seeks to use a post MI 
cohort to identify associations between demographic factors, previous 
adherence, lipid results, and testing frequency, with subsequent statin non-
adherence and failure to achieve cholesterol targets. Second, it seeks to develop 
an algorithm that will identify patients within this cohort for whom the results of 
an annual lipid test are unlikely to change clinical advice or decisions, and 
therefore it could be omitted. 
6.2 Methods 
This chapter uses data previously derived and described in Chapter 4. In this 
chapter, identical methods were used for both the prediction of a patient’s 
adherence and predicted achievement of cholesterol targets in the next year. 
However, only the LDL target of ≤1.8mmol/l from the 2016 ESC guidelines was 
considered in the case of the latter outcome (Piepoli et al., 2016). Although the 
target of ≥40% reduction in non-HDL recommended by NICE (NICE, 2014) showed 
stronger associations with outcomes than the 2016 ESC target in Chapter 5, 
percentage change variables are likely to prove difficult to implement in 
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secondary prevention populations with many patients lacking a suitable baseline 
to facilitate their calculations. This was the case here, with just 30% of this 
cohort having at least one percentage change result available. Therefore, as the 
LDL target relies on its absolute value and has greater coverage, only this target 
was used throughout this chapter. Both 50% and 80% thresholds were used in the 
estimated statin adherence analyses. 
Descriptive demographics are presented for all patients using the methods 
outlined in Chapter 5.2.1. Demographics were split by the consistency of 
meeting the adherence threshold or LDL target, although in the latter patients 
were only included if they had at least one LDL test result available post MI. For 
all subsequent analyses, patients were excluded if they were never prescribed a 
statin at any point in the duration of their follow up as it is likely these 
individuals are statin intolerant and will therefore have been monitored 
differently to the majority of the population.  
In addition to descriptive analysis, Kaplan-Meier plots and Cox regression models 
were fitted to determine factors associated with time to (first) non-adherence 
or non-target LDL. In these models, some time-varying covariates were 
considered, thus building on the methods outlined in Chapters 5.2.4 and 5.2.5 
and are described below. Using the factors identified, latent class analysis (LCA) 
was used to identify groups of patients and their likelihood of adherence 
thresholds or LDL targets being met in each year of follow up. The diagnostic 
accuracy of these was assessed using the predicted class assignments from the 
model, and these predictions were then bootstrapped with one time window per 
patient to assess the robustness of the analysis to a violation of independence 
(due to multiple time windows included per patient).  
Cox regression models (as described in Chapter 5.2.5) were then used for models 
in years 2 and 3 of follow up separately to investigate any association between 
the predicted classes and mortality. These years were selected due to the higher 
number of patients with data available than for other periods of follow up. 
However, due to the need for the previous year’s information, year 1 could not 
be considered for these models where the mortality rate was highest. 
Furthermore, a longer-term and time-varying model could not be implemented 
in this instance due to immortality bias (arising from the need to have survived 
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Year 1 to have a predicted class), as well as the possible impact of legacy 
effects for those changing between assigned classes.  
Finally, latent class growth analysis (LCGA) was conducted using baseline 
covariates identified in the earlier Cox models to identify trajectories in 
proportions of patients who are adherent or on target in each year of follow up. 
Kaplan-Meier plots and Cox regression models were used to examine the 
associations between the predicted classes and mortality. 
6.2.1 Cox Regression with Time-Varying Covariates 
Cox regression models with time-independent covariates were first implemented 
in Chapter 5.2.5 and seek to compare the survival distributions of patients by 
certain risk factors (Xu, 2020). These models can be extended to incorporate 
time-dependent covariates, that is, the presence or the measurement of risk 
factors may alter during a patient’s follow up (Fisher and Lin, 1999; Zhang et 
al., 2018; Xu, 2020). Consequently, models with time-varying covariates instead 
compare the risks of an outcome by covariates at the time of each outcome (Xu, 
2020).  
The structure of such models is similar to that of the conventional Cox model but 
includes the addition of a time-interaction function within the main hazard 
equation, as shown in Equation 6.1. As a result, the hazard function at time t is 
only dependent on the covariate values at that particular time, and the 
corresponding hazard ratio is not constant and varies over time (Zhang et al., 
2018; Xu, 2020). The estimation of the model’s coefficients is then the same as 
for a time-independent model using partial likelihood, with the only difference 
being that the set of covariates changes at each event time (Xu, 2020).  
𝐶𝑜𝑛𝑠𝑖𝑑𝑒𝑟 𝑡ℎ𝑒 𝑐𝑜𝑛𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝐶𝑜𝑥 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 ℎ𝑎𝑧𝑎𝑟𝑑:  
ℎ(𝑡) =  ℎ0(𝑡) ∗ exp(𝛽𝑋),  
𝑤ℎ𝑒𝑟𝑒 𝑋 𝑖𝑠 𝑎 𝑣𝑒𝑐𝑡𝑜𝑟 𝑜𝑓 𝑡𝑖𝑚𝑒 𝑖𝑛𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 𝑎𝑛𝑑 𝛽 𝑖𝑠 𝑎 𝑣𝑒𝑐𝑡𝑜𝑟 𝑜𝑓 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡𝑠.  
𝑁𝑜𝑤, 𝑎𝑙𝑙𝑜𝑤 𝑡𝑖𝑚𝑒 𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑡 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 𝑏𝑦 𝑎𝑙𝑡𝑒𝑟𝑖𝑛𝑔 ℎ(𝑡) 𝑡𝑜: 
ℎ(𝑡) =   ℎ0(𝑡) ∗ exp(𝛽′𝑋(𝑡)),  
𝑤ℎ𝑒𝑟𝑒 𝛽 𝑖𝑠 𝑎 𝑣𝑒𝑐𝑡𝑜𝑟 𝑜𝑓 𝑐𝑜𝑒𝑓𝑓𝑖𝑒𝑛𝑡𝑠, 𝑎𝑛𝑑 𝑋(𝑡) 𝑖𝑠 𝑎 𝑣𝑒𝑐𝑡𝑜𝑟 𝑜𝑓 𝑡𝑖𝑚𝑒 𝑣𝑎𝑟𝑦𝑖𝑛𝑔 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠.  
Equation 6.1: Cox Regression Model with Time-Varying Covariates (Zhang et al., 2018; Xu, 
2020) 
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The ‘survival’ package in R was used to produce time-varying Cox regression 
models in this chapter for time to (first) non-adherence (for both the 50% and 
80% thresholds) and non-target LDL (Therneau, 2020), with patients assumed to 
be adherent or on target at time 0. To assess the impact of this assumption, 
sensitivity analyses were also performed starting at the time window where the 
patient was first adherent or had LDL on target. The time-varying covariates 
considered were whether the patient experienced a further MI in the previous 
year of follow up and whether the patient received a diagnosis of diabetes. 
Time-independent covariates considered were age at baseline MI, sex, 
deprivation quintile, whether the patient had experienced an MI before their 
baseline, and the year of MI. Further sensitivity analyses were considered 
whereby year of MI was removed as a covariate in the final model, as, whilst this 
variable may improve the fit, its use within a clinical setting is unclear unless 
significant changes in the clinical management of these patients had occurred at 
a particular time point. Age was categorised into <50, 50-<60, 60-<70, 70-<80, 
≥80 years to allow for its inclusion in the subsequent latent class analysis 
(Chapter 6.2.2).  
In the final models, the number of lipid tests conducted in the previous year was 
also added as a time-varying covariate, with the value set to the recommended 
annual 1 test for Year 1. However, changing this assumption to 0 tests and >1 
test did not alter the results, as changes between time 0 and time 1 are 
cancelled out during the partial likelihood calculation (Xu, 2020). Before models 
were run, the ‘tmerge’ function was used to divide a patient’s follow up into 
multiple records with a new record created each time a covariate changed 
(Therneau, 2020; Therneau, Crowson and Atkinson, 2020). The optimal model for 
each outcome was determined through best subsets regression using Akaike’s 
Information Criteria (AIC) to determine the best fit. AIC was used instead of 
hypothesis testing for the selection criteria, as the aim was to build a prediction 
model and it is asymptomatically equivalent to leave-one-out cross-validation 
prediction error (Stone, 1977). The results of the final models were plotted using 
the ‘forestplot’ package in R (Gordon and Lumley, 2020). 
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6.2.2 Latent Class Analysis Adjusting for Covariates 
LCA is a type of mixture model applied to data whose variables are categorical 
only, either dichotomous or polytomous (Agresti, 2012; Masyn, 2013; Oberski, 
2015). The nature of these variables leads to a distribution that is also 
qualitative, and the model in analyses clustering and patterns within the data 
arising from the generation of multi-way tables (Agresti, 2012; Linzer and Lewis, 
2016). These patterns are then considered to be indicators for an unobserved 
variable which would divide the data into specific subgroups. This variable, 
which is also categorical, is called a latent class (Agresti, 2012; Masyn, 2013; 
Oberski, 2015). Figure 6.1 illustrates a generic path diagram for such a model 
(Oberski, 2015). 
 
Figure 6.1: Path Diagram for an LCA Model with p observed categorical variables (Yi), one 
latent class variable, and one categorical covariate (Oberski, 2015). 
For the main part of the LCA model, there are two key assumptions. The first of 
these is the mixture assumption, which specifies that a given combination of the 
observed variables is a joint distribution of the class-specific distributions, as 
shown in Equation 6.2 (Agresti, 2012; Oberski, 2015).  
𝐿𝑒𝑡 ℙ(𝑦1, 𝑦2, … 𝑦𝑝) =  ℙ(𝑌1 = 𝑦1, 𝑌2 = 𝑦2, … 𝑌𝑝 = 𝑦𝑝),  
ℙ(𝑦1, 𝑦2, … 𝑦𝑝) =  ∑ ℙ(𝑋 = 𝑘) ∗ ℙ(
𝐾
𝑘=1
𝑦1, 𝑦2, … 𝑦𝑝| 𝑋 = 𝑘)  
Equation 6.2: Assumed Joint Distribution Mixture of Class-Specific Distributions for an LCA 
Model with p observed parameters and a latent class variable with K classes (Agresti, 2012; 
Oberski, 2015). 
The second assumption is that of conditional or local independence of the 
observed variables (Yi) included in the model within the classes, i.e. within a 
particular latent class (k), these observations are assumed to be independent, as 
shown in Equation 6.3 (Agresti, 2012; Oberski, 2015). 
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𝐹𝑜𝑟 𝑡ℎ𝑒 𝑘𝑡ℎ 𝑐𝑙𝑎𝑠𝑠, 𝑖. 𝑒. 𝑋 = 𝑘, 




Equation 6.3: Assumed Local Independence of Observed Variables in an LCA Model with p 
observed parameters for the kth class of K latent classes (Agresti, 2012; Oberski, 2015). 






Equation 6.4: Latent Class Measurement Model Assuming Local Independence with p 
observed parameters and K latent classes (Agresti, 2012; Masyn, 2013). 
Using this assumption, the earlier joint distribution of the mixture model can be 
simplified by substituting Equation 6.3 into Equation 6.2, to give the equation 
given above (Equation 6.4) (Agresti, 2012; Masyn, 2013). This is also known as 
the latent class measurement model (Masyn, 2013).  
Once the LCA model has been fitted, posterior class probabilities can be 
calculated to assign observations to latent classes. These can be calculated using 
the parameters from the LCA model, the above equations, and Bayes theorem. 
Equation 6.5 illustrates how this can be derived for class c (Oberski, 2015). Once 
these have been calculated for each class, the observation is assigned to the 
class with the highest probability, in a process known as modal assignment 
(Oberski, 2015; Linzer and Lewis, 2016). 
ℙ(𝑋 = 𝑐|𝑦1, 𝑦2, … 𝑦𝑝) =  
ℙ(𝑋 = 𝑐) ∗  ℙ(𝑦1, 𝑦2, … 𝑦𝑝| 𝑋 = 𝑐)
ℙ(𝑦1, 𝑦2, … 𝑦𝑝)
 
=  
ℙ(𝑋 = 𝑐) ∗ ∏ ℙ(𝑦𝑖|𝑋 = 𝑐)
𝑝
𝑖=1






Equation 6.5: Posterior Class Probability of a Latent Class Model with p observed 
parameters, and K latent classes, for a class c where c≤K (Oberski, 2015). 
As suggested earlier in Figure 6.1, LCA models can be extended to adjust for 
further covariates to ascertain the presence of any association with the latent 
classes (Bolck, Croon and Hagenaars, 2004; Oberski, 2015; Linzer and Lewis, 
2016). However, this should be conducted either simultaneously to the LCA 
model fitting or in a three-step process. Otherwise, any estimates from the 
multinomial model generated are highly likely to be biased and standard errors 
likely to be incorrect (Bolck, Croon and Hagenaars, 2004; Oberski, 2015).  
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In this chapter, LCA was selected as the method to identify classes of time 
windows which would be likely to meet adherence thresholds or the LDL target. 
For the eventual model to have sufficient predictive value, it was likely that 
higher-order interactions between the covariates would need to be included in a 
standard regression model, and therefore the use of a clustering-based method 
would be highly appropriate (Vermunt and Magidson, 2003). Such methods can 
be split into two types: distance-based and probability-based. Distance-based 
methods, such as k-means and hierarchical clustering, first create a measure of 
the differences between individuals and then endeavour to minimise the 
variability of this within subgroups and maximise the variability between them. 
Probability-based methods, such as LCA, identify distributions in the data and 
where individuals fall within them first, before seeking to maximise the 
variability explained in the simplest terms (Kent, Jensen and Kongsted, 2014). 
The advantages of this latter approach include greater classification accuracy 
and more easily interpretable output including the classification probabilities for 
individuals and parameters that can be used to classify new individuals (Vermunt 
and Magidson, 2003; Kent, Jensen and Kongsted, 2014). This would be 
particularly beneficial as the purpose of this work is to ultimately develop a 
clinical prediction tool for new patients to ascertain the necessity of a lipid test 
within an annual review. This, combined with the output of a categorical latent 
variable, which would aid this implementation further, made LCA the preferred 
method. 
LCA models, which adjusted for either achievement of adherence thresholds or 
the LDL target, were produced using the ‘polca’ package in R, which performed 
the adjustment simultaneously (Linzer and Lewis, 2011, 2016). Models were also 
fitted using available case analysis, with each time window taken as an 
observation. Variables included in the LCA models were those identified in the 
time-varying cox models as well as binary variables indicating whether the 
adherence threshold and LDL target had been met in the previous year. Testing 
frequency in the previous year was not included. For each outcome, models 
were run with 2, 3, and 4 classes, replicated 10 times, allowing for 7,000 
iterations, with a tolerance for convergence of 1e-7. Within the ten replications, 
the optimal model was selected using the Bayesian Information Criterion (BIC) 
(Oberski, 2015; Linzer and Lewis, 2016). To determine the optimal number of 
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classes, the diagnostic measures outlined in Chapter 6.2.3 were used, selecting 
the model with the highest positive predictive value.  
The likelihood of a class meeting an adherence threshold or LDL target was 
determined using the regression coefficient from the resulting adjusted 
multinomial model. Throughout this chapter, classes have been renumbered to 
ensure consistency between the models, making class 1 always the most likely to 
meet the threshold/target. 
Two measures were calculated to assess the overall fit of the final models: 
relative entropy and average classification rates. Relative entropy (Equation 
6.6), which ranges from 0 to 1, provides an estimate of the precision of the 
classification of the time windows fitted using the model. A value close to 0 is 
suggestive that class assignment is no better than random chance, and values 
close to 1 indicate high certainty in the predicted classes (Masyn, 2013).  
𝐿𝑒𝑡 ?̂?𝑖𝑘 = 𝑝𝑜𝑠𝑡𝑒𝑟𝑖𝑜𝑟 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛 𝑖 𝑖𝑛 𝑙𝑎𝑡𝑒𝑛𝑡 𝑐𝑙𝑎𝑠𝑠 𝑘,  
𝐸𝐾 = 1 −  





𝑛 ∗ log (𝐾)
 
Equation 6.6: Relative Entropy for an LCA model for n observations with k classes (Masyn, 
2013) 
𝐿𝑒𝑡 ?̂?𝑚𝑜𝑑𝑎𝑙,𝑖 = 𝑚𝑜𝑑𝑎𝑙𝑙𝑦 𝑎𝑠𝑠𝑖𝑔𝑛𝑒𝑑 𝑐𝑙𝑎𝑠𝑠 𝑓𝑜𝑟 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛 𝑖,  
𝐴𝑣𝑒𝑃𝑃𝑘 = 𝑚𝑒𝑎𝑛{?̂?𝑖𝑘, ∀ 𝑖: ?̂?𝑚𝑜𝑑𝑎𝑙,𝑖 = 𝑘} 
Equation 6.7: Average Posterior Class Probabilities for an LCA model with K classes 
(Masyn, 2013) 
Average posterior class probabilities were also calculated using the formula 
given above (Equation 6.7), which returns the average probability for those 
modally assigned to that class. As this is an average of probabilities, these values 
are also bounded at 0 and 1. However, unlike relative entropy, these look at the 
certainty of the classification within a specific class rather than looking at the 
model’s certainty in classification as a whole. Nonetheless, higher values suggest 
greater model fit, with an arbitrary threshold of 0.7 for all classes considered to 
indicate the accuracy of class assignment is adequate (Masyn, 2013). 
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6.2.3 Diagnostic Accuracy Measures 
As part of the LCA modelling process, classes were categorised based on their 
likelihood of meeting either the adherence threshold (50% or 80%) or the LDL 
target depending on the model specified. This likelihood was determined by the 
regression coefficients as described above, but the accuracy of this was yet to 
be assessed.  
For each time window included, posterior probabilities for the assignment to 
each class were generated and time windows were assigned to the class which 
had the highest posterior probability, in a process known as modal assignment 
(Masyn, 2013). These predicted classes were then cross-tabulated with whether 
the adherence threshold or LDL target had been achieved, as shown in Table 
6.1. For optimal models which contained more than two classes, some rows of 
these tables were combined to form a 2x2 table so that the diagnostics accuracy 
measures introduced below could be calculated.  
Table 6.1: Example Diagnostic Accuracy Table for LCA Class Assignment  
  Adherence/LDL Target 
Achieved 
 
  Yes No Total 
Class Likelihood of Meeting 
Adherence/LDL Target 
Most A B A+B 
Least C D C+D 
 Total A+C B+D N 
 
Using this cross-tabulation, the accuracy of using this class assignment to predict 
whether a patient’s adherence would be above a threshold, or their LDL would 
be ≤1.8mmol/l in a given time window could then be determined. The first 
measure of this, sensitivity (Equation 6.8a), is the percentage of time windows 
where the threshold or target was met that were predicted to have achieved it. 
This differs from the positive predictive value (Equation 6.8c) which is the 
percentage of time windows where the threshold or target was met within the 
time windows where it was predicted to be. Both of these focus on the accurate 
identification of true positives, i.e. time windows who are predicted to meet the 
threshold or target. In contrast, the remaining measures, specificity and 
negative predictive value focus on the accurate identification of those who will 
not meet the threshold or target. Specificity (Equation 6.8b) is the percentage 
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of time windows where the threshold or target was not met that were predicted 
to have not achieved it, and negative predictive value (Equation 6.8d) is the 
percentage of time windows where the threshold or target was not achieved 









) ∗ 100                                       (b) 
𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑣𝑒 𝑉𝑎𝑙𝑢𝑒 =  (
𝐴
𝐴 + 𝐵
) ∗ 100         (c)  
𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑣𝑒 𝑉𝑎𝑙𝑢𝑒 =  (
𝐷
𝐶 + 𝐷
) ∗ 100       (ⅆ)  
Equation 6.8: Measures of Diagnostic Accuracy (Kirkwood and Sterne, 2003). A, B, C, D are 
values from the appropriate cell in Table 6.1 
6.2.4 Bootstrapping 
LCA modelling assumes that each time window included in the dataset is 
independent (Masyn, 2013). However, this is not the case in this analysis as 
multiple time windows were included per patient. Therefore, an internal 
bootstrap of the final model was used to gauge the impact of this violation.  
Within a bootstrap, one time window per patient was randomly selected, giving 
a sample size of 8,626 and 6,274 for the adherence and LDL models respectively. 
The predicted classes for these selected observations were then cross-tabulated 
with whether the threshold or target was achieved, as in the main model. From 
this, the diagnostic accuracy measures, namely: sensitivity, specificity, positive 
predictive value, and negative predictive value were calculated. Once 
bootstrapped 5,000 times, the mean-average for each measure was obtained. 
Confidence intervals for these were calculated using the percentile method, 
with bounds obtained from the 2.5th and 97.5th percentiles (Helwig, 2017).  
However, under this method, if diagnostic accuracy measures were 100% under 
the main LCA model, no different value will arise during this bootstrapping 
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method. This occurs because in the cross-tabulation stage the adjacent cell in 
the table for that particular measure will always be equal to 0, regardless of the 
sampling, making any percentage calculations 100%. 
6.2.5 Latent Class Growth Analysis 
As multiple time windows were available per patient, LCGA, a type of growth 
mixture modelling, was used to examine patient’s trajectories in the 
achievement of adherence thresholds and LDL targets separately. Growth 
mixture models differ from multilevel random-effects models by allowing for 
patient variations, thereby considering that subgroups with different trajectories 
may exist within the single dataset (Jung and Wickrama, 2008; Cécile Proust-
Lima, Philipps and Liquet, 2017). In LCGA, this classification of individual 
trajectories into identifiable subgroups is performed in a similar probability-
based approach to that of LCA for the class-membership component of the 
model and consequently yields similar advantages to those outlined above 
(Section 6.2.2). Specifically, these models allow for easy interpretation and 
description of patient trajectories, which would prove beneficial within a 
clinical setting, and allow subsequent individuals to be classified using their 
baseline characteristics (Jung and Wickrama, 2008; Kent, Jensen and Kongsted, 
2014).  
 
Figure 6.2: Path Diagram for a Latent Class Growth Model (adapted from (Berlin, Parra and 
Williams, 2014)). 
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LCGA (shown in Figure 6.2) is a special case of these models, where trajectories 
within such classes are assumed to be homogenous and that, as a result, all 
variation occurs between subgroups and not within them (Jung and Wickrama, 
2008; Berlin, Parra and Williams, 2014; Cécile Proust-Lima, Philipps and Liquet, 
2017). This is induced by the assumption that the variance of the slope and 
intercept coefficients within each of the latent classes is fixed at zero. This, in 
turn, results in the covariance of these parameters also assumed to be zero, and 
therefore variation can only occur across the latent classes, allowing groups of 
patients to be identified, rather than the prediction of individual trajectories. 
Practically, this can substantially reduce computation time due to the need to 
estimate fewer parameters and increased likelihood of model convergence (Jung 
and Wickrama, 2008; Berlin, Parra and Williams, 2014). However, whilst 
covariates can be included within the class-membership model, only those 
obtained at baseline that are time-independent should be included (Cécile 
Proust-Lima, Philipps and Liquet, 2017; Proust-Lima et al., 2020). Additionally, 
as with all growth mixture models, data is assumed to be missing at random 
across repeated measures (Cécile Proust-Lima, Philipps and Liquet, 2017).  
In this chapter, LCGA was performed using the ‘lcmm’ package in R using the 
‘gridsearch’ function and the ‘lcmm’ function with the ‘thresholds’ link. Models 
were fitted using available case analysis for the class-membership component, 
and those with at least one estimated adherence or LDL result, as applicable 
(Cecile Proust-Lima, Philipps and Liquet, 2017; Proust-Lima et al., 2020). As 
before, the covariates included within the class-membership model were those 
ascertained in the earlier time-varying cox models, but only those that were 
captured at their baseline MI. Models were generated with 2, 3, and 4 classes, 
replicated 10 times and allowing for 100 iterations with a tolerance for 
convergence of 1e-4. Within each set of replications, the optimal model was 
selected with the best log-likelihood, and the model with the optimal number of 
classes was determined using BIC (Cecile Proust-Lima, Philipps and Liquet, 2017; 
Proust-Lima et al., 2020). 
Similar to LCA, conditional class probabilities can be obtained, and patients are 
assigned to classes using modal assignment from the posterior probabilities. Both 
relative entropy and average posterior probabilities were also calculated and 
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compared as detailed above (Chapter 6.2.2). Using the predicted class 
assignments, the percentage of patients who were adherent or at target LDL at 
each year of follow up could also be calculated and were plotted to indicate 
class trajectories. Finally, predicted classes were used to compare survival 
probabilities between the classes in a Kaplan-Meier and an unadjusted Cox 
regression model.  
6.3 Factors Associated with Statin Adherence 
6.3.1 Patterns in Statin Adherence (within patients) 
Figure 6.3 shows the statin adherence patterns of patients during their follow 
up, with green indicating that the adherence threshold (50% and 80%) was met in 
that year of follow up. These graphs suggest that for both adherence thresholds, 
the majority of patients remained adherent throughout their follow up, with 
those who were non-adherent, also likely to remain so. With the 50% threshold, 
after becoming non-adherent, comparatively few became adherent again, with 
these numbers slightly higher at the 80% threshold. At the 80% threshold, a small 
number of patients who were non-adherent in the first year became adherent in 
the second year, with many then remaining so for the remainder of their follow 
up. However, more than two crossovers between states (adherent/non-
adherent) was relatively rare. 
Using these adherence patterns, for each threshold, patients were then 
manually classified as being consistently adherent, consistently non-adherent, or 
inconsistently adherent, and their demographics are shown in Table 6.2. Using 
the 50% adherence threshold, 66% of the patients were consistently adherent, 
23% were inconsistently adherent, and 10% were never adherent to statins during 
follow up. In comparison, only 38% were consistently adherently adherent at the 







Figure 6.3 Individual Patterns of Statin Adherence During Follow Up (including incomplete years). Each time window was categorised by whether the 
patient achieved the adherence threshold (50% and 80%). Patient number on the y-axis is arbitrary, and patients were sorted by their adherence 




Table 6.2: Demographics by Consistency of Achieving Adherence Thresholds (50% and 80%) 
 50% Adherence 80% Adherence 












Gender       
   Male 4,641 (63.3%) 1,530 (59.5%) 561 (46.6%) 2,668 (63.1%) 3,025 (62.1%) 1,039 (51.7%) 
   Female 2,694 (36.7%) 1,040 (40.5%) 644 (53.4%) 1,561 (36.9%) 1,846 (37.9%) 971 (48.3%) 
       
Age at MI (years)       
   Mean (SD) 66.2 (13.3) 65.4 (14.1) 74.0 (15.2) 66.7 (13.0) 64.9 (13.6) 72.0 (15.2) 
   Median 66.4 65.4 77.1 67.1 64.5 74.8 
   IQR 55.9 – 76.8 54.3 – 76.8 65.2 – 85.3 56.9 – 76.9 54.4 – 75.9 61.8 – 83.9 
   Range 21.9 – 102.4 24.9 – 101.0 19.3 – 102.6 21.9 – 99.2 23.5 – 101.0 19.3 – 102.6 
       
SIMD 2012 Quintile (NHS GGC)       
   1 (Most) 1,769 (24.3%) 632 (24.8%) 249 (20.8%) 981 (23.4%) 1,213 (25.1%) 456 (22.9%) 
   2 1,727 (23.7%) 556 (21.8%) 245 (20.5%) 970 (23.1%) 1,121 (23.2%) 437 (21.9%) 
   3 1,463 (20.1%) 558 (21.9%) 273 (22.8%) 848 (20.2%) 999 (20.7%) 447 (22.4%) 
   4 1,232 (16.9%) 417 (16.3%) 228 (19.1%) 752 (17.9%) 774 (16.0%) 351 (17.6%) 
   5 (Least) 1,094 (15.0%) 388 (15.2%) 200 (16.7%) 648 (15.4%) 730 (15.1%) 304 (15.2%) 
   Missing 50 19 10 30 34 15 
       
Diabetes at MI 1,386 (18.9%) 474 (18.4%) 239 (19.8%) 798 (18.9%) 873 (17.9%) 428 (21.3%) 
   Type 1 73 (1.0%) 27 (1.1%) 20 (1.7%) 44 (1.0%) 48 (1.0%) 28 (1.4%) 
   Type 2 1,313 (17.9%) 447 (17.4%) 219 (18.2%) 754 (17.8%) 825 (16.9%) 400 (19.9%) 
       
Prior MI 473 (6.4%) 172 (6.7%) 69 (5.7%) 267 (6.3%) 304 (6.2%) 143 (7.1%) 
   1 370 (5.0%) 132 (5.1%) 56 (4.6%) 206 (4.9%) 237 (4.9%) 115 (5.7%) 
   >1 103 (1.4%) 40 (1.6%) 13 (1.1%) 61 (1.4%) 67 (1.4%) 28 (1.4%) 
All patients in cohort included (n=11,110). Consistency of achievement of adherence thresholds defined using all full and partial years of follow up.
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For both adherence thresholds, in univariable analysis, those who never met 
them were more likely to be female (50%: 53.4% vs 36.7%, 40.5%; 80%: 48.3% vs 
36.9%, 37.9%). For 80%, approximately similar proportions were male between 
those who constantly adhered and those whose adherence was inconsistent 
(63.1% vs 62.1%), whereas for 50%, there was a slightly lower proportion of males 
who were inconsistent, compared to those who remained adherent (63.3% vs 
59.5%). Those who were never adherent tended to be older, whereas those who 
were inconsistent were very slightly younger than those who were always 
adherent, for both thresholds. There were no clear patterns by deprivation 
quintile for the 80% threshold, though those never adherent at the 50% threshold 
were less likely to come from the most deprived quintile (20.8% vs 24.3%, 
24.8%). Those who were inconsistent in their adherence were less likely to have 
been diagnosed with diabetes before their baseline MI, especially at the 80% cut-
off. Those with a diagnosis of Type 1 diabetes were slightly more likely to never 
be adherent at both cut-offs. At the 80% cut-off, this pattern was also observed 
in those with a diagnosis of Type 2 diabetes. At the 50% threshold, those who 
were never adherent were less likely to have experienced an MI before their 
baseline MI, and more likely at the 80% threshold. 
6.3.2 Time to Statin Non-Adherence 
Before the optimal models for each threshold were found, Kaplan-Meier survival 
probabilities were plotted for the non-time-varying covariates considered for 
inclusion into the optimal models (not presented). These revealed the biggest 
differences were present for sex and age category, where females, and the 
oldest and youngest, were more likely to become non-adherent. There were 
minimal differences by deprivation quintile and whether the patient had 
experienced an MI before their baseline one. 
Only patients who were prescribed statins at any point during their follow up 
were considered in these models (and subsequent analyses in the remainder of 
this chapter for adherence). The optimal model for time to adherence <50% 
contained the variables, age at MI, sex, and deprivation quintile only, all of 
which were non-time-varying. Consistent with the Kaplan-Meiers, a U-shaped 
association with age was observed: those over the age of 80 years were most 
likely to become non-adherent, whilst those aged 70-80 years, and less than 50 
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years had a similar hazard, and those aged 50-70 years were less likely. 
Additionally, males were also less likely to become non-adherent than females. 
Finally, hazard ratios for the association between becoming non-adherent and 
deprivation did not demonstrate a discernible trend. Similar hazard ratios were 
observed when patients were only followed up from the first time that they 
were adherent after their baseline MI (sensitivity results not presented). 
 
Figure 6.4: Time-Varying Cox Regression for Time to Non-Adherence (50% Threshold) with 
Lipid Testing Frequency Covariate. Testing frequency was the number of lipid tests 
conducted in the previous year of follow up, with the recommended one test per year as the 
reference level. Testing frequency was a time-varying covariate with one test assumed for 
the first year of follow up. AIC for this model was 55,302.72. Patients only included if ever 
prescribed statins during follow up. 
These associations were not altered substantially following the inclusion of the 
number of lipid tests results in the previous year as a time-varying covariate, 
with this final model shown in Figure 6.4, and full details provided in Appendix 
O1. Furthermore, the inclusion of lipid testing frequency was statistically 
significant at the 5% level and slightly improved the fit of the model, decreasing 
the AIC from 55362.50 to 55302.72. Under-testing was associated with an 
increased likelihood of becoming non-adherent, with those with no lipid tests in 
the year before 60% more likely to become non-adherent at the 50% threshold. 
Meanwhile, those with more than one test per year were also more likely to 
become non-adherent, but to a lesser extent than those under-tested, with a 
hazard only 13% higher than those tested once in the previous year.  




Figure 6.5: Time-Varying Cox Regression for Time to Non-Adherence (80% Threshold) with 
Lipid Testing Frequency Covariate. Testing frequency was the number of lipid tests 
conducted in the previous year of follow up, with the recommended one test per year as the 
reference level. Testing frequency was a time-varying covariate with one test assumed for 
the first year of follow up. AIC for this model was 108,472.8. Patients only included if ever 
prescribed statins during follow up. 
Using the 80% adherence threshold, the optimal model for time to non-
adherence contained the variables: age at MI, sex, deprivation quintile, further 
MI in the last year, and year of MI. In keeping with findings for the 50% 
threshold, there was a U-shaped association with age, males were less likely to 
become non-adherent than females, and there was no clear trend between 
deprivation and non-adherence despite its statistical significance at the 5% level. 
The only time-varying covariate in this model, a further MI in the previous year, 
was associated with an increased likelihood of becoming non-adherent, although 
this was not statistically significant despite its inclusion in the optimal model. 
Finally, the year of the baseline MI showed that those with more recent baseline 
MIs were less likely to become non-adherent. However, this could be a reflection 
of the reduced follow-up time available for those with later baseline MIs 
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compared to those whose follow up commenced in 2009. Nevertheless, whilst 
year of MI was significant in the final model, when it was removed in a 
sensitivity analysis the effect sizes observed for the remaining variables 
remained consistent, with only further MI in the previous year’s hazard ratio 
increasing marginally (model not presented). Meanwhile, in a separate 
sensitivity analysis of the optimal model (not presented), similar associations 
with becoming non-adherent were also obtained when patients were considered 
only from the first year of follow up that they were adherent at the 80% 
threshold. 
When the number of tests in the previous year was added as a time-varying 
covariate to this final model (Figure 6.5), these associations were minimally 
affected, and the model fit marginally improved (AIC decreased from 108490.1 
to 108472.8). As noted in the model with the 50% threshold, no lipid tests in the 
previous year were associated with an increased likelihood of becoming non-
adherent, although this increased hazard was lower at only 26%. However, unlike 
the 50% model, over-testing in the previous year was not associated with an 
increased likelihood of adherence <80%, with this hazard nearly equivalent to 
that of those tested once in the previous year. Further details of the model can 
be found in Appendix O2.  
6.4 Latent Class Analysis for Adherence 
6.4.1 Optimal Model for 50% Adherence 
There were 26,565 time windows from 8,626 patients used in the generation of 
the adherence LCA models. The variables used to determine class-membership 
were whether the patient’s adherence was ≥50% the previous year, whether the 
patient’s LDL was ≤1.8mmol/l the previous year, and those variables identified 
in the earlier time-varying cox models (Chapter 6.3.2): age at MI, sex, and 
deprivation quintile.  
The optimal LCA model for the achievement of the 50% adherence threshold 
converged after 795 iterations and contained four classes. Using modal 
assignment, the predicted class shares were 21.7%, 33.4%, 30.7%, and 14.2%, for 
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classes 1-4 respectively. Full model details, including conditional class 
probabilities, can be found in Appendix P1.  
When the conditional class probabilities were compared, the largest differences 
between these classes were in the patient’s achievement of the 50% adherence 
threshold in the previous year. Specifically, there were low numbers of those 
who were non-adherent in the first three classes, and then the majority of 
patients in class 4 (the least likely to achieve the threshold) had not achieved 
the target the previous year. This pattern was also observed for the achievement 
of the LDL target in the previous year in this model, with more meeting the 
target of LDL≤1.8mmol/l in classes 1, 2, and 3 in the previous year, and fewer in 
class 4.  
The predicted class assignments for the time windows were cross-tabulated with 
the achievement of the 50% adherence threshold (Table 6.3). This revealed that 
all patients who were assigned to classes 1, 2, and 3 would have adherence ≥50% 
that year. Therefore, if these classes were all considered as predictions that the 
adherence would be achieved, the table could be collapsed to form a 2x2 table, 
with model diagnostics calculated, as shown in Table 6.4.  
Table 6.3: Predicted Class Assignments for Optimal 50% Adherence LCA Model by 
Achievement of Adherence Threshold  
 Meet Not Meet Total 
Class 1 (Most) 5,762 0 5,762 
Class 2 8,871 0 8,871 
Class 3 8,156 0 8,156 
Class 4 (Least) 313 3,463 3,776 
Total 23,102 3,463 26,565 
 
Time windows assigned to classes using predicted modal assignment. Only time windows 
with complete data available included in the LCA model. Likelihood of classes to meet the 
adherence threshold of 50% was ascertained through multinomial regression coefficients 
produced during a one-step model fitting process.  
Therefore, if classes 1, 2, and 3, are combined, this yields a positive predictive 
value of 100%. Specifically, this means that of those predicted to have 
adherence ≥50% (by being assigned to class 1, 2, or 3), all of them will achieve 
this. This also resulted in a specificity of 100%, with all instances where 
adherence would be <50% being assigned to class 4 under this model. There were 
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only 313 time windows in class 4 where the adherence threshold would have 
been met. This meant that sensitivity was also high, with 98.6% of those who 
would have adherence ≥50% being assigned to these classes 1, 2, and 3. 
Additionally, this also translated into a fairly high negative predictive value of 
91.7%; meaning that nearly 92% of those assigned to class 4 would not achieve 
the adherence target of 50%.  
Table 6.4: Diagnostic Table for Optimal LCA Predictions for 50% Adherence  
 1,2,3 vs 4 
 LCA Bootstrap (95% CI) 
Sensitivity 98.6% 98.7% (98.5%, 98.8%) 
Specificity 100.0% 100.0% (100.0%, 100.0%) 
Positive Predictive Value 100.0% 100.0% (100.0%, 100.0%) 
Negative Predictive Value 91.7% 91.6% (90.5%, 92.8%) 
LCA = Latent Class Analysis; CI = Confidence Interval. LCA diagnostics calculated by 
collapsing rows for classes 1-3 in Table 6.3. Diagnostics were bootstrapped 5,000 times with 
confidence intervals ascertained using the percentile method. Within each bootstrap, one 
time window per patient and its predicted class was selected, and cross-tabulations and 
diagnostic measures were calculated as on the full set of time windows above. 
Following 5,000 bootstraps using one time window per patient, these diagnostic 
values were largely unaffected, with a minor increase in sensitivity observed, 
and a minor decrease in negative predictive value. Both specificity and positive 
predictive values, which were 100%, were not affected by this bootstrap, as 
outlined in Chapter 6.2.4. 
Table 6.5: Average Posterior Probabilities for Optimal LCA for 50% Adherence  





Ave PP = Average Posterior Probability. Ave PP for a class is the mean of the posterior 
class probabilities for all time windows modally assigned to that class (i.e. only includes the 
time windows where the posterior probability was highest for that class). 
Furthermore, the relative entropy for this model was also reasonable, at 0.6015, 
suggesting that there was some adequate separation between the classes. This 
was reinforced by the average posterior probabilities for each class (as shown in 
Table 6.5). These further suggested that the classes were distinct, and the LCA 
model fitted adequately with all values above 0.7. This was especially true for 
class 4, where the average probability was approaching one. This was 
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particularly beneficial, with class 4 being the only class to be treated as 
indicative of likely to not be adherent at the 50% threshold.  
6.4.2 Optimal Model for 80% Adherence 
Like the 50% adherence model, the optimal model for the 80% threshold also 
contained four classes and converged after 2,638 iterations. The variables used 
to determine class membership were similar, with the addition of whether the 
patient had experienced a further MI in the previous time window and the year 
of the baseline MI, and adherence in the previous year captured using the 80% 
threshold instead of 50%. All other variables considered in the model remained 
the same. Following modal assignment, the predicted class shares were 29.7%, 
39.8%, 14.2%, and 16.4% for classes 1–4 respectively. Full model details, 
including conditional class probabilities, are provided in Appendix P2. 
The conditional class probabilities revealed that the largest differences between 
these classes were in the patient’s adherence last year, with low numbers of 
those with adherence <80% the previous year in the first three classes and nearly 
all of the patients in class 4 (the least likely) were non-adherent by this 
measure. This was also the case for achieving the LDL target in the previous year 
although the differences in proportions of those meeting and not meeting the 
target was less pronounced between the classes. 
Table 6.6: Predicted Class Assignments for Optimal 80% Adherence LCA Model by 
Achievement of Adherence Threshold  
 Meet Not Meet Total 
Class 1 (Most) 7035 858 7893 
Class 2  9416 1143 10559 
Class 3  3305 462 3767 
Class 4 (Least) 0 4346 4346 
Total 19756 6809 26565 
 
Time windows assigned to classes using predicted modal assignment. Only time windows 
with complete data available included in the LCA model. Likelihood of classes to meet the 
adherence threshold of 80% was ascertained through multinomial regression coefficients 
produced during a one-step model fitting process.  
Cross-tabulating the class predictions with the achievement of the 80% 
adherence threshold (Table 6.6) yielded less conclusive results than had been 
seen at the 50% threshold. Nonetheless, the optimal way of grouping the classes 
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to form a 2x2 table remained the same, producing the diagnostics in Table 6.7, 
and patients assigned to classes 1, 2, and 3 more likely to have adherence ≥80%, 
and class 4 the least likely.  
However, unlike in the 50% model, some patients assigned to classes 1, 2, and 3 
did not meet the 80% target, resulting in a positive predictive value of 88.9%. 
Despite this, all patients who did meet the threshold were assigned to one of 
these three classes, meaning that all patients that were predicted to be in class 
4 did not meet the threshold. Consequently, the sensitivity and negative 
predictive value of the model were both equal to 100%. Therefore, the 
diagnostics of this model mean that whilst all patients predicted to not have 
adherence ≥80% (class 4) would do so, only 88.9% of those predicted to meet the 
target (classes 1-3) would. As a result, implementing this model to identify those 
who could safely receive less frequent monitoring may be problematic, with 
around 1 in 10 patients incorrectly considered for reduced monitoring. 
Table 6.7: Diagnostic Table for Optimal LCA Predictions for 80% Adherence  
 1,2,3 vs 4 
 LCA Bootstrap 
Sensitivity 100.0% 100.0% (100.0%, 100.0%) 
Specificity 63.8% 63.3% (62.2%, 64.4%) 
Positive Predictive Value 88.9% 88.7% (88.1%, 89.2%) 
Negative Predictive Value  100.0% 100.0% (100.0%, 100.0%) 
LCA = Latent Class Analysis; CI = Confidence Interval. LCA diagnostics calculated by 
collapsing rows for classes 1-3 in Table 6.6. Diagnostics were bootstrapped 5,000 times with 
confidence intervals ascertained using the percentile method. Within each bootstrap, one 
time window per patient and its predicted class was selected, and cross-tabulations and 
diagnostic measures were calculated as on the full set of time windows above. 
Bootstrapping these diagnostics 5,000 times and using one observation per 
patient (n=8,626) resulted in slight decreases in the two diagnostic measures not 
equal to 100% (for reasons detailed in Chapter 6.2.4). The largest decrease was 
in the model’s specificity, the percentage of those who didn’t meet the 
threshold who were assigned to class 4, which decreased by 0.5% to 63.3%. A 
minimal decrease was noted in the positive predictive value to 88.7%.   
Nevertheless, there was evidence of some adequate separation between the 
classes, as the relative entropy of the LCA model was 0.6231. In Table 6.8, the 
average posterior probabilities for each class also support this, with all above 
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0.7. Furthermore, the highest average posterior probability was for class 4, the 
only class indicative of being not likely to achieve the adherence target of 80%, 
with a probability above 0.9, suggesting that this class was highly separated from 
the other three.  
Table 6.8: Average Posterior Probabilities for Optimal LCA for 80% Adherence  





Ave PP = Average Posterior Probability. Ave PP for a class is the mean of the posterior 
class probabilities for all time windows modally assigned to that class (i.e. only includes the 
time windows where the posterior probability was highest for that class). 
6.4.3 Mortality by Predicted Class  
6.4.3.1 Mortality by Predicted Class for 50% Adherence 
As combining classes 1-3 offered the optimal model diagnostics, these classes 
were also grouped when associations with mortality were examined (Table 6.9). 
In both years 2 and 3, there was a higher ratio of mortality amongst those 
predicted to not meet the adherence threshold of 50% (class 4) than those 
predicted to meet it. All results were statistically significant at the 5% level.  
Table 6.9: Mortality by Predicted 50% Adherence Class (from Optimal LCA Model) 
 Year 2 Year 3 
Classes 








N 6,234 902 4,711 760 
Events (%) 324 (5.2%) 96 (10.6%) 212 (4.5%) 79 (10.4%) 
     
Cox PH     
   Hazard Ratio 1.00 (ref.) 2.13 1.00 (ref.) 2.40 
   95% CI  -- (1.70, 2.67) -- (1.86, 3.11) 
 p-value<0.0001 p-value <0.0001 
CI = Confidence Interval, PH = Proportional Hazards, ref = reference category. Patients only 
included if a predicted class assignment was available for that year of follow up from the 
50% adherence LCA model. Models fitted are unadjusted for further covariates. 
The percentage of patients who died in class 4 (the least likely to have 
adherence ≥50%) for both year 2 and 3, was more than double the percentage 
who died in classes 1, 2, and 3 (the most likely). This was also reflected in the 
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associated hazard ratios, of which both were statistically significant at the 5% 
level. Hazards of mortality in the second year of follow up were 2.13 times 
greater in class 4 than classes 1, 2, and 3 combined, and they were 2.40 times 
greater in the third year of follow up. Full details of all models are provided in 
Appendix Q.  
6.4.3.2 Mortality by Predicted Class for 80% Adherence 
The same approach was also taken using the predicted class assignments for the 
optimal 80% model, with classes 1, 2, and 3 combined, as shown in Table 6.10, 
with full details of the models fitted provided in Appendix R. In both years 2 and 
3, those assigned to the least likely to achieve adherence ≥80% class (class 4) 
were at an increased risk of mortality compared to those assigned to the other 
three classes (classes 1-3), with hazard ratios statistically significant at the 5% 
level.  
Table 6.10: Mortality by Predicted 80% Adherence Class (from Optimal LCA Model)  
 Year 2 Year 3 
Classes 








N 6,043 1,093 4,590 881 
Events (%) 327 (5.4%) 93 (8.5%) 230 (5.0%) 61 (6.9%) 
     
Cox PH     
   Hazard Ratio 1.00 (ref.) 1.61 1.00 (ref.) 1.40 
   95% CI  -- (1.28, 2.03) -- (1.06, 1.86) 
 p-value: 0.0001 p-value: 0.0239 
CI = Confidence Interval, PH = Proportional Hazards, ref = reference category. Patients only 
included if a predicted class assignment was available for that year of follow up from the 
80% adherence LCA model. Models fitted are unadjusted for further covariates. 
Overall, the difference in the risk of mortality was less evident in these 80% 
adherence threshold models than in the 50% adherence threshold models 
discussed above. However, the percentage of patients who died in the second 
year of follow up was higher amongst patients assigned to class 4, compared to 
the other three classes combined (8.5% vs 5.4% respectively). This was also the 
case in the third year of follow up, with the number of events slightly lower and 
a smaller difference in the percentages (6.9% vs 5.0%). The associated hazard 
ratios reflected this, with those assigned to class 4 with 61% greater hazard of 
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mortality compared to classes 1, 2, and 3 in the second year of follow up, with 
40% higher risk in the third year.  
6.5 Latent Class Growth Analysis for Adherence 
6.5.1 Optimal Model for 50% Adherence 
 
Figure 6.6: Trajectory Curves for % Adherent (50% Threshold) by Assigned Class from 
Optimal LCGA Model. Class was predicted for a patient using modal assignment. 
Percentages calculated using the number of patients with data available for that year of 
follow up. 
For the 50% adherence LCGA, the variables considered were those identified in 
the earlier time-varying Cox models (Chapter 6.3.2) that were captured at 
baseline: age at MI, sex, and deprivation quintile. The optimal model for the 50% 
adherence threshold was run on data from 10,418 patients and contained four 
classes. Over three-quarters of these patients were assigned to class 1, and 8%, 
5%, and 11% assigned to classes 2, 3, and 4 respectively. Full model details, 
including comparisons of the model diagnostics for those with 2, 3, and 4 classes 
are provided in Appendix S1. 
As shown in Figure 6.6, within the largest class (class 1), in any given year, 
nearly 95% of the patients had adherence ≥50%. Unsurprisingly, as a result of its 
Chapter 6  236 
 
 
large size, the characteristics of this group were similar to those of the overall 
population, with the highest proportion of those aged between 60 and 70 years, 
and male of all the classes (63%). The proportion in each SIMD quintile was also 
similar to that of the overall cohort.  
In contrast, those in classes 2 and 4 show similar trajectories in adherence 
achievement, with rapid declines in the proportion achieving the threshold after 
the first couple of years, although class 2’s adherence is initially comparable to 
those in class 1. These classes have the highest proportions of females 
(compared to classes 1 and 3), and higher proportions within the oldest age 
brackets. This is particularly true for class 4 (the worst-performing adherence 
trajectory), where just over half of the class were female, and 55% were over 
the age of 70. In terms of deprivation, there were some differences between the 
two; class 4 had the highest proportions of patients in the third and fourth 
quintiles of all classes, whilst class 2 had the highest proportion in the fifth (and 
least deprived) quintile.  
Finally, class 3, which was the smallest of the classes, initially has a low 
proportion of patients who are adherent, with the percentage gradually 
increasing throughout follow up to around 85% in years 8 and 9. This group was 
similar to class 1 in its proportion of males yet had the highest proportion of 
patients under the age of 60 years and from the most deprived quintile of all the 
classes. This trajectory could be partly explained by survival bias, as there was a 
higher rate of death among those who were non-adherent within this class near 
the beginning of their follow up time with only those who are adherent 
remaining alive causing the proportion to increase. However, this impact is likely 
to be minimal, as a sensitivity analysis run only in patients who did not die 
during follow up assigned only 0.5% of patients to a different class. 
Classification diagnostics suggested that the model fit was reasonable and the 
distinction between the class trajectories was adequate. Relative entropy was 
fairly high with a value of 0.7639 and all average posterior probabilities for each 
class (Table 6.11) above 0.7. This is especially true for the consistently adherent 
class (class 1), which had the highest average posterior probability of all the 
groups, with a probability of 0.9185. This suggests that whilst classification in 
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groups 2-4 is sufficiently high, there is very little uncertainty in the assignment 
of patients to the consistent group. 
Table 6.11: Average Posterior Probabilities for Optimal LCGA for 50% Adherence  





Ave PP = Average Posterior Probability. Ave PP for a class is the mean of the posterior 
class probabilities for all patients modally assigned to that class (i.e. only includes the 
patients where the posterior probability was highest for that class). 
6.5.2 Optimal Model for 80% Adherence 
 
Figure 6.7: Trajectory Curves for % Adherent (80% Threshold) by Assigned Class from 
Optimal LCGA Model. Class was predicted for a patient using modal assignment. 
Percentages calculated using the number of patients with data available for that year of 
follow up. 
As with the 50% adherence model, only variables captured at baseline that were 
included in the optimal time-varying cox models discussed earlier (Chapter 
6.3.2) were included within the latent classes. Specifically, these were the age 
at the time of MI, sex, deprivation quintile, and the year of MI, with only the 
latter variable differing from the model fitted to the 50% adherence threshold. 
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The optimal model contained four classes and revealed similar patient 
trajectories to those observed with the 50% model. However, there were 
substantial differences in the estimated class shares for the 10,418 patients 
included. Class 1 remained the largest group, with an estimated class share of 
48%, with the remaining three classes, representing 26%, 8%, and 19%, 
respectively. Comparisons of model diagnostics for the LCGA models with 2, 3, 
and 4 classes, and full model details of the optimal model are provided in 
Appendix S2. 
The trajectories of these groups (Figure 6.7) are approximately similar to those 
seen in the 50% adherence model. However, class 1, whilst generally remaining 
consistently adherent, starts with only 81% of the patients achieving the 80% 
adherence threshold in the first year of follow up, with this increasing to 100% in 
year 4 and then remaining so. Furthermore, in class 2, the decline in the 
proportion with adherence ≥80% is less pronounced than in the 50% model, with 
this decreasing to just less than 50% adhering compared to less than 10% using 
the other adherence threshold. In contrast, class 3 started with lower levels of 
patients with adherence ≥80%, although the proportion did increase to just 
below 80% in year 9 of follow up. Finally, class 4 showed a similar trend in the 
two adherence models, although the percentage adherent in the first year of 
follow up for the 80% model was approximately half that of the 50% model.  
The consistent class (class 1) is characterised by high proportions of those aged 
between 60 and 80 years at the time of their MI and a gender divide comparable 
to the overall population. There was also the highest proportion of patients in 
the least deprived quintile within class 1, with also relatively high proportions of 
those assigned to the third and fourth quintiles. Those assigned to class 1 were 
also more likely to have experienced their baseline MIs later in the period of 
interest, with a third of patients assigned to this group commencing their follow 
up in 2013 or 2014.  
The gender divide in class 1 was similar in class 2, but those assigned to this 
class were marginally older with a high proportion aged over 70 years at the 
start of their follow up. There was also a trend towards residing in more 
deprived areas in patients assigned to this class. The year of the baseline MI was 
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also earlier with the highest proportion of MIs in 2011 of any classes and a 
relatively high proportion in 2010, resulting in a longer average duration of 
follow up for this class.  
The characteristics of class 3 in this model were similar to those of class 3 in the 
model for the 50% adherence threshold. Specifically, patients assigned to this 
class were more likely to be male, be younger than 60 years at the time of their 
baseline MI and reside in areas in the two most deprived quintiles. This class 
were also likely to have a longer duration of follow up available, with 57% of 
those assigned experiencing their baseline MIs in 2009 and 2010.  
Finally, within the class whose proportion of patients who were adherent rapidly 
approached 0% (class 4), there was the highest percentage of females of the four 
classes. This class was also most likely to reside in the third deprivation quintile 
and were the oldest, with more than a quarter of the patients over the age of 80 
years. However, average follow up was likely to be fairly short for this group, 
with many patients experiencing their baseline MI in 2012 and 2013.  
Table 6.12: Average Posterior Probabilities for Optimal LCGA for 80% Adherence  





Ave PP = Average Posterior Probability. Ave PP for a class is the mean of the posterior 
class probabilities for all patients modally assigned to that class (i.e. only includes the 
patients where the posterior probability was highest for that class). 
Overall, the classification diagnostics for this model suggested that the fit of this 
model was likely to be reasonably adequate. However, these were less 
convincing than those that had been observed for the LCGA model for the 50% 
adherence threshold. Relative entropy for this 80% model was 0.5914, suggesting 
that there was some distinction between the classes assigned, this was 
considerably lower than the 0.7639 observed for the earlier adherence model. 
Furthermore, only three of the four classes had an average posterior probability 
above 0.7 (Table 6.12), and class 3 (which had poor initial adherence before 
improving) had the lowest average posterior probability, equal to 0.6897. Lower 
average posterior probabilities lead to greater uncertainty in the assignment of 
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patients to the class and therefore increase the possibility of incorrect 
assignments and reduced accuracy of the model.  
This model was also more sensitive to mortality within the classes, possibly as a 
consequence of the inclusion of year of MI within the class-membership model. 
Indeed, following exclusion of patients who died before the end of follow up, 
whilst the four adherence trajectories were broadly similar, 22.8% of the 
remaining were assigned to a different adherence trajectory in this sensitivity 
analysis.  
6.5.3 Mortality by Predicted LCGA Class 
6.5.3.1 Mortality by Predicted LCGA Classes for 50% Adherence 
The Kaplan-Meier in Figure 6.8 compares the overall survival probabilities within 
each of the groups identified by the LCGA for 50% adherence trajectories. 
Patients assigned to class 2, where the proportion adherent started high and 
then decreased rapidly experienced no deaths in the first two years of follow up 
where their adherence was highest. However, after two years, the number of 
events increased rapidly resulting in a decrease in survival probability with only 
those assigned to the least adherent class (class 4) faring worse by the end of 
follow up. This pattern in class 2 occurred despite no substantial differences 
between this group with any others in terms of class-membership variables 
(Appendix S1), and no information included in the model could have resulted in 
overfitting. Consequently, such a curve is likely the result of substantial clinical 
differences in the baseline health and the comparatively small group size (8%).  
For patients in class 3, where the proportion with adherence ≥50% increased 
throughout follow up, there was an initial rapid decline in survival probability 
where adherence was worst followed by a plateauing in the curve when the 
proportion of those adherent within the class was increasing. For patients 
assigned to the consistently adherent group (class 1), the survival probability 
curve showed a steadily decreasing survival probability over follow up. Initially, 
these probabilities were lower than those observed within class 2, but due to the 
steep increase in events for class 2 after two years of follow up, class 1 had the 
optimal survival curve from year 5 onwards.  




Figure 6.8: Kaplan-Meier Curve for Mortality by Predicted 50% Adherence LCGA Class Class 
was predicted for patients using modal assignment. Patients only included if a predicted 
class assignment was available from the 50% adherence LCGA model. Numbers in table are 
number at risk (cumulative number of events). 
Table 6.13: Hazard Ratios of Mortality by Predicted 50% Adherence LCGA Class  
 HR (95% CI) p-value 
Class 1 (ref) 1.00 
<0.0001 
Class 2 0.99 (0.87, 1.12) 
Class 3 1.26 (1.09, 1.46) 
Class 4 1.84 (1.67, 2.02) 
HR = Hazard Ratio, CI = Confidence Interval. Class was predicted for patients using modal 
assignment. Patients only included if a predicted class assignment was available from the 
50% adherence LCGA model. Models fitted are Cox proportional hazards and were 
unadjusted for further covariates.  
The hazard ratios from a Cox regression model are presented in Table 6.13 and 
illustrate the differing risks of mortality between the assigned classes. 
Furthermore, this also found that these latent classes were significantly 
associated with mortality risk within this population at the 5% level. Full model 
details, including the Schoenfeld residual plot, are provided in Appendix T1. 
Taking the consistently adherent group (class 1) as a reference, both classes 3 
and 4 had an increased risk, whilst the risk of mortality in class 2 was 
approximate to the risk observed in class 1. Specifically, patients in class 4 were 
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at the greatest risk of mortality, with an associated hazard 84% higher than for 
patients assigned to class 1. For patients in class 3, the associated hazard for 
mortality was 26% higher. There was no significant difference in the mortality 
hazards between classes 2 and 1, with the hazard ratio suggesting that there was 
a 1% lower risk for class 2. However, this lack of significant difference for these 
two classes is likely to have occurred due to a violation of the proportional 
hazards assumption of the Cox regression model. This violation was evident in 
the earlier Kaplan-Meier (Figure 6.8) where the two lines for these classes 
crossed. Therefore, this HR from the Cox model (comparing class 1 and 2) is 
included for completeness only and should not be taken as indicative of the true 
underlying trends illustrated in the Kaplan-Meier curve. 
6.5.3.2 Mortality by Predicted LCGA Classes for 80% Adherence 
 
Figure 6.9: Kaplan-Meier Curve for Mortality by Predicted 80% Adherence LCGA Class. 
Class was predicted for patients using modal assignment. Patients only included if a 
predicted class assignment was available from the 80% adherence LCGA model. Numbers 
in table are number at risk (cumulative number of events). 
For the 80% adherence LCGA, the Kaplan-Meier revealed similar survival 
probabilities for classes 1, 3 and 4 (Figure 6.9) to those seen in the previous 50% 
adherence model. However, in this instance, those assigned to class 2 (high 
starting adherence with a large decrease) had survival probabilities between 
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classes 1 and 3 throughout follow up. Therefore, those assigned to class 1, whose 
adherence was fairly consistent following their baseline MI, had the optimal 
survival of all the classes in this model. The survival probabilities of those 
assigned to classes 3 (improved adherence) and 4 (low and decreasing 
adherence) were initially similar for the first three years of follow up, with 
survival only marginally improving for class 3 during the later years of data 
compared to class 4. 
Table 6.14: Hazard Ratios of Mortality by Predicted 50% Adherence LCGA Class  
 HR (95% CI) p-value 
Class 1 (ref) 1.00 
<0.0001 
Class 2  1.30 (1.19, 1.42) 
Class 3 1.71 (1.51, 1.93) 
Class 4 2.04 (1.87, 2.22) 
HR = Hazard Ratio, CI = Confidence Interval. Class was predicted for patients using modal 
assignment. Patients only included if a predicted class assignment was available from the 
80% adherence LCGA model. Models fitted are Cox proportional hazards and were 
unadjusted for further covariates.  
These differences were also reflected in the hazard ratios from a Cox regression 
model, as shown in Table 6.14, with full details provided in Appendix T2. This 
regression found that there was a statistically significant association between 
mortality and the latent classes from this LCGA model at the 5% level. Using the 
consistently adherent group (class 1) as the reference group, patients assigned 
to each of the three other classes had a higher risk of mortality. Those assigned 
to class 2 (high initial and then decreasing adherence) had the smallest 
associated increase in the risk of mortality, with a hazard 30% greater than those 
in class 1. Meanwhile, those with increasing adherence over follow up (class 3) 
had a 71% increased risk of mortality than those consistently adherent. Class 4, 
low and decreasing proportions adherent, however, were most at risk, with an 
associated hazard more than twice that of those assigned to class 1.  
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6.6 Factors Associated with LDL Target Achievement 
6.6.1 Patterns in Achieving LDL Targets (within patients) 
 
Figure 6.10 Individual Patterns of LDL Target Achievement During Follow Up (including 
incomplete years). Each time window was categorised by whether the patient achieved the 
LDL target of ≤1.8mmol/l, or whether no test result was available. Patient number on the y-
axis is arbitrary, and patients were sorted by their LDL target achievement patterns before 
plotting, with lower patient numbers assigned to those with a longer period of not achieving 
the target.  
In the first year after their baseline MI, approximately half of the patients were 
on target, with many remaining so throughout follow up, as shown in Figure 
6.10. Similarly, many patients with no results in their first year of follow up also 
did not have results for the remainder. Of those that did have a test in 
subsequent years, similar proportions achieved and did not achieve the LDL 
target of ≤1.8mmol/l. For all years of follow up, patients with a lipid test result 
were more likely in the following year to have not had a test than having had a 
test result with a differing conclusion, regardless of whether they had achieved 
or not achieved the target in the current year. Furthermore, once one test was 
missed, only a minority of patients were subsequently tested again. 
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Table 6.15: Demographics by Consistency of Achieving Target LDL (LDL≤1.8mmol/l) 






Gender    
   Male 2,056 (62.5%) 2,537 (64.6%) 1,352 (59.1%) 
   Female 1,232 (37.5%) 1,390 (35.4%) 937 (40.9%) 
    
Age at MI (years)    
   Mean (SD) 68.3 (13.7) 62.9 (12.3) 65.5 (14.0) 
   Median 69.8 62.7 65.2 
   IQR 58.0 – 79.1 53.7 – 72.4 54.8 – 76.6 
   Range 19.3 – 102.2 20.5 – 99.3 22.5 – 98.1 
    
SIMD 2012 Quintile (NHS GGC) 
   1 (Most) 952 (29.2%) 872 (22.3%) 412 (18.2%) 
   2 738 (22.6%) 882 (22.6%) 551 (24.3%) 
   3 625 (19.1%) 813 (20.8%) 535 (23.6%) 
   4 488 (15.0%) 652 (16.7%) 454 (20.0%) 
   5 (Least) 461 (14.1%) 688 (17.6%) 317 (14.0%) 
   Missing 24 20 20 
    
Diabetes at MI    
   Any 771 (23.4%) 676 (17.2%) 315 (13.8%) 
   Type 1 33 (1.0%) 40 (1.0%) 32 (1.4%) 
   Type 2 738 (22.4%) 636 (16.2%) 283 (12.4%) 
    
Prior MI 249 (7.6%) 224 (5.7%) 115 (5.0%) 
   1 184 (5.6%) 177 (4.5%) 95 (4.2%) 
   ≥1 65 (2.0%) 47 (1.2%) 20 (0.9%) 
Consistency does not allow for years where an LDL result is missing, e.g. a patient may 
only have LDL results every other year, but each time meet the target, and therefore would 
fall into all ≤1.8mmol/l group. Patients only included if at least one LDL result was available 
during their follow up (n=9,504). 
Patients with at least one LDL result (n=9,504) were then categorised into those 
who only ever achieved the LDL target of ≤1.8mmol/l (35%), those who never 
achieved the target (24%), and those who achieved it inconsistently (41%). Those 
who consistently met the target had the highest average age, were more likely 
to reside in the most deprived areas, have a diagnosis of type 2 diabetes at their 
baseline MI, and have experienced a prior MI. In contrast, those who never met 
the target were the most likely to be female, most likely to reside in deprivation 
quintiles 2-4, and have a diagnosis of type 1 diabetes. Finally, patients who 
inconsistently achieved the target were younger and more likely to reside in the 
least deprived areas.  
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6.6.2 Time to Non-Target LDL 
Kaplan-Meier plots (not presented) for the non-time-varying covariates 
considered in these models revealed the biggest differences were present by age 
category and deprivation quintile, where the oldest, and most deprived were 
less likely to become not on target. There was also a small difference noted by 
the prior MI status, with those with an MI before their baseline less likely to not 
meet the LDL target. There were no differences observed by sex.  
 
Figure 6.11: Time-Varying Cox Regression for Time to Non-Target LDL (>1.8mmol/l) with 
Lipid Testing Frequency Covariate Testing frequency was the number of lipid tests 
conducted in the previous year of follow up, with the recommended one test per year as the 
reference level. Testing frequency was a time-varying covariate with one test assumed for 
the first year of follow up. AIC for this model was 102802.8. Patients only included if ever 
prescribed statins during follow up. 
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Patients were only considered in these models (and subsequent analyses in the 
remainder of this chapter for non-target LDL) if they were prescribed statins at 
any point during their follow up. The optimal model for time to LDL>1.8mmol/l 
contained all the variables considered: age at MI, sex, deprivation, diagnosis of 
diabetes (time-varying), further MI in the last year (time-varying), prior MI to the 
baseline, and year of MI. The relationship with age was almost an inverse to that 
which had been observed with adherence, with those over the age of 70 
increasingly less likely to become off-target, and those under 70 years more 
likely. However, consistent with the earlier adherence models, males were less 
likely to have non-target LDL than females. There was also a curved association 
with deprivation, where those residing in the most deprived areas were less 
likely to have LDL>1.8mmol/l. A diagnosis of diabetes and experiencing an MI 
before their baseline were both individually also associated with a decreased 
likelihood of not meeting the LDL target. A further MI in the last year, however, 
increased the likelihood of not meeting this target, although this did not reach 
statistical significance despite its inclusion in the optimal model. Finally, those 
with more recent MIs were more likely to have non-target LDL. These patterns 
remained consistent, although with slightly greater uncertainty, in a sensitivity 
analysis where time to non-target was measured from the time the LDL target 
was first achieved by the patient during follow up (results not presented). In a 
separate sensitivity analysis (not presented), the removal of the year of MI from 
the final model resulted in the hazard ratio for further MI in the last year 
increasing marginally and consequently reaching statistical significance, whilst 
the effects of all other covariates were not substantially altered.  
The final model is shown in Figure 6.11, with full details provided in Appendix U. 
As was the case with the adherence models, the addition of the testing 
frequency as a time-varying covariate did not significantly alter any of these 
associations but did improve the fit of the model very slightly (AIC decreased 
from 102810.7 to 102802.8). Testing frequency in the previous year was 
significantly associated with time to not meeting the LDL target, with those 
over-tested more likely to not meet the target, and those under-tested less 
likely.  
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6.7 Latent Class Analysis for Target LDL Achievement 
6.7.1 Optimal Model for Target LDL Achievement 
The LCA model for target LDL of ≤1.8mmol/l used data from 16,215 time 
windows from 6,274 patients. To determine class membership, the following 
variables were considered: age at MI, sex, deprivation quintile, whether a 
patient had experienced an MI before their baseline, the year of their baseline 
MI, whether the patient’s adherence was ≥50% the previous year, and whether 
the patient’s LDL was ≤1.8mmol/l the previous year. Analyses were run using 
adherence in the previous year with both thresholds, with nearly identical 
models produced for both thresholds. The LCA using the 50% adherence 
threshold for the previous year demonstrated marginally superior diagnostic 
value over the one using the 80% threshold, so is included here, with full details 
for both optimal models in Appendix V. The optimal model (using the previous 
50% adherence), which converged after 144 iterations, had two classes with 
predicted class shares of 43.2% and 56.8% respectively. 
As expected, the largest differences in the conditional class probabilities were 
between whether the target of ≤1.8mmol/l had been met the previous year, 
with a high proportion achieving this in class 1, and a lower proportion in class 2. 
There was also a higher proportion of patients with adherence ≥50% in the 
previous year in class 1. There were also marginally higher proportions of 
patients from the most deprived quintile, with a diagnosis of diabetes, further 
MIs in the last year, and MIs before their baseline in class 1. In class 2, there was 
a slightly higher number of females and those under the age of 70 years than in 
class 1. 
Table 6.16: Predicted Class Assignments for Optimal LDL Target LCA Model by 
Achievement of LDL Target  
 Meet Not Meet Total 
Class 1 (More) 7009 0 7009 
Class 2 (Less) 1397 7809 9206 
Total 8406 7809 16215 
 
Time windows assigned to classes using predicted modal assignment. Only time windows 
with complete data available included in the LCA model. Likelihood of classes to meet the 
LDL target of ≤1.8mmol/l was ascertained through multinomial regression coefficients 
produced during a one-step model fitting process.  
Chapter 6  249 
 
 
Comparing the predicted class assignments with whether an LDL≤1.8mmol/l was 
achieved, showed that all patients assigned to class 1 did so (Table 6.16). This 
resulted in 100% positive predictive value, and 100% specificity as all of the time 
windows where the target was not met were assigned to class 2 (Table 6.17). 
However, around 1,400 time windows assigned to class 2 also met the target. 
Nevertheless, this model still results in reasonable sensitivity and negative 
predictive value, with 83.4% of all time windows meeting the target identified, 
and 84.8% of time windows assigned to class 2 failing to achieve the target of 
≤1.8mmol/l. 
Sensitivity was the only diagnostic measure affected by the bootstrapping of this 
model, and increased by 0.4% to 83.8%, although its associated confidence 
interval contained the value observed in the original model. The estimated 
negative predictive value remained the same following bootstrapping, and for 
reasons expanded on in Chapter 6.2.4, the 100% values for both specificity and 
positive predictive value were also unaffected during the bootstrapping.  
Table 6.17: Diagnostic Table for Optimal LCA Predictions for Target LDL  
 1 vs 2 
 LCA Bootstrap 
Sensitivity 83.4% 83.8% (83.1%, 84.5%) 
Specificity 100.0% 100.0% (100.0%, 100.0%) 
Positive Predictive Value 100.0% 100.0% (100.0%, 100.0%) 
Negative Predictive Value 84.8% 84.8% (84.0%, 85.6%) 
LCA = Latent Class Analysis; CI = Confidence Interval. LCA diagnostics calculated using 
numbers presented in Table 6.16. Diagnostics were bootstrapped 5,000 times with 
confidence intervals ascertained using the percentile method. Within each bootstrap, one 
time window per patient and its predicted class was selected, and cross-tabulations and 
diagnostic measures were calculated as on the full set of time windows above. 
Table 6.18: Average Posterior Probabilities for Optimal LCA for Target LDL   
Class Ave PP 
1 0.9322 
2 0.9431 
Ave PP = Average Posterior Probability. Ave PP for a class is the mean of the posterior 
class probabilities for all time windows modally assigned to that class (i.e. only includes the 
time windows where the posterior probability was highest for that class). 
The distinction between classes, as measured by relative entropy, was higher 
than had been observed within the adherence LCA models, with a value of 
0.7486. Furthermore, the average posterior probabilities (shown in Table 6.18) 
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were above 0.9 for both classes. This suggested that the two classes were well 
separated from each other due to the high levels of certainty in the assignment 
of time windows to classes. 
6.7.2 Mortality by Predicted Class  
The results for the associations between mortality and assigned class in the 
second and third years of follow up were very similar (Table 6.19) and were 
similar when the LCA model using previous adherence at the 80% threshold was 
used (Appendix X). Contrary to expectations, when comparing the raw 
proportions, there was a higher rate of mortality in patients assigned to class 1 
(the most likely to meet the target) than in class 2 (the least likely). This was 
then also reflected in the hazard ratios from the Cox proportional hazards 
models, respectively. Specifically, in the second year of follow up, there was a 
28% reduction in mortality for those in class 2 compared to class 1, and in the 
third year, this reduction was 27%. In both instances, however, this reduction 
was not statistically significant at the 5% level. Full details of these models are 
provided in Appendix W.  
Table 6.19: Mortality by Predicted LDL Class (from Optimal LCA Model) 










N 2,412 2,332 1,682 1,940 
Events (%) 84 (3.5%) 59 (2.5%) 46 (2.7%) 39 (2.0%) 
     
Cox PH     
   Hazard Ratio 1.00 (ref.) 0.72 1.00 (ref.) 0.73  
   95% CI  -- (0.52, 1.01) -- (0.48, 1.12) 
    p-value: 0.0527 p-value: 0.1500 
CI = Confidence Interval, PH = Proportional Hazards, ref = reference category. Patients only 
included if a predicted class assignment was available for that year of follow up from the 
target LDL LCA model. Models fitted are unadjusted for further covariates. 
However, this increased risk of mortality may not be due to the failure of the 
LCA to identify those most at risk. In years 2 and 3 of follow up, there were also 
a higher number of deaths among those who had achieved the target compared 
to those who had not. In year 2, 12 more patients died who met the LDL target 
than who were assigned to the class most likely to meet the target, and in year 
3, this number was seven. Therefore, in these cases, if the results of the LCA 
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were used to make decisions for these patients, they would have been assigned 
to class 2 and would have received their annual plasma lipid test. However, their 
LDL would have been ≤1.8mmol/l, and therefore it is unlikely that any further 
intervention would have been made.  
6.8 Latent Class Growth Analysis for Target LDL 
Achievement 
6.8.1 Optimal Model for Target LDL Achievement 
 
Figure 6.12: Trajectory Curves for % at Target LDL by Assigned Class from Optimal LCGA 
Model. Class was predicted for a patient using modal assignment. Percentages calculated 
using the number of patients with data available for that year of follow up. As patients may 
not be tested each year of follow up, this could lead to their inclusion in non-consecutive 
years until the end of their follow up or death. 
For the LCGA model, the variables considered for the class-membership 
component of the model were those captured at baseline and identified earlier 
in the chapter as part of the optimal time-varying cox model for time to non-
target LDL (Chapter 6.6.2). These were age at MI, sex, deprivation quintile, MI 
before baseline, and year of MI. The model was generated using data from 9,079 
patients, and as with the adherence LCGA models, the optimal model contained 
four classes and had similar trajectory patterns (as shown in Figure 6.12). 
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However, there was little to no association between a patient’s adherence 
trajectory and their target LDL trajectory. Furthermore, the estimated class 
shares were also very different, with just 17% assigned to class 1, and 37%, 14%, 
and 32% assigned to class 2, 3, and 4 respectively. The full details for this model 
are available in Appendix Y, including a comparison of model diagnostics for 2, 
3, and 4 class models. 
The two classes with declining proportions of patients achieving the LDL target 
over follow up (classes 2 and 4) have some similar characteristics. Both have 
higher proportions of females and higher proportions of patients under the age 
of 60 years at baseline, with class 4 (the least on target group) having the 
highest of both. Those assigned to classes 2 and 4 were also more likely to have 
experienced their baseline MIs later in the period of interest. Indeed, over one-
fifth of those assigned to class 4 had their baseline MI in 2014, and for both 
classes more than half of the patients had their baseline MI in or after 2012. 
However, one of the biggest differences between these two groups was in terms 
of their deprivation profile. Those assigned to class 2 (high percentage on target 
at the start) had higher proportions of patients in the two most deprived 
quintiles, whereas those assigned to class 4 (a third on target at the start) were 
more likely to reside in the least deprived quintile (of all four classes). Patients 
in class 4 were also the least likely to have experienced an MI before baseline 
across the four groups.  
In contrast, the group with a consistently high percentage of patients on target 
(class 1) had the highest percentage of patients with MIs before their baseline, 
over double that of class 4. This group were also more likely to be male and 
were older with a high proportion of patients over the age of 70 at the time of 
their baseline admission. They were also more likely to reside in the most 
deprived quintile and would have a longer average duration of follow up with 
high numbers of baseline MIs occurring in 2009 and 2010. Class 3 (whose 
percentage on target started low and increased substantially) shares some 
similar characteristics with this class; namely, higher proportions of males, and 
earlier baseline years, with many admissions occurring in 2010 and 2011. 
However, whilst they were likely to be older than those assigned to classes 2 and 
4, they were slightly younger than class 1 with a quarter of the class aged 
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between 60 and 70 years. They were also less deprived with the majority of 
patients residing in the second, third, and fourth quintiles of deprivation, and 
had lower rates of MIs before their baseline admission. 
Table 6.20: Average Posterior Probabilities for Optimal LCGA for 80% Adherence   





Ave PP = Average Posterior Probability. Ave PP for a class is the mean of the posterior 
class probabilities for all patients modally assigned to that class (i.e. only includes the 
patients where the posterior probability was highest for that class). 
However, the relative entropy for this model was lower than the LCGA models 
for adherence, with a value of 0.5257. This would suggest that there was a 
limited distinction between the classes within the model and consequently there 
may be an increased risk of the misclassification of patients. This was also 
supported by the average posterior probabilities (Table 6.20) where three out of 
the four classes were above 0.7. The lowest of these probabilities, 0.6634, was 
for the group of patients who were predominantly on target at the start of 
follow up before declining substantially in likelihood (class 2). As this is below 
0.7, this could be an indicator that there may be greater uncertainty surrounding 
the correct allocation of patients to this group.  
There was also reasonable sensitivity to mortality within the classes in this 
model. This could, in part, be due to the inclusion of year of MI within the class-
membership model with higher rates of mortality likely in classes with earlier MI 
dates. Nonetheless, in a sensitivity analysis where patients who died during 
follow up were excluded, the trajectories remained similar for the four classes, 
but 18.7% of included patients were assigned to a different class.  
6.8.2 Mortality by Predicted Class 
Figure 6.13 compares the overall survival probabilities for the classes from the 
LCGA model for target LDL trajectories. Patients assigned to class 4, which had 
the worst target LDL trajectory, had the highest survival probability throughout 
follow up. This was consistent with class 2, where those assigned to this other 
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decreasing trajectory had the next highest survival probabilities. This was in 
contrast to those assigned to the consistently on target class (class 1) and the 
increasingly on target class (class 3), which both had similar survival 
probabilities throughout follow up and the poorest survival curves of the classes 
assigned in this LCGA model. 
 
Figure 6.13: Kaplan-Meier Curve for Mortality by Predicted 50% Adherence LCGA Class. 
Class was predicted for patients using modal assignment. Patients only included if a 
predicted class assignment was available from the target LDL LCGA model. Numbers in 
table are number at risk (cumulative number of events).  
These patterns were also evident in the hazard ratios from a Cox regression 
model looking at the association between these assigned classes and their 
association with mortality. In this model, where the hazard ratios are presented 
in Table 6.21 and the full details are available in Appendix Z, the latent classes 
were found to be statistically significant in the risk of mortality at the 5% level.  
As with the adherence LCGA models, patients assigned to the consistently on 
target group (class 1) were considered to be the reference group. Patients 
assigned to classes 2 and 4 (the two decreasingly on target groups) had the lower 
associated risks of mortality, compared to the reference group (29% lower and 
65% lower respectively). In line with expectations from the earlier Kaplan-Meier 
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curve, the associated hazard of mortality from this Cox regression model for 
class 3 (increasingly likely to meet target) was similar to that of class 1. In 
particular, the associated hazard ratio was 0.98, conferring a nonsignificant 2% 
reduced likelihood of mortality for patients in class 3.  
Table 6.21: Hazard Ratios of Mortality by Predicted Target LDL LCGA Class  
 HR (95% CI) p-value 
Class 1 (ref) 1.00 
<0.0001 
Class 2 0.71 (0.64, 0.79) 
Class 3 0.98 (0.87, 1.10) 
Class 4 0.35 (0.30, 0.40) 
HR = Hazard Ratio, CI = Confidence Interval. Class was predicted for patients using modal 
assignment. Patients only included if a predicted class assignment was available from the 
target LDL LCGA model. Models fitted are Cox proportional hazards and were unadjusted 
for further covariates.  
6.9 Discussion 
6.9.1 Identification of Potential Patients for Reduced Lipid 
Monitoring  
Within this post MI cohort from NHS GGC, the analysis in this chapter has shown 
that simple clinical and demographic factors, as well as the last year’s 
adherence and lipid data, are associated with future adherence and meeting 
lipid targets. Using this routine clinical information, it is possible to identify 
patients for whom an annual lipid test could be considered unnecessary. All 
patients predicted to meet the 50% adherence threshold in a given time window 
(accounting for 85% of the years of follow up available) did so, and all time 
windows where patients were expected to meet the LDL target of ≤1.8mmol/l 
(43% of all years available) also did so. For adherence, this was supported 
further by survival models where those predicted to not have adherence ≥50% in 
the second and third years of follow up had a higher risk of mortality, with 
smaller effect sizes observed for adherence ≥80% adherence, giving these 
findings face validity. Furthermore, using patient trajectories identified in LCGA, 
patients assigned to the class with consistent adherence throughout follow up 
also had optimal survival probabilities. This analysis raises the possibility that 
annual lipid monitoring could be targeted in secondary prevention, potentially 
saving GP time, lab costs, and patient time in a sizable group of the most 
adherent patients. 
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To date, attempts to personalise testing schedules within chronic diseases have 
been limited to screening programmes outside of cardiovascular disease, thus 
emphasising the novelty of this approach. A systematic review published in 2016 
seeking to evaluate the evidence for such risk-based approaches in the use of 
diabetic retinopathy screening found that RCTs were needed to draw reliable 
conclusions, whilst others have raised concerns about the possibilities of missed 
interventions should the interval between checks be extended significantly 
(McGhee, Harding and Wong, 2012; Lund et al., 2016; Taylor-Phillips et al., 
2016). However, before such trials can take place to test reduced monitoring, 
models first need to exist to identify such patients. This was the case for one 
such risk score derived from data in Liverpool using electronic records, that has 
now been tested in an RCT and safely reduced the number of appointments 
needed by 40% with comparable risks between routine annual monitoring 
(Eleuteri et al., 2017; Broadbent et al., 2020). The analysis in this chapter, 
therefore, sought only to provide some foundations towards any implementation 
of such personalisation.  
One of the main considerations in putting this data into context is what annual 
lipid tests are trying to achieve: adherence or cholesterol levels. The current 
SIGN guidelines do not specify a lipid target. Instead, it is stated that a 
reduction of 1 mmol/l or a 40% reduction in non-HDL would suggest adequate 
adherence and lifestyle changes following commencement of statin therapy 
(SIGN, 2017, p. 44), suggesting that adherence may be the primary purpose of 
such a test. Throughout this thesis, two adherence thresholds have been 
considered, 50% and 80%. Of these, the 50% adherence threshold, equivalent to 
alternate-day dosing, has been shown in this chapter to be relatively easy to 
predict and can be done so with high accuracy. Furthermore, in clinical practice, 
such a treatment regimen may be recommended in patients who experience side 
effects of statin treatment, as the duration of the lipid-lowering effect exceeds 
its half-life (Jordanov and Abou Assi, 2015). Regardless, using adherence as a 
marker would also yield practical benefits to the identification of patients whose 
test may be unnecessary as if this were ever to be implemented, monitoring 
lipid targets among patients who do not have tests would be difficult to achieve.   
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Another limitation of clinical use of lipid targets in this context is the direction 
of the, albeit not statistically significant, associations between predicted LCA 
LDL classes and survival. Higher rates of mortality were also observed in those 
that had met the LDL target that year. Consequently, the results of the LCA are 
not suggestive of an increased risk of mortality due to the predictions 
themselves. Indeed, a smaller proportion of patients died who were predicted to 
meet the target than those who had met the target in both the second and third 
years of follow up. This was also supported by the results of the LCGA for LDL, 
where the classes with the lowest proportions of patients achieving the LDL 
targets having the greatest survival probabilities. One explanation could lie in 
the causes of these deaths, if such causes result in lower cholesterol levels, 
although the small numbers in the groups with the cause of death information 
available prevented such comparisons being investigated. This also meant that in 
the case of the LCGA, repeating the Cox regression analysis by excluding those 
with deaths in the first two years to attempt to address issues of reverse 
causality was also not possible. Additionally, however, when looking at the 
characteristics of those predicted to meet the target in the LCA and consistently 
meeting it in the LCGA, it is clear that these groups have higher rates of 
cardiovascular risk factors such as being male, older, having a diagnosis of 
diabetes, and experiencing further and previous MIs. Therefore, the presence of 
these may have led to more intense risk management in these patients resulting 
in the confounding of these associations.  
This confounding could also offer an insight into some of the discrepancy 
between adherence and the achievement of lipid targets. Previous research has 
shown that although statin adherence is reasonable in secondary prevention 
cohorts, this does not fully account for the achievement of cholesterol targets 
with many adherent patients not meeting the recommended LDL levels despite 
excellent adherence (Nordstrom et al., 2015; Danese et al., 2017). This has also 
been observed in earlier chapters, in this cohort (Chapter 4 and Chapter 5). 
Additionally, in this chapter there was little association between a patient’s 
class trajectory for adherence and their class trajectory for achieving lipid 
targets, suggesting that these two outcomes are capturing different elements of 
a patient’s risk. Given the lack of association between predicted classes and 
mortality, this further enforces the idea that the use of lipid targets in terms of 
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the effective identification of a suitable subgroup may be limited at a population 
level.  
Furthermore, the time pressures on primary care physicians and the burden of 
risk scoring for various conditions should be recognised (Challener, Prokop and 
Abu-Saleh, 2019). The identification process developed in this chapter is not a 
manual risk scoring process, but an automated system that could be 
implemented using EMIS or VISION software in primary care, incorporating 
encashed prescription data. This means GPs would have real-time data informing 
them whether a lipid test is required or not as part of the visit, although they 
would also be able to request tests if they feel this is indicated. This may be 
particularly relevant in the context of other comorbidities that were not 
captured within the current cohort. Indeed, a diabetes diagnosis was only 
identified reliably using the diabetes register, but other comorbidities which 
may impact a patient’s ability to adhere to medication, such as dementia (Smith 
et al., 2017), were not routinely or reliably captured in GP local enhanced 
services data and were therefore not incorporated in the present analysis. 
Nevertheless, the additional burden required to implement this approach should 
be viewed in the context of health care resources saved through performing 
unnecessary tests. 
6.9.2 Strengths and Limitations 
External validation of these results is required. Nonetheless, given that the 
demographics of this cohort have been shown to broadly in line with other 
similar cohorts within the literature (Chapter 4), it is anticipated that this 
subgroup of patients is also likely to be present and reasonably accurately 
identified. However, the exact size of this subgroup may differ, as rates of 
adherence and LDL target achievement were slightly higher within this cohort 
than in other cohorts.  
One limitation of the initial Cox regression models to identify the factors 
associated with non-adherence or non-achievement of the LDL target was that 
no interactions between the covariates were considered. For example, a 
significant interaction between sex and age was likely, as females experience 
their MIs at an older age (Mosca, Barrett-Connor and Kass Wenger, 2011) and are 
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less likely to be prescribed statins (Eindhoven et al., 2018). This could have 
partly explained the increased likelihood of non-adherence at an older age 
observed within this cohort and the literature (Hope et al., 2019). Therefore, 
stratification by sex could prove beneficial in future research into factors 
associated with non-adherence and non-target lipids. However, this should not 
have substantially impacted the results of the LCA or LCGA as these methods are 
well suited to data where high-order interactions are likely to be present 
(Vermunt and Magidson, 2003). 
Nevertheless, LCA models were only run for years of follow up where all data 
was available for the necessary covariates, and LCGA was only run in patients 
where baseline covariates were available, and the outcome data was captured 
at least once during the patient’s follow up. For LCA, this may not be a problem 
if the patterns of missing data within patients’ follow up in this cohort are 
representative and similar to other cohorts.  
Moreover, for the LCA models, the independence assumption of observations was 
violated as multiple years of follow up were included per patient. Despite this 
though, internal bootstrapping of the model predictions did little to alter the 
model’s diagnostic accuracy measures and other measures of fit suggested that 
the overall fit of the final models was reasonable. However, methods which 
allow for changing covariates (which LCGA does not), such as Latent Transition 
Analysis should be considered in future research into this area. 
In the LCGA models, missing data is assumed to be missing at random by the 
model, which may not have been the case in these data. For example, the 
percentage who were adherent may increase in a class due to patients who are 
non-adherent being more likely to die earlier within the follow-up period. To 
assess this possibility, sensitivity analyses excluding patients who died during 
follow up were conducted. These found similar trajectories of patient groups for 
all models, although with the exception of the 50% adherence model where less 
than 1% changed class, around a fifth of patients were reassigned, suggesting 
there may be some influence of mortality here. This may be explained by the 
inclusion of the year of MI within the class membership component of the model, 
with those experiencing later baseline MIs less likely to experience mortality 
before the end of follow up. Given that removal of the year of MI did not 
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substantially impact the associations observed between the other covariates and 
time to non-adherence or non-target LDL in the Cox regression, further analysis 
without year of MI could be considered, but other methods, such as joint 
modelling, may be needed to fully account for this.  
Furthermore, despite the low percentage change in the 50% adherence model, 
when survival among the classes was compared, one class (class 2) did have an 
unusual survival curve with no events in the first two years, resulting in a 
violation of the proportional hazards assumption in the subsequent Cox model 
implemented. The reasons for this pattern were unclear, but the small class size 
means that this is likely the result of clinical differences in baseline health 
arising through chance, and the relatively small differences in class 
characteristics would make it difficult to identify such a group in other cohorts. 
Indeed, the relatively small differences in the conditional class probabilities, 
particularly in the LCGA, may also make the accurate allocation of patients to 
latent groups more challenging when validating results in other cohorts. 
As indicated above, a key strength of this analysis is that to date and our 
knowledge, no previous research has attempted to identify a group of patients 
who may not require an annual lipid test as part of their annual review within a 
cardiovascular prevention setting. Although the exact purpose of a lipid test in 
this context remains unclear, if its purpose is to see if sufficiently reduced lipids 
have been achieved then using the LCA predictions, potentially 40% of tests 
might not be needed, and if it is to ascertain a patient’s adherence, this could 
be as high as 85% if a 50% threshold is deemed adequate. However, it is 
important to emphasise that this approach refers only to the lipid test 
component of a patient’s annual review. Other risk management tests, such as 
for blood pressure and diabetes, that form part of the review would still be 
needed, and therefore, attendance at appointments should still be required. 
Furthermore, as no lipid tests in the year before was associated with an 
increased likelihood of becoming non-adherent, it is unclear whether it is the 
engagement with health services that sustains adherence or vice versa, and 
therefore the act of attending an appointment may have an important role in 
CVD risk management. Nevertheless, lowering the number of lipid tests 
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conducted as part of these annual reviews would still have an impact on the 
financial burden and primary care workload. 
6.9.3 Conclusions 
In this chapter, analyses have identified factors associated with becoming non-
adherent or having non-target LDL and used these to identify a group of patients 
within the post MI population who could be considered for reduced lipid testing 
with reasonable levels of accuracy. Additionally, the associations between 
predicted classes for adherence using the 50% threshold and mortality are similar 
to those observed between adherence and mortality in the previous chapters, 
suggesting that such a prediction is likely to be safe. No significant associations 
were observed between class predictions for achieving the LDL target of 
≤1.8mmol/l and mortality, although the hazard ratio was suggestive of an 
increased risk for those on target. However, as this was also present amongst 
those achieving the target, this indicated that the predictions did not pose an 
additional risk to the patient. Nevertheless, the associations with adherence and 
their face validity, and the lack of an association between those predicted to 
meet the LDL target and those predicted to be adherent, suggested that the 
prediction of a patient’s adherence alone could be sufficient to ascertain 
whether a lipid test is required when considering patient outcomes. 
However, whilst this is encouraging, further research is needed to externally 
validate these findings in other populations with established cardiovascular 
disease and to evaluate the impact. Additionally, other statistical models may 
be needed to improve the robustness of these predictions to increase the 
certainty in the accuracy of the identification process. Nonetheless, this chapter 
has demonstrated that, in principle, it could be possible to personalise the 
frequency of lipid testing using routinely collected data already available in 
patients’ electronic health records.  
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Chapter 7 Final Discussion  
7.1 Summary of Chapters  
The contents of this thesis have sought to address the aims and objectives 
outlined in Chapter 1.8. In Chapter 2, the systematic review laid the groundwork 
for the subsequent chapters by presenting and comparing the international 
guidelines for lipid-lowering in secondary prevention populations. Through this, 
it was clear that although the evidence base for the use of statins in this 
population was well-established, this was not the case for the use of lipid 
targets or the frequency that such patients should be monitored. For the former, 
targets were often stated with values derived from those used within clinical 
trials for lipid-lowering therapies, and in the latter, any recommendations were 
often supported only by the clinical opinion of the creators (Brown, Welsh and 
Logue, 2020). This lays the groundwork for epidemiological work, exploring 
whether existing opinion-driven clinical targets are frequently achieved, 
whether achieving targets has important consequences for clinical outcomes, 
and whether continuous monitoring of targets on an annual basis is necessary for 
all patients. 
In the remainder of the thesis, data from the NHS GGC Safe Haven was used, 
with Chapter 3 looking at the derivation of the post MI population within that 
region and subsequent chapters focussing on the remaining aims of the thesis. 
Specifically, this population contained all patients in NHS GGC who experienced 
a non-fatal MI between 2009 and 2014. This is therefore a locally representative 
population of post MI patients, and inferences about the prevalence of meeting 
or missing targets are likely to be more widely valid. Patients were followed up 
until July 2017 or death, and data captured included baseline demographics, 
hospital admissions, death certificates, blood test results, diabetes status (from 
the diabetes register), and prescribing records for lipid-lowering therapies.  
Following this derivation, the second aim sought to understand the 
demographics, adherence, and achievement of cholesterol-lowering targets of 
this population was addressed in Chapter 4. This found that the demographics of 
the 11,110 patients included in the post MI population were broadly similar to 
those observed in other cohorts outlined in the literature, with patients more 
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likely to be male, reside in more deprived areas, and had an average age at the 
time of MI of 67 years. Furthermore, the prevalence of diabetes within this 
population was also similar to other secondary prevention cohorts which 
focussed on patients admitted with acute cardiovascular events. This further 
supports the idea that these patients are representative of those seen in wider 
clinical practice. The size of the cohort, duration of follow up, and the use of 
real-world lipid results in repeated annual time windows, are less common in the 
literature, and represent significant strengths of the dataset. 
In terms of average statin adherence, there was a higher proportion of patients 
with adherence <80%, and a lower proportion with adherence <50%, when 
compared to other similar cohorts. Length of follow up was likely to have played 
some role in the former, with adherence known to decrease as the duration 
increased (Naderi, Bestwick and Wald, 2012; Khunti et al., 2018), and the high-
risk nature of the cohort and the lack of prescription charge also likely to 
increase adherence in the case of the latter (Naderi, Bestwick and Wald, 2012; 
Leslie, McCowan and Pell, 2018). Achievement of lipid targets, both the 2016 
ESC target of LDL≤1.8mmol/l (Piepoli et al., 2016) and the 2014 NICE target of 
≥40% reduction in non-HDL (NICE, 2014), was higher than observed in other 
cohorts, although achievement in this instance was defined by whether the 
target was achieved at any point during follow up, rather than a specific time 
following an event or statin initiation.  
Associations between statin adherence, achievements of cholesterol targets, 
further MIs and mortality were explored in Chapter 5 and found that non-
adherence and failure to achieve lipid targets were strongly associated with all-
cause mortality within this population and similar patterns were also observed 
for death due to circulatory causes. However, their associations with further MIs 
resulting in hospitalisation were not significant in either direction, although 
confounding and temporal elements could explain this uncertainty. Indeed, 
adherence was calculated as an average over the duration of follow up (of both 
before and after further events), and patients were categorised as achieving 
lipid targets if they did so at any point during their follow up. Nevertheless, an 
association between average statin adherence and the achievement of lipid 
targets was also found, expanding on the associations with mortality and in line 
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with the mechanism of action of statins. However, as observed in other cohorts, 
adherence could not fully account for the achievement of lipid targets with not 
all adherent patients achieving lipid targets, and vice versa. Since adherence 
itself has a clear association with hard clinical outcomes, and those who achieve 
at least 50% adherence are significantly more likely to meet lipid targets, it is 
perhaps valid to query whether continuous monitoring of lipid targets is 
necessary in all patients. For example, for patients who have previously met the 
target, and continue to be adherent, there may not be any changes to clinical 
decisions that could be made with further lipid measurements. 
The final two aims were investigated in Chapter 6. First, associations between 
demographic factors, previous adherence, and previous lipid results were 
examined. Few demographic factors were significantly associated with 
adherence, whilst for the LDL target of ≤1.8mmol/l, all demographic factors 
considered were included in the final model. With these factors determined, the 
final aim was addressed. This sought to identify patients who would not require 
any intervention in response to an annual lipid test and could therefore be 
tested less frequently. This process identified a significant proportion of patients 
assigned to classes most likely to meet the LDL target who were also extremely 
likely to have met the target, using latent class analysis. When using the 50% 
adherence threshold, similar accuracy was also demonstrated (both had 100% 
PPV) with higher sensitivity than observed with LDL models (98.6% vs 83.4%, 
respectively). Furthermore, there were no significant associations between 
predicted LDL classes and mortality, but strong associations were observed 
between those predicted to have adherence ≥50% and mortality, and therefore 
adherence may make an effective and practical marker for accurately 
identifying patients for reduced lipid testing.  
7.2 Strengths and Limitations  
One strength of this thesis is the data used in Chapters 3-6, which is from a 
large, contemporary, real-world cohort with numerous variables captured 
through patient interactions with all aspects of the NHS in the GGC area, 
including hospital admissions, lab results, and dispensed prescriptions. Following 
the derivation of the cohort, the description of the characteristics of this 
population allowed comparisons to be drawn with other similar cohorts. The 
Chapter 7  265 
 
 
similarities of this cohort to other observational secondary prevention cohorts in 
the literature, as discussed in previous chapters, provide some external 
validation to these results. Nonetheless, further validation is required, 
particularly for the novel findings within Chapter 6 before widespread 
implementation is considered in clinical practice. For instance, CPRD data could 
be used to validate and expand on the results from Chapter 6. 
Additionally, this cohort could also be used to demonstrate the extent to which 
the current, and previous, Scottish guidelines (SIGN, 2007, 2017) were being 
adhered to regarding the frequency of lipid monitoring. In particular, this 
highlighted a higher rate of testing in the year immediately following a non-fatal 
MI, which is likely to be the result of the initiation or modification of lipid-
lowering therapy prescribed (Danese et al., 2017). Additionally, only half of the 
patients with data available at each year of follow up had the recommended one 
test per year, and the proportion who received no tests in each year of follow up 
increased as the time from baseline MI also increased. However, whilst there 
was also some decrease in the proportion adherent as follow up increased, this 
was to a lesser extent, suggesting that some patients may have simply stopped 
attending reviews only.  
Another possible explanation is that patient’s annual reviews were still 
occurring, but a lipid test was not taken during them, and therefore decisions 
regarding the necessity of the test are already taking place in clinical practice 
based on expert opinion. This could not be verified within the variables captured 
within the data, as the presence of a lipid test result was the only indicator that 
such an annual review had taken place. Furthermore, not all of the variables 
contained within the original extracted data were routinely captured and 
consequently variables that were included had to be selected carefully. For 
example, all blood test results are automatically included in SCI store from the 
lab systems, meaning all tests that took place were recorded. However, blood 
pressure, another important cardiovascular risk factor that is likely to be 
checked at an annual review, may have been checked by the GP at a review, but 
was not consistently recorded into the enhanced services data for the entire 
post MI population. Similarly, with the exception of a diabetes diagnosis which 
could be reliably derived through the diabetes register, a patient’s comorbidities 
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could not be reliably attained within the data available. These comorbidities, 
such as severe mental illness and dementia, could have a significant impact on 
the patient’s cardiovascular risk directly and on the patient’s ability to adhere 
to regular medications (Hippisley-Cox, Coupland and Brindle, 2017; Smith et al., 
2017; Hope et al., 2019). Therefore, the scope of this project was limited to 
only the lipid test component of the annual review, rather than the review 
itself, with a view that a GP could still request the test if they believed it was 
indicated. Nevertheless, reducing the number of tests safely using the methods 
identified in this thesis could still be associated with a significant reduction in 
financial costs, as discussed below (Chapter 7.3). 
The analytical methods employed on this observational real-world cohort means 
that it is difficult to draw causal inferences regarding the associations presented 
in this thesis, as has been discussed throughout. Both a patient’s adherence and 
plasma lipid levels are influenced by a plethora of factors, and the plausible and 
established interactions between these and each other have likely resulted in 
confounding and mediating in the various relationships that have been presented 
in this thesis. For example, a patient’s LDL cholesterol level is likely to be a 
mediator in the relationship between adherence and mortality, and 
consequently may have accounted for a non-negligible proportion of this 
observed relationship.  
7.3 Application to Clinical Practice and Next Steps  
The results in this thesis have shown that it is likely that a reasonable proportion 
of lipid tests in any given year would not require intervention in response to it, 
with the exact proportion dependent on whether the test’s purpose is to assess 
lipids or adherence. For reasons discussed in Chapter 6, adherence, specifically 
using a 50% threshold, may be the preferred marker for a test’s necessity, and in 
this population, its use translated to around 85% of tests being considered 
unnecessary. However, annual reviews of such patients are likely to involve 
more than simply a blood test, and therefore, these results do not suggest that 
such a review may also be always unnecessary. Nevertheless, removing the need 
for a blood test may facilitate a transition, which has been accelerated by the 
COVID-19 pandemic, to more virtual and remote reviews of patients, especially 
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as adherence could be monitored using prescribing records and home blood 
pressure monitoring has become more widely available.  
However, reducing the number of tests conducted will still reduce the burden of 
biochemistry tests and the time required for processing the samples and results 
by healthcare professionals. As an approximation, using figures from the 2018-19 
NHS National Cost Collection figures for England, the average cost of an 
individual lipid test (including phlebotomy) is £5 (National Health Service, 
2019a), and with an estimated 1.4 million survivors of MI in the UK each year 
(British Heart Foundation, 2020b) who should be receiving an annual lipid test 
under current guidance (NICE, 2014; SIGN, 2017), this would be equivalent to a 
saving of £5.95million per year. In addition, it is possible that repeat 
appointments might be avoided, if for instance, a separate appointment is 
needed for the test, and another for the interpretation of the results and other 
CVD risk factors. If such repeat appointments, which are estimated to cost £30 
each (National Health Service, 2019b), can be avoided, then this would translate 
into a further savings of £35.7million. However, these are clearly illustrative 
costs and are solely from the NHS perspective. Therefore the full impact of 
these results, including opportunity costs whereby more time would be available 
to focus on those patients most at risk, would need to be considered in a full 
cost-effectiveness modelling study. 
Moreover, before implementation, several steps would be needed to confirm 
that this identification process is safe and cost-effective. Consequently, the 
analysis contained within this thesis provides only the groundwork to assess the 
potential viability that such a group could be identified. The first step towards 
implementation, therefore, is to validate these findings within other similar 
datasets containing survivors of MIs. Furthermore, as the post MI population 
accounts for only a proportion of the secondary prevention population, 
validation or the derivation of similar models would be needed in other 
subgroups to increase the overall cost-effectiveness benefits of reduced testing. 
A similar approach could also be considered in primary prevention populations, 
although some differences in population characteristics could result in reduced 
accuracy using the models from this thesis, and therefore separate models may 
need to be developed. Moreover, the proportion whose tests could be considered 
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unnecessary may well be smaller in this population as adherence has been shown 
to be lower in primary prevention (Naderi, Bestwick and Wald, 2012).  
Nevertheless, whilst validation in other observational cohorts is important, cost-
effectiveness studies and the safety of this approach should be formally tested 
in an RCT, before clinical implementation is considered. One approach to the 
latter could be similar to that used in the area of diabetic retinopathy, which 
has tested a risk score developed using the 12,000 patients from the Liverpool 
Diabetic Eye Screening Programme in a two-arm, parallel-assignment 
equivalence RCT (Eleuteri et al., 2017; Broadbent et al., 2020). This trial, which 
followed up patients for just over two years, randomised participants to either 
annual reviews as recommended by current guidelines, or to variable-interval 
screening using the risk calculator. Attendance at appointments and detection of 
advancing retinopathy rates were the primary and secondary outcomes and were 
formally tested using equivalence and non-inferiority testing, thereby testing the 
feasibility and safety of such an approach is comparable to current schedules 
(Broadbent et al., 2019, 2020). In the case of the results presented in this thesis, 
possible durations of the intervals between tests that would be safe and cost-
effective would also need to be determined, with biennial testing considered in 
the first instance to coincide with review appointments. 
7.4 Final Conclusions 
This thesis has found that whilst it is consistent across many guidelines, the 
recommendation for annual monitoring within cardiovascular disease risk 
management has little robust evidence to support it nor any other monitoring 
schedules. The remainder of the thesis has focussed on a subpopulation of the 
secondary prevention population, survivors of MIs, in the NHS GGC region which 
included data from over 11,000 patients. Descriptive statistics showed that this 
cohort’s demographics, adherence, and lipid control was similar to other 
observational cohorts, and validated associations between adherence, and lipid 
control, with mortality. This also highlighted that although not all patients 
achieve sufficiently decreased lipid levels or satisfactory statin adherence, a 
significant proportion of patients did. Finally, this thesis identified factors 
associated with non-adherence and used latent class methods to accurately 
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identify a significant group of patients for whom an annual lipid test could be 
considered unnecessary. 
However, whilst these latter findings do equate to large potential cost savings, it 
is important to emphasise that this thesis sought only to assess the potential of a 
personalised approach to the lipid testing component of the annual review. 
Consequently, the results presented will need further validation in different 
cohorts and other high-risk populations, and cost-effectiveness studies and more 
robust evidence, such as an RCT as outlined above, will be needed before 





Appendix A Handling of Duplicate Statin Prescriptions 
Appendix A1 Method for the Extraction of Start and End Dates 
This method should be run three times – firstly for the statins, then ezetimibe, then 
fibrates, before moving on to the final stage. Specific information for each drug class is 
detailed in each step. The following prescriptions should be extracted for each time of 
running through:  
 









All from Prescription data 
Ezetimibe 









Combination from already 








Source: All except 
combination from 
Prescriptions.  
Combination from already 
sorted statin file. 
 
1. Order by SafeHavenID, dispensed date, and prescribed date. 
2. Calculate the prescription end date (which is the first day that the individual 
should have run out of drug) as the date dispensed plus the days supplied 
(dispensed quantity/number of doses per day). Day dispensed is used over 
date prescribed as this is the day that the individual first had access to the 
drugs.  
a. For statins, assume one dose daily. Four entries did not work due to a 
comma erroneously contained in the quantity variable “1,200”. Visual 
inspection of the data, and the other records for this individual, 
confirmed the correct value for this should be 200, and this was 
corrected. 
b. For ezetimibe, this should be done for the ezetimibe only 
prescriptions (as the combination dates will have already been 
adjusted for other statin courses).  Assume one dose daily.  
c. For fibrates, this should be done for the fibrate only prescriptions (as 
the combination dates will have already been adjusted for other statin 
courses). Most fibrates are taken as one dose per day, however, 
Gemfibrozil is assumed to be taken three times per day, and 
Bezafibrate 200mg is assumed to be taken twice daily, so adjustments 
should be made for these medications. 
3. Remove any prescriptions issued after death. Set any prescription end dates 
currently after the date of death to be the date of death (which assumes no 
medication was taken on the day of death) and adjust quantities dispensed to 
reflect this (= Quantity – (Prescription End Date – Updated End Date)). 
4. Identify those with multiple prescriptions dispensed on the same day. Use the 
subsequent separate method to resolve these before continuing. 




a. Create variables containing previous drug (and dose) dispensed, and 
end date for the previous prescription, for the individual (with first entry 
set to NA). 
b. Create a new course indicator variable which is set to 1 (and 0, 
otherwise) if:  
i. The dispensed date is more than six months (182 days) since the 
end date of the previous prescription OR 
ii. The drug (or dose) dispensed is different from the previously 
dispensed drug (and dose).  
6. Create a running total for each individual to assign each course and the 
prescriptions contained within each course a course number. Use this to create 
a course ID with the format: SafeHavenID – CourseNumber. 
7. Identify the last prescription of a course with an indicator variable (1, if last; 0, 
otherwise). 
8. Determine the start and end dates for each course:  
a. Use the indicator variable to extract the relevant observations into two 
datasets; start and end.  
b. In the start dataset, rename the dispensed date as the start date.  
c. In the end dataset, rename the prescription end date as the end date.  
9. Merge the start and end dates by SafeHavenID and Course ID. 
10. Order by SafeHavenID and course number. 
11. Remove course overlaps:  
a. Create a variable containing the next start date (set to NA if new 
SafeHavenID).  
b. If the next start date is before the course end date, set end date equal to 
the day of next start date to prevent overlap.  
12. Check no end dates for a course are prior to the same courses start date. 
13. To extract all relevant prescriptions, merge start and end dates by 
SafeHavenID and course ID and keep if dispensed date falls within window. If 
prescription end date is after course end date, set prescription end date equal 
to course end date and adjust quantities (= Quantity – (Prescription End Date – 
Updated End Date)). 
 
Appendix A2 Method for the Removal of Multiple Prescriptions for 
the Same Dispensed Dates 
This should be performed prior to implementing steps 5 onwards in the above method, 
and repeated for each group of drugs.  
 
1. Create an ID for the prescription equal to: SafeHavenID – Dispenseddate 
2. Extract all IDs which have duplicates into a separate dataset, and all those 
without duplicates into a different dataset (which won’t be required until the 
end).  
3. Remove complete duplicates from the duplicate dataset (i.e. same prescribed 
date and drug and dose too) 
4. Extract the now single entries from the duplicates dataset ready to be 
remerged and remove them from the duplicates dataset. 
5. Aggregate totals for those dispensed multiple prescriptions for the same drug 
and dose on the same day: 
a. Extract the first entry for each batch of prescriptions (this will be the first 
prescribed one of the multiple prescriptions all dispensed the same day). 
However, as the dispensed date is the date primarily used, the selection 




b. Calculate the total quantity dispensed for each dispensed date and set 
the dispensed quantity equal to this for the first entries extracted. 
Remove the other prescriptions which the total was derived from, as this 
single entry will replace them all.  
c. (For all statins and non-combination Ezetimibe and Fibrates only) 
Recalculate the end date for the single entries with new totals and if end 
date is after death, set end date to date of death, and readjust quantities 
(= Quantity – (Prescription End Date – Updated End Date)). After 
implementation on statins, combination drugs should not contain 
duplicates, however, be sure in the Ezetimibe and Fibrate cases that the 
end dates for the combination drugs are not adjusted at this stage as 
they have already been adjusted for other statin courses. 
d. Once these single entries have been recombined with the duplicates, 
and entries which now have a unique prescription ID (i.e. no other drugs 
and doses dispensed on same day also) can be extracted and remerged 
with non-duplicates. 
6. (For all statins ONLY) Determine drugs taken prior to and post the remaining 
duplicate entries:  
a. Extract all non-duplicate prescriptions for those with a duplicate entry.  
b. In the duplicate dataset, rename the dispensed date as the duplicate 
date, and merge the duplicate date to the data set with all prescriptions 
for these individuals. 
c. Split this dataset into two: Those collected prior to the duplicate date 
and those collected after. Remove any duplicates arisen as part of the 
merging process in both datasets. 
d. Keep the last prescription dispensed prior to, and the first prescription 
dispensed after, the duplicate date(s) in their respective datasets. 
e. Rename the drugs as the prior and post drugs respectively and merge 
the drug (and dose) to the duplicate dataset. 
7. (For all statins and fibrates ONLY) If the drug (and dose) prescribed after the 
duplicate date is the same as one of the drugs dispensed in the duplicate, keep 
the record in the duplicate that matches the post duplicate drug and discard all 
others for that ID. For fibrates, due to the small numbers affected, this was 
done by hand. 
8. (For all statins and fibrates ONLY) If the prior drug (and dose) does not 
match any of the drugs dispensed (and is not NA), but the post drug is equal to 
NA, then keep the different one. This rule retains some duplicates, but these 
can be removed at a later stage in the process. Remove all others for those 
prescription IDs. For fibrates, due to the small numbers affected, this was 
done by hand. 
9. (For fibrates ONLY) If the prior and the post are the same, keep the different 
one and remove all others. 
10. For those prescribed only one drug but at different doses:  
a. (For all statins ONLY) Extract those who were prescribed different 
doses of the same drug only. Calculate the maximum strength of the 
drug prescribed for each prescription ID. Keep the record which 
matches the max for each prescription to be remerged and remove all 
others (i.e. keep the highest dose). For combination drugs, as strength 
is captured in a different variable, implement same rule but for the 
correct variable. 
b. (For Fenofibrate only) Given the limited numbers, by hand:  
i. If one of the duplicates is for maximum tolerated dose 267 mg, 




ii. If one of the duplicates is for 160 mg dose (different release 
mechanism), keep the 67 mg dose and discard all others.  
iii. No other duplicates remained in this data.  
c. (For Gemfibrozil only) Take the record corresponding to the maximum 
tolerated dose (600 mg) and discard all others.  
d. For Bezafibrate and Ciprofibrate a similar approach should be taken 
but was not the case in this data.  
11. For remaining duplicates, a hierarchy is established with regards to which 
records should be kept.  
a. For statins, the basic idea is that the highest dose of the highest 
intensity statin should be kept, except in cases of Fluvastatin and 
Pravastatin. The basic rules were shown below and should be 
implemented in this order to avoid incorrect selection:  
i. If one of the duplicates is Fluvastatin, keep the highest dose 
Fluvastatin and discard all others from that duplicate date. 
ii. If one of the duplicates is Pravastatin, keep the highest dose 
Pravastatin and discard all others from that duplicate date. 
iii. If one of the duplicates is Rosuvastatin, keep the highest dose 
Rosuvastatin and discard all others from that duplicate date.  
iv. If one of the duplicates is Atorvastatin, keep the highest dose 
Atorvastatin and discard all others from that duplicate date.  
v. If one of the duplicates is a Simvastatin combination, keep the 
highest dose of Simvastatin (whether in combination or not) and 
discard all others from that duplicate date. If simvastatin dose is 
the same, keep the combination one. 
vi. Otherwise, assume highest dose Simvastatin.  
b. For Ezetimibe, the combination drug represents a higher dose of 
treatment than Ezetimibe on its own so the combination drug should be 
retained, and others discarded.  
c. For fibrates, no other duplicates remained so a hierarchy was not 
needed.  
12. Combine all entries to be remerged and check for duplicates. If duplicates 
remain, repeat steps 6 – 11. If none, all duplicate dispensing dates have been 
removed and previous method can be resumed.  
 
Appendix A3 Statin Combinations: Method for adding adjusted 
dates back into Statin Datasets 
Once all dates have been adjusted to prevent any overlap within the drug groups, the 
following method should be used to ensure that the dates in the statin dataset are 
corrected (as the Ezetimibe and Fibrate groups were corrected as part of the sequence).  
 
1. Extract the dates and the prescriptions for Simvastatin & Ezetimibe (from the 
ezetimibe datasets) and Fenofibrate/Simvastatin (from the fibrate datasets), 
into a dates and prescriptions datasets.  
2. Remove the dates and the prescriptions from the statin datasets for the 
combination drugs.  
3. Combine the combination dates with the statin dates, and the prescriptions 
similarly.  
4. Order the statin dates dataset by SafeHavenID, start date, and end date. 
5. Order the statin prescriptions dataset by SafeHavenID, dispensed date, and 




6. Correct the course numbering system in the dates dataset and merge the 
numbering with the prescriptions dataset. Correct the course ID with the 





Appendix B Calculating Medication Possession Ratio 
(MPR) 
1. Identify the dates for the first non-fatal MIs of the individual within the time 
window of interest (1st January 2009 to 31st July 2014, inclusive), from the 
SMR01 file. 
2. Set the first start date to be equal to this date in a new variable. The end date 
is then this date plus 364 days. Run an adjustment of +1 if this time window 
includes 29th February 2012 or 2016 as these are the two leap years that fall 
within the follow up period. 
3. The next year starts the day after the previous end date. Repeat this until there 
are nine start and end dates for each individual as this is the maximum 
duration of follow up (up to 31st July 2017, inclusive). At each stage of creating 
an end date, adjust for the leap year as in step 2.  
4. Transpose the data set so start and end dates are now in long form, with each 
window labelled. Merge with the individuals date of death. 
5. Remove time windows which start after, and including, 1st August 2017, or 
which start on or after date of death.  
6. Create two indicator variables (1,0). One should be used to indicate if the 
individual dies during the time interval, and the other should be used to indicate 
if the end of follow up (1st August 2017) occurs during the time interval.  
7. If a death occurs in the time window, set the end date as equal to the date of 
death. After this, for all time windows, if the end date is equal to the 1st August 
2017 or after, set the end date to the 31st July 2017.  
8. In a separate dataset, merge the time windows with the dates of MIs occurring 
in follow up. Keep time windows where a follow up MI occurs during the time 
window and create an indicator variable (by setting it equal to one). Keep a list 
of SafeHavenID, time window number and the indicator variable, and then find 
unique records (as individuals may have more than one MI in the time window). 
9. Merge this indicator variable into the time window data. Set the indicator 
variable equal to 0 for records which did not exist in the list devised in step 8.  
10. Combine this time window dataset with the file of individual prescriptions. Order 
by SafeHavenID, time window number, and dispensed date. 
11. Restrict to the prescriptions where the calculated end date is on or after the 
time window start date, and the dispensed date is prior to the time window end 
date. 
12. Create a time window ID consisting of the SafeHavenID – time window. 
13. Identify prescriptions which had started prior to the time window and those 
which would carry on after the time window with indicator (1,0) variables.  
14. Format the quantity dispensed variable to be numeric, and adjust the quantity 
dispensed according to the number that should have already been 
administered prior to the time window start date, and the number that should 
be remaining after the time window end date (for each prescription). Remove 
prescriptions where the total is less than zero as a result of this calculation.  
15. Calculate the number of prescriptions dispensed for each unique time window 
in a separate dataset. 
16. Sum the total quantity of doses dispensed for each unique time window in a 
separate dataset. 
17. Calculate the length of each time window (end date – start date +1). The +1 is 
added as it is assumed that a dose is taken on both the start and the end date. 
18. Subset the prescription data to contain only the ID variables, the start and end 




19. Combine this subsetted data with the datasets created in 15 and 16, merging 
by time window ID. Then order the data by SafeHavenID and time window ID.  
20. Calculate the MPR as the (total quantity/length of time window) *100. 
21. Merge with the original time window list, as this dataset would only contain 
those where at least one prescription is dispensed.  
22. Re-establish the time window ID and calculate the duration as in step 17. For 
those with missing numbers of prescriptions, and days of doses dispensed, set 
these equal to zero. (These would have been the time windows that were 
dropped during the merge with prescription data. They should be included in 
the analysis though, as post MI, all individuals should be prescribed a statin, 
and therefore their adherence should be 0.) 
23. Calculate MPR as zero for the time windows where no doses were dispensed.  
24. Finally, set the MPR to be missing for those time windows where a death or the 





Appendix C Handling Duplicate Lipid Profile Results 
The multiple components of the lipid profiles represented the same observation, so were 
transposed from the long form (where the observations collected for each of the 
components are listed one below the other) to the wide form (where the observations are 
combined onto the same entry in the dataset). If duplicates are present for any of the 
values, this can result in exacerbated duplication following transposition. A systematic 
method was employed to remove both the exacerbated duplication and handle instances 
of genuine duplication. 
 
The components of the lipid profile test used are:  
• Total Cholesterol 
• Total:HDL Cholesterol 
• HDL Cholesterol  
• Triglycerides 
• LDL Cholesterol  
 
Whilst transposition of the dataset could be performed using a transpose command, due 
to the size of the dataset, for this analysis this was performed using the following method 
instead. If the dataset has already been transposed, skip to step 5.  
 
1. Ensure the long dataset contains all the components of the lipid profiles listed 
above. In the SafeHaven, these have several names and checks for variations 
were conducted throughout the extraction of relevant data. For this analysis, 
the names of tests included:  
 




Chol/HDL Ratio  









HDL Cholesterol UC 
HDL Chol (mmol/l) 
 





LDL Chol  









2. Check all results are reported in the same unit. If this is not the case, either 
convert all to the same unit, or ensure that the units are also transposed (and 
that they are consistently reported, i.e. no different levels of spaces or cases). 
3. Create a dataset for each of the components of the lipid profile and rename the 




unnecessary variables. Remove any complete duplicates to limit subsequent 
exacerbation 
4. Combine each of the five components by SafeHavenID and the datetime to 
create a wide version of the dataset. Create a sample ID formatted as: 
SafeHavenID – SampleDateTime. 
5. Remove any inconsistent naming before removing any complete record 
duplicates. 
6. Identify those that are duplicates and create two separate datasets; one for all 
samples with duplicates, and one for samples with no duplicates.  
7. Within the duplicates data set, calculate the LDL and Total:HDL Cholesterol 
ratio for each of the combinations. If both match for a record, extract these 
entries and discard all remaining duplicates for these samples.  
8. If, in the remaining duplicated samples, there is a complete zero entry for a 
sample, extract all records for these samples into a separate dataset. The most 
complete row for each sample should then be retained, with all other records 
removed. All records from these samples should then be removed from the 
remaining duplicates. 
9. Divide the remaining samples into three datasets: (a) the records with 
triglycerides too high to calculate LDL, and with LDL equal to zero or NA; (b) 
the records with the same sample IDs as the first group, but where the criteria 
isn’t met; and (c) those samples where this is not the case.  
10. In dataset (a), if the Total:HDL matches, keep the record that matches and 
discard the remaining records for that sample in (a). Due to rounding and the 
calculation method in some programs, the two numbers may not match due to 
a floating point error. Therefore, if subsequently, there is a match within 0.05 
for the Total:HDL, these records should also be retained, with others with the 
same sample ID removed (only in (a)). All remaining records in (a) should also 
be kept.  
11. In dataset (b), remove all records with triglycerides too high to calculate LDL as 
these will have been captured in (a). Records with triglycerides or LDL equal to 
zero should also be removed. Finally, records with matching Total:HDL and 
LDL matching after the 0.05 adjustment for floating point error should also be 
kept, with all other records removed. 
12. Identify those in dataset (c) to keep where Total:HDL matches, and remove all 
records in (c) for the same samples.  
13. Identify those where the Total:HDL matches after 0.05 adjustment for floating 
point error, and discard all remaining records for these samples from the 
dataset. Within those that do match, identify those that match LDL and discard 
all remaining records for these samples. Within those remaining, keep those 
with matching LDL after floating point error adjustment of 0.05 (discarding 
those from the same sample), and subsequently remaining records where LDL 
is not equal to NA.  
14. Within those where Total:HDL did not match after adjustment of 0.05 for 
floating point error, keep those that matched LDL after floating point error 
adjustment, and those that did not but were not from the same samples where 
a match was achieved.  
15. Combine all observations to be kept. Identify duplicates in this dataset again. 
Many of these duplicates are likely to have been present in the original long 
form, with some unable to be distinguished by the previous steps.  
16. Repeat step 6. 





18. Calculate mean and mean excluding zeros of the minimum and maximum 
value (removing NAs where applicable). If the mean value is not equal to zero, 
keep the one excluding zeros, otherwise keep the one equal to zero. 
19. Keep these means and rename them as the original variables, removing 






Appendix D Calculating Baseline Change in Non-HDL 
Cholesterol 
1. Extract the lipid profile results for those within the post MI population, and 
merge with the date of the first MI of interest. Order the results by SafeHaven 
ID and sample date.  
2. Restrict further to tests where the sample date is before the date of admission 
with the MI.  
3. Extract the statin prescriptions for those within the post MI population and 
merge with the date of the first MI of interest. Order the results by SafeHaven 
ID and dispensed date. Restrict further to prescriptions where the dispensed 
date is before the date of admission with the MI. 
4. Merge the lipid profile and statin prescription datasets by SafeHaven ID. This 
will result in the creation of many duplicates.  
5. Extract lipid profile tests that were collected after the prescriptions dispensed 
date but before or on the prescription end date. Remove all records with the 
sample IDs in this list from the combined dataset.  
6. Repeat step 5 but for all lipid profile tests that were collected within six months 
of the prescription end date.  
7. Restrict the lipid profile results file to those with sample IDs which were 
remaining in the combined dataset or for individuals who had had no statin 
prescriptions prior to their MI 
8. Order by SafeHaven ID and sample date once more. Keep only the results of 
the last sample per individual.  
9. Calculate the non HDL by subtracting the HDL from the total cholesterol value.  
10. Relabel all the components of the lipid profile to indicate that they are the pre-
MI results.  
11. For the lipids post MI (lipid results collected in the population on or after the 
admission date), calculate the non HDL for the samples.  
12. Merge the baseline samples with the post MI samples.  
13. Calculate the percentage change for each of the components including the non 
HDL component as: ((sample – baseline)/baseline)*100.  
14. If the baseline component is equal to zero, this may autogenerate the 
percentage change as infinity or NaN (Not A Number). Set these cases equal 






Appendix E Extracting Type and Date of Diagnosis of 
Diabetes 
The date of diagnosis is in the same observation line as the type of diabetes meaning that 
observations relating to date and type did not have to be matched. The date of diagnosis 
is also the date of entry in subsequent patient observations, so the first date in the dataset 
for each patient is taken as the date of diagnosis. Due to the numerous variations of the 
types of diabetes given within the data, the definitions are collapsed to Type 1, Type 2, 
Not Diabetes and Not Known. The original descriptions and their mappings are shown 
below. Those considered to not have diabetes were subsequently removed from the 
diabetes dataset. Once this was complete, the method below could be implemented. 
 
Type 1 Type 2 
Latent autoimmune diabetes of adulthood 




Diabetes in Remission  
Diabetes Resolved 
Maturity Onset Diabetes of youth 
Other Type of Diabetes 
Secondary – Disease 
Secondary – Drug Induced 
Secondary – Pancreatic Pathology 
 
Not Diabetes Not Known 
Current Gestational Diabetes 
History of Gestational Diabetes 
Impaired Fasting Glucose 
Impaired Glucose Tolerance 
Not Diabetic 




1. Extract valid dates of entry of the information:  
a. Calculate age at date of entry of the type of diabetes (date of birth 
available in the demography file).   
b. Identify entries occurring prior to date of birth. 
c. Calculate the number of entries prior to date of birth per patient.  
d. Calculate the total number of type of diabetes entries per patient.  
e. Combine these values with the SafeHaven ID into one dataset and 
remove duplicates. 
f. Merge this dataset with the original type of diabetes dataset.  
g. Keep only the observations with date of entry after birth, or where the 
total number of entries is equal to the number collected prior to date of 
birth. 
h. For entries remaining with age less than zero, set the age to NA. 
2. Determine type of diabetes for the majority of the individuals:  
a. Using the categories in the previous table, for each individual, calculate 
the number of times they have been diagnosed with Type 1, Type 2, or 
Not Known, and combine the totals in a separate dataset. 
b. For most individuals, diabetes type can then be determined using the 
following rules: 
i. If all entries are Not Known, then Type = 2.  
ii. If only entries for Type 1 (or Not Known), Type = 1.  
If only entries for Type 2 (or Not Known), Type = 2. 





If no Not Known entries and more for Type 2 than Type 1, Type = 
2. 
iv. If more Type 1 entries than Type 2 entries and Not Known entries 
combined, Type =1.  
If more Type 2 entries than Type 1 entries and Not Known entries 
combined, Type = 2. 
3. Extract the first date of diagnosis: 
a. Find the first observation for each individual in list of valid dates and 
combine with type of diagnosis determined in last step. 
4. Determine the remainder of the missing information for an individual’s types of 
diabetes: 
a. Use the individual’s age at first diagnosis to implement the following 
rules for those with missing type of diabetes:  
i. If age less than 20 years, Type = 1. 
ii. If age greater than or equal to 20 years, Type = 2. 
5. Adjust those with Type 2 diabetes and less than 20 years at first diagnosis to 





Appendix F Baseline Hazards from Kaplan-Meiers for 







Appendix G Logistic Regression Models for Further 
Hospitalised MIs by Lipid Target Achievement  
Appendix G1 Model for Further Hospitalised MIs by Non-HDL 
Target 
Model/Variable Odds Ratio (95% CI) p-value 
Unadjusted Model   
Non-HDL Target   
   Achieved (ref.) 1.00 
0.0721 
   Not Achieved 1.15 (0.99, 1.33) 
   
Adjusted Model   
Non-HDL Target   
   Achieved (ref.) 1.00 
0.0561 
   Not Achieved 1.16 (1.00, 1.35) 
   
Sex   
   Female (ref.) 1.00 
0.9147 
   Male  1.01 (0.86, 1.18) 
   
Age at MI (years) 1.00 (0.99, 1.01) 0.8183 
   
SIMD (NHS GGC)   
   1 [most] 0.86 (0.67, 1.10) 
0.0288 
   2 1.01 (0.79, 1.28) 
   3 0.90 (0.70, 1.15) 
   4 0.69 (0.53, 0.91) 
   5 [least] (ref.) 1.00 
   
Year of MI   
   2009 (ref.) 1.00 
0.1650 
   2010 0.98 (0.71, 1.36) 
   2011 0.96 (0.70, 1.32) 
   2012 1.22 (0.90, 1.66) 
   2013 1.23 (0.91, 1.67) 





Appendix G2 Model for Further Hospitalised MIs by LDL Target 
Model/Variable Odds Ratio (95% CI) p-value 
Unadjusted Model   
LDL Target   
   Achieved (ref.) 1.00 
0.4302 
   Not Achieved 0.96 (0.86, 1.06) 
   
Adjusted Model   
LDL Target   
   Achieved (ref.) 1.00 
0.3336 
   Not Achieved 0.95 (0.85, 1.06) 
   
Sex   
   Female (ref.) 1.00 
0.6709 
   Male  0.98 (0.89, 1.08) 
   
Age at MI (years) 1.00 (1.00, 1.01) 0.3928 
   
SIMD (NHS GGC)   
   1 [most] 1.17 (1.00, 1.35) 
0.0611 
   2 1.05 (0.91, 1.22) 
   3 1.09 (0.94, 1.27) 
   4 0.95 (0.81, 1.12) 
   5 [least] (ref.) 1.00 
   
Year of MI   
   2009 (ref.) 1.00 
<0.0001 
   2010 1.00 (0.85, 1.17) 
   2011 1.07 (0.91, 1.25) 
   2012 1.38 (1.18, 1.61) 
   2013 1.32 (1.13, 1.54) 






Appendix H Baseline Hazards from Kaplan-Meiers for 
Mortality by Lipid Target Achievement 













Appendix I Cox Regression Models for Mortality by Lipid 
Target Achievement 
Appendix I1 Model for Overall Mortality by Non-HDL Target 
Model/Variable Hazard Ratio (95% CI) p-value PH Test 
Unadjusted Model    
Non-HDL Target    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 2.16 (1.87, 2.49) 0.7793 
    
Adjusted Model    
Non-HDL Target    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 1.76 (1.52, 2.03) 0.9259 
    
Sex    
   Female (ref.) 1.00 
0.0014 
 
   Male  1.26 (1.09, 1.46) 0.7266 
    
Age at MI (years) 1.08 (1.08, 1.09) <0.0001 0.7177 
    
SIMD (NHS GGC)    
   1 [most] 1.95 (1.53, 2.49) 
<0.0001 
0.1351 
   2 1.56 (1.23, 1.99) 0.5209 
   3 1.60 (1.26, 2.03) 0.9457 
   4 1.22 (0.95, 1.57) 0.9544 
   5 [least] (ref.) 1.00  
    
Year of MI    
   2009 (ref.) 1.00 
0.0441 
 
   2010 0.90 (0.70, 1.16) 0.8186 
   2011 0.79 (0.61, 1.02) 0.9816 
   2012 0.76 (0.58, 0.99) 0.4332 
   2013 0.85 (0.64, 1.11) 0.8313 
   2014 0.57 (0.39, 0.83) 0.8121 






Appendix I2 Schoenfeld Residuals for Model for Overall Mortality 









Appendix I3 Model for Overall Mortality by LDL Target 
Model/Variable Hazard Ratio (95% CI) p-value PH Test 
Unadjusted Model    
LDL Target    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 1.27 (1.16, 1.39) 0.1626 
    
Adjusted Model    
LDL Target    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 1.32 (1.20, 1.44) 0.1000 
    
Sex    
   Female (ref.) 1.00 
0.0361 
 
   Male  1.09 (1.01, 1.18) 0.0261 
    
Age at MI (years) 1.08 (1.08, 1.09) <0.0001 0.4214 
    
SIMD (NHS GGC)    
   1 [most] 1.92 (1.68, 2.20) 
<0.0001 
0.4524 
   2 1.66 (1.45, 1.90) 0.8088 
   3 1.57 (1.37, 1.80) 0.7265 
   4 1.32 (1.14, 1.52) 0.5184 
   5 [least] (ref.) 1.00  
    
Year of MI    
   2009 (ref.) 1.00 
<0.0001 
 
   2010 1.01 (0.90, 1.14) 0.1343 
   2011 0.94 (0.83, 1.06) 0.4654 
   2012 0.87 (0.76, 0.99) 0.0440 
   2013 0.83 (0.72, 0.96) 0.2703 
   2014 0.64 (0.52, 0.79) 0.1858 






Appendix I4 Schoenfeld Residuals for Model for Overall Mortality 









Appendix I5 Model for Circulatory Mortality by Non-HDL Target 
Model/Variable Hazard Ratio (95% CI) p-value PH Test 
Unadjusted Model    
Non-HDL Target    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 2.24 (1.74, 2.87) 0.6669 
    
Adjusted Model    
Non-HDL Target    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 1.82 (1.41, 2.34) 0.9308 
    
Sex    
   Female (ref.) 1.00 
0.0101 
 
   Male  1.38 (1.08, 1.78) 0.8413 
    
Age at MI (years) 1.08 (1.07, 1.09) <0.0001 0.9796 
    
SIMD (NHS GGC)    
   1 [most] 1.66 (1.07, 2.58) 
0.0286 
0.6247 
   2 1.65 (1.08, 2.52) 0.8143 
   3 1.91 (1.26, 2.90) 0.6429 
   4 1.46 (0.95, 2.26) 0.8093 
   5 [least] (ref.) 1.00  
    
Year of MI    
   2009 (ref.) 1.00 
0.4666 
 
   2010 0.90 (0.55, 1.46) 0.7389 
   2011 1.14 (0.71, 1.83) 0.2070 
   2012 1.22 (0.76, 1.98) 0.2100 
   2013 1.35 (0.82, 2.23) 0.0971 
   2014 1.00 (0.53, 1.90) 0.1271 






Appendix I6 Schoenfeld Residuals for Model for Circulatory 









Appendix I7 Model for Circulatory Mortality by LDL Target 
Model/Variable Hazard Ratio (95% CI) p-value PH Test 
Unadjusted Model    
LDL Target    
   Achieved (ref.) 1.00 
0.0011 
 
   Not Achieved 1.30 (1.11, 1.51) 0.0997 
    
Adjusted Model    
LDL Target    
   Achieved (ref.) 1.00 
0.0012 
 
   Not Achieved 1.30 (1.11, 1.52) 0.1641 
    
Sex    
   Female (ref.) 1.00 
0.0062 
 
   Male  1.22 (1.06, 1.40) 0.1970 
    
Age at MI (years) 1.08 (1.08, 1.09) <0.0001 0.6139 
    
SIMD (NHS GGC)    
   1 [most] 2.01 (1.58, 2.56) 
<0.0001 
0.4073 
   2 1.71 (1.34, 2.18) 0.2462 
   3 1.75 (1.38, 2.23) 0.1838 
   4 1.53 (1.19, 1.97) 0.8450 
   5 [least] (ref.) 1.00  
    
Year of MI    
   2009 (ref.) 1.00 
0.0570 
 
   2010 1.04 (0.83, 1.30) 0.6806 
   2011 1.20 (0.96, 1.50) 0.7131 
   2012 1.33 (1.06, 1.68) 0.3064 
   2013 1.31 (1.02, 1.68) 0.2464 
   2014 0.98 (0.69, 1.39) 0.3206 






Appendix I8 Schoenfeld Residuals for Model for Circulatory 









Appendix J Logistic Regression Models for Further 
Hospitalised MIs by Average Statin Adherence 
Appendix J1 Model for Further Hospitalised MIs by Continuous 
Adherence 
Model/Variable Odds Ratio (95% CI) p-value 
Unadjusted Model   
Continuous Adherence   
   10% Decrease 1.00 (0.98, 1.01) 0.5179 
   
Adjusted Model   
Continuous Adherence   
   10% Decrease 1.00 (0.98, 1.01) 0.5775 
   
Sex   
   Female (ref.) 1.00 
0.9147 
   Male  0.99 (0.91, 1.09) 
   
Age at MI (years) 1.00 (1.00, 1.00) 0.5852 
   
SIMD (NHS GGC)   
   1 [most] 1.16 (1.00, 1.34) 
0.0610 
   2 1.06 (0.92, 1.23) 
   3 1.08 (0.93, 1.26) 
   4 0.95 (0.81, 1.11) 
   5 [least] (ref.) 1.00 
   
Year of MI   
   2009 (ref.) 1.00 
<0.0001 
   2010 0.98 (0.83, 1.14) 
   2011 1.03 (0.88, 1.20) 
   2012 1.33 (1.14, 1.54) 
   2013 1.26 (1.08, 1.47) 






Appendix J2 Model for Further Hospitalised MIs by Average 
Adherence (50%) 
Model/Variable Odds Ratio (95% CI) p-value 
Unadjusted Model   
Average Adherence (50%)   
   Achieved (ref.) 1.00 
0.0734 
   Not Achieved 0.89 (0.79, 1.01) 
   
Adjusted Model   
Average Adherence (50%)   
   Achieved (ref.) 1.00 
0.0748 
   Not Achieved 0.89 (0.79, 1.01) 
   
Sex   
   Female (ref.) 1.00 
0.8644 
   Male  0.99 (0.90, 1.09) 
   
Age at MI (years) 1.00 (1.00, 1.00) 0.6342 
   
SIMD (NHS GGC)   
   1 [most] 1.16 (1.00, 1.34) 
0.0653 
   2 1.06 (0.91, 1.23) 
   3 1.08 (0.93, 1.26) 
   4 0.95 (0.81, 1.11) 
   5 [least] (ref.) 1.00 
   
Year of MI   
   2009 (ref.) 1.00 
<0.0001 
   2010 0.98 (0.83, 1.14) 
   2011 1.03 (0.88, 1.20) 
   2012 1.33 (1.15, 1.55) 
   2013 1.26 (1.08, 1.47) 






Appendix J3 Model for Further Hospitalised MIs by Average 
Adherence (80%) 
Model/Variable Odds Ratio (95% CI) p-value 
Unadjusted Model   
Average Adherence (80%)   
   Achieved (ref.) 1.00 
0.1651 
   Not Achieved 1.07 (0.97, 1.17) 
   
Adjusted Model   
Average Adherence (80%)   
   Achieved (ref.) 1.00 
0.1520 
   Not Achieved 1.07 (0.97, 1.18) 
   
Sex   
   Female (ref.) 1.00 
0.9927 
   Male  1.00 (0.91, 1.10) 
   
Age at MI (years) 1.00 (1.00, 1.00) 0.5457 
   
SIMD (NHS GGC)   
   1 [most] 1.16 (1.00, 1.34) 
0.0612 
   2 1.06 (0.92, 1.23) 
   3 1.08 (0.93, 1.26) 
   4 0.95 (0.81, 1.11) 
   5 [least] (ref.) 1.00 
   
Year of MI   
   2009 (ref.) 1.00 
<0.0001 
   2010 0.98 (0.83, 1.14) 
   2011 1.03 (0.88, 1.20) 
   2012 1.33 (1.14, 1.54) 
   2013 1.27 (1.09, 1.47) 






Appendix K Baseline Hazards from Kaplan-Meiers for 
Mortality by Average Statin Adherence 












Appendix L Cox Regression Models for Mortality by 
Average Statin Adherence 
Appendix L1 Model for Overall Mortality by Continuous 
Adherence 
Model/Variable Hazard Ratio (95% CI) p-value PH Test 
Unadjusted Model    
Continuous Adherence    
   10% Decrease 1.07 (1.06, 1.08) <0.0001 0.0057 
    
Adjusted Model    
Continuous Adherence    
   10% Decrease 1.03 (1.02, 1.05) <0.0001 0.2042 
    
Sex    
   Female (ref.) 1.00 
0.0343 
 
   Male  1.09 (1.01, 1.18) 0.0859 
    
Age at MI (years) 1.08 (1.08, 1.09) <0.0001 0.1613 
    
SIMD (NHS GGC)    
   1 [most] 1.91 (1.67, 2.18) 
<0.0001 
0.1865 
   2 1.70 (1.49, 1.94) 0.1917 
   3 1.63 (1.43, 1.86) 0.2363 
   4 1.34 (1.16, 1.54) 0.8158 
   5 [least] (ref.) 1.00  
    
Year of MI    
   2009 (ref.) 1.00 
0.0031 
 
   2010 1.01 (0.90, 1.13) 0.1938 
   2011 0.93 (0.82, 1.04) 0.8900 
   2012 0.93 (0.82, 1.06) 0.6904 
   2013 0.83 (0.72, 0.96) 0.6431 
   2014 0.73 (0.60, 0.89) 0.4724 






Appendix L2 Schoenfeld Residuals for Model for Overall Mortality 









Appendix L3 Model for Overall Mortality by Average Adherence 
(50%) 
Model/Variable Hazard Ratio (95% CI) p-value PH Test 
Unadjusted Model    
Average Adherence (50%)    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 1.57 (1.44, 1.73) 0.0085 
    
Adjusted Model    
Average Adherence (50%)    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 1.24 (1.13, 1.37) 0.1830 
    
Sex    
   Female (ref.) 1.00 
0.0448 
 
   Male  1.08 (1.00, 1.17) 0.0918 
    
Age at MI (years) 1.08 (1.08, 1.09) <0.0001 0.1801 
    
SIMD (NHS GGC)    
   1 [most] 1.91 (1.67, 2.18) 
<0.0001 
0.1930 
   2 1.69 (1.48, 1.93) 0.1954 
   3 1.63 (1.43, 1.86) 0.2400 
   4 1.34 (1.17, 1.54) 0.8481 
   5 [least] (ref.) 1.00  
    
Year of MI    
   2009 (ref.) 1.00 
0.0033 
 
   2010 1.01 (0.90, 1.13) 0.2007 
   2011 0.93 (0.82, 1.04) 0.9116 
   2012 0.93 (0.82, 1.06) 0.7008 
   2013 0.83 (0.72, 0.96) 0.6424 
   2014 0.73 (0.61, 0.89) 0.4820 






Appendix L4 Schoenfeld Residuals for Model for Overall Mortality 









Appendix L5 Model for Overall Mortality by Average Adherence 
(80%) 
Model/Variable Hazard Ratio (95% CI) p-value PH Test 
Unadjusted Model    
Average Adherence (80%)    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 1.53 (1.41, 1.65) <0.0001 
    
Adjusted Model    
Average Adherence (80%)    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 1.37 (1.26, 1.48) 0.0008 
    
Sex    
   Female (ref.) 1.00 
0.0337 
 
   Male  1.09 (1.01, 1.18) 0.0775 
    
Age at MI (years) 1.08 (1.08, 1.09) <0.0001 0.1241 
    
SIMD (NHS GGC)    
   1 [most] 1.90 (1.67, 2.17) 
<0.0001 
0.1949 
   2 1.70 (1.49, 1.94) 0.1799 
   3 1.62 (1.42, 1.86) 0.2778 
   4 1.34 (1.16, 1.54) 0.8606 
   5 [least] (ref.) 1.00  
    
Year of MI    
   2009 (ref.) 1.00 
0.0079 
 
   2010 1.01 (0.90, 1.14) 0.2026 
   2011 0.93 (0.83, 1.05) 0.9084 
   2012 0.94 (0.83, 1.07) 0.7274 
   2013 0.85 (0.74, 0.98) 0.7264 
   2014 0.74 (0.61, 0.90) 0.4880 







Appendix L6 Schoenfeld Residuals for Model for Overall Mortality 








Appendix L7 Model for Circulatory Mortality by Continuous 
Adherence 
Model/Variable Hazard Ratio (95% CI) p-value PH Test 
Unadjusted Model    
Continuous Adherence    
   10% Decrease 1.06 (1.04, 1.08) <0.0001 0.1839 
    
Adjusted Model    
Continuous Adherence    
   10% Decrease 1.03 (1.01, 1.05) 0.0072 0.7382 
    
Sex    
   Female (ref.) 1.00 
0.0039 
 
   Male  1.23 (1.07, 1.41) 0.4338 
    
Age at MI (years) 1.08 (1.08, 1.09) <0.0001 0.3271 
    
SIMD (NHS GGC)    
   1 [most] 1.70 (1.35, 2.14) 
<0.0001 
0.9938 
   2 1.56 (1.25, 1.96) 0.5648 
   3 1.53 (1.22, 1.92) 0.2697 
   4 1.36 (1.08, 1.73) 0.8035 
   5 [least] (ref.) 1.00  
    
Year of MI    
   2009 (ref.) 1.00 
0.0005 
 
   2010 0.98 (0.79, 1.22) 0.4219 
   2011 1.23 (0.99, 1.53) 0.0359 
   2012 1.51 (1.21, 1.88) 0.0003 
   2013 1.22 (0.95, 1.56) 0.0183 
   2014 0.96 (0.68, 1.36) 0.1008 






Appendix L8 Schoenfeld Residuals for Model for Circulatory 









Appendix L9 Model for Circulatory Mortality by Average 
Adherence (50%) 
Model/Variable Hazard Ratio (95% CI) p-value PH Test 
Unadjusted Model    
Average Adherence (50%)    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 1.59 (1.35, 1.87) 0.3440 
    
Adjusted Model    
Average Adherence (50%)    
   Achieved (ref.) 1.00 
0.0116 
 
   Not Achieved 1.24 (1.05, 1.46) 0.9652 
    
Sex    
   Female (ref.) 1.00 
0.0042 
 
   Male  1.22 (1.07, 1.40) 0.4562 
    
Age at MI (years) 1.09 (1.08, 1.09) <0.0001 0.3573 
    
SIMD (NHS GGC)    
   1 [most] 1.70 (1.36, 2.14) 
<0.0001 
0.9901 
   2 1.56 (1.24, 1.95) 0.5674 
   3 1.53 (1.22, 1.92) 0.2651 
   4 1.37 (1.08, 1.73) 0.8082 
   5 [least] (ref.) 1.00  
    
Year of MI    
   2009 (ref.) 1.00 
0.0006 
 
   2010 0.98 (0.79, 1.22) 0.4147 
   2011 1.23 (0.99, 1.53) 0.0340 
   2012 1.50 (1.21, 1.88) 0.0003 
   2013 1.22 (0.95, 1.56) 0.0175 
   2014 0.96 (0.68, 1.36) 0.0974 






Appendix L10 Schoenfeld Residuals for Model for Circulatory 









Appendix L11 Model for Circulatory Mortality by Average 
Adherence (80%) 
Model/Variable Hazard Ratio (95% CI) p-value PH Test 
Unadjusted Model    
Average Adherence (80%)    
   Achieved (ref.) 1.00 
<0.0001 
 
   Not Achieved 1.42 (1.24, 1.63) 0.0082 
    
Adjusted Model    
Average Adherence (80%)    
   Achieved (ref.) 1.00 
0.0003 
 
   Not Achieved 1.29 (1.12, 1.48) 0.0494 
    
Sex    
   Female (ref.) 1.00 
0.0039 
 
   Male  1.23 (1.07, 1.41) 0.3988 
    
Age at MI (years) 1.08 (1.08, 1.09) <0.0001 0.2681 
    
SIMD (NHS GGC)    
   1 [most] 1.70 (1.35, 2.14) 
<0.0001 
0.9704 
   2 1.56 (1.25, 1.96) 0.5487 
   3 1.52 (1.21, 1.91) 0.2984 
   4 1.36 (1.08, 1.73) 0.7574 
   5 [least] (ref.) 1.00  
    
Year of MI    
   2009 (ref.) 1.00 
0.0004 
 
   2010 0.98 (0.79, 1.23) 0.4208 
   2011 1.24 (1.00, 1.54) 0.0359 
   2012 1.52 (1.22, 1.90) 0.0003 
   2013 1.24 (0.97, 1.59) 0.0157 
   2014 0.97 (0.69, 1.38) 0.1000 







Appendix L12 Schoenfeld Residuals for Model for Circulatory 









Appendix M Logistic Regression Models for Not 
Achieving Target Non-HDL by Average Statin Adherence 
Appendix M1 Model for Not Achieving Target Non-HDL by 
Continuous Adherence 
Model/Variable Odds Ratio (95% CI) p-value 
Unadjusted Model   
Continuous Adherence   
   10% Decrease 1.24 (1.20, 1.27) <0.0001 
   
Adjusted Model   
Continuous Adherence   
   10% Decrease 1.23 (1.20, 1.26) <0.0001 
   
Sex   
   Female (ref.) 1.00 
0.0062 
   Male  0.81 (0.69, 0.94) 
   
Age at MI (years) 1.01 (1.01, 1.02) <0.0001 
   
SIMD (NHS GGC)   
   1 [most] 1.34 (1.05, 1.71) 
0.2136 
   2 1.24 (0.97, 1.58) 
   3 1.21 (0.94, 1.54) 
   4 1.22 (0.95, 1.58) 
   5 [least] (ref.) 1.00 
   
Year of MI   
   2009 (ref.) 1.00 
0.9033 
   2010 1.12 (0.82, 1.54) 
   2011 1.12 (0.83, 1.51) 
   2012 1.19 (0.88, 1.60) 
   2013 1.16 (0.86, 1.56) 






Appendix M2 Model for Not Achieving Target Non-HDL by 
Average Adherence (50%) 
Model/Variable Odds Ratio (95% CI) p-value 
Unadjusted Model   
Average Adherence (50%)   
   Achieved (ref.) 1.00 
<0.0001 
   Not Achieved 4.76 (3.86, 5.88) 
   
Adjusted Model   
Average Adherence (50%)   
   Achieved (ref.) 1.00 
<0.0001 
   Not Achieved 4.47 (3.62, 5.54) 
   
Sex   
   Female (ref.) 1.00 
0.0046 
   Male  0.80 (0.69, 0.93) 
   
Age at MI (years) 1.01 (1.01, 1.02) <0.0001 
   
SIMD (NHS GGC)   
   1 [most] 1.32 (1.04, 1.68) 
0.2405 
   2 1.24 (0.97, 1.58) 
   3 1.23 (0.96, 1.56) 
   4 1.21 (0.94, 1.57) 
   5 [least] (ref.) 1.00 
   
Year of MI   
   2009 (ref.) 1.00 
0.9455 
   2010 1.13 (0.82, 1.54) 
   2011 1.12 (0.83, 1.51) 
   2012 1.18 (0.88, 1.58) 
   2013 1.13 (0.84, 1.51) 






Appendix M3 Model for Not Achieving Target Non-HDL by 
Average Adherence (80%) 
Model/Variable Odds Ratio (95% CI) p-value 
Unadjusted Model   
Average Adherence (80%)   
   Achieved (ref.) 1.00 
<0.0001 
   Not Achieved 3.02 (2.59, 3.52) 
   
Adjusted Model   
Average Adherence (80%)   
   Achieved (ref.) 1.00 
<0.0001 
   Not Achieved 2.98 (2.55, 3.48) 
   
Sex   
   Female (ref.) 1.00 
0.0014 
   Male  0.78 (0.67, 0.91) 
   
Age at MI (years) 1.02 (1.01, 1.02) <0.0001 
   
SIMD (NHS GGC)   
   1 [most] 1.26 (0.99, 1.60) 
0.3969 
   2 1.22 (0.96, 1.55) 
   3 1.17 (0.92, 1.49) 
   4 1.21 (0.94, 1.56) 
   5 [least] (ref.) 1.00 
   
Year of MI   
   2009 (ref.) 1.00 
0.7523 
   2010 1.19 (0.87, 1.62) 
   2011 1.14 (0.85, 1.54) 
   2012 1.25 (0.93, 1.67) 
   2013 1.23 (0.91, 1.65) 






Appendix N Logistic Regression Models for Not 
Achieving Target LDL by Average Statin Adherence 
Appendix N1 Model for Not Achieving Target LDL by Continuous 
Adherence 
Model/Variable Odds Ratio (95% CI) p-value 
Unadjusted Model   
Continuous Adherence   
   10% Decrease 1.10 (1.08, 1.12) <0.0001 
   
Adjusted Model   
Continuous Adherence   
   10% Decrease 1.11 (1.09, 1.12) <0.0001 
   
Sex   
   Female (ref.) 1.00 
0.0002 
   Male  0.82 (0.73, 0.91) 
   
Age at MI (years) 1.00 (0.99, 1.00) 0.0285 
   
SIMD (NHS GGC)   
   1 [most] 0.81 (0.68, 0.97) 
<0.0001 
   2 1.23 (1.04, 1.45) 
   3 1.28 (1.09, 1.52) 
   4 1.52 (1.28, 1.81) 
   5 [least] (ref.) 1.00 
   
Year of MI   
   2009 (ref.) 1.00 
<0.0001 
   2010 1.11 (0.92, 1.34) 
   2011 1.39 (1.16, 1.66) 
   2012 1.40 (1.17, 1.68) 
   2013 1.67 (1.39, 1.99) 






Appendix N2 Model for Not Achieving Target LDL by Average 
Adherence (50%) 
Model/Variable Odds Ratio (95% CI) p-value 
Unadjusted Model   
Average Adherence (50%)   
   Achieved (ref.) 1.00 
<0.0001 
   Not Achieved 1.98 (1.74, 2.24) 
   
Adjusted Model   
Average Adherence (50%)   
   Achieved (ref.) 1.00 
<0.0001 
   Not Achieved 2.03 (1.78, 2.31) 
   
Sex   
   Female (ref.) 1.00 
<0.0001 
   Male  0.81 (0.73, 0.90) 
   
Age at MI (years) 1.00 (0.99, 1.00) 0.0306 
   
SIMD (NHS GGC)   
   1 [most] 0.81 (0.68, 0.97) 
<0.0001 
   2 1.22 (1.04, 1.45) 
   3 1.29 (1.09, 1.53) 
   4 1.51 (1.27, 1.80) 
   5 [least] (ref.) 1.00 
   
Year of MI   
   2009 (ref.) 1.00 
<0.0001 
   2010 1.11 (0.92, 1.33) 
   2011 1.38 (1.15, 1.65) 
   2012 1.39 (1.16, 1.66) 
   2013 1.63 (1.37, 1.96) 






Appendix N3 Model for Not Achieving Target LDL by Average 
Adherence (80%) 
Model/Variable Odds Ratio (95% CI) p-value 
Unadjusted Model   
Average Adherence (80%)   
   Achieved (ref.) 1.00 
<0.0001 
   Not Achieved 1.60 (1.45, 1.78) 
   
Adjusted Model   
Average Adherence (80%)   
   Achieved (ref.) 1.00 
<0.0001 
   Not Achieved 1.70 (1.53, 1.88) 
   
Sex   
   Female (ref.) 1.00 
<0.0001 
   Male  0.80 (0.72, 0.89) 
   
Age at MI (years) 1.00 (0.99, 1.00) 0.0757 
   
SIMD (NHS GGC)   
   1 [most] 0.80 (0.67, 0.95) 
<0.0001 
   2 1.21 (1.02, 1.42) 
   3 1.27 (1.07, 1.50) 
   4 1.51 (1.27, 1.79) 
   5 [least] (ref.) 1.00 
   
Year of MI   
   2009 (ref.) 1.00 
<0.0001 
   2010 1.12 (0.93, 1.35) 
   2011 1.40 (1.17, 1.68) 
   2012 1.43 (1.19, 1.71) 
   2013 1.70 (1.42, 2.03) 





Appendix O Cox Regression Models for Time to Non-
Adherence with Lipid Testing Frequency  
Appendix O1 Optimal Model for Time to Non-Adherence (50%) 
with Lipid Testing Frequency 
Model 
Variable Hazard Ratio (95% CI) p-value 
Sex   
   Female (ref.) 1.00 
<0.0001 
   Male  0.82 (0.76-0.89) 
   
Age at MI (years)   
   <50 (ref.) 1.00  
   50-60 0.84 (0.74-0.95)  
   60-70 0.78 (0.69-0.88) <0.0001 
   70-80 1.01 (0.90-1.13)  
   ≥80 1.33 (1.18-1.51)  
   
SIMD (NHS GGC)   
   1 [most]  1.02 (0.91-1.15) 
0.1118 
   2 0.97 (0.87-1.09) 
   3 1.12 (1.00-1.26) 
   4 1.04 (0.92-1.18) 
   5 [least] (ref.) 1.00 
   
Testing Frequency   
   0 Tests 1.59 (1.43-1.78) 
<0.0001    1 Test (ref.) 1.00 






Appendix O2 Optimal Model for Time to Non-Adherence (80%) 
with Lipid Testing Frequency 
Model 
Variable Hazard Ratio (95% CI) p-value 
Sex   
   Female (ref.) 1.00 
0.0018 
   Male  0.92 (0.87-0.97) 
   
Age at MI (years)   
   <50 (ref.) 1.00 
<0.0001 
   50-60 0.89 (0.82-0.97) 
   60-70 0.81 (0.74-0.88) 
   70-80 0.93 (0.86-1.02) 
   ≥80 1.12 (1.03-1.23) 
   
SIMD (NHS GGC)   
   1 [most]  1.09 (1.01-1.19) 
0.0352 
   2 1.06 (0.98-1.15) 
   3 1.09 (1.00-1.19) 
   4 0.99 (0.90-1.08) 
   5 [least] (ref.) 1.00 
   
Further MI Last Year   
   No (ref.) 1.00 
0.0737 
   Yes 1.11 (0.99-1.25) 
   
Year of MI   
   2009 (ref.) 1.00 
<0.0001 
   2010 0.95 (0.87-1.03) 
   2011 0.89 (0.82-0.97) 
   2012 0.87 (0.80-0.94) 
   2013 0.78 (0.72-0.85) 
   2014 0.79 (0.71-0.88) 
   
Testing Frequency   
   0 Tests 1.26 (1.14-1.40) 
<0.0001    1 Test (ref.) 1.00 






Appendix P Optimal Latent Class Analysis for Adherence 
Appendix P1 Model for 50% Adherence 
Conditional Class Probabilities 








Sex     
   Male 0.3127 0.8983 0.7127 0.5822 
   Female 0.6873 0.1017 0.2873 0.4178 
     
Age at MI (years)     
   <50 0.0000 0.1276 0.2848 0.1597 
   50-60 0.1034 0.2800 0.3743 0.2422 
   60-70 0.2385 0.3381 0.2399 0.2173 
   70-80 0.4091 0.1923 0.1010 0.2476 
   ≥80 0.2490 0.0620 0.0000 0.1331 
     
SIMD (NHS GGC)     
   1 (Most) 0.1924 0.0000 0.4967 0.1980 
   2 0.2654 0.1570 0.2755 0.2199 
   3 0.2091 0.2181 0.1704 0.2316 
   4 0.1584 0.2882 0.0573 0.1772 
   5 (Least) 0.1747 0.3367 0.0000 0.1733 
     
50% Adherent Last Year     
   No 0.0137 0.0156 0.0312 0.5992 
   Yes 0.9863 0.9844 0.9688 0.4008 
     
LDL on Target Last Year     
   No 0.4096 0.4654 0.4164 0.5706 
   Yes 0.5904 0.5346 0.5836 0.4294 
Est. Class Pop. Shares 0.2424 0.3080 0.3001 0.1494 
Pred. Class Memberships 0.2169 0.3339 0.3070 0.1421 
Maximum Log-Likelihood -123644.0 
BIC 247797.4 
AIC 247388.1 







Regression  Coefficient SE(Coef) exp(Coef) p-value 
2 vs 1     
   Intercept 1.37290 0.04256 3.94678 <0.001 
   Meeting Target -1.13353 0.04256 0.32189 <0.001 
3 vs 1     
   Intercept  3.42169 0.03478 30.62112 <0.001 
   Meeting Target -3.20819 0.03478 0.04043 <0.001 
4 vs 1     
   Intercept 20.63205 0.11316 912820669.2 <0.001 
   Meeting Target -23.17646 0.11316 <0.00001 <0.001 
 
Model Comparisons 
# Class Log-Likelihood # Paras BIC Relative Entropy 
2 -124597.2 24 249438.8 0.9116 
3 -123856.3 37 248089.5 0.7488* 
4 -123644.0 50 247797.4 0.6015 
*To calculate relative entropy, those with posterior predictions of zero were set 




Appendix P2 Model for 80% Adherence 
Conditional Class Probabilities 








Sex     
   Male 0.5503 1.0000 0.2827 0.6162 
   Female 0.4497 0.0000 0.7173 0.3838 
     
Age at MI (years)     
   <50 0.0275 0.2406 0.1635 0.1837 
   50-60 0.1603 0.3700 0.2193 0.2841 
   60-70 0.2874 0.2861 0.2429 0.2130 
   70-80 0.3358 0.1033 0.2620 0.2112 
   ≥80 0.1890 0.0000 0.1123 0.1080 
     
SIMD (NHS GGC)     
   1 (Most) 0.0000 0.2669 0.5183 0.2191 
   2 0.2012 0.2186 0.2914 0.2219 
   3 0.2301 0.1914 0.1589 0.2330 
   4 0.2665 0.1664 0.0314 0.1655 
   5 (Least) 0.3022 0.1568 0.0000 0.1604 
     
Further MI Last Year      
   No 0.9283 0.9320 0.9085 0.9159 
   Yes 0.0717 0.0680 0.0915 0.0841 
     
Year of MI     
   2009 0.2025 0.2397 0.1912 0.2260 
   2010 0.2210 0.2332 0.2133 0.2103 
   2011 0.1954 0.1934 0.2157 0.2032 
   2012 0.1681 0.1503 0.1834 0.1841 
   2013 0.1414 0.1188 0.1339 0.1180 
   2014 0.0716 0.0646 0.0625 0.0585 
     
80% Adherent Last Year     
   No 0.1151 0.1275 0.1228 0.9979 
   Yes 0.8849 0.8725 0.8772 0.0021 
     
LDL on Target Last Year     
   No 0.4676 0.4217 0.3814 0.5801 
   Yes 0.5324 0.5783 0.6186 0.4199 
Est. Class Pop. Shares 0.3171 0.3260 0.2010 0.1558 
Pred. Class Memberships 0.2971 0.3975 0.1418 0.1636 
Maximum Log-Likelihood -183050.0 
BIC 366853.9 
AIC 366248.1 








Regression Coefficient SE(Coef) Exp(Coef) p-value 
2 vs 1     
   Intercept  0.03208 0.08460 1.03260 0.705 
   Meeting 80% Target -0.00512 0.07300 0.99489 0.944 
3 vs 1     
   Intercept -0.39313 0.10055 0.67494 <0.001 
   Meeting 80% Target -0.07210 0.08198 0.93044 0.379 
4 vs 1     
   Intercept 1.34134 0.08663 3.82416 <0.001 
   Meeting 80% Target -5.21688 0.64308 0.00524 <0.001 
 
Model Comparisons 
# Class Log-Likelihood # Paras BIC Relative Entropy 
2 -184046.6 36 368460.0 0.7753 
3 -183354.4 55 367269.0 0.7367 





Appendix Q Models for Mortality by Predicted Class from 
Latent Class Analysis (50% Adherence) 
Appendix Q1 Models for Year 2 
Cox Regression  
Variable Hazard Ratio (95% CI) p-value PH Test 
Class    
   1,2,3 [Most] (ref.) 1.00 
<0.0001 
 
   4 [Least] 2.13 (1.70, 2.67)  
Global PH Test   0.0039 
 





Appendix Q2 Models for Year 3 
Cox Regression  
Variable Hazard Ratio (95% CI) p-value PH Test 
Class    
   1,2,3 [Most] (ref.) 1.00 
<0.0001 
 
   4 [Least] 2.40 (1.86,3.11)  
Global PH Test   0.0367 
 





Appendix R Models for Mortality by Predicted Class from 
Latent Class Analysis (80% Adherence) 
Appendix R1 Models for Year 2 
Cox Regression  
Variable Hazard Ratio (95% CI) p-value PH Test 
Class    
   1,2,3 [Most] (ref.) 1.00 
0.0001 
 
   4 [Least] 1.61 (1.28, 2.03)  
Global PH Test   0.0322 
 





Appendix R2 Models for Year 3 
Cox Regression  
Variable Hazard Ratio (95% CI) p-value PH Test 
Class    
   1,2,3 [Most] (ref.) 1.00 
0.0239 
 
   4 [Least] 1.40 (1.06, 1.86)  
Global PH Test   0.3008 
 





Appendix S Optimal Latent Class Growth Analyses for 
Time to Non-Adherence 
Appendix S1 Model for 50% Adherence  
Class Proportions 








Sex     
   Male 5,017 (63.5%) 494 (57.2%) 338 (63.1%) 554 (49.6%) 
   Female 2,885 (36.5%) 369 (42.8%) 198 (36.9%) 563 (50.4%) 
     
Age at MI (years) 
   <50 1,014 (12.8%) 102 (11.8%) 100 (18.7%) 145 (13.0%) 
   50-60 1,780 (22.5%) 180 (20.9%) 128 (23.9%) 156 (14.0%) 
   60-70 1,916 (24.3%) 184 (21.3%) 116 (21.6%) 194 (17.4%) 
   70-80 1,877 (23.8%) 221 (25.6%) 125 (23.3%) 282 (25.2%) 
   ≥80 1,315 (16.6%) 176 (20.4%) 67 (12.5%) 340 (30.4%) 
     
SIMD (NHS GGC) 
   1 (Most) 1,940 (24.6%) 190 (22.0%) 191 (35.6%) 196 (17.5%) 
   2 1,850 (23.4%) 204 (23.6%) 133 (24.8%) 234 (20.9%) 
   3 1,599 (20.2%) 175 (20.3%) 111 (20.7%) 269 (24.1%) 
   4 1,327 (16.8%) 140 (16.2%) 60 (11.2%) 230 (20.6%) 
   5 (Least) 1,186 (15.0%) 154 (17.8%) 41 (7.6%) 188 (16.8%) 
 
Model Comparisons 
# Class Log-Likelihood # Paras BIC Relative Entropy 
1 -22341.17 2 44700.86 1.0000 
2 -16386.10 8 32846.21 0.8289 
3 -15883.88 14 31897.27 0.7605 





Appendix S2 Model for 80% Adherence  
Class Proportions 








Sex     
   Male 3,155 (63.1%) 1,676 (62.3%) 540 (69.1%) 1,032 (53.1%) 
   Female 1,845 (36.9%) 1,106 (37.7%) 242 (31.0%) 912 (46.9%) 
     
Age at MI (years) 
   <50 599 (12.0%) 344 (12.8%) 131 (16.8%) 287 (14.8%) 
   50-60 1,121 (22.4%) 548 (20.4%) 206 (26.3%) 369 (19.0%) 
   60-70 1,292 (25.8%) 600 (22.3%) 174 (22.3%) 344 (17.7%) 
   70-80 1,238 (24.8%) 660 (24.5%) 173 (22.1%) 434 (22.3%) 
   ≥80 750 (15.0%) 540 (20.1%) 98 (12.5%) 510 (26.2%) 
     
SIMD (NHS GGC) 
   1 (Most) 1,131 (22.6%) 705 (26.2%) 266 (34.0%) 415 (21.3%) 
   2 1,153 (23.1%) 661 (24.6%) 204 (26.1%) 403 (20.7%) 
   3 1,022 (20.4%) 520 (19.3%) 155 (19.8%) 457 (23.5%) 
   4 884 (17.7%) 420 (15.6%) 92 (11.8%) 361 (18.6%) 
   5 (Least) 810 (16.2%) 386 (14.3%) 65 (8.3%) 308 (15.8%) 
     
Year of MI  
   2009 658 (13.2%) 521 (19.4%) 249 (31.8%) 237 (12.2%) 
   2010 820 (16.4%) 564 (21.0%) 200 (25.6%) 292 (15.0%) 
   2011 913 (18.3%) 533 (19.8%) 136 (17.4%) 369 (19.0%) 
   2012 955 (19.1%) 450 (16.7%) 116 (14.8%) 445 (22.9%) 
   2013 1,042 (20.8%) 411 (15.3%) 62 (7.9%) 374 (19.2%) 
   2014 612 (12.2%) 213 (7.9%) 19 (2.4%) 227 (11.7%) 
 
Model Comparisons 
# Class Log-Likelihood # Paras BIC Relative Entropy 
1 -32551.84 2 65122.20 1.0000 
2 -26763.31 9 53609.87 0.7662 
3 -26327.46 16 52802.95 0.5951 





Appendix T Cox Models for Mortality by Predicted Class 
from Latent Class Growth Analysis (Adherence) 
Appendix T1 Model from 50% Adherence Analysis 
Model 
 Hazard Ratio (95% CI) p-value PH Test 
Class     
   1 (ref.) 1.00 
<0.0001 
 
   2 0.99 (0.87, 1.12) <0.0001 
   3 1.26 (1.09, 1.46) 0.0010 
   4 1.84 (1.67, 2.02) 0.9191 
Global PH Test <0.0001 
 





Appendix T2 Model from 80% Adherence Analysis 
Model 
 Hazard Ratio (95% CI) p-value PH Test 
Class     
   1 (ref.) 1.00 
<0.0001 
 
   2 1.30 (1.19, 1.42) 0.1089 
   3 1.71 (1.51, 1.93) <0.0001 
   4 2.04 (1.87, 2.22) <0.0001 
Global PH Test <0.0001 
 





Appendix U Cox Regression Model for Time to Non-
Target LDL with Lipid Testing Frequency  
Model 
Variable Hazard Ratio (95% CI) p-value 
Sex   
   Female (ref.) 1.00 
0.0001 
   Male  0.90 (0.85-0.95) 
   
Age at MI (years)   
   <50 (ref.) 1.00 
<0.0001 
   50-60 1.05 (0.96-1.14) 
   60-70 1.05 (0.97-1.14) 
   70-80 0.81 (0.74-0.89) 
   ≥80 0.59 (0.53-0.65) 
   
SIMD (NHS GGC)   
   1 [most]  0.68 (0.62-0.74) 
<0.0001 
   2 0.94 (0.86-1.02) 
   3 1.03 (0.95-1.12) 
   4 1.07 (0.98-1.17) 
   5 [least] (ref.) 1.00 
   
Diabetes Diagnosis   
   No (ref.) 1.00 
<0.0001 
   Yes 0.82 (0.77-0.88) 
   
Further MI Last Year   
   No (ref.) 1.00 
0.0718 
   Yes 1.10 (0.99-1.22) 
   
Previous MI   
   No (ref.) 1.00 
0.0254 
   Yes 0.88 (0.79-0.99) 
   
Year of MI   
   2009 (ref.) 1.00 
<0.0001 
   2010 1.12 (1.02-1.22) 
   2011 1.28 (1.18-1.40) 
   2012 1.29 (1.18-1.41) 
   2013 1.30 (1.19-1.43) 
   2014 1.72 (1.55-1.91) 
   
Testing Frequency   
   0 Tests 0.91 (0.83-1.00) 
0.0026    1 Test (ref.) 1.00 






Appendix V Optimal Latent Class Analysis for Target LDL 
Appendix V1 Model for Target LDL Model (Using 50% Adherence)  
Conditional Class Probabilities 




Sex   
   Male 0.6836 0.6407 
   Female 0.3164 0.3593 
   
Age at MI (years)   
   <50 0.1335 0.1494 
   50-60 0.2501 0.2680 
   60-70 0.2707 0.2885 
   70-80 0.2452 0.2161 
   ≥80 0.1004 0.0780 
   
SIMD (NHS GGC)   
   1 (Most) 0.2646 0.1760 
   2 0.2264 0.2222 
   3 0.1784 0.2225 
   4 0.1506 0.1886 
   5 (Least) 0.1800 0.1907 
   
Diabetes   
   No 0.6902 0.7717 
   Yes 0.3098 0.2283 
   
Further MI Last Year    
   No 0.9159 0.9282 
   Yes 0.0841 0.0718 
   
Previous MI   
   No 0.9234 0.9460 
   Yes 0.0766 0.0540 
   
Year of MI   
   2009 0.2914 0.1919 
   2010 0.2594 0.2061 
   2011 0.1934 0.2054 
   2012 0.1362 0.1840 
   2013 0.0814 0.1435 
   2014 0.0383 0.0691 
   
50% Adherent Last Year   
   No 0.0569 0.1282 
   Yes 0.9431 0.8718 
   
LDL on Target Last Year   
   No 0.0741 0.7113 




Class Shares and Model Fit 




Est. Class Pop. Shares 0.4353 0.5647 
Pred. Class Memberships 0.4323 0.5677 
Maximum Log-Likelihood -120047.9 
BIC 240483.6 
AIC 240175.9 




Regression Coefficient SE(Coef) Exp(Coef) p-value 
1 vs 2     
   Intercept -4.48151 1.26060 0.01132 <0.001 
   Meeting LDL Target 6.06149 1.32112 429.01419 <0.001 
 
Model Comparisons 
# Class Log-Likelihood # Paras BIC Relative Entropy 
2 -120047.9 40 240483.6 0.7486 
3 -119724.2 61 240039.8 0.6665 





Appendix V2 Model for Target LDL Model (Using 80% Adherence)  
Conditional Class Probabilities 




Age at MI (years)   
   <50 0.1328 0.1497 
   50-60 0.2494 0.2684 
   60-70 0.2712 0.2880 
   70-80 0.2458 0.2160 
   ≥80 0.1009 0.0778 
   
Sex   
   Male 0.6831 0.6415 
   Female 0.3169 0.3585 
   
SIMD (NHS GGC)   
   1 (Most) 0.2637 0.1775 
   2 0.2266 0.2220 
   3 0.1786 0.2220 
   4 0.1513 0.1878 
   5 (Least) 0.1798 0.1908 
   
Diabetes   
   No 0.6902 0.7710 
   Yes 0.3098 0.2290 
   
Further MI Last Year    
   No 0.9162 0.9279 
   Yes 0.0838 0.0721 
   
Previous MI   
   No 0.9236 0.9456 
   Yes 0.0764 0.0544 
   
Year of MI   
   2009 0.2917 0.1926 
   2010 0.2597 0.2064 
   2011 0.1936 0.2052 
   2012 0.1358 0.1838 
   2013 0.0809 0.1432 
   2014 0.0384 0.0688 
   
80% Adherent Last Year   
   No 0.2001 0.2858 
   Yes 0.7999 0.7142 
   
LDL on Target Last Year   
   No 0.0759 0.7041 





Class Shares and Model Fit 




Est. Class Pop. Shares 0.4301 0.5699 
Pred. Class Memberships 0.4318 0.5682 
Maximum Log-Likelihood -124008.2 
BIC 248404.1 
AIC 248096.3 




Regression Coefficient SE(Coef) Exp(Coef) p-value 
1 vs 2     
   Intercept -15.36150 0.05436 <0.00001 <0.001 
   Meeting LDL Target 16.94450 0.05436 22850875.74 <0.001 
 
Model Comparisons 
# Class Log-Likelihood # Paras BIC Relative Entropy 
2 -124008.2 40 248404.1 0.7796 
3 -123775.5 61 248142.3 0.7495 
4 -123511.6 82 247818.1 0.6486 
 
Predicted Class Assignments by Achievement of LDL Target 
 Meet Not Meet Total 
Class 1 (More) 7002 0 7002 
Class 2 (Less) 1404 7809 9213 
Total 8406 7809 16215 
 
Diagnostic Accuracy Measures 
 1 vs 2 
 LCA Bootstrap 
Sensitivity 83.3% 84.2% (83.5%, 85.0%) 
Specificity 100.0% 100.0% (100.0%, 100.0%) 
Positive Predictive Value 100.0% 100.0% (100.0%, 100.0%) 
Negative Predictive Value 84.8% 85.3% (84.5%, 86.1%) 
 
Average Posterior Probabilities 







Appendix W Models for Mortality by Predicted Class from 
Latent Class Analysis (using 50% Adherence) 
Appendix W1 Models for Year 2 
Cox Regression  
Variable Hazard Ratio (95% CI) p-value PH Test 
Class    
   1 [More] (ref.) 1.00 
0.0527 
 
   2 [Less] 0.72 (0.52, 1.01)  
Global PH Test   0.1083 
 





Appendix W2 Models for Year 3 
Cox Regression 
Variable Hazard Ratio (95% CI) p-value PH Test 
Class    
   1 [More] (ref.) 1.00 
0.1500 
 
   2 [Less] 0.73 (0.48,1.12)  
Global PH Test   0.4247 
 





Appendix X Models for Mortality by Predicted Class from 
Latent Class Analysis (using 80% Adherence) 
Appendix X1 Models for Year 2 
Cross-tabulation 
 Class 1 (Most) Class 2 (Least) 
N 2,408 2,336 
Events (%) 84 (3.5%) 59 (2.5%) 
 
Cox Regression  
Variable Hazard Ratio (95% CI) p-value PH Test 
Class    
   1 [More] (ref.) 1.00 
0.0502 
 
   2 [Less] 0.72 (0.52, 1.00)  
Global PH Test   0.1083 
 





Appendix X2 Models for Year 3 
Cross-tabulation 
 Class 1 (Most) Class 2 (Least) 
N 1,681 1,941 
Events (%) 47 (2.8%) 38 (2.0%) 
 
Cox Regression 
Variable Hazard Ratio (95% CI) p-value PH Test 
Class    
   1 [More] (ref.) 1.00 
0.0964 
 
   2 [Less] 0.70 (0.45, 1.07)  
Global PH Test   0.6071 
 





Appendix Y Optimal Latent Class Growth Analysis for 
Time to Non-Target LDL 
Class Proportions 








Sex     
   Male 1,050 (68.6%) 2,150 (63.6%) 842 (67.4%) 1,688 (57.8%) 
   Female 480 (31.4%) 1,230 (36.4%) 408 (32.6%) 1,231 (42.2%) 
     
Age at MI (years) 
   <50 138 (9.0%) 514 (15.2%) 97 (7.8%) 523 (17.9%) 
   50-60 262 (17.1%) 818 (24.2%) 218 (17.4%) 823 (28.2%) 
   60-70 338 (22.1%) 775 (22.9%) 332 (26.6%) 773 (26.5%) 
   70-80 444 (29.0%) 808 (23.9%) 333 (26.6%) 559 (19.2%) 
   ≥80 348 (22.8%) 465 (13.8%) 270 (21.6%) 241 (8.3%) 
     
SIMD (NHS GGC) 
   1 (Most) 448 (29.3%) 971 (28.7%) 166 (13.3%) 576 (19.7%) 
   2 363 (23.7%) 764 (22.6%) 325 (26.0%) 655 (22.4%) 
   3 276 (18.0%) 647 (19.1%) 321 (25.7%) 649 (22.2%) 
   4 216 (14.1%) 496 (14.7%) 263 (21.0%) 552 (18.9%) 
   5 (Least) 227 (14.8%) 502 (14.9%) 175 (14.0%) 487 (16.7%) 
     
Year of MI  
   2009 607 (39.7%) 351 (10.4%) 385 (30.8%) 111 (3.8%) 
   2010 555 (36.3%) 531 (15.7%) 401 (32.1%) 196 (6.7%) 
   2011 249 (16.3%) 757 (22.4%) 330 (26.4%) 403 (13.8%) 
   2012 107 (7.0%) 776 (23.0%) 115 (9.2%) 690 (23.6%) 
   2013 12 (0.8%) 695 (20.6%) 19 (1.5%) 894 (30.6%) 
   2014 0 (0.0%) 270 (8.0%) 0 (0.0%) 625 (21.4%) 
     
Previous MI 
   Yes 166 (10.8%) 204 (6.0%) 77 (6.2%) 117 (4.0%) 
   No 1,364 (89.2%) 3,176 (94.0%) 1,173 (93.8%) 2,802 (96.0%) 
 
Model Comparisons 
# Class Log-Likelihood # Paras BIC Relative Entropy 
1 -20069.76 2 40157.75 1.0000 
2 -17938.69 10 35968.52 0.5851 
3 -17402.87 18 34969.80 0.6124 






Appendix Z Cox Model for Mortality by Predicted Class 
from Latent Class Growth Analysis (Target LDL) 
Model 
 Hazard Ratio (95% CI) p-value PH Test 
Class     
   1 (ref.) 1.00 
<0.0001 
 
   2 0.71 (0.64, 0.79) 0.0060 
   3 0.98 (0.87, 1.10) 0.6536 
   4 0.35 (0.30, 0.40) 0.0161 
Global PH Test <0.0001 
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